Natural Polymer Drug Delivery Systems

Saurabh
Bhatia
Natural
Polymer
Drug Delivery
Systems
Nanoparticles, Plants, and Algae
Natural Polymer Drug Delivery Systems
Saurabh Bhatia
Natural Polymer Drug

Delivery Systems
Nanoparticles, Plants, and Algae
Saurabh Bhatia
Assistant Professor
School of Medical and Allied Sciences
GD Goenka University
Gurgaon, India
ISBN 978-3-319-41128-6 ISBN 978-3-319-41129-3 (eBook)

DOI 10.1007/978-3-319-41129-3
Library of Congress Control Number: 2016944154
© Springer International Publishing Switzerland 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of
the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation,
broadcasting, reproduction on microfilms or in any other physical way, and transmission or information
storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology
now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication
does not imply, even in the absence of a specific statement, that such names are exempt from the relevant
protective laws and regulations and therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and information in this book
are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the
editors give a warranty, express or implied, with respect to the material contained herein or for any errors
or omissions that may have been made.
Printed on acid-free paper
This Springer imprint is published by Springer Nature

The registered company is Springer International Publishing AG Switzerland
Author Bio
Saurabh Bhatia, is currently working as an Assistant Professor at the School of

Medical and Allied sciences, GD Goenka University, Gurgaon, Haryana, India. He
has several years of academic experience, teaching such specialized subjects as
Natural product science, nanotechnology, biotechnology, parasitology, polymeric
sciences, biomaterials. He has promoted several marine algae and their derived
polymers throughout India. He has written more than 30 international publications
in these areas and has been an active participant of more than 35 national and inter-
national conferences. So far he has successfully finished nine books in pharma and
its allied sciences. His published books include Modern Applications of Plant
Biotechnology in Pharmaceutical Sciences, Academic press, Elsevier, 2015;
Nanotechnology in Drug Delivery: Fundamentals, Design, and Applications, Apple
Academic Press 2016; Leishmaniasis: Biology, Control and New Approaches for Its
Treatment, Apple Academic Press 2016; Natural polymer drug delivery systems:
Nanoparticles, plants and algae, Springer, 2016, Natural polymer drug delivery
systems: Nanoparticles, Mammals and microbes, Springer, 2016. Dr. Bhatia has
graduated from Kurushetra University followed by M. Pharm from Bharati
Vidyapeeth University, Pune, India. He has received his Ph.D. degree from Jadavpur
University, Kolkata, India.
v
Contents
1 Nanotechnology and Its Drug Delivery Applications............................. 1

1.1 Introduction ........................................................................................ 1
1.2 Historical Prospects of Nanotechnology ............................................ 2
1.3 Promising Role in Drug Delivery ...................................................... 3
1.3.1 Nanoparticles and Drug Delivery .......................................... 8
1.3.2 Use of NPs Formulation in Drug Delivery ............................ 9
1.3.3 Cellular and Intracellular Targets ........................................... 11
1.3.4 The Brain—The Ultimate Target for Drug Delivery.............. 12
1.4 Innovations in Nanotechnology ......................................................... 14
1.5 Nanotechnology Theory to Applications ........................................... 16
1.6 Nanomedicine/Nanoscience/Nano-Engineering
and Relationship with Drug Delivery ................................................ 19
1.6.1 Nanomedicine and Drug Delivery ......................................... 19
1.6.2 Nanoengineering and Drug Delivery ..................................... 21
1.7 Types of Nanodelivery: Natural or Synthetic..................................... 23
1.7.1 Synthetic Polymers ................................................................ 23
1.7.2 Natural Polymers ................................................................... 23
1.8 Natural and Synthetic Polymeric Nanoparticles ................................ 24
2 Nanoparticles Types, Classification, Characterization,
Fabrication Methods and Drug Delivery Applications .......................... 33
2.1 Introduction ........................................................................................ 34
2.2 Classification of Nanoparticles .......................................................... 40
2.3 Characterization of Nanoparticles...................................................... 40
2.3.1 Particle Size ........................................................................... 40
2.3.2 Surface Charge ....................................................................... 43
2.3.3 Surface Hydrophobicity ......................................................... 44
2.3.4 Drug Release .......................................................................... 44
vii
viii Contents
2.4 Preparation of Nanoparticles.............................................................. 44

2.4.1 Solvent Evaporation Method ............................................... 45
2.4.2 Spontaneous Emulsification or Solvent Diffusion
Method ................................................................................. 46
2.4.3 Double Emulsion and Evaporation Method ........................ 46
2.4.4 Salting Out Method ............................................................. 46
2.4.5 Emulsions-Diffusion Method .............................................. 47
2.4.6 Solvent Displacement/Precipitation Method ....................... 48
2.4.7 Coacervation or Ionic Gelation Method .............................. 48
2.4.8 Polymerization Method ....................................................... 49
2.4.9 Production of Nanoparticles Using Supercritical
Fluid Technology ................................................................. 49
2.5 Most Favorable Requirements for Designing Therapeutic
Nanoparticles ..................................................................................... 50
2.6 Types of Pharmaceutical Nanosystems .............................................. 51
2.6.1 Carbon Based Structures ..................................................... 51
2.6.2 Fullerenes ............................................................................ 53
2.6.3 Quantum Dots ...................................................................... 54
2.6.4 Nanoshells ........................................................................... 56
2.6.5 Nanobubbles ........................................................................ 57
2.6.6 Paramagnetic Nanoparticles ................................................ 58
2.6.7 Nanosomes .......................................................................... 59
2.6.8 Pharmacyte .......................................................................... 59
2.6.9 Dendrimers .......................................................................... 60
2.6.10 Nanopores ............................................................................ 64
2.6.11 Microbivores ........................................................................ 64
2.6.12 Nanocrystals and Nanosuspension ...................................... 65
2.6.13 Solid Lipid Nanoparticles .................................................... 65
2.6.14 Silicon-Based Structures ..................................................... 66
2.6.15 Metallic Nanoparticles......................................................... 67
2.6.16 Liposomes............................................................................ 67
2.6.17 Polymeric Micelles .............................................................. 68
2.6.18 Polymer Drug Conjugate ..................................................... 69
2.6.19 Polyplexes/Lipopolyplexes .................................................. 69
2.6.20 Respirocytes......................................................................... 69
2.6.21 Polymeric Nanoparticles ..................................................... 70
2.6.22 Applications of Nanoparticulate Delivery Systems............. 72
2.6.23 Passive Targeting ................................................................. 73
2.6.24 Active Targeting................................................................... 73
2.6.25 Tumor Targeting Using Nanoparticulate
Delivery Systems ................................................................. 75
2.6.26 Long-Circulating and Target-Specific Nanoparticles .......... 76
2.6.27 Nanoparticles for Oral Delivery of Peptides
and Proteins ......................................................................... 78
2.6.28 Nanoparticles for Gene Delivery ......................................... 79
Contents ix
2.6.29
Nanoparticles for Drug Delivery into the Brain .................. 80
2.6.30
Anthrax Vaccine Uses Nanoparticles
to Produce Immunity ........................................................... 81
2.6.31 Stem Cell Therapy ............................................................... 81
2.6.32 Gold Nanoparticles Detect Cancer ...................................... 82
2.7 Hazards and Toxicity Profile of Nanoparticles .................................. 84
2.7.1 Health Implication of Nanoparticles ................................... 84
3 Natural Polymers vs Synthetic Polymer ................................................. 95
3.1 Bioengineered Materials: Nano-Engines
of Drug Delivery Systems .................................................................. 95
3.2 Polymeric Nanoparticles .................................................................... 96
3.3 Contemporary Methodologies for Fabrication
of Polymeric Nanoparticles................................................................ 97
3.4 Activation-Modulated Drug Delivery: Environmental
Activation/Stimuli Responsive Smart Delivery System..................... 98
3.5 Time to Move on Innovative Methods of Administration .................. 100
3.6 History of Drug Delivery from the Ancient to Date .......................... 102
3.6.1 Historical Role of Polymers as Plastics ............................... 105
3.7 Shift from Nature to Synthetic (Including the Merits
and Demerits of Synthetic Polymers) ................................................ 106
3.7.1 Natural Polymers and Synthetic Polymers for Scaffolds .... 109
3.7.2 Natural vs Synthetic Polymer (as Biomaterial) ................... 110
3.7.3 Natural vs Synthetic Polymer in Tissue Engineering .......... 112
3.7.4 Natural vs Synthetic Polymer Hydrogels ............................ 113
3.8 Natural Polymers (Reasons for Reverting to Nature) ........................ 114
3.8.1 Need of Natural Polymers ................................................... 115
3.8.2 Disadvantages of Herbal Polymers...................................... 116
4 Plant Derived Polymers, Properties, Modification & Applications ...... 119
4.1 Introduction ........................................................................................ 119
4.2 Sources of Plant Polymers ................................................................. 121
4.3 Methods of Extractions ...................................................................... 124
4.3.1 Cold Extraction .................................................................... 124
4.3.2 Hot Extraction [Mild Acidic (EHA), Alkaline (EHB)
and Radical Hydrolysis (EHR)]........................................... 125
4.3.3 Radical Hydrolysis (EHR) ................................................... 125
4.3.4 Microwave Assisted Extraction (EM).................................. 125
4.3.5 Ultrasonic Extraction (EU) .................................................. 126
4.3.6 Enzymatic Hydrolysis (EE) ................................................. 126
4.4 Chemical Composition Analysis ........................................................ 126
4.5 Physical Properties ............................................................................. 126
4.5.1 Determination of Gelling Strength (GS) ............................. 126
4.5.2 Determination of Gelling Temperature (GT)
and Melting Temperature (MT) ........................................... 126
4.5.3 Viscosity Measurement (VS) ................................................. 127
4.5.4 Molecular Mass Determination (MM) ................................... 127
x Contents
4.6 Physical-Chemical Modification of Plant Based

Natural Polymers (PBNPS)................................................................ 127
4.6.1 Chemical Modifications of Plant Based
Natural Polymers (PBNPS).................................................... 128
4.6.2 Procedure for the Development of Microfibrillated Plant
Based Polymers (MPBPS) by Physical Modification ............ 134
4.6.3 Pre-treatment .......................................................................... 138
4.6.4 Post-treatments....................................................................... 139
4.6.5 Dual Modifications................................................................. 140
4.6.6 Ozonation ............................................................................... 142
4.7 Genetic/Biotechnology Modification ................................................. 143
4.8 Applications of Plant Based Polysaccharides .................................... 144
4.8.1 Cellulose ................................................................................ 144
4.8.2 Hemicellulose ........................................................................ 152
4.8.3 Starches .................................................................................. 153
4.8.4 Pectin...................................................................................... 154
4.8.5 Inulin ...................................................................................... 155
4.8.6 Rosin ...................................................................................... 156
4.8.7 Plant Based Gums .................................................................. 157
5 Marine Polysaccharides Based Nano-Materials
and Its Applications .................................................................................. 185
5.1 Introduction ........................................................................................ 185
5.2 Polysaccharides Derived from Marine Sources ................................. 186
5.2.1 Marine Algae Based Polysaccharides .................................... 192
5.2.2 Marine Crustaceans Derived Polysaccharides ....................... 194
5.3 Nanomaterials Derived from Marine Sources ................................... 195
5.3.1 Nano Scaffolds Derived from Fucoidan ................................ 195
5.3.2 Alginate Nanoparticles........................................................... 197
5.3.3 Carrageenan Based Nanoparticles ......................................... 199
5.3.4 Agarose Nanoparticles ........................................................... 202
5.3.5 Porphyran Based Nanoparticles ............................................. 203
5.3.6 Nanofibers of Ulvan ............................................................... 205
5.3.7 Mauran Based Nanoparticles ................................................. 205
5.3.8 Chitin and Its Nanoparticles................................................... 206
5.3.9 Chitosan Based Nanoparticles ............................................... 206
5.3.10 Chitooligosaccharide Based Nanoparticles............................ 210
5.4 Marine Polysaccharide-Based Nanomaterials
and Its Biomedical and Biotechnological Applications ..................... 210
5.4.1 Biomedical Applications of Marine Polysaccharides ............ 211
5.4.2 Role of Marine Based Polysaccharides
for Biotechnological Applications ......................................... 214
5.5 Marine Polysaccharide-Based Nanomaterials and Its Patents ........... 215
Chapter 1
Nanotechnology and Its Drug Delivery
Applications
Abstract Drug delivery is attractive approach for medicine field, as more potent
and specific drugs are being developed. With the integration of nanotechnology, so-
called smart drug-delivery systems integrate biosensing functionalities which sus-
tain independently in vivo reaction control that resulting in part unique features of
the term Nanomedicine. Nanotechnology is one of the very frontiers of science
today. Current polymeric research is dominantly participating in the advancement
of nanotechnology by offering the controlled release of therapeutic agents in con-
stant doses over prolong periods, cyclic dosage, and tunable release of both hydro-
philic and hydrophobic drugs. Many biomaterials can be used to this end, offering
extensive chemical diversity and the potential for further modification using
nanoparticles. Conventional methods of drug delivery present several disadvan-
tages, mainly due to off-target effects that may originate severe side and toxic effect
to healthy tissues. New drug delivery systems based on nanoscale devices showing
new and improved properties and developed as promising solutions for achieving
desirable therapeutic efficacy. Here, we provide a broad overview of novel nanopar-
ticle based drug delivery systems, covering its innovations, applications and com-
mercialization systems using both natural and synthetic polymers.
Keywords Drug delivery • Cancer therapy • Nanoparticles • Toxicology •

Pharmaceuticals
1.1 Introduction
Various researchers are currently working on nanotechnology especially in medi-

cine and further more specifically in drug delivery. Wide ranges of materials are
under examination investigation for drug delivery and more specifically for can-
cer therapy. Potential sectors in biomedical field has started using nanoparticles
to minimize the toxicity and side effects of drugs and up to recently did not real-
ize that carrier systems themselves may impose risks to the patient. The kind of
hazards that are introduced by using nanoparticles for drug delivery are beyond
that posed by conventional hazards imposed by chemicals in classical delivery
© Springer International Publishing Switzerland 2016 1

S. Bhatia, Natural Polymer Drug Delivery Systems,
DOI 10.1007/978-3-319-41129-3_1
2 1 Nanotechnology and Its Drug Delivery Applications
matrices. For nanoparticles the knowledge on particle toxicity as obtained in

inhalation toxicity shows the way how to investigate the potential hazards of
nanoparticles. The toxicology of particulate matter differs from toxicology of
substances as the composing chemical(s) may or may not be soluble in biological
matrices, thus influencing greatly the potential exposure of various internal
organs. This may vary from a rather high local exposure in the lungs and a low or
neglectable exposure for other organ systems after inhalation. However, absorbed
species may also influence the potential toxicity of the inhaled particles. For
nanoparticles the situation is different as their size opens the potential for cross-
ing the various biological barriers within the body. From a positive viewpoint,
especially the potential to cross the blood brain barrier may open new ways for
drug delivery into the brain. In addition, the nanosize also allows for access into
the cell and various cellular compartments including the nucleus. A multitude of
substances are currently under investigation for the preparation of nanoparticles
for drug delivery, varying from biological substances like albumin, gelatin and
phospholipids for liposomes, and more substances of a chemical nature like vari-
ous polymers and solid metal containing nanoparticles. It is obvious that the
potential interaction with tissues and cells, and the potential toxicity, greatly
depends on the actual composition of the nanoparticle formulation. This paper
provides an overview on some of the currently used systems for drug delivery.
Besides the potential beneficial use also attention is drawn to the questions how
we should proceed with the safety evaluation of the nanoparticle formulations for
drug delivery. For such testing the lessons learned from particle toxicity as
applied in inhalation toxicology may be of use. Although for pharmaceutical use
the current requirements seem to be adequate to detect most of the adverse effects
of nanoparticle formulations, it cannot be expected that all aspects of nanoparti-
cle toxicology will be detected. So, probably additional more specific testing
would be needed.
1.2 Historical Prospects of Nanotechnology
Though researchers have been learning nanoscience facts for many years, scien-
tific growth in the second half of the twentieth century offers precious tools that
allows the scientist to study and develop materials in the nanoscale size range and
facilitated to formalize nanotechnology as a scientific field [1]. Historical repre-
sentation of development phases encompasses various concepts and research
work related with nanotechnology has started in the 1980s was caused by the
convergence of several experimental work e.g. the discovery of the scanning tun-
neling microscope in 1981 and the discovery of fullerenes in 1985 [1]. Based on
the explanation and wide acceptance of concepts of nanotechnology a book
called Engines of Creation publicized in 1986 [2]. Nanotechnology was first
described by the Feyman (1959), Professor, Californian institute of technology
during his lecture in American physical society. During this lecture he has used
1.3 Promising Role in Drug Delivery 3
the statements such as “There’s Plenty of Room at the Bottom” which clearly
means the prospect to create nanosize objects with the use of atoms as structural
particles was considered [3]. Presently this speech is considered as beginning of
nano-technological paradigm [3]. Later on in 1974, Taniguchi uses term “nano-
technology” at the international conference in order to explain the super thin
dispensation of objects with nanometer precision and nanosized mechanism [4].
During 1985 Harold Kroto, Sean O’Brien, Robert Curl, and Richard Smalley
(Rice University researchers) discovered the Buckminsterfullerene (C60), more
commonly known as the buckyball, which is a molecule similar to a soccer ball
in shape and composed entirely of carbon, as are graphite and diamond [5]. In the
similar year of 1985, Bell Labs’s Louis Brus revealed colloidal semiconductor
nanocrystals (quantum dots), for which he shared the 2008 Kavli Prize in
Nanotechnology [6]. In 1988 the first university course of “Nanotechnology and
Exploratory Engineering” was taught by FI’s president Eric Drexler at Stanford
[7, 8]. Carbon nanotubes discovered in 1991 by Sumio Iijima bear a resemblance
to rolled up graphite, while they cannot really be made that way [9]. During the
same period Vice President for Science and Technology, J.A. Armstrong, spoke
at the Symposium on the 100th Anniversary of the Birth of Vannevar Bush.
“I believe that nanoscience and nanotechnology will be central to the next epoch
of the information age, and will be as revolutionary as science and technology, at
the micron scale have been since the early 70’s.” In 1992 the first book published
on Nanosystems: Molecular Machinery, Manufacturing, and Computation by
K. Eric Drexler [8]. Rest events are mentioned Table 1.1.
1.3 Promising Role in Drug Delivery
Recent researches have evidenced extraordinary development of research and appli-

cations in the nanoscience and nanotechnology. There is a growing interest in the
confidence that nanoscience when functionalized in therapeutic field will certainly
pass on the significant advances in the diagnosis and treatment of disease. The most
expected functions of nanotechnology in medicine include both in vitro and in vivo
diagnostics, drug delivery, nutraceuticals and production of improved biocompati-
ble materials [39–43]. Additionally nanotechnology has also proven for their sig-
nificant applications in medical devices and other instruments utilized in medical
field. Several nanoforms especially nanoparticles with advance designs and struc-
tures act as an essential device to comprehend these applications. To comply with
medical applications considering the safe utilization of nanoparticles in medical
field the Royal Society and Royal Academy of Engineering (2004), established size
range (size ≤100 nm) for the particles that can easily comply with guidelines and
regulations and can safely used in medical field [44]. Nevertheless, such range does
not essentially influence their role in medical applications. Owing to their unique
features such as their surface to mass ratio (much larger than that of other particles),
their quantum properties and their capability to adsorb and carry other therapeutic
Table 1.1 List of historical events reported in nanotechnological science

Year Event and researchers involved Even description References
1992 C.T. Kresge and colleagues at Nanostructured catalytic materials [10]
Mobil Oil MCM-41 and MCM-48
1993 Moungi Bawendi of MIT Discovered a method for [11]
controlled production of
nanocrystals (quantum dots)
1993 First Feynman Prize in For modeling a hydrogen [12]
Nanotechnology awarded abstraction technique significant in
nanotechnology
1994 Nanosystems textbook used in Book was based on the book [13]
first university course Nanosystems: Molecular
Machinery, Manufacturing, and
Computation
1995 Foresight Institute awarded the In appreciation of revolutionary [14]
1995 Feynman Prize in work to synthesize complex
Nanotechnology to Nadrian three-dimensional structures with
C. Seeman (Ph.D., chemistry DNA molecules
professor at New York
University)
1996 NASA’s Ames Research Center NASA’s Ames Research Center is [15]
is begins work in computational becoming a significant force in
molecular nanotechnology computational molecular
nanotechnology
1996 First nanobio conference Based on “Biological approaches [16]
and novel applications for
molecular nanotechnology” was
held December 9–10, in San
Diego, CA
1997 Commercialization started by The first nanotechnology [17]
Zyvex development company, started
business
1998 First DNA-based This invention was based on the [18, 19]
nanomechanical device creation of devices from branched
pioneered by Dr. Seeman and DNA molecules This scientific
his co-workers at New York work was reported in January 1999
University issue of Nature
1999 Ho and Lee investigated facts of This work was performed with the [20]
chemical bonding by structuring help of tunneling microscope
a molecule [iron carbonyl
Fe(CO)2] from constituent
components [iron (Fe) and
carbon monoxide (CO)]
1999 Mirkin, discovered dip-pen For cell biology research, [21]
nanolithography® (DPN®) nanoencryption, and other
applications
1999 First Nanomedicine book Nanomedicine, Volume I: Basic [22]
published Capabilities 1st Edition by Robert
A. Freitas, CRC Press
(continued)
Table 1.1 (continued)

1999 First safety guidelines drafted by For Responsible Nanotechnology [23]
Neil Jacobstein Development
2000 Commercialization making use Various consumer products based [24]
of nanotechnology began on nanotechnology appeared.
appearing in the marketplace During the same time President
Clinton announces U.S. National
Nanotechnology Initiative
2001 Feynman Prize in For speculation of nanometer-scale [25]
Nanotechnology awarded electronic devices and for
production and description of
carbon nanotubes and nanowires
2002 Feynman Prize in For employing DNA to facilitate [26]
Nanotechnology awarded the self-assembly of new structures
and for advancing our skill to
represent molecular machine
systems
2003 Feynman Prize in For representing the molecular and [26]
Nanotechnology awarded electronic structures of novel
materials and for incorporating
single molecule biological motors
with nano-scale silicon devices
2003: Halas, West, Drezek, and These nanoshells when converted [27]
Pasqualin at Rice University in nano size range to absorb
developed gold nanoshells near-infrared light, provide a
platform for the innovation,
diagnosis, and management of
breast cancer without persistent
surgery, biopsies, or systemically
destructive radiation or
chemotherapy
2003 Emergence of National On December 3, 2003 Bush signed [28]
Nanotechnology Initiative or the into law the 21st Century
science, engineering, and Nanotechnology Research and
technology research and Development Act
development for nanoscale
projects
President George W. Bush
increased funding for
nanotechnology
2004 Britain’s Royal Society and the This document supports issues that [29, 30]
Royal Academy of Engineering address environmental, potential
published Nanoscience and health, ethical, social and
Nanotechnologies: regulatory issues associated with
Opportunities and Uncertainties nanotechnology
2004 Feynman Prize in For manipulating stable protein [31]
Nanotechnology awarded structures and for synthesizing a
novel enzyme with an modified
function
(continued)

2005: Winfree and Rothemund at In these theories computations are [32]
California Institute of set in the process of nanocrystal
Technology developed theories growth
for DNA-based computation and
“algorithmic self-assembly”
2005 Feynman Prize in For synthesizing various single [33–37]
Nanotechnology awarded molecular functional
nanomachines and for producing
macromolecules of intermediate
sizes with desirable shapes and
functions
2006: Tour and colleagues at Rice These nanoscale carmade was [33–37]
University built a nanoscale synthesized with oligo(phenylene
carmade ethynylene), alkynyl axles and four
spherical C60 fullerene
(buckyball) wheels
2006 Feynman Prize in For his invention in molecular [33–37]
Nanotechnology awarded computation and algorithmic
self-assembly, and for producing
complex two-dimensional arrays
of DNA nanostructures
2007 Feynman Prize in For building molecular machine [33–37]
Nanotechnology awarded systems that function in the area of
Brownian motion, and molecular
machines based upon two-state
mechanically interlocked
compounds
2008 Feynman Prize in For his achievement in molecular [33–37]
Nanotechnology awarded electronics and the production of
molecular motors and nanocars,
and for theoretical contributions to
nanofabrication and sensing
2009– Seeman and colleagues at Created several DNA-like robotic [33–38]
2010 New York University nanoscale assembly devices
2010 Andre Geim and Konstantin For groundbreaking experiments [33–37, 39]
Novoselov have just won the regarding the two-dimensional
2010 Nobel Prize in Physics material graphene, and their work
has opened a broad frontier in
nanotechnology
2011 First programmable nanowire [33–37]
circuits for nanoprocessors
2012 The National Nanotechnology Nanosensors and the [33–37]
Initiative launched two more Nanotechnology Knowledge
Nanotechnology Signature Infrastructure-bringing the total to
Initiatives five NSIs
(continued)

2014 The National Nanotechnology Progress Review on the [33–37]
Initiative releases the updated Coordinated Implementation of the
2014 Strategic Plan. The NNI 2011 Environmental, Health,
National Nanotechnology and Safety Research Strategy
Initiative releases the 2014
substances make these nanoparticles (NPs) as an attractive tool for medical pur-
poses. One of the most important features of nanoparticles that encourage their
utilization in drug delivery is relatively large surface which is functional and can
potentially bind to adsorb and carry other compounds such as drugs, probes and
proteins. Nanotechnology yet to face more challenges or establishing the better per-
ceptive of the patho-physiological basis of disease, explore more advance diagnos-
tic opportunities, and yield better treatments. Nanoparticles range comply
dimensions below 0.1 μm or 100 nm, however size >100 nm is required for loading
adequate quantity of drug onto the particles. Positive attributes of engineered
nanoparticles is that besides of their potential usage in drug delivery, drug itself can
be formulated in nano range and function as its own “carrier” [45–47]. Nanoparticles
are advantageous since they can be engineered according to the mode of delivery
and target sites. Therefore different types of engineered materials can be used for
the composition of the engineered nanoparticles such as biomaterials (phospholip-
ids, lipids, lactic acid, dextran, chitosan) can be used safely or materials those are
either synthesized or having chemical nature e.g. carbon, silica, various polymers,
and metals can be used for this purpose. Nanoparticles can be engineered according
to the type of interaction required with cells since biomaterials acts differently than
non biological components mentioned above. As a result nano engineering may
offer different nanoparticles with different chemical composition and possibility
different action. In most of events solid NPs may be used for drug targeting which
have to release the drug after reaching the intended diseased site in the body. So to
anticipate the effective drug delivery system biodegradable nanoparticle formula-
tions are required to transport and release the drug in order at specific site.
Nevertheless non-degradable particles are usually experimented in designed model
studies to determine the behavior of nanoparticles. Previous nanoparticles based
toxicity reports discovered the extreme relative toxicities obtained from inhaled
nanoparticles as part of the accidental release of ultrafine or nanoparticles by com-
bustion derived processes such as diesel exhaust particles [48–52]. It has been real-
ized that these combustion derived ultrafine particles/nanoparticles are associated
with serious health problems [53] such as blood coagulation and pulmonary immune
adjuvant effects, inflammation [54] and cardiovascular effects [52]. Since ultrafine
and nanoparticles falls under nanorange (100 nm) so both terms are equivalent,
therefore nanoparticles may be supposed of having similar toxicities as associated
with engineered nanoparticles (environmental pollutant).
1.3.1 Nanoparticles and Drug Delivery
Current nanomedicine science constitutes nanometer scale complex systems (10–

1000 nm), having two essential components. Among these two one is a active phar-
maceutical ingredient [43], whereas nanoparticle formulations of the drug itself can
also be possible [45–47]. Either of these two system results in special function
related to preventing, treating, or diagnosing diseases. Such potential system some-
times called smart-drugs or theragnostics [55]. Nano-bio-technologies aided therag-
nostics play a major role in drug delivery to achieve more specific drug targeting
and delivery, minimize toxicity profile while maintaining therapeutic effects, better
safety and biocompatibility, and faster development of new safe medicines. Selection
of suitable carrier system requires the study of following basic factors that are
involved in drug delivery and designing:
• Good understanding of biodistribution and targeting
• Good information of biocompatibility and functionality
• Knowledge of formulation stability and shelf life
• Information related with drug incorporation and release
During the drug delivery when carrier is used exclusively the possible adverse
effects of residual material should be considered. In this respect biodegradable
nanoparticles with a limited life span as long as therapeutically needed would be
optimal. There are different types of chemical structures available (natural or
synthetic) for the preparation of nanoscale [56]. However none of the carrier
system complies with the parameters discussed above to the full extent.
Therefore more development is required in polymeric chemistry and its related
nano-therapeutical applications which can provide more interesting basis to deal
with this issue in a promising way. For medicinal or diagnostic purpose nanopar-
ticles are entrapped and this entrapment results in enhanced drug delivery or
uptake by, target cells and/or to minimize toxicity of the free drug to non-target
organs. During both events increase of therapeutic index is reported which will
certainly results in enhanced therapeutic efficacy (e.g. tumor cell death) with
toxicity to other organ systems. Thus for these purposes long-lived and target-
specific nanoparticles are created. In most of the cases substances are bio-
degradable resulting in drug release after complete degradation. Most critical
problem encountered by the particulate drug carriers is their entrapment in the
mononuclear phagocytic systems that are present in the liver and spleen [57–
59]. Nevertheless, targeting of organ may be favorable as in the case of liver
targeting of nanoparticles in treating liver ailments like tumor metastasis or
hepatitis. Nanoparticles can be surface modified with polyethylene glycol which
results in its delayed retention time in the blood stream by hindering its recogni-
tion and phagocytosis by the mononuclear phagocytic system [60–62]. Moreover
PEG modification can also affect the distribution and minimize in vitro toxicity
when gold nanorods were modified using PEG. Nanoparticle coating is required
to avoid agglomeration. Different types of coating can be employed to avoid
agglomeration. This can be achieved by and keeping the particles in colloidal

suspension including various polymers like poly(vinylpyrrolidone) (PVP), poly-
ethylene glycol (PEG), etc, natural polymers like chitosan, pullulan, dextran,
etc., and surfactants like sodium dodecylamine, oleate, etc. [63]. Seki et al. dem-
onstrated that size of particle affects the NP distribution as reported for lipo-
somes for which a lower liver uptake was found for the smaller vesicles
(200/300 nm versus 25/50 nm) [64].
Slight variation in size affects the actual distribution and thus bioavailability
[65–69]. In liposomal delivery size greater than 100 nm enhances the clearance
rate by the mononuclear phagocytic system whereas charge factor is more consid-
erable for those particles that are having size less than 100 [70], however this is not
true for all particles since composition will be important as well. In addition to
degradation certain more strategies can be used to trigger the release of the drug
e.g. light and heating may be used to enhance the therapeutic effect (cell death) or
for local drug release, respectively. Thus selective release of the content after spe-
cific localization can be encouraged by using thermosensitive nanoparticles e.g. at
42 °C doxorubicin showed enhanced cytotoxicity then at 37 °C using copolymers
of poly-L-lactide (PLLA) and polyethylene glycol [71]. Furthermore the discharge
of photosensitizers from nanoparticles can be encouraged by using photodynamic
therapy. Such light dependent release can potentially induce cytotoxicity as dem-
onstrated for PLGA nanoparticles containing zinc(II) phthalocyanine [72] and
indocyanine green [73].
1.3.2 Use of NPs Formulation in Drug Delivery
Different physiological barriers, solubility of drug under in vivo conditions (dif-

ferent biological fluids), permeation rate, and environment of targeted site decides
the fate of the drug or carrier or whole formulation. Primary objective of drug
delivery is to deliver the drug at desirable place in the body thereby preventing the
potential side effects to non diseased organs. Such type of specific cellular or tis-
sue or organ mediated nanoparticulate target system is especially required in can-
cer treatment where the tumor may be localized as distinct metastases in various
organs. Undesirable cell toxicities associated with therapeutics restrict the utiliza-
tion of chemotherapeutics. Targeted drug delivery system especially local drug
delivery or drug targeting lead to increase in drug concentrations and provides
strategies for more compartment specific therapy. Owing to the unique futures of
nanoparticles such as binding and stabilization of proteins, small size which allows
penetration of cell membranes and lysosomal escape after endocytosis, it can be
used as potential tool in drug delivery to encourage more specific targeting of
organelle, cell, tissue or organ or any compartment specific in the body.
Chemotherapeutics entrapment in form of nanoparticles has been reported in vari-
ous researches [74–76].
Significant features of liposomes(nanosized phospholipid “fatty” structures)

such as small, flexible and biocompatible are explored in several reports. Such fea-
tures allow them to bypass smallest arterioles and endothelial fenestrations without
causing clotting. Currently potential materials such as (co-)polymers and den-
drimers at the nanosize range are being utilized to improve the distribution of encap-
sulated or attached drugs.
Among the anticancer chemotherapeutic agents, paclitaxel (taxol) is currently
under more intensive study due to its potential cytotoxicity against tumor cells.
Under in vitro conditions paclitaxel based nanoparticle formulation reported for its
enhanced cytotoxicity for tumor cells. In addition it has been discovered therapeu-
tic efficacy was enhanced at the same time under in vivo animal model. Furthermore
encapsulation of paclitaxel in vitamin E TPGS-emulsified poly (D,L-lactic-co-
glycolic acid) nanoparticles resulted in higher and prolonged effect then the effec-
tive concentration in vivo.
In addition to the size, surface characteristics play an important role in particle
uptake, distribution and effects. Schins et al. and Albrecht et al. studied acute and
chronic models of surface modified micro quartzes with their toxicity [77, 78].
They have observed the uptake of PVNO-polymer coated quartz by macrophages
without toxicity and showed no genotoxicity in epithelial cells or acute and chronic
inflammation whereas naïve quartz caused these effects to a great extent. Polymer
particles mediated altered body distribution for two different types of particles was
reported [79]. He has reported that after intraperitoneal administration PMMA
particles having size range of about 1.4 μm and about 6.4 μm can be easily recov-
ered in contrast with PS particles having size of about 1.2, 5.2 and 12.5 μm from
the spleen. So far this situation hasn’t applied over nano range, however surface
modification of polystyrene particles suggest various effects on cellular oxidative
[80], mitochondrial ROS formation and burst blood coagulation [81]. Moreover
polyethylene glycol coated nanoparticles enhance the time in circulation for the
nanoparticles [60–62]. Primary objective of entrapment of drug is to reduce toxic-
ity of the free drug to non-target organs and ultimately to enhance delivery to, or
uptake by, target cells. To achieve these set of goals establishment of long-lived
and target-specific nanoparticles is required. Entrapment of nanoparticles in the
mononuclear phagocytic system as present in the liver and spleen is a major set-
back during nanodrug delivery system [57, 59, 82, 83]. Nevertheless liver targeting
is encouraged during the treatment of disease like tumor metastasis or hepatitis.
Certain drugs are supposed to be transported to liver such as migration of oligo-
nucleotides for modification of gene expression when bound to biodegradable
polyalkylcyanoacrylate nanoparticles [84]. As suggested earlier PEG mediated
surface modification of nanoparticles reduces recognition and phagocytosis by the
mononuclear phagocytic system [59–62].
Decline in therapeutic efficacy and inference with liver function was reported
after the entrapment of drug in form of nanoparticles. Fernandez-Urrusuno et al.
reported the transient liver alterations after acute and chronic intravenous adminis-
tration of cyanoacrylate and polystyrene nanoparticles [57]. He has also reported

the liver associated inflammation after secretion of acute phase protein α1-acid gly-
coprotein by hepatocytes. Noticeably owing to the local release of oxidative species
antioxidant defenses of hepatocytes were depleted. In contrast a study based on the
comparative evaluation between insulin-chitosan nanoparticles to chitosan solution
and chitosan powder formulations shown that insulin-chitosan nanoparticles were
less effective in terms of bioavailability and lowering blood glucose level in both a
rat and sheep mode [82]. This study has proven the potential of nanoformulation in
enhancing drug delivery without loss of drug activity.
1.3.3 Cellular and Intracellular Targets
In addition role of organ or cellular targeting, the fate of the nanoparticles within the
cells also decides the effectiveness for drug delivery system. Nanoparticles usually
suffer from intracellular degradation in endosomes or lysosomes. Therefore for
exhibiting the potential activity the drug should be designed/ encapsulated to
encourage their release into the cytosol. In contrast Edetsberger et al. demonstrated
that the particle size of about 20 nm escape from cellular uptake without involve-
ment of endocytic mechanisms [83]. Since it has been reported that chemical fea-
tures (e.g. surface charge) also determine the fate of nanoparticles in cells which
may results in efficient internalization in endosomes and cytosol, and localization in
the nuclear region [84]. This was found in surface functionalization of gold nanopar-
ticles with PEG resulted in effective internalization. Certain nanoparticles such as
poly(DL-lactide-co-glycolide) nanoparticles couldn’t be able to escape from endo-
somes hence ingested by cells by endocytosis [85]. Therefore change in surface
charge is required to escape nanoparticle from these endosomes into the cellular
cytoplasm. This concept was implemented over PLGA nanoparticles to allow their
escape from endosomes and resulting in cytoplasmic delivery of the incorporated
drugs. Theory of easy escape of positive surface charge nanoparticles from the
endosomes was supported by Panyam et al. [86]. In contrast with positively charged
he has suggested that negatively charged polystyrene nanoparticles did not reach the
cytosol but remained in the endosomal compartment of the smooth muscle cells.
Bourges et al. suggested that there is a possibility of specific targeting to retinal
pigment epithelium cells [87]. Åkerman et al. developed the small quantum dots
having size less than (<10 nm), for specific targeting of peptide coated dots to the
vasculature of lungs and tumors [88]. Additionally conjugation of polymer shells
with quantum dots was later studied by Ballou et al. [89]. In this report he has
described the role of quantum dots cores coated with hydrophilic polyethylene
glycol to trigger the half life time. Nevertheless drug passage in to by lymph nodes
was demonstrated by Ballou et al. [89]. In this study translocated quantum dots
could be examined up to 4 months after administration. Therefore greater chances
of accumulation were observed. It has been reported that polymeric coating espe-
cially with PEG abolishes the uptake of drug by the reticuloendothelial system of
liver and spleen whereas 40–50 nm magnetic PEG coated nanoparticles were well
taken up by endocytosis [90].
Weissenböck et al. adopted the strategy to increase cellular binding by carbohy-
drate binding ligands on the surface of biodegradable and biocompatible poly(D,L-
lactic-co-glycolide) acid (PLGA) nanospheres [91]. Such enhancement in cellular
binding may results in enhanced activity of the drug presented as or incorporated in
nanoparticles. Moreover it has been reported that conjugation of specific protein
e.g. with antibodies to the nanoparticle surface may allow a more specific targeting
of the particles [92, 93]. Ultimately it has been concluded that surface modifications
of nanoparticles offer enormous opportunities for medical applications like uptake,
intracellular transport and drug targeting in terms of cellular binding.
1.3.4 The Brain—The Ultimate Target for Drug Delivery
From several perspectives the brain is a challenging organ since incidence of degen-
erative diseases in the brain will increase with the aging population and secondly
blood brain barrier (BBB) found to act as rate limiting factor in drug delivery to
brain in fighting against various the central nervous system (CNS) disorders. The
most critical issue in brain drug delivery is that the blood brain barrier fence interior
from the exogenous substances [94]. Blood brain barrier is equipped with some
limiting physiological factors such as reticuloendothelial system and protein opso-
nization, which play major role in decreasing the transport of drug. Usually almost
all therapeutic drugs including small molecules do not cross the blood brain barrier.
From brain physiology point of view endothelial barrier is having tight junctions at
the interface with the brain astrocytes. Some of the alternative mechanisms can be
adopted to facilitate the transport in normal conditions such as using endogenous
BBB transporters resulting in active efflux transport, receptor mediated transport
and carrier mediated transport. Nevertheless utilization of drug in form of nanopar-
ticles facilitate transport of drug by compromising barrier properties intentionally or
unintentionally [95–97]. Several approaches employed to improve the drug delivery
across the BBB. Owing to its size (ranges from 1 to 1000 nm), functionalization
characteristics and ability to reduce the need for invasive procedures can be utilized
as career for drug delivery and found to play a significant advantage over the other
methods of available drug delivery systems to deliver the drug across the
BBB. Various mechanisms and strategies involved in this process. These strategies
are exclusively based on the on the type of nanomaterials used and its combination
with therapeutic agents (such materials include non-viral vectors of nano-sizes for
CNS gene therapy, polymeric nanoparticles and liposomes, etc.). Olivier et al. sug-
gested that transport of the drug across blood brain barrier can be possible by the
toxic effect of nanoparticles (about 200 nm) on cerebral endothelial cells, while
Kreuter et al. contradicted this study by utilizing similar nanoparticles with size
range about 300 nm [95, 96]. Moreover Lockman et al. reported that effect was not
common for a different type of nanoparticles [97]. Due to the reported ill effects of
nanoparticles some devices such as implanted catheters and reservoirs are encour-
aged in effective drug delivery to the CNS. Currently several researchers are work-
ing on different nanomaterials to improve the safety and efficacy level of drug
delivery devices in brain targeting. It’s advisable to determine the physical and
chemical association between drug, carrier, excipients and desired organelle, para-
site, cell, tissue and receptor, for drug delivery into the brain. Transport of nanoen-
gineered device at cellular levels can be achieved by -fluidic channels [96]. Various
drug delivery systems such as nanoparticles, nanogels, liposomes, microspheres,
and nanobiocapsules have been employed to improve the bioavailability of the drug
in the brain. However, so far, biodegradable polymeric nanoparticulate careers and
microchips are found to be more effective therapeutically in treating brain tumor.
Distinct strategies based on physiological concepts can also be employed to stimu-
late the transcytosis ability of specific receptors expressed across the BBB. According
to reports low density lipoproteins related protein with engineered peptide com-
pound created an area for introducing Angiopep peptide as a new potential
therapeutics.
Previous studies have determined that nanoparticles having different surface
characteristics such as neutral nanoparticles and particles having low concentrations
of anionic nanoparticles were found to have no effect on BBB integrity. In contrast
NPs with high concentrations of anionic nanoparticles and cationic nanoparticles
were toxic for the BBB. It was later discovered that neutral or cationic nanoformula-
tions showed lesser uptake in brain in contrast with anionic nanoparticles at low
concentrations exhibit higher uptake in brain. It has been concluded that surface
charge of nanoparticle plays an important role in determining toxicity and brain
distribution profiles [97]. Surfactant assisted transport of nanoparticle across the
blood brain barrier was recently reported with the polysorbate (Tween) surfactants.
Coating of nanoparticle with polysorbate (Tween) surfactants stimulates endocyto-
sis mechanism via the Low Density Lipoprotein receptor of the endothelial cells
after adsorption of lipoproteins form blood plasma to the nanoparticles [98].
Moreover it has been further revealed the function of apolipoprotein-E for carry
drugs across the BBB. However failure in transportation of drug across the BBB
occurs when apolipoprotein-E variants that did not recognized lipoprotein receptors
[99]. Later on it was realized that recognition and interaction with lipoprotein recep-
tors on brain capillary endothelial cells plays an important role in brain uptake of
the drug. Transport of several drugs can also be attained by masking their features
or limiting their binding efficiency/sites to cellular efflux systems e.g. p-glycoprotein.
Binding of drug with p-glycoprotein limits its cellular transportation and encourage
the drug removal from cells. P-glycoprotein belongs to ATP dependent efflux trans-
porters that plays have a major role in preventing delivery into the brain [100].
P-glycoprotein role become more critical in drug resistant tumor cells where there
expression becomes high and act as multidrug resistance protein to limit the entry
of drug inside the cell. It was observed that entrapment of certain cytotoxic drug
such as in surfactant coated nanoparticles increases the brain drug uptake and its
toxicity towards p-glycoprotein expressing tumor cells. Alyautdin et al. reported
that surfactant coated poly(butyl) cyanoacrylate nanoparticles have been used to
deliver drugs to the CNS [101]. Similarly Koziara et al. determined the effect of
entrapment of a cytotoxic drug paclitaxel in cetyl alcohol/polysorbate nanoparticles
and further he hypothesized that paclitaxel nanoparticles restrict paclitaxel conjuga-
tion to p-glycoprotein and successive efflux from the cells [102]. This hypothesis
led down conclusion which would consequently trigger the brain and tumor cell
drug levels. Many other additional routes to deliver the drug in brain which could
circumvent the BBB such as via migration along the olfactory or trigeminal nerve
endings could only possible after the deposition on the olfactory mucosa in the nasal
region [103]. This procedure was experimented by translocation of ultrafine 13C
particles in the brain olfactory bulb after inhalation exposure. Based on amount of
manganese present in different parts of the brain, Elder et al. demonstrated the role
of solid NP like manganese oxide to translocate to the brain by the olfactory route
[104]. In subsequent report nanoparticles have been functionalized by conjugation
with bioactive ligands-lectins to the surface of poly (ethylene glycol)-poly (lactic
acid) nanoparticles to trigger specific uptake via the inhalation route nanoparticles.
Similarly Gao et al. utilized wheat germ agglutinin to enhance the brain uptake of
such functionalized NP by encouraging their binding with N-acetyl-D-glucosamine
and sialic acid. Nevertheless transport of drug across BBB and the olfactory route
only report for up to 2 % nanoparticles uptake in contrast with the drug delivery that
desires to make substantial increments prior to use [105].
Latest concepts and techniques should be applied to design and develop the drug
delivery careers for efficiently delivering the drug across the BBB at a safe and
effective manner. Among all current advance delivery systems nanoparticles are
found to be the most effective careers in delivery of conventional drugs, vaccines,
recombinant proteins, as well as nucleotides. Drug features such as pharmacoki-
netic properties (such as biodistribution, bioavailability and drug release character-
istics) can be improved by nanoparticulate drug delivery systems. Nanoparticulate
drug delivery systems allow the controlled and effective release of the drug with site
specific drug delivery targeting to tissue or cell with reduced side effects. Hence
application of nanotechnology in pharmaceutical biotechnology facilitates the
development in drug delivery strategy to explain the delivery problems of protein
based drugs including oligonucleotides and recombinant proteins.
1.4 Innovations in Nanotechnology
Revolution has started in 1989, when IBM researchers established a scientific

invention by building 35-atom depiction of the company’s logo at nano scale.
Nanomaterials are the objects having size range of at least one dimension of
1.4 Innovations in Nanotechnology 15
100 nm or less. This size range is approximate size of your average virus.
Nanotechnology field encompasses creation, manipulation, and application of
materials at the nanoscale. Additionally it may also involve the capability to engi-
neer, control, and exploit the unique chemical, physical, and electrical properties
of these nano scale particles. As far as the their properties are concerned nanopar-
ticles neither behave like solids, liquids, nor gases and exist in the world of quan-
tum physics, and small enough escape the laws of Newtonian physics. This feature
makes them more conductive, reactive and optically sensitive among others.
Nanotechnology is considered as the most powerful technology to bring “the next
Industrial Revolution.” “That’s why nanomaterials are useful and interesting and
so hot right now,” says Kristen Kulinowski, executive director for education and
policy at the Rice University Center for Biological and Environmental
Nanotechnology (CBEN). Being in this quantum regime enables new properties
to emerge that are not possible or not exhibited by those same chemicals when
they’re much smaller or much larger. These include different colors, electronic
properties, magnetic properties, mechanical properties depending on the particle;
any or all of these can be altered at the nanoscale. That’s the power of nanotech.
The National Nanotechnology Initiative, federal government program for the sci-
ence, engineering, and technology research and development for nanoscale proj-
ects, has predicted the field will be worth $1 trillion to the U.S. economy alone by
2015 or sooner. Noticeably, nanotech is balanced to develop into a major factor in
the world’s economy and part of our everyday lives in the near future. In future,
draft science is going to be very giant, shortly. Owing to its widespread it’s very
difficult to trace the application of nanotechnology, although we can consider
some of the recent events of nanotechnology and the most considerable achieve-
ments. Nanotechnology solutions are already beginning to shape industries like
electronics, medical technologies, advanced materials, or pharmaceuticals.
Nanotechnology can be connected to world’s most serious advance issues/prob-
lems. Nevertheless there has been no organized precedence of applications of
nanotechnology that can be directed towards the most critical issues face by the
five billion people from developing world.
In order to strengthen their capacity and sustain economic growth [106], sev-
eral developing countries have launched nanotechnology initiatives. Department
of Science and Technology, India invested $20 million from (2004–2009) for their
Nanomaterials Science and Technology Initiative [107]. China ranks third in num-
ber of nanotechnology patent applications whereas United States and Japan ranked
still saving its first two positions [108]. According to previous report Brazil, pro-
jected budget for nanoscience during the 2004–2007 period was found to be is $25
million [109]. Organizations that belong to South African Nanotechnology
Initiative are involved in areas such as nanophase catalysts, nanofiltration, nanow-
ires, nanotubes, and quantum dots. Some other developing countries such as the
Philippines, Chile, Argentina, Thailand, and Mexico, are also practicing nano-
technology [106]. It’s very difficult to address all the events progressing in nano-
technology, though it’s possible rank the ten applications of nanotechnology most
likely to benefit developing countries, and demonstrate that these applications can
contribute to the attainment of the United Nations Millennium Development
Goals (MDGs) as suggested by Salamanca-Buentello et al. [110]. To encourage
more advance innovations in nanotechnology Salamanca-Buentello et al. also pro-
posed a way for the international community to accelerate the use of these top
nanotechnologies by less industrialized countries to meet critical sustainable
development challenges [110]. Salamanca-Buentello and his coworkers explored
Correlation between the Top Ten Applications of Nanotechnology for Developing
Countries and the UN Millennium Development Goals [110]. Salamanca-
Buentello and his coworkers identified and ranked the ten applications of nano-
technology most likely to benefit developing countries [110]. These applications
provide systematic approach with which to address sustainable development
issues in the developing world. Salamanca-Buentello and his coworkers used
modified Delphi Method to identify and prioritize the applications. They have
addressed top ten applications of nanotechnology and compared with the UN
Millennium Development Goals. These applications covers energy storage, con-
version and production, agricultural productivity enhancement, water treatment
and remediation, disease diagnosis and screening, drug delivery system, food pro-
cessing and storage, air pollution and remediation, construction, health monitor-
ing, vector and pest detection and control.
1.5 Nanotechnology Theory to Applications
Nanotechnology is serving to significantly develop, even reform, many technol-

ogy and industry areas. It has significant applications in information environmen-
tal science, medicine, technology, energy, food safety, homeland security, and
transportation, among many others. Nanotechnology act as a significant tools in
food industry for detection of pathogen, disease treatment delivery systems, food
packaging, and delivery of bioactive compounds to target sites. This wide applica-
tion generates novel methods to improve safety and the nutritional value of food
products [111].
In addition to food industry, nanotechnology also involved in design, produc-
tion, characterization, and application of materials and such devices that are hav-
ing significant applications in medicine [112]. Nanotechnology applications to
medicine and physiology involve materials and devices that are perfectly designed
to interact with the body at subcellular (i.e., molecular) scales with a high degree
of specificity. Such application cab effectively transform into targeted cellular and
tissue-specific clinical applications considered to attain therapeutic affects with
least side effects.
Nanotechnology can also be employed in various surgical procedures to treat
human cancers. Additionally nanotechnology is the single most prominent fore-
caster of patient survival is a complete surgical resection [113]. These innova-
1.5 Nanotechnology Theory to Applications 17
tive technologies can assist the surgeon to describe tumor margins, to identify
residual tumor cells and micrometastases, and to verify if the tumor has been
entirely removed. Recent advances in nanotechnology and optical instrumenta-
tion, advances can be integrated for applications in surgical oncology, achieved
by nanometer-sized particles such as quantum dots and colloidal gold.
Conjugation of such nanoparticles with targeted ligands such as monoclonal
antibodies, peptides, or small molecules allows to target malignant tumor cells
and tumor microenvironments with high specificity and affinity. Singhal et al.
have reported that the size range of 10–100 nm (mesoscopic) nanoparticles hav-
ing large surface areas for conjugating to multiple diagnostic and therapeutic
agents, opening new possibilities in integrated cancer imaging and therapy.
There are so many reports [114].
Saini et al. reported possible mechanism of nanotechnological procedures in
relation to medicine, in which he has described various materials and devices that
were designed to interact with cells and tissues at a molecular (i.e., sub cellular)
level, for applications in medicine and physiology, with a high degree of functional
specificity, thus allowing a degree of integration between technology and biological
systems not previously attainable [114].
The most appreciable thing of nanotechnology is to unite different traditional
sciences, such as, chemistry, physics, materials science and biology, to bring
together the required collective expertise needed to develop these novel technolo-
gies [114]. To achieve this nanotechnology carry is versatile function by offering
not only improvements to the current techniques, but also providing entirely new
tools and capabilities.
• Alteration in solubility and blood pool retention time
• Controlled release over short or long durations
• Environmentally triggered controlled release or highly specific site-targeted
delivery
Potential of nanotechnology can also be employed in construction industry
where amazing chemical and physical features of materials (at the nanometer scale)
allows new array of application such as structural strength enhancement, energy
conservation to antimicrobial properties and self-cleaning surfaces [115]. Therefore
manufactured nanomaterials and nanocomposites are being considered for various
uses in the construction and related infrastructure industries. It’s essential to con-
sider the lifecycle impacts of manufactured nanomaterials on the health of con-
struction workers and dwellers; therefore it’s more important to achieve
environmentally responsible nanotechnology in construction. Such development of
environmentally friendly nanotechnology products avoids environmentally respon-
sible nanotechnology [115]. Lee et al. reported applications of manufactured nano-
materials that improve conventional construction materials, promote the
environmentally friendly nanoproducts with reduced adverse biological and toxico-
logical effects and their mitigation [115]. Various applications of nanotechnology
in different areas are mentioned in Table 1.2.
Table 1.2 Applications of nanotechnology in different domain

Area Applications
Everyday material and • Nanoscale additives in polymer composite materials and for
processes surface treatments of fabrics
• Nanoscale thin film
• Nanoscale materials in cosmetic products
• Nano-engineered materials in the food industry, in automotive
products and to make superior household products
• Nanostructured ceramic coatings
• Nanoparticles are used increasingly in catalysis
Electronic and • Applications of nanotechnology in computing and electronic
information technology products include, ultraresponsive hearing aids flash memory chips
application for iPod nanos conductive inks for printed electronics for RFID/
smart cards/smart packaging, flexible displays for e-book readers
more life-like video games, antimicrobial/antibacterial coatings
on mouse/keyboard/cell phone casings
• Magnetic random access memory (MRAM)
• Nanoscale transistors
• Nanostructured polymer films known as organic light-emitting
diodes for the displays for many new TVs, laptop computers, cell
phones, digital cameras, and other devices incorporate
Sustainable energy • Prototype solar panels incorporating nanotechnology
applications • Nanotechnology is improving the efficiency of fuel production
• Nano-bioengineering of enzymes
• Nanotechnology for development of advanced batteries
• Nanostructured materials to improve hydrogen membrane and
storage materials and the catalysts
• Nanotechnology in thin-film solar electric panels to power mobile
electronic devices
Environmental remedial • For affordable, clean drinking water
applications • To clean industrial water pollutants in ground water
• Nanofabric “paper towel,” woven from tiny wires potentially
absorb 20 times its weight in oil for cleanup applications
• Nanotechnology-based filters that allow “mechanical filtration”
• Novel nanotechnology-enabled sensors and solutions to detect,
identify, and Filter out, and/or neutralize harmful chemical or
biological agents in the air and soil with much higher sensitivity
Nanobiosystem, • Quantum dots for enhancing biological imaging for medical
medical and health diagnostics
applications • For diagnosis of atherosclerosis, or the buildup of plaque in
arteries
• Gold nanoparticles to detect early-stage Alzheimer’s disease
• Molecular imaging for the early detection
• Multifunctional therapeutics to facilitate its specific targeting to
cancer cells
• Microfluidic chip-based nanolabs for monitoring and
manipulating individual cells and nanoscale probes,
• Nanotechnology to encourage the growth of nerve cells
(continued)
1.6 Nanomedicine/Nanoscience/Nano-Engineering and Relationship with Drug Delivery 19

Area Applications
Future transportation • Nano-engineering of concrete, steel, asphalt, and other
technologies cementitious materials, and their recycled forms
• Nanoscale sensors and devices for cost-effective continuous
structural monitoring of the condition and performance of bridges,
tunnels, rails, parking structures, and pavements over time
1.6 Nanomedicine/Nanoscience/Nano-Engineering
and Relationship with Drug Delivery
1.6.1 Nanomedicine and Drug Delivery
Emergence of nanotechnology in medicine led to the exploration of more specified

drug delivery systems in pharmaceutical sciences. Currently better understanding
has been established between nanomedicine and its drug delivery applications in
pharmaceutical sciences to minimize toxicity and side effects of drugs. Exploration
of such cell/tissue specific drug delivery system avoids the health hazards that some
time occur due to the carrier systems themselves that may impose risks to the
patient. In last few years several reports have been come up with a conclusion of
health risks associated with nanoparticles and associated their preventive measures.
Therefore currently various substances are under examination for drug delivery.
More interestingly type of health risks that are caused by using nanoparticles for
drug delivery are ahead of that caused by conventional hazards introduced by chemi-
cals in traditional delivery matrices. More understanding is required to investigate the
nanoparticle toxicity and its potential hazards as in the case of inhalation toxicity.
Risks associated with nanoparticulate materials may vary from toxicology of sub-
stances since the composing chemical(s) may or may not be soluble in biological
matrices. Therefore their solubility issues greatly influence their potential exposure
against various internal organs. Considering this aspect nanoparticulate systems
when administered through the most critical route such as lungs get high exposure in
the lungs and a low exposure for other organ systems after inhalation. Since these
nanoparticles are more specified therefore accumulation or absorption in undesirable
organs may cause potential toxicity. Lungs is an organ where exchange off oxygen
occurs, accumulation of drug or nano matrix may influence the potential effects of
drug and may generate toxic products at different interface. In contrast the positive
facts about nanoparticles is their size which may offer opportunities of crossing the
various biological barriers within the body such as their potential to cross the blood
brain barrier may open new ways for drug delivery into the brain. Moreover small
size of these particles permits their entry into the cell and various cellular compart-
ments such as nucleus. Various natural and synthetic substances are under investigation
for the preparation of nanoparticles for drug delivery such as biological substances
(albumin, gelatin and phospholipids), and more substances of a chemical nature like
various polymers and solid metal containing nanoparticles. These substances are
selected according to the desirable target, diagnosis procedure, and clinical condi-
tions, type of tissue or cell, type, organ, type of drug (physic-chemical aspects),
ingredients and delivery device and type of biological barrier. The most understand-
able fact is that the real composition of the nanoparticle formulation always decides
the possible interaction between with tissues and cells, and the potential toxicity.
1.6.1.1 Advantages of Nanoparticles for Nanomedicine
• Nanoparticles used for therapeutic purposes fulfill with the newly projected and cur-
rent accepted general definition of a size ≤100 nm [44]. Nevertheless, this does not
essentially have an influence on their functionality in therapeutic applications. The
royal society and the royal academy of engineering. Nanoscience and nanotechnolo-
gies: opportunities and uncertainties. London, UK: 2004.
• Nanoparticles are considered as attractive therapy for several medicinal purposes
since these nano based particles are having important and exclusive features,
such as their quantum properties and their ability to absorb, their surface to mass
ratio that is much larger than that of other particles and carry other compounds.
• Nanoparticles have a comparatively large (functional) surface which is able to
bind, adsorb and carry other compounds such as drugs, proteins and probes.
• These nanoengineered particles not only used for drug delivery as carrier, but
also the drug itself may be formulated at a nanoscale, and then function as its
own “carrier” [39, 45–47].
1.6.1.2 Challenges
• More improved understanding of the patho-physiological basis of disease is

required which will bring more sophisticated diagnostic opportunities, and cer-
tainly increase the whole cost the therapy
• Significant dimensions (below 0.1 μm or 100 nm) of nanoparticles doesn’t allow
sufficient loading of drug onto the particles.
• Some of the serious health risk associated with nanoparticles need to be resolved
such as exposure of biological materials with inhaled nanoparticles as part of the
unintended release of ultrafine or nanoparticles by combustion derived processes
such as diesel exhaust particles [48, 49, 51–54, 116–118]. Exposure to these
combustion derived ultrafine particles/nanoparticles is associated with a wide
variety of effects [53] including pulmonary inflammation, immune adjuvant
effects [54] and systemic effects including blood coagulation and cardiovascular
effects [52, 116].
1.6 Nanomedicine/Nanoscience/Nano-Engineering and Relationship with Drug Delivery 21
1.6.2 Nanoengineering and Drug Delivery
Nanoengineered drug delivery systems (nDDS) are those systems in which nanopar-
ticulate system or its environment is modified or manipulated to avoid the in limita-
tions induced by general nanoparticles. Currently nDDS is used as potential clinical
tools for modulation of pharmacological drug release profile and for but specific
targeting of diseased tissues especially cancer tissue or cells [119]. Till date various
anticancer drugs such as doxorubicin, paclitaxel, and vincristin has been the main
target of nDDS. Liposomes and polymer-drug conjugates are known to be the most
accepted group of nDDS used for this purpose. Nano engineering procedure require
careful selection and optimization of the different factors that affect drug release
profile (i.e. type of biomaterial, size, system architecture, and biodegradability
mechanisms) along with the selection of an appropriate manufacture technique that
does not compromise the desired release profile, while it also offers possibilities to
scale up for future industrialization [119].
Nano engineering or manipulation of drug delivery system can be achieved at
various levels during the formulation of drug within a carrier e.g. modulation of
drug environment at molecular level, alteration of physic-chemical characteristics
of the drug, control of diffuse mobility, and modification of bulk and surface chem-
istry of nano carrier [119]. These approaches are successful enough in establishing
favorable therapeutic end points such as enhanced drug efficacy for prolonged
period, reduced drug toxicity; reduce dosage and cost burden and improved patience
compliance [119].
nDDS comprised of various controlled and triggered release systems such as
polymeric drug delivery system and lipid based drug delivery systems for sustained
and triggered release. This can be achieved by the modulation of drug environment
and physico-chemical properties, enhancement of drug stability and duration of
activity which may further includes formulation processing strategies and poly-
meric strategies [119]. For specific targeting of therapeutics to disease sites, for
maximizing effective dose and from sparing health risks from various adverse
effects, several strategies have been adopted such as active and passive tissue target-
ing and strategies for transport across the tight endothelial junctions [119].
In 1999 Allen et al. describes the properties of block copolymer micelles which
influence their efficiency as drug delivery vehicles for hydrophobic drugs. In this
review he has explained properties such as loading capacity, release kinetics, circu-
lation time, biodistribution, size, size distribution and stability to promote research-
ers to tailor-make block copolymer micelles for a particular application [120].
Various researchers considering nanoengineered drug delivery systems as a
potential strategy to overcome limitations associated with antibiotic drug therapy. It
has been reported that antibiotics encapsulated into nanodelivery systems play sig-
nificant role in overcoming the serious global burden of antibiotic resistance and
provide improved management to patients with various infectious diseases [121].
According to previous reports there are several antibiotic-loaded nanocarriers that
have been formulated to target drugs to infectious sites, achieve controlled drug
release profiles, and address formulation challenges, such as low-drug entrapment
efficiencies, poor solubility and stability [121]. Additionally the in vitro/in vivo per-
formances and physicochemical properties of various antibiotic-loaded delivery
systems (polymeric nanoparticles, micelles, dendrimers, liposomes, solid lipid
nanoparticles, lipid–polymer hybrid nanoparticles, nanohybirds, nanofibers/scaf-
folds, nanosheets, nanoplexes, and nanotubes/horn/rods and nanoemulsions) should
be evaluated [121]. Future investigations is required to optimize formulation and
commercialization of these antibiotic-loaded nanosystems to develop the most
effective nanoengineered antibiotic drug delivery systems for enhancing the treat-
ment of patients with a range of infections.
Owing to its unique features such as its potential in the formation of supramo-
lecular biomaterials through inclusion complexes as part of drug delivery systems,
moderate drug solubility, drug stability and absorption, cyclodextrin is now
considered as excipients in the formulation of drugs and played a pivotal role in
designing novel drug delivery systems such as liposomes, dendrimers, nanosponges,
microspheres and nanoparticles. Recent reports have proven that molecular
complexation involving cyclodextrins is expected to reduce or eliminate some prob-
lems associated with novel drug delivery in the field of nanotechnology [122].
Various applications of nanomedicines are highlighted in Fig. 1.1.
Neuro-electronic
interfacing (nanoscale
enzymatic biofuel cell) Targeted therapy
Nanonephrology
Bone tissue engineering Localized therapy
applications Medical devices Cancer diagnosis
Homing on tumor
Photodynamic therapy
Tissue
Liposomes Cancer
engineering
Abraxane, Doxil, C-dots Commercially NANO Carbon nanowires

(Cornell dots), Minicell available/human Dendrimers MEDICINE Nanoelectro Biosensor & nanotubes
nanopartice, clinical trials mechanical Technology for
Nanoparticleloteprednol based nano drugs biorecognition
etabonate
Visualization Nanoshells Sensing
In vivo imaging Lab-on-a-chip

Nonaparticle contrast Blood purification technology
agents
Quantum dots Magnetic nanoparticles
PK of drug, Tumors Magnetic micro
MRI particles
Magnetic-activated cell
sorting or Dynabeads
Dark gray: Building blocks of
Iron oxide or carbon nanomedicine
coated metal
nanoparticles Light gray: Applications of
with ferromagnetic or nanomedicine
superparamagnetic
properties
Fig. 1.1 Nano medicine and its applications

1.7 Types of Nanodelivery: Natural or Synthetic 23
1.7 Types of Nanodelivery: Natural or Synthetic
Natural and synthetic are the two types of polymers that can be used for nanodeliv-
ery. Natural polymers or biopolymers are directly obtained from natural resources
such as green plants, animals, algae, bacteria and fungi are polymers or polymer
matrix composites. Synthetic polymers are those polymers that are refined or modi-
fied or synthesized in laboratory by using different chemical of more often basic
structure of natural polymers can be modified to avoid the limitations incurred dur-
ing the drug delivery. Collagen while synthetic polymers from the ester family.
Currently natural and synthetic polymers are extensively used for nanoparticles
design and synthesis. Owing to outstanding advantages of high purity and reproduc-
ibility over natural polymers, synthetic polymers such as poly(-caprolactone)
(PCL), poly(lactic acid) (PLA), poly(lactide-co-glycolide) (PLGA), poly(glycolic
acid) (PGA), poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), poly
(-hydroxybutyrate) (PHB), or other families such as poly(cyanoacrylates), poly
(p-dioxanone) (PPDO), poly(acrylic acid) (PAA), poly(amides) (PA), poly(anhydrides),
poly(ethylene glycol) (PEG), poly(ortho esters) (PES), and poly(vinyl alcohol)
(PVA), are usually recommended in most of the research. These polymers are suit-
able for drug delivery due to their special release profiles biodegradability, and bio-
compatibility [123, 124]. Additionally PLGA has been approved by Food and drug
administration (FDA) for human therapy.
1.7.1 Synthetic Polymers
Emulsion techniques and/or solvent exchange, salting out, freeze drying or spray
drying of the emulsion and supercritical fluid technology are the principal methods
used to formulate and manufacture polymeric particles. Noticeably multiple-
emulsion spray-drying technique has potential advantages over freeze-drying tech-
nique such as it’s more convenient and reproducible, rapid, and can easily be scaled
up. Therefore these methodologies can be modified with the objective of encapsu-
lating hydrophilic or hydrophobic drugs into particular polymeric nanoparticles.
Utilization of synthetic polymers is encouraged owing to their ability to modify the
functional groups and the versatility in the preparation techniques. Additionally
polymeric nanoparticles give more response against different stimuli has been of
big advantage for targeted delivery systems.
1.7.2 Natural Polymers
Due to some unique and relatively safe features of biocompatibility, biodegradability,

abundance in nature, inexpensive than bioresorbable synthetic polymers interest has
been generated to produce nanoparticles using natural polymers with aim to
Table 1.3 Advantages and disadvantages of natural and synthetic polymers

Natural polymer Synthetic polymer
Cellulose, starch, chitosan, Synthetic polymers from the ester family such as poly(lactic
carrageenan, aliginates, acid) (PLA), poly(cyanoacrylates) (PACA), poly(acrylic acid),
xantham gum, gellan gum, poly(anhydrides), poly(amides), poly (ortho esters),
pectins poly(ethylene glycol), and poly(vinyl alcohol) (PVA) and other
like poly(isobutylcynoacrylate) (PIBCA), poly(ethylene oxide)
(PEO), poly(åcaprolac-tone) (PCL)
Advantages Advantages
• Less toxic • Biocompatibility
• Biocompatibility
• Biodegradable
• Easily available
Disadvantages Disadvantages
• High degree of • Toxic
variability in natural • Non degradable
materials derived from • Synthetic process is very complicated and high cost
animal sources
• Structurally more
Complex
• Extraction process very
complicated and high cost
encourage their use in drug delivery for exploring more advance pharmaceutical
applications against different indications. The most extensively used natural poly-
mers in drug delivery systems include alginate, chitosan, gelatine, albumin and col-
lagen. Different types of procedures are adopted to make natural polymer-based
nanodevices. Selection of the technique is based on the nature of the active com-
pound, the polymer and the specifications of the nanoparticles, such as size, zeta
potential and encapsulation efficiency. Among all the most extensively used tech-
niques include emulsion-cross linking, coacervation and ionotropic gelation. Different
advantages and disadvantages of natural and synthetic polymers are mentioned in
Table 1.3.
1.8 Natural and Synthetic Polymeric Nanoparticles
Collective term nanoparticle constitute nanospheres and nanocapsules which are

made up of solid carriers that can be either made up of natural or synthetic polymers
and whether or not biodegradable. These solid carriers potentially encapsulate
Drug/gene by embedding into the matrix or absorbed onto the surface of nanopar-
ticles. Because of their therapeutic potential and greater stability in biological fluids
as well as during storage nanoparticles have received more consideration than have
liposomes [125]. In addition high encapsulation efficiency, provide fencing drug
against degradation from the external environment and use the exclusive
1.8 Natural and Synthetic Polymeric Nanoparticles 25
micro-anatomy of the inflamed tissue blood capillaries, which have gaps between
the lining of endothelial cells causing vessel leakiness [126]. There are several fab-
rication methodologies available for nanoparticles however these methods use safe
solvents for industrial application. Solvents like DMSO, DMF are known are hav-
ing the tendency to dissolve many insoluble drugs but there cost and toxicity pose
their utilization for any therapeutic purpose especially when the process of nanopar-
ticles preparation conducted at industrial scale. Nanoparticles preparation by
polymerization of a monomer or from pre-formed polymers is highly acceptable
nowadays. According to our database survey utilization of polymers (synthetic/
natural) are highly encouraged since nanoparticles properties can be tailored by
using different polymers and co-polymers. According to last 2 years survey it has
been discovered that as chitosan (among all natural polymers) is known to be the
most leading natural polymer, relatively safe biocompatible, mucoadhesiveness and
permeability enhancing properties [127, 128] and its derivates have shown improved
characteristics. Additionally it is also used as food additive in food industries.
Another example of albumin widely utilized as natural carrier for hydrophobic mol-
ecules such as fatty acids, hormones and fat-soluble vitamins has been extensively
used as it as non-toxic and non-immunogenic. Natural polymers have their serious
concerns in terms of purity and stability and therefore synthetic polymers have been
applied. Owing to their biodegradability certain synthetic polymers are highly
encouraged in drug delivery such as poly(cyanoacrylates) (PACA), poly(lactic acid)
(PLA), poly(anhydrides), poly(ethylene glycol), poly(acrylic acid), poly(amides),
poly (ortho esters), and poly(vinyl alcohol) (PVA) and other like poly(isobutyl
cynoacrylate) (PIBCA), poly(ε-caprolac-tone) (PCL), poly(ethylene oxide) (PEO).
These biocompatible polymers can be conjugated with protein to form different
structures with different properties such as controlled release profiles and strong
cell biocompatibility. Among all PLGA, is known to be the suitable polymer for
biomedical applications such as suture materials [129] and bone fixation nails and
screws [130] as well as in diverse drug delivery applications [131, 132], though cost
is always a concern for such polymers. Owing to its features of biocompatibility and
biodegradability it has extensively studied for various applications. PLGA forms
compatible moieties of lactic acid and glycolic acid which are further eliminated by
the citric acid cycle. Since this whole procedure is slow so slow it doesn’t influence
the normal cell function. Owing to the recent innovations in polymeric science,
various other polymers such as poly(β-amino ester) (PbAE) has emerged in the
spotlight because it demonstrates unique features such as pH sensitive release [133,
134] in which at acid pH it rapidly releases its contents. According to recent reports
poly(β-amino ester) has shown to be less toxic than other cationic polymers such as
poly(ethyleneimine) and poly(L-lysine) (PLL) [133, 134], and insoluble at physio-
logical pH but solubilized in aqueous media at pH below 6.5. Polymeric agents like
poly(β-amino ester) are significant for therapeutics in the surrounding area of tumor
mass [133, 134] and for others they must escape endosomal compartmentalization
prior to fusion with lysosomes [133, 134]. Various natural/synthetic polymer based
commercialized nanomedicines and their applications are highlighted in Table 1.4.
26
Table 1.4 Commercialization of nano-drug delivery systems using both natural and synthetic polymers
Mode of
Trade name Encapsulated drug Type of nanoparticles administration Application Manufacturer
Abraxane Paclitaxel Albuminbound nanoparticles IV injection Metastatic breast cancer American Biosciences
(Blauvelt, NY)
Amphocil Amphotericin B Lipocomplex IV infusion Serious fungal infections Sequus
Pharmaceuticals
Ambisome Amphotericin B Liposome IV infusion Serious fungal infections NeXstar
Pharmaceutical
(Boulder, CO)
Abelcet Amphotericin B Lipid complex IV infusion Serious fungal infections The Liposome
Company (Princeton,
1
NJ)
DaunoXome Daunorubicin Liposome Liposome Kaposi sarcoma in AIDS NeXstar
citrate Pharmaceutical
(Boulder, CO)
Doxil Doxorubicin Liposome IV injection Kaposi sarcoma in AIDS Sequus
Pharmaceuticals
Elestrin Estradiol Calciumphosphatebased Transdermal Moderated to severe vasomotors BioSante (Lincolnshire,
nanoparticles Symptoms (hot flashes) in IL)
menopausal women
Emend Aprepitant, MK869 Nanocrystal particles Oral To delay nausea and vomiting Merck/Elan
(Whitehouse Station,
NJ)
Megace ES Megaestrol acetate Nanocrystal particles Oral Anorexia, cachexia or unexplained PAR Pharmaceutical
significant weight loss (WoodCliff Lake, NJ)
Rapamune Sirolimus Nanocrystal particles Oral Immunosuppressant in kidney Wyeth/Elan (Madison,
transplant patients NJ)
Tricor Fenofibrate Nanocrystal particles Oral Primary hypercholestrolemiamixed Abbott (Abbot Park,
lipidemia, hypertriglyceridemia IL)
Nanotechnology and Its Drug Delivery Applications
References 27
References
1. Santamaria A. Historical overview of nanotechnology and nanotoxicology. Methods Mol

Biol. 2012;926:1–12.
2. Drexler E. Engines of creation: the coming era of nanotechnology. Anchor Library of Science,
1987.
3. Feynman R. There’s plenty of room at the bottom. In: Gilbert HD, editor. Miniaturization.
New York: Reinhold; 2004. p. 282–96.
4. Taniguchi N. On the basic concept of ‘Nano-technology’. In: Proceedings of the international
conference on production engineering, Tokyo, Part II. Japan Society of Precision Engineering,
1974. p. 5–10, 10.
5. Curl RF, Smalley RE, Kroto HW, O'Brien S, Heath JR. How the news that we were not the
first to conceive of soccer ball C60 got to us. J Mol Graph Model. 2001;19(2):185–6.
6. Davis T. Biography of Louis E. Brus. Proc Natl Acad Sci U S A. 2005;102(5):1277–9.
7. Drexler KE. Unbounding the future: the nanotechnology revolution. New York: Harper
Collins; 1991.
8. Drexler KE. Nanosystems: molecular machinery, manufacturing, and computation. New York:
Wiley; 1992.
9. Iijima S. Helical microtubules of graphitic carbon. Nature. 1991;354:56–8.
10. Kresge CT, Leonowicz ME, Roth WJ, Vartuli JC, Beck JS. Ordered mesoporous molecular
sieves synthesized by a liquid-crystal template mechanism. Nature. 1992;359:710–2.
11. Murray CB, Norris DJ, Bawendi. Synthesis and characterization of nearly monodisperse CdE
(E = sulfur, selenium, tellurium) semiconductor nanocrystallites. J Am Chem Soc.
1993;115:8706–15.
12. Foresight institute first formen prize in nanotechnology. http://www.foresight.org/FI/1997Feynman.
html.
13. Foresight institute. http://www.foresight.org/nano/history.html.
14. Seeman NC. Structural DNA nanotechnology: an overview. Methods Mol Biol.
2005;303:143–66.
15. Foresight Update 26, NASA Unit putting major resources into computational nanotechnol-
ogy. https://www.foresight.org/Updates/Update26/Update26.1.html, by Lew Phelps.
16. Webster TJ. IJN’s second year is now a part of nanomedicine history. Int J Nanomed.
2007;2(1):1–2.
17. Nanalyze. The World’s Oldest and Biggest Nanotechnology Company, 2014. http://www.
nanalyze.com/2014/06/the-worlds-oldest-and-biggest-nanotechnology-company.
18. Seeman NC. From genes to machines: DNA nanomechanical devices. Trends Biochem Sci.
2005;30(3):119–25.
19. Mao C, Sun W, Shen Z, Seeman NC. A nanomechanical device based on the B-Z transition
of DNA. Nature. 1999;397:144–6.
20. Kateb B, Heiss JD. The textbook of nanoneuroscience and nanoneurosurgery. Boca Raton,
FL: CRC Press; 2013. p. 4.
21. Ginger DS, Zhang H, Mirkin CA. The evolution of dip-pen nanolithography. Angew Chem
Int Ed. 2003;43(1):30–45.
22. Freitas RA. Nanomedicine, Vol. I: Basic capabilities. Georgetown, TX: Landes Bioscience;
1999.
23. Paradise J, Wolf SM, Ramachandran G, Kokkoli E, Hall R, Kuzma J. Developing oversight
frameworks for nanobiotechnology. Minn J L Sci Tech. 2008;9(1):399–416.
24. Roco MC, Mirkin CA, Hersam MC. Nanotechnology research directions for societal needs in
2020: retrospective. New York: Springer; 2011. p. 12.
25. Lieber C. Nanowires take the prize. Marer Today. 2002;5(2):48.
26. Nikalje AP. Nanotechnology and its applications in medicine. Med Chem. 2015;5:081–9.
27. Gupta SRN. Advances in molecular nanotechnology from premodern to modern era. Int
J Mater Sci Eng. 2014;2:2.
28. Wonders S. Endless frontiers: a review of the national nanotechnology initiative. National
Academies Press. http://www.ncbi.nlm.nih.gov/books/NBK220670/.
29. Nanoscience and nanotechnologies: opportunities and uncertainties, 2004. https://royalsoci-
ety.org/topics-policy/publications/2004/nanoscience-nanotechnologies/.
30. Guston DH. Encyclopedia of Nanoscience and Society. SAGE Publications, 2010, Social
Science. p. 598.
31. http://www.foresight.org/nano/history.html.
32. Rothemund PWK, Papadakis N. Winfree E algorithmic self-assembly of DNA Sierpinski
triangles. PLoS Biol. 2004;2(12):e424. doi:10.1371/journal.pbio.0020424.
33. Peterson C. Nanotechnology: from Feynman to the grand challenge of molecular manufac-
turing. IEEE Technology and Society, Winter 2004.
34. Peterson C. Molecular nanotechnology: the next industrial revolution. IEEE Computer, 2000.
35. Regis E, Brown L. Nano: the emerging science of nanotechnology, 1995.
36. Peterson C, Wired H. Nanotechnology: from concept to R&D Goal, 1995.
37. Peterson C. Nanotechnology: evolution of the concept. In: Krummenacker M, Lewis J, edi-
tors. Prospects in nanotechnology: toward molecular manufacturing. New York: Wiley; 1995.
38. Geim A, Konstantin. The Nobel Prize in Physics 2010. Novoselov. http://www.nobelprize.
org/nobel_prizes/physics/laureates/2010/press.html.
39. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov.
2003;2:347–60.
40. De Jong WH, Geertsma RE, Roszek B. Possible risks for human health. Report
265001002/2005. Bilthoven, The Netherlands: National Institute for Public Health and the
Environment (RIVM); 2005. Nanotechnology in medical applications.
41. European Science Foundation. Policy Briefing (ESF), ESF Scientific Forward Look on
Nanomedicine IREG Strasbourg, France, 2005. ISBN: 2-912049-520.
42. European Technology Platform on Nanomedicine. Vision paper and basis for a strategic
research agenda for nanomedicine. European Commission Luxembourg, Office for Official
Publications of the European Commission, 2005. ISBN: 92-894-9599-5.
43. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer.
2005;5:161–71.
44. The Royal Society and The Royal Academy of Engineering. Nanoscience and nanotechnolo-
gies: opportunities and uncertainties, London, UK, 2004.
45. Kipp JE. The role of solid nanoparticle technology in the parental delivery of poorly water-
soluble drugs. Int J Pharm. 2004;284:109–22.
46. Cascone MG, Lazzeri L, Carmignani C, et al. Gelatin nanoparticles produced by a simple
W/O emulsion as delivery system for methotrexate. J Mater Sci Mater Med.
2002;13:523–6.
47. Baran ET, Özer N, Hasirci V. In vivo half life of nanoencapsulated L-asparaginase. J Mater
Sci Mater Med. 2002;13:1113–21.
48. Oberdörster G. Significance of particle parameters in the evaluation of exposure-dose-
response relationships of inhaled particles. Inhal Toxicol. 1996;8:73–89.
49. Donaldson K, Stone V, Clouter A, et al. Ultrafine particles. Occup Environ Med. 2001;58:211–1651.
50. Donaldson K, Stone V, Tran CL, et al. Nanotoxicology. Occup Environ Med. 2004;61:727–2852.
51. Donaldson K, Stone V. Current hypotheses on the mechanism of toxicity of ultrafine parti-
cles. Ann Ist Super Sanita. 2003;39:405–10.
52. Borm PJ, Kreyling W. Toxicological hazards of inhaled nanoparticles—potential implica-
tions for drug delivery. J Nanosci Nanotechnol. 2004;4:521–31.
53. Donaldson K, Tran L, Jimenez LA, et al. Combustion-derived nanoparticles: a review of their
toxicology following inhalation exposure. Part Fibre Toxicol. 2005;2:10.
54. Granum B, Lovik M. The effect of particles on allergic immune responses. Toxicol Sci.
2002;65:7–17.
55. LaVan DA, McGuire T, Langer R. Small scale systems for in vivo drug delivery. Nat
Biotechnol. 2003;21:1184–91.
References 29
56. Borm PJ, Muller-Schulte D. Nanoparticles in drug delivery and environmental exposure:
same size, same risks? Nanomedicine. 2006;1:235–49.
57. Gibaud S, Demoy M, Andreux JP, et al. Cells involved in the capture of nanoparticles in
hematopoietic organs. J Pharm Sci. 1996;85:944–50.
58. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target specific nanoparticles:
theory and practice. Pharmacol Rev. 2001;53:283–318.
59. Demoy M, Gibaud S, Andreux JP, et al. Splenic trapping of nanoparticles: complementary
approaches for in situ studies. Pharm Res. 1997;14:463–8.
60. Bazile D, Prud’Homme C, Bassoullet M-T, et al. Stealth PEG-PLA nanoparticles avoid
uptake by the mononuclear phagocytes system. J Pharm Sci. 1995;84:493–8.
61. Peracchia MT, Fattal E, Desmaele D, et al. Stealth PEGylated polycyanoacrylate nanoparti-
cles for intravenous administration and splenic targeting. J Control Release. 1999;60:121–8.
62. Niidome T, Yamagata M, Okamoto Y, et al. PEG-modified gold nanorods with a stealth char-
acter for in vivo applications. J Control Release. 2006;114:343–7.
63. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for bio-
medical applications. Biomaterials. 2005;26:3995–4021.
64. Seki J, Sonoke S, Saheki A, et al. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a
parenteral drug carrier for passive drug targeting. Int J Pharm. 2004;273:75–83.
65. Saez A, Guzman M, Molpeceres J, et al. Freeze-drying of polycaprolactone and poly(D,L-
lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmaco-
kinetics of loaded drugs. Eur J Pharm Biopharm. 2000;50:379–87.
66. Fishbein I, Chorny M, Banai S, et al. Formulation and delivery mode affect disposition and
activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc
Biol. 2001;21:1434–9.
67. Shim J, Seok Kang H, Park WS, et al. Transdermal delivery of minoxidil with block copoly-
mer nanoparticles. J Control Release. 2004;97:477–84.
68. Fang C, Shi B, Pei YY, et al. In vivo tumor targeting of tumor necrosis factor-alpha-loaded
stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci.
2006;27:27–36.
69. Zhang L, Hu Y, Jiang X, et al. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-
b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice.
J Control Release. 2004;96:135–48.
70. Senior J, Gregoriadis G. Is half-life of circulating small unilamellar liposomes determined by
changes in their permeability? FEBS Lett. 1982;145:109–14.
71. Na K, Lee KH, Lee DH, et al. Biodegradable thermo-sensitive nanoparticles from poly(L-
lactic acid)/poly(ethylene glycol) alternating multiblock copolymer for potential anti-cancer
drug carrier. Eur J Pharm Sci. 2006;27:115–22.
72. Ricci-Junior E, Marchetti JM. Preparation, characterization, photocytotoxicity assay of
PLGA nanoparticles containing zinc(II) phthalocyanine for photodynamic therapy use.
J Microencapsul. 2006;23:523–38.
73. Gomes AJ, Lunardi LO, Marchetti JM, et al. Indocyanine green nanoparticles useful for pho-
tomedicine. Photomed Laser Surg. 2006;24:514–21.
74. Crommelin DJ, Storm G. Liposomes: from the bench to the bed. J Liposome Res.
2003;13:33–6.
75. Metselaar JM, Storm G. Liposomes in the treatment of inflammatory disorders. Expert Opin
Drug Deliv. 2005;2:465–76.
76. Minko T, Pakunlu RI, Wang Y, et al. New generation of liposomal drugs for cancer. Anticancer
Agents Med Chem. 2006;6:537–52.
77. Win KY, Feng SS. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-
co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials. 2006;27:2285–91.
78. Albrecht C, Knaapen AM, Becker A, et al. The crucial role of particle surface reactivity in
respirable quartz induced reactive oxygen/nitrogen species formation and APE/Ref-1 induc-
tion in rat lung. Respir Res. 2005;6:129.
79. Tomazic-Jezic VJ, Merritt K, Umbreit TH. Significance of the type and size of biomaterial
particles on phagocytosis and tissue distribution. J Biomed Mater Res. 2001;55:523–9.
80. Xia T, Kovochich M, Brant J, et al. Comparison of ambient and manufactured nanoparticles
to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett.
2006;6:1794–807.
81. Nemmar A, Hoylaerts MF, Hoet PH, et al. Size effect of intratracheally instilled particles on
pulmonary inflammation and vascular thrombosis. Toxicol Appl Pharmacol. 2003;186:38–45.
82. Dyer M, Hinchcliffe M, Watts P, et al. Nasal delivery of insulin using novel chitosan based
formulations: a comparative study in two animal models between simple chitosan formula-
tions and chitosan nanoparticles. Pharm Res. 2002;19:998–1008.
83. Edetsberger M, Gaubitzer E, Valic E, et al. Detection of nanometer-sized particles in living
cells using modern fluorescence fluctuation methods. Biochem Biophys Res Commun.
2005;332:109–16.
84. Shenoy D, Fu W, Li J, et al. Surface functionalization of gold nanoparticles using hetero-
bifunctional poly(ethylene glycol) spacer for intracellular tracking and delivery. Int
J Nanomed. 2006;1:51–7.
85. Konan YN, Chevallier J, Gurny R, et al. Encapsulation of p-THPP into nanoparticles: cellular
uptake, subcellular localization and effect of serum on photodynamic activity. Photochem
Photobiol. 2003;77:638–44.
86. Panyam J, Zhou WZ, Prabha S, et al. Rapid endo-lysosomal escape of poly(DL-lactide-co-
glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16:1217–26.
87. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal
pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci.
2003;44:3562–9.
88. Åkerman ME, Chan WCW, Laakkonen P, et al. Nanocrystal targeting in vivo. Proc Natl Acad
Sci U S A. 2002;99:12617–21.
89. Ballou B, Lagerholm BC, Ernst LA, et al. Non-invasive imaging of quantum dots in mice.
Bioconjug Chem. 2004;15:79–86.
90. Gupta AK, Curtis ASG. Surface modified supermagnetic nanoparticles for drug delivery:
interaction studies with human firbroblasts in culture. J Mater Sci Mater Med.
2004;15:493–6.
91. Weissenbock A, Wirth M, Gabor F. WGA grafted PLGA-nanospheres: preparation and asso-
ciation with Caco-2 cells. J Control Release. 2004;99:383–92.
92. Nobs L, Buchegger F, Gurny R, et al. Poly(lactic acid) nanoparticles labeled with biologi-
cally active Neutravidin™ for active targeting. Eur J Pharm Biopharm. 2004;58:483–90.
93. Prinzen L, Miserus R-JJHM, Dirksen A, et al. Optical and magnetic resonance imaging of
cell death and platelet activation using annexin A5-functionalized quantum dots. Nano Lett.
2007;7:93–100.
94. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12:54–61.
95. Olivier JC, Fenart L, Chauvet R, et al. Indirect evidence that drug brain targeting using poly-
sorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res.
1999;16:1836–42.
96. Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-80-coated
poly(butylcyanoacrylate) nanoparticles deliver drugs of the CNS via specific mechanisms
requiring prior binding of drug to the nanoparticles. Pharm Res. 2003;20:409–16.
97. Koziara JM, Lockman PR, Allen DD, et al. The blood brain barrier and brain drug delivery.
J Nanosci Nanotechnol. 2006;6:2712–35.
98. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev.
2001;47:65–81.
99. Michaelis K, Hoffmann MM, Dreis S, et al. Covalent linkage of apolipoprotein E to albumin
nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther.
2006;317:1246–53.
100. Girardin F. Membrane transporter proteins: a challenge for CNS drug development. Dialogues
Clin Neurosci. 2006;8:311–21.
References 31
101. Alyautdin RN, Petrov VE, Langer K, et al. Delivery of loperamide across the blood-brain
barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. J Pharm Res.
1997;14:325–8.
102. Koziara JM, Lockman PR, Allen DD, et al. Paclitaxel nanoparticles for the potential treat-
ment of brain tumors. J Control Release. 2004;99:259–69.
103. Oberdörster G, Sharp Z, Atudorei V, et al. Translocation of inhaled ultrafine particles to the
brain. Inhal Toxicol. 2004;16:437–45.
104. Elder A, Gelein R, Silva V, et al. Translocation of inhaled ultrafine manganese oxide particles
to the central nervous system. Environ Health Perspect. 2006;114:1172–8.
105. Gao X, Tao W, Lu W, et al. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain
delivery after intranasal administration. Biomaterials. 2006;27:3482–90.
106. Court E, Daar AS, Martin E, Acharya T, Singer PA. Will Prince Charles et al. diminish the
opportunities of developing countries in nanotechnology? 2004.
107. U.S., Indian high technology will benefit through cooperation, 2003. Available: http://newd-
elhi.usembassy.gov/wwwhpr0812a.htm.
108. China’s nanotechnology patent applications rank third in world, 2003. http://www.investo-
rideas.com/Companies/Nanotechnology/Articles/China'sNanotechnology1003,03.asp.
109. Meridian Institute Report of the international dialogue on responsible research and develop-
ment of nanotechnology, 2004.
110. Salamanca-Buentello F, Persad DL, Court EB, Martin DK, Daar AS, Singer PA. Nanotechnology
and the developing world. PLoS Med. 2005;2(5):e97. doi:10.1371/journal.pmed.0020097.
111. Rashidi L, Khosravi-Darani K. The applications of nanotechnology in food industry. Crit Rev
Food Sci Nutr. 2011;51(8):723–30. doi:10.1080/10408391003785417.
112. Silva GA. Introduction to nanotechnology and its applications to medicine. Surg Neurol.
2004;61(3):216–20.
113. Singhal S, Nie S, Wang MD. Nanotechnology applications in surgical oncology. Annu Rev
Med. 2010;61:359–73.
114. Saini R, Saini S, Sharma S. Nanotechnology: the future medicine. J Cutan Aesthet Surg.
2010;3(1):32–3.
115. Lee J, Mahendra S, Alvarez PJ. Nanomaterials in the construction industry: a review of their
applications and environmental health and safety considerations. ACS Nano.
2010;4(7):3580–90.
116. Oberdörster G, Maynard A, Donaldson K, et al. Principles for characterizing the potential
human health effects from exposure to nanomaterials: elements of a screening strategy. Part
Fibre Toxicol. 2005;2:8.
117. Borm PJ. Particle toxicology: from coal mining to nanotechnology. Inhal Toxicol.
2002;14:311–24.
118. Kreyling WG, Semmler M, Möller W. Dosimetry and toxicology of ultrafine particles.
J Aerosol Med. 2004;17:140–52.
119. Felicea B, Prabhakaranc MP, Rodrígueza AP, Ramakrishnac S. Drug delivery vehicles on a
nano-engineering perspective. Mater Sci Eng C. 2014;41:178–95.
120. Allen C, Maysinger D, Eisenberg A. Nano-engineering block copolymer aggregates for drug
delivery. Colloids Surf B Biointerfaces. 1999;16:1–4. 3–27.
121. Kalhapure RS, Suleman N, Mocktar C, Seedat N, Govender T. Nanoengineered drug delivery
systems for enhancing antibiotic therapy. J Pharm Sci. 2015;104(3):872–905.
122. Lakkakula J, Krause RWM. Cyclodextrin-based nanoengineered drug delivery system. In:
Mishra AK, editor. Nanomedicine for drug delivery and therapeutics. Hoboken, NJ: Wiley;
2013.
123. Barratt GM. Therapeutic applications of colloidal drug carrier. Pharm Sci Technol Today.
2000;3:163–71.
124. Ghosh S. Recent research and development in synthetic polymer-based drug delivery sys-
tems. J Chem Res. 2004;4:241–6.
125. Reis CP, Neufeld RJ, Ribeiro ANJ, Veiga F. Nanoencapsulation II. Biomedical applications
and current status of peptide and protein nanoparticulate delivery systems. Nanomed
Nanotechnol Biol Med. 2006;2(2):53–65.
126. Alvarez-Roman R, Naik A, Kalia YN, Guy RH, Fessi H. Enhancement of topical delivery
from biodegradable nanoparticles. Pharm Res. 2004;21(10):1818–25.
127. Nafee N, Schneider M, Schaefer UF, Lehr CM. Relevance of the colloidal stability of chito-
san/PLGA nanoparticles on their cytotoxicity profile. Int J Pharm. 2009;381(2):130–9.
128. Reis ACBP. Encapsulação de Fármacos Peptídicos Pelo Método de Emulsificação/Gelificação
Interna. Ph.D. Thesis, Faculdade Farmácia Universidade de Coimbra, 2007.
129. Lim TY, Poh CK, Wang W. Poly(lactic-co-glycolic acid) as a controlled release delivery
device. J Mater Sci Mater Med. 2009;20(8):1669–75. doi:10.1007/s10856-009-3727-z.
130. Park JK, Yeom J, Oh EJ, Reddy M, Kim JY. Guided bone regeneration by poly(lactic-co-
glycolic acid) grafted hyaluronic acid bi-layer films for perio-dontal barrier applications.
Acta Biomater. 2009;5(9):3394–403.
131. Vij N, Min T, Marasigan R, Belcher CN, Mazur S. Development of PEGylated PLGA
nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J Nanobiotechnol.
2010;8:22.
132. Csaba N, Sanchez A, Alonso MJ. PLGA: Polox-amer and PLGA: poloxamine blend nano-
structures as carriers for nasal gene delivery. J Control Release. 2006;113(2):164–72.
133. Little SR, Lynn DM, Ge Q, Anderson DG, Puram SV. Poly-beta amino ester-containing mic-
roparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci U S A.
2004;101(26):9534–9.
134. Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(beta-amino
ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic
drugs. In Vitro Eval Mol Pharm. 2005;2(5):357–66.
Chapter 2
Nanoparticles Types, Classification,
Characterization, Fabrication Methods
and Drug Delivery Applications
Abstract The most emerging branch in pharmaceutical sciences known as

“Pharmaceutical nanotechnology” presents new tools, opportunities and scope,
which are expected to have significant applications in disease diagnostics and ther-
apeutics. Recently nano-pharamceuticals reveal enormous potential in drug deliv-
ery as carrier for spatial and temporal delivery of bioactive and diagnostics.
Additionally it also provides smart materials for tissue engineering. This disci-
pline is now well-established for drug delivery, diagnostics, prognostic and treat-
ment of diseases through its nanoengineered tools. Some nanotech based products
and delivery systems are already in market. Pharmaceutical nanotechnology com-
prised of nano-sized products which can be transformed in numerous ways to
improve their characteristics. Drugs that are transformed in to nano range offer
some unique features which can lead to prolonged circulation, improved drug
localization, enhanced drug efficacy etc. Various pharmaceutical nanotechnology
based systems which can be termed as nanopharmaceuticals like polymeric
nanoparticles, magnetic nanoparticles, liposomes, carbon nanotubes, quantum
dots, dendrimers, metallic nanoparticles, polymeric nanoparticles, etc. have
brought about revolutionary changes in drug delivery as well as the total medical
service system. With the aid of nanopharmaceuticals, Pharmaceutical nanotech-
nology could have a profound influence on disease prevention to provide better
insights into the molecular basis of disease. However some recently found health
risk evidences limits their utilization in pharmaceutical industry. Some concerning
issues like safety, bioethical issues, toxicity hazards, physiological and pharma-
ceutical challenges get to be resolved by the scientists. Current researchers are still
lacking sufficient data and guidelines regarding safe use of these nanotechnology
based devices and materials. Therefore pharmaceutical nanotechnology is still in
infancy. The present chapter summarizes the types of nanopharmaceuticals with
the most important applications and nanoparticles associated health risk related
information available till present.
Keywords Nanotechnology • Nanoparticles • Types • Applications • Fabrication

DOI 10.1007/978-3-319-41129-3_2
34 2 Nanoparticles Types, Classification, Characterization, Fabrication Methods…
2.1 Introduction
Delivering therapeutic compound to the desirable site is a major problem in treat-

ment of many diseases. Conventional utilization of drugs is characterized by poor
biodistribution, limited effectiveness, undesirable side effects, and lack of selectiv-
ity. Strategies like controlling drug delivery can potentially overcome these limita-
tions by transporting drug to the place of action. Moreover drug delivery system
provides protection against rapid degradation or clearance. It also enhances drug
concentration in target tissues; therefore, lower doses of drug are required. Such
type of therapy is required when there is a discrepancy between a dose or concentra-
tion of a drug and its therapeutic results or toxic effects. Targeting cell or specific
tissue by the means individually designed carriers that are attached to drugs is a
more reliable approach in drug delivery system. Such approach is known as cell or
tissue specific targeting. Size reduction of targeted formulation and designing its
pathways for suitable drug delivery system is a more fundamental and successful
approach that forms the basis of nanotechnology. Recent advancement in nanotech-
nology has proven that nanoparticles acquire a great potential as drug carriers. Size
reduction methods and technologies yields different types of nanostructures that
exhibit unique physicochemical and biological properties. These methods make the
nanostructures favorable material for biomedical applications and thus acquire the
significance importance in pharmaceutical sciences. In addition these methods help
in reducing toxicity, enhancing release, improving solubility and bioavailability and
provide better formulation opportunities for drugs. Nanotechnology offers drugs in
the nanometer size range which enhances the performance in a variety of dosage
forms. Various advantages of nano sizing are mentioned below:
• Decreased fed/fasted variability
• Decreased patient-to-patient variability
• Enhanced solubility
• Increased oral bioavailability
• Increased rate of dissolution
• Increased surface area
• Less amount of dose required
• More rapid onset of therapeutic action
Nano word is originated from Latin word, which means dwarf. Ideal size range
offered by nanotechnology refers to one thousand millionth of a particular unit thus
nanometer is one thousand millionth of a meter (i.e. 1 nm = 10−9 m). The branch nan-
otechnology is the science that particularly deals with the processes that occur at
molecular level and of nano length scale size. Nanotechnology is now become an
allied science which is most commonly used in other fields of science like electronic,
physics and engineering since many decades. Recent exploration of nanotechnology
in biomedical and pharmaceutical science results in successful improvement of con-
ventional means of drug delivery system. This multidisciplinary science also covers
several applications in other disciplines such as biophysics, molecular biology, and
2.1 Introduction 35
bioengineering. Nanotechnology has created potential impact in various fields like

medicine including immunology, cardiology, endocrinology, ophthalmology, oncol-
ogy, pulmology etc. In addition it’s highly utilized in specialized areas like brain
targeting, tumor targeting, and gene delivery. Nanotechnology also provides signifi-
cant systems, devices and materials for better pharmaceutical applications.
Nanotechnology is the science of material featuring between 10−9 and 10−7 of a
meter [1]. Or in another words it’s the science of materials and devices whose struc-
tures and constituents demonstrate novel and considerably altered physical, chemi-
cal and biological phenomenon due to their nanoscale size. Thus nanotechnology is
defined as the manipulation of matter on an atomic, molecular, and supramolecular
scale involving the design, production, characterization and application of different
nanoscale materials in different potential areas providing novel technological
advances mainly in the field of medicine. This forms an independent branch of
nanostructures, referred as nanomedicine which is specifically utilized for medi-
cines. Nanomedicine involves utilization of nanotechnology for the benefit of
human health and well being. Nanomedicine was defined by European Science
Foundation as ‘the science and technology of diagnosing, treating and preventing
disease and traumatic injury, of relieving pain, and of preserving and improving
human health, using molecular tools and molecular knowledge of the human body
[1]. This definition was revised by the US NIH as: ‘Nanomedicine refers to highly
specific medical intervention at the molecular scale for curing diseases or repairing
damaged tissues, such as bone, muscle, or nerve’. The European Science Foundation
specified five sub-disciplines of nanomedicines [1]:
• Analytical tools
• Nanoimaging tools
• Nanomaterials and nanodevices
• Clinical and toxicological issues
• Novel therapeutics and drug delivery systems
These specified disciplines are overlapping which in many ways. The use of
nanotechnology in various sectors of therapeutics has revolutionized the field of
medicine where nanoparticles are designed and used for therapeutics, diagnostics,
and as biomedical tools for research. With the help of nanotechnology it’s now pos-
sible to provide therapy at a molecular level which may further help in treating and
pathogenesis of disease. Major limitations of conventional drugs (such as non speci-
ficity of drug action) urgently requires the developed system of nanomaterials which
can be easily used in the diagnosis and treatment of various diseases especially
cancer (have major limitations such as poor sensitivity or specificity and drug tox-
icities). Recently various novel and advance methods of cancer detection based on
nanoparticles are being developed. These designed nanostructures are used as fluo-
rescent materials, contrast agents, drugs with targeting antibodies and for molecular
research tools. Recent modifications of nanoparticulate systems such as paramag-
netic nanoparticles, quantum dots, nanoshells and nanosomes are widely used for
diagnostic purposes. Nanotechnology provides the better safety profile against
drugs with high toxic potential and these nanoforms can be directed to act specifi-
cally at the target tissue by active as well as passive means. In addition other modali-
ties of therapy such as heat induced ablation of cancer cells by nanoshells and gene
therapy are also being developed. Optimization of nanoparticles based drug delivery
approaches concerns the early detection of cancer cells and/or specific tumor
biomarkers, and the enhancement of the efficacy of the treatments applied.
Prominent applications of nanomaterials in biomedical sciences are demonstrated
in Figs. 2.1 and 2.2. Potential of nanomedicines in cancer is dependent on passive
targeting (due to the enhance of the permeability and retention effect promoted by
angiogenic vessels) which can be reinforced by specific targeting (based on multi-
functional nanomaterials that bypass the biological barriers and reach cancer cells).
Nanoparticles based specific drug targeting and delivery platforms reduce toxicity
and other side effects and also improve the therapeutic index of the targeted drug. In
the primary objective of nanotechnology especially in cancer therapy is the develop-
ment of suitable targeting delivery systems which has been taking the lead in what
concerns overcoming the MDR problem. Such targeted delivery systems that are
based ‘Nanosizing’ of drugs:
• Decrease drug resistance
• Decrease toxicity [2]
• Enhance oral bioavailability [3]
• Enhance rate of dissolution
• Enhance solubility [4]
• Increase the stability of drug and formulation [5]
• Increase drug targeting ability [6–8]
• Increase patient compliance [5]
• Increase surface area
• Reduce the dose needed [9]
Fig. 2.1 Various nanoforms and their morphological features

2.1 Introduction 37
Respirocytes
Nanoparticles
Nanodevices NEMS/MEMS
Denderimer
NEMS/MEMS Polymer
Micelles
Nanotechnology Drug conjugates
Nanostructured
Carbon
Nanomaterials nanotubes
Metallic
Non Polymer nanoparticles
Nanocrysttaline
Silica
nanoparticles
Quantumdots
Fig. 2.2 Illustrations demonstrating various types of pharmaceutical nanosystems
Such advantages lead to the development of most efficient targeted therapeutic

nanoparticle which is the potential to revolutionize the drug development process
and change the landscape of the pharmaceutical industry [10, 11]. Considering the
unique physicochemical properties, nanoparticles have shown promise in delivering
a range of molecules to desired sites in the body. These targeted nanomedicines may
improve the therapeutic index of drugs by enhancing their efficacy and/or increas-
ing their tolerability in the body. Nanotechnology is also efficient in improving the
bioavailability of water-insoluble drugs, protect the therapeutic agents from physi-
ological barriers, enable the development of novel classes of bioactive macromole-
cules as well as carry large payloads. In addition integration of imaging contrast
agents within nanoparticles can allows the drug delivery site visible to us and exam-
ination of in vivo efficacy of the therapeutic agent [12]. So far various nanotechnol-
ogy products have been approved by the US Food and Drug Administration (FDA)
for clinical use, and many are under clinic and preclinic development [13]. Among
these clinically approved products the first-generation nanotechnology products are
liposomal drugs and polymer–drug conjugates, which are relatively simple and gen-
erally lack active targeting or controlled drug release components. While designing
therapeutic nanoparticles the ultimate goal of nanotechnology is to develop safer
and more effective therapeutic nanoparticles. Therefore the main focus of current
researchers is to design novel multifunctional nanoparticle platforms for cell/tissue-
specific targeting, sustained or triggered drug delivery, co-delivery of synergistic
drug combinations, etc.
This chapter discuss the various platforms of nanotechnology that are being used
in different aspects of medicine with special focus on targeted drug delivery systems
and novel therapeutics based on nanotechnology. Here, we have also discussed the
recent applications on nanoparticles as platforms for anticancer therapy, emphasizing
strategies for targeted delivery for gene silencing focusing on the optimal pathways
to test these therapeutics in vitro and in vivo. It’s very essential to report toxicological
aspects of these nano materials. Therefore potential toxicities of the nanoparticles are
also described in addition to the safety of nanomedicine is not fully defined yet.
However, it is possible that nanomedicine in future would play a crucial role in the
treatment of human diseases and also in enhancement of normal human physiology.
One of the emerging branches among biomedical sciences is pharmaceutical
technology. Pharmaceutical nanotechnology covers the applications of nanotechnol-
ogy to pharmacy as nanomaterials, and as devices like drug delivery, diagnostic,
imaging and biosensor. Pharmaceutical nanotechnology has provided more fine-
tuned diagnosis and focused treatment of disease at a molecular level. Pharmaceutical
nanotechnology offers various opportunities to fight against many diseases. It helps
in detecting the antigen associated with diseases such as cancer, diabetes mellitus,
neurodegenerative diseases, as well as detecting the microorganisms and viruses
associated with infections. It is expected that in next 10 years market will be flooded
with nanotechnology devised medicine. Applications of nanotechnology to phar-
macy that provide intelligent and smart drug delivery systems is expected to emerge
as most important and powerful tool as alternate to conventional dosage form. These
nano-intelligent drug delivery systems need little investment while expected to be a
high profit making deal due to new patent protection for current or soon-to-be off-
patent drugs. A recent report claimed that 23 major pharmaceutical patents would
expire by 2008 leading to revenue loss of US $ 46 billion and by 2011, US $ 70–80
billion loss is expected as various drugs go off-patent. Pharmaceutical Nanotechnology
based systems presents two basic types of nano tools viz. nanomaterials and nanode-
vices, which play a key role in realm of pharmaceutical nanotechnology and related
fields. Nanomaterials are biomaterials used, for example, in orthopedic or dental
implants or as scaffolds for tissue-engineered products. Their surface modifications
or coatings might greatly enhance the biocompatibility by favoring the interaction of
living cells with the biomaterial. These materials can be sub classified into nano-
crystalline and nanostructured materials. Nano crystalline materials are readily man-
ufactured and can substitute the less performing bulk materials. Raw nanomaterials
can be used in drug encapsulation, bone replacements, prostheses, and implants.
Nanostructured materials are processed forms of raw nanomaterials that provide
special shapes or functionality, for example quantum dots, dendrimers, fullerenes
and carbon nanotubes. Nanodevices are miniature devices in the nanoscale and
some of which include nano- and microelectromechanical systems, microfluidics,
and microarrays. Examples include biosensors and detectors to detect trace quanti-
ties of bacteria, airborne pathogens, biological hazards, and disease signatures and
some intelligent machines like respirocyte (Figs. 2.1 and 2.2). Various prominent
features and applications of nanosystems are mentioned Table 2.1.
2.1 Introduction 39
Table 2.1 Various characteristics and brief applications of nanosystems [14]

Types of
Nanosystems Size (nm) Characteristics Applications
Carbon 0.5–3 Third allotropic crystalline Functionalization enhanced
nanotubes diameter form of carbon sheets either solubility, penetration to cell
and single layer (single walled cytoplasm and to nucleus, as
20–1000 nanotube, SWNT) or multiple carrier for gene delivery,
length layer (multi-walled nanotube, peptide delivery
MWNT). These crystals have
remarkable strength and
unique electrical properties
(conducting, semi conducting,
or insulating)
Dendrimer <10 Highly branched, nearly Long circulatory, controlled
monodisperse polymer system delivery of bioactives,
produced by controlled targeted delivery of
polymerization; three main bioactives to macrophages,
parts core, branch and surface liver targeting
Liposome 50–100 Phospholipid vesicles, Long circulatory, offer
biocompatible, versatile, good passive and active delivery
entrapment efficiency, offer of gene, protein, peptide and
easy various other
Metallic <100 Gold and silver colloids, very Drug and gene delivery,
nanoparticles small size resulting in high highly sensitive diagnostic
surface area available for assays, thermal ablation and
functionalization, stable radiotherapy enhancement
Nanocrystals 2–9.5 Semi conducting material Long term multiple color
Quantum dots synthesized with II-VI and imaging of liver cell; DNA
III-V column element; Size hybridization, immunoassay;
between 10 and 100 Å; Bright receptor mediated
fluorescence, narrow emission, endocytosis; labeling of
Broad UV excitation and high breast cancer marker HeR2
photo stability surface of cancer cells
Polymeric 10–100 nm Block amphiphilic copolymer Long circulatory, target
micelles micelles, high drug specific active and passive
entrapment, payload, drug delivery, diagnostic
biostability value
Polymeric 10–1000 Biodegradable, biocompatible, Excellent carrier for
nanoparticles offer complete drug protection controlled and sustained
delivery of drugs. Stealth
and surface modified
nanoparticles can be used for
active and passive delivery
of bioactives
2.2 Classification of Nanoparticles
Nanoparticles are broadly classified in to three classifications [15]

• One dimension nanoparticles
One dimensional system (thin film or manufactured surfaces) has been used for
decades. Thin films (sizes 1–100 nm) or monolayer is now common place in the
field of solar cells offering, different technological applications, such as chemi-
cal and biological sensors, information storage systems, magneto-optic and opti-
cal device, fiber-optic systems.
• Two dimension nanoparticles
Carbon nanotubes
• Three dimension nanoparticles
Dendrimers, Quantum Dots, Fullerenes (Carbon 60), (QDs)
2.3 Characterization of Nanoparticles
Characterization of nanoparticles is based on the size, morphology and surface

charge, using such advanced microscopic techniques as atomic force microscopy
(AFM), scanning electron microscopy (SEM) and transmission electron micros-
copy (TEM). Properties such as the size distribution, average particle diameter,
charge affect the physical stability and the in vivo distribution of the nanoparticles.
Properties like surface morphology, size and overall shape are determined by elec-
tron microscopy techniques. Features like physical stability and redispersibility of
the polymer dispersion as well as their in vivo performance are affected by the sur-
face charge of the nanoparticles. Different characterization tools and methods for
nanoparticles are mentioned in Table 2.2. Therefore it’s very important to evaluate
the surface charge during characterization of nanoparticles.
2.3.1 Particle Size
Characterizations of nanoparticles are primarily evaluated by the particle size distri-

bution and morphology. With the aid of electron microscopy it’s now possible to
ascertain the morphology as well as the size of nanoparticles. Application of
nanoparticles in drug release and drug targeting can be conveniently determined by
various tools. It has already been reported that particle size of nanoparticles has
profound effect on the drug release.
2.3 Characterization of Nanoparticles 41
Table 2.2 Various characterization tools and methods for nanoparticles [16]
Parameter Characterization method
Carrier-drug interaction Diffential scanning calorimetry
Charge determination Laser Doppler Anemometry
Zeta potentiometer
Chemical analysis of surface Static secondary ion mass spectrometry
Sorptometer
Drug stability Bioassay of drug extacted from Nanoparticles
Chemical analysis of drug
Nanoparticle dispersion stability Critical flocculation temperature (CFT)
Particle size and distribution Atomic force microscopy
Laser defractometry
Photon correlation spectroscopy (PCS)
Scanning electron microscopy
Transmission electron microscopy
Release profile In vitro release characteristics under physiologic and sink
conditions
Surface hydrophobicity Rose Bengal(dye) binding
Water contact angle measurement
X-ray photoelectron spectroscopy
Smaller the size of nanoparticles larger surface area, which results in to fast drug
release. Loaded drug when exposed to the particle surface area causes significant
drug release. In contrast, inside the nanoparticles drugs slow diffusion of larger
particles occurs. Consequently smaller particles tend to aggregate during storage
and transportation of nanoparticle dispersion. Therefore there is a mutual compro-
mise between maximum stability and small size of nanoparticles [17]. In addition
degradation of the polymer can also be affected by the particle size e.g. the extent of
poly (lactic-co-glycolic acid) degradation was found to increase with increasing
particle size in vitro [18]. With the advancement in analytical tools various tech-
niques are now available for determining nanoparticle size as discussed below:
2.3.1.1 Photon-Correlation Spectroscopy (PCS) or Dynamic Light

Scattering (DLS)
Current research demands the fastest and most popular method of determining par-
ticle size. The fastest and most popular techniques like photon-correlation spectros-
copy (PCS) or dynamic light scattering (DLS), widely used to determine the size of
Brownian nanoparticles in colloidal suspensions in the nano and submicron ranges.
In this technique solution of spherical particles in Brownian motion causes a
Doppler shift when they are exposed against shining monochromatic light (laser).
Such monochromatic light exposure hits the moving particle which results in
changing the wavelength of the incoming light. Extent of this change in wavelength
determines the size of the particle. This parameter assists in evaluation of the size
distribution, particle’s motion in the medium, which may further assists in measur-
ing the diffusion coefficient of the particle and using the autocorrelation function.
Dynamic light scattering (DLS) offer the most frequently used technique for accu-
rate estimation of the particle size and size distribution [19].
2.3.1.2 Scanning Electron Microscopy (SEM)
This electron microscopy based technique determines the size, shape and surface
morphology with direct visualization of the nanoparticles. Therefore scanning elec-
tron microscopy offer several advantages in morphological and sizing analysis.
However they provide limited information about the size distribution and true popu-
lation average. During the process of SEM characterization, solution of nanoparti-
cles should be initially converted into a dry powder. This dry powder is then further
mounted on a sample holder followed by coating with a conductive metal (e.g. gold)
using a sputter coater. Whole sample is then analyzed by scanning with a focused
fine beam of electrons [20]. Secondary electrons emitted from the sample surface
determine the surface characteristics of the sample. This electron beam can often
damage the polymer of the nanoparticles which must be able to withstand vacuum.
Average mean size evaluated by SEM is comparable with results obtained by
dynamic light scattering. In addition these techniques are time consuming, costly
and frequently need complementary information about sizing distribution [21].
2.3.1.3 Transmission Electron Microscope
Experimental difficulties in studying nanostructures stem from their small size,

which limits the use of traditional techniques for measuring their physical proper-
ties. Transmission electron microscopy techniques can provide imaging, diffraction
and spectroscopic information, either simultaneously or in a serial manner, of the
specimen with an atomic or a sub-nanometer spatial resolution. TEM operates on
different principle than SEM, yet it often brings same type of data. The sample
preparation for TEM is complex and time consuming because of its requirement to
be ultra thin for the electron transmittance. High-resolution TEM imaging, when
combined with nanodiffraction, atomic resolution electron energy-loss spectros-
copy and nanometer resolution X-ray energy dispersive spectroscopy techniques, is
critical to the fundamental studies of importance to nanoscience and nanotechnol-
ogy. During the TEM characterization nanoparticles dispersion is deposited onto
support grids or films. After dispersion they are fixed using either a negative stain-
ing material (phosphotungstic acid or derivatives, uranyl acetate, etc., or by plastic
embedding). This is done to make nanoparticles withstand against the instrument
vacuum and facilitate handling. Alternatively nanonoparticles sample can also be
exposing to liquid nitrogen temperatures after embedding in vitreous ice. When a
2.3 Characterization of Nanoparticles 43
beam of electrons is transmitted through an ultra thin sample it interacts with the
sample as it passes through The surface characteristics of the sample are obtained
[21]. TEM imaging mode has certain benefits compared with the broad-beam illu-
mination mode:
• Collection of the information about the specimen using a high angular annular
dark field (HAADF) detector (in which the images registered have different lev-
els of contrast related to the chemical composition of the sample)
• It can be utilized for the analysis of biological samples is its contrast for thick
stained sections, since high angular annular dark field images (samples with
thickness of 100–120 nm) have better contrast than those obtained by other
techniques.
• Combining HAADF-TEM imaging leads to imaging the atomistic structure and
composition of nanostructures at a sub-angstrom resolution.
• Availability of sub-nanometer or sub-angstrom electron probes in a TEM instru-
ment, due to the use of a field emission gun and aberration correctors, ensures the
greatest capabilities for studies of sizes, shapes, defects, crystal and surface
structures, and compositions and electronic states of nanometer-size regions of
thin films, nanoparticles and nanoparticle systems.
2.3.1.4 Atomic Force Microscopy
This technique is also known as scanning force microscopy (technique that forms
images of surfaces using a prob that scans the specimen), very high resolution type
of scanning probe microscopy, with reported resolution on the order of fractions of
a nanomerter, more than 100 times better than the optical diffraction limit. The
atomic force microscopy is based on a physical scanning of samples at sub-micron
level using a probe tip of atomic scale and offers ultra-high resolution in particle
size measurement [22]. Depending upon properties, samples are usually scanned in
contact or noncontact mode. During contact mode, the topographical map is gener-
ated by tapping the probe on to the surface across the sample and probe hovers over
the conducting surface in non-contact mode. One of the prime advantage of AFM is
its ability to image non-conducting samples without any specific treatment. This
feature allows the imaging of delicate biological and polymeric nano and micro-
structures [23]. Moreover AFM (without any mathematical calculation) provides
the most accurate description of size, size distribution and real picture which helps
in understanding the effect of various biological conditions [24].
2.3.2 Surface Charge
Surface charge and intensity determines the interaction of nanoparticles with the
biological environment as well as their electrostatic interaction with bioactive com-
pounds. Stability of colloidal material is usually analyzed through zeta potential of
nanoparticles. Zeta potential is an indirect measure of the surface charge. It can be

obtained by evaluating the potential difference between the outer Helmholtz plane
and the surface of shear. Thus zeta potential of colloidal based dispersion assists in
directly evaluating its storage stability. Zeta potential values (high zeta potential
values, either positive or negative) are achieved in order to ensure stability and avoid
aggregation of the particles. Zeta potential values can be utilized in evaluating sur-
face hydrophobicity and the nature of material encapsulated within the nanocap-
sules or coated onto the surface [25].
2.3.3 Surface Hydrophobicity
Techniques such as hydrophobic interaction chromatography, biphasic partitioning,

adsorption of probes, contact angle measurements etc. can be utilized for the deter-
mination of surface hydrophobicity. Recent advancement in research offers several
sophisticated analytical tools for surface property analysis of nanoparticles. modern
technique such as X-ray photon correlation spectroscopy not only determine surface
hydrophobicity but also permits the identification of specific chemical groups on the
surface of nanoparticles [26].
2.3.4 Drug Release
It’s very essential to determine extent of the drug release and in order to obtain such
information most release methods require that the drug and its delivery vehicle be
separated. drug loading capacity of the nanoparticles is defined as the amount of drug
bound per mass of polymer or in another term it is the moles of drug per mg polymer
or mg drug per mg polymer or it could also be given as percentage relative to the poly-
mer. Various techniques such as UV spectroscopy or high performance liquid chroma-
tography (HPLC) after ultracentrifugation, ultra filtration, gel filtration, or centrifugal
ultrafiltration are used to determine this parameter. Methods that are employed for
drug release analysis are also similar to drug loading assay which is more often
assessed for a period of time to evaluate the drug release mechanism [27, 28].
2.4 Preparation of Nanoparticles
The selection of appropriate method for the preparation of nanoparticles depends on

the physicochemical character of the polymer and the drug to be loaded. Nanoparticles
can be prepared from a variety of materials such as proteins, polysaccharides and
synthetic polymers. The selection of matrix materials is dependent on many factors
including [29]:
• Antigenicity of the final product.
• Biocompatibility and toxicity
2.4 Preparation of Nanoparticles 45
• Degree of biodegradability
• Drug release profile desired
• Inherent properties of the drug (aqueous solubility and stability)
• Size of nanoparticles required
• Surface characteristics (charge and permeability)
Nanoparticles have been usually prepared by three methods:
• Dispersion of preformed polymers
• Ionic gelation or coacervation of hydrophilic polymers
• Polymerization of monomers
However, other methods such as supercritical fluid technology [30] and particle
replication in non-wetting templates [31] have also been described in the literature
for production of nanoparticles. The latter was claimed to have absolute control of
particle size, shape and composition, which could set an example for the future
mass production of nanoparticles in industry.
Dispersion of preformed polymers: This technique is based on the preparation of
biodregerable nanoparticles via dispersion of biodegradable polymers such as poly
(D, L-glycolide), poly (lactic acid) (PLA); poly (cyanoacrylate) (PCA), and PLG;
poly (D, L-lactide-co-glycolide) (PLGA) [32–34]. Dispersion of preformed poly-
mers to prepare the nanoparticles can be used in various ways:
2.4.1 Solvent Evaporation Method
Solvent evaporation method is one of the most frequently used methods for the
preparation of nanoparticles. This method involves two steps (first is emulsification
of the polymer solution into an aqueous phase and second is evaporation of polymer
solvent, inducing polymer precipitation as nanospheres). This method is based on
the solubility of polymer and hydrophobic drug since both polymer and hydropho-
bic drug are dissolved in an organic solvent (dichloromethane, chloroform or ethyl
acetate) which is also used as the solvent for dissolving the. Mixture obtained from
polymer and drug solution is then emulsified in an aqueous solution. This aqueous
solution contains surfactant or emulsifying agent to form oil in water (o/w) emul-
sion. Once the stable emulsion forms, the organic solvent is evaporated either by
continuous stirring or by reducing the pressure. Size range of nanoparticles was
found to be influenced by the concentrations and type of stabilizer, polymer concen-
tration and homogenizer speed [35]. Ultrasonication or high-speed homogenization
may be often employed in order to produce small particle size [36]. The nano par-
ticles are collected by ultracentrifugation and washed with distilled water to remove
stabilizer residue or any free drug and lyophilized for storage [37]. Modification of
this method is known as solvent evaporation method and high pressure emulsifica-
tion [38]. This method involves preparation of a emulsion which is then subjected
to homogenization under high pressure followed by overall stirring to remove
organic solvent [39]. The size can be controlled by adjusting the stirring rate, type
and amount of dispersing agent, viscosity of organic and aqueous phases and
temperature [40]. However this method can be applied to liposoluble drugs and
limitation are imposed by the scale up issue. Polymers used in this method are
PLGA [41], PLA [42], cellulose acetate phthalate [43], EC [44], Poly (β -hydroxy-
butyrate) (PHB) [45], Poly (β-caprolactone)\ (PCL) [46].
2.4.2 Spontaneous Emulsification or Solvent Diffusion Method
This method is developed from solvent evaporation method [47], in which the water
miscible solvent along with a small amount of the organic solvent (water immisci-
ble) is used as an oil phase. During the spontaneous diffusion of solvents between
the two phases an interfacial turbulence is generated which may ultimately leads to
the formation of small particles. Smaller particle size can be achieved by increasing
the concentration of water miscible solvent increases. This method can be used for
hydrophobic or hydrophilic drugs. In the case of hydrophilic drug, a multiple w/o/w
emulsion needs to be formed with the drug dissolved in the internal aqueous phase.
2.4.3 Double Emulsion and Evaporation Method
Most of the emulsion and evaporation based methods suffer from the limitation of
poor entrapment of hydrophilic drugs. Therefore to encapsulate hydrophilic drug
the double emulsion technique is employed, which involves the addition of aqueous
drug solutions to organic polymer solution under vigorous stirring to form w/o
emulsions. This w/o emulsion is added into second aqueous phase with continuous
stirring to form the w/o/w emulsion. The emulsion then subjected to solvent removal
by evaporation and nano particles can be isolated by centrifugation at high speed.
The formed nanoparticles must be thoroughly washed before lyophilisation [48]. In
this method the amount of hydrophilic drug to be incorporated, the concentration of
stabilizer used, the polymer concentration, the volume of aqueous phase are the
variables that affect the characterization of nanoparticles [48, 49].
2.4.4 Salting Out Method
Method involves the separation of a water-miscible solvent from aqueous solution

via a salting-out effect [50]. It’s based on the on the separation of a water miscible
solvent from aqueous solution via a salting-out effect. During the initial process
polymer and drug are dissolved in a solvent which is subsequently emulsified into
an aqueous gel containing the salting out agent and a colloidal stabilizer. Various
types of salting out agents (electrolytes, such as magnesium chloride and calcium
chloride, or non- electrolytes such as sucrose) and colloidal stabilizer (such as
polyvinylpyrrolidone or hydroxyethylcellulose) have been used. This lead to forma-

tion of oil/water emulsion which is further diluted with a sufficient volume of water
or aqueous solution to enhance the diffusion of solvent into the aqueous phase,
ultimately induce the formation of nanospheres. Parameters such as stirring rate,
internal/external phase ratio, concentration of polymers in the organic phase, type of
electrolyte concentration and type of stabilizer in the aqueous phase can be varied
in this process [43]. Salting out method is reported for preparation of ethyl cellulose
and PLA, Poly(methacrylic) acids nanospheres. leads to high efficiency and is eas-
ily scaled up [51, 52].
2.4.4.1 Advantages
• Does not require an increase of temperature and therefore may be useful when
heat sensitive substances have to be processed [53].
2.4.4.2 Disadvantages
• Limited application to lipophilic drug and the extensive nanoparticles washing

steps
2.4.5 Emulsions-Diffusion Method
This is another widely used method to prepare nanoparticles. The encapsulating

polymer is dissolved in a partially water-miscible solvent (such as propylene car-
bonate, benzyl alcohol), and saturated with water to ensure the initial thermody-
namic equilibrium of both liquids. Subsequently, the polymer-water saturated
solvent phase is emulsified in an aqueous solution containing stabilizer, leading to
solvent diffusion to the external phase and the formation of nanospheres or nano-
capsules, according to the oil-to-polymer ratio. Finally, the solvent is eliminated by
evaporation or filtration, according to its boiling point. This technique presents sev-
eral advantages, such as high encapsulation efficiencies (generally 70 %), no need
for homogenization, high batch-to-batch reproducibility, ease of scaleup, simplicity,
and narrow size distribution.
2.4.5.1 Disadvantages
Disadvantages are the high volumes of water to be eliminated from the suspension
and the leakage of water-soluble drug into the saturated-aqueous external phase
during emulsification, reducing encapsulation efficiency [54]. Several drug-
loaded nanoparticles were produced by the technique, including mesotetra
(hydroxyphenyl) porphyrin-loaded PLGA (p-THPP) nanoparticles [55], doxoru-

bicin-loaded PLGA nano particles, and cyclosporine (cy-A-); loaded sodium gly-
colate nanoparticles [56].
2.4.6 Solvent Displacement/Precipitation Method
In this method preformed polymer is precipitated in an organic solution and

organic solvent is diffused in the aqueous medium. Diffusion of organic solvent
can be achieved in the presence or absence of surfactant. Semi polar water mis-
cible solvent such as acetone or ethanol can be used to dissolve the polymers,
drug, and or lipophilic surfactant. After their complete dissolution, solution is
then poured or injected into an aqueous solution containing stabilizer under mag-
netic stirring. Nano particles are formed immediately by the rapid solvent diffu-
sion. This step is followed by the removal of solvent from the suspensions under
reduced pressure. Particles size is dependent on the extent of addition of the
organic phase into the aqueous phase. It was also found that decrease in both
particles size and drug entrapment occurs as the mixing rate of the two phase
increases [57]. This method is more suitable for poorly soluble drugs. Optimization
of various parameters (preparation parameters) can effectively control size, drug
release and yield of nanosphere.
Nanosphere size, drug release and yield were shown to be effectively con-
trolled by adjusting preparation parameters. Regulation the concentration of poly-
mer in the organic phase was reported to be useful in the production of smaller
sized nanospheres. However size range is restricted to minimum range of the
polymer to drug ratio.
2.4.7 Coacervation or Ionic Gelation Method
Recent exploration of biodegradable polymers such as gelatin and sodium alginate

has been focused now to yield biodegradable nanoparticles having features like bio-
compatibility and low toxicity. Methods such as ionic gelation can be used for pre-
paring hydrophilic polymer based nanoparticles. Calvo and co-workers developed
method for preparing chitosan based nanoparticles by ionic gelation method [58,
59]. In this method two different aqueous phases are prepared for polymer [chito-
san, a di-block co-polymer ethylene oxide or propylene oxide (PEO-PPO)] and the
other is for polyanion sodium tripolyphosphate. This method is based on the strong
electrostatic interaction between positively charged amino group of chitosan and
negative charged tripolyphosphate to form coacervates with a size in the range of
nanometer. Existence of strong electrostatic interaction between two aqueous
phases leads to the formation of coacervates. In contrast ionic gelation involves the
material undergoing transition from liquid to gel due to ionic interaction conditions
at room temperature.
2.4.8 Polymerization Method
This method involves polymerization of monomers to form nanoparticles in an

aqueous solution. In polymerization drug is incorporated at two different stages
(either by being dissolved in the polymerization medium or by adsorption onto the
nanoparticles after polymerization completed) [60, 61]. Ultracentrifugation can be
used to purify nanoparticle suspension by removing various stabilizers and surfac-
tants employed for polymerization, followed by the re-suspension of particles in an
isotonic surfactant-free medium. This technique is reported for making poly (alkyl-
cyanoacrylate) or polybutylcyanoacrylate nanoparticles. Desirable size of nanocap-
sule can be achieved by optimization of concentration of the surfactants and
stabilizers [62].
2.4.9 Production of Nanoparticles Using Supercritical Fluid

Technology
Above mentioned conventional methods (such as solvent extraction-evaporation,

solvent diffusion and organic phase separation methods) obligatory use organic sol-
vents which are hazardous to the environment as well as to physiological systems.
Therefore, there is an urgent requirement of suitable technology which avoid the
usage of organic solvents or any other ingredient hazardous to health. Since super-
critical fluids are environmentally safe, therefore, the supercritical fluid technology
has been investigated as an alternative to prepare biodegradable micro- and nanopar-
ticles [63]. Supercritical fluid technology technique, although environmentally
friendly and suitable for mass production, requires specially designed equipment
and is more expensive. Supercritical fluids are those fluids which are at a tempera-
ture above its critical temperature remains in a single phase regardless of pressure
[63]. CO2 (SC CO2) is the most widely used supercritical fluid because of its mild
critical conditions, non-flammability, low price and nontoxicity. Among the various
processing techniques involving supercritical fluids, supercritical anti-solvent
(SAS) and rapid expansion of critical solution (RESS) are the most common one. In
former process a liquid solvent (methanol) is selected on the basis of it’s completely
miscibility with the supercritical fluid (SC CO2). This is done to dissolve the solute
to be micronized at the process conditions. Since the solute is insoluble in the super-
critical fluid, the extract of the liquid solvent by supercritical fluid leads to the
instantaneous precipitation of the solute, results in the formation of nanoparticles.
This process is reported for formation of hydrophilic drug dexamethasone phos-
phate drug nanoparticles for microencapsulation purpose. In later process called as
RESS, solute is dissolved in a supercritical fluid such as supercritical methanol and
then the solution is rapidly expanded through a small nozzle into a region lower
pressure [63]. This dramatically affects the solvent power of supercritical fluids
which is ultimately decreases and the solute eventually precipitates. RESS and its
modified process have been used for the product of polymeric nanoparticles [64].
2.5 Most Favorable Requirements for Designing Therapeutic

Nanoparticles
One of the most primary requirements before designing therapeutic nanoparticles is

the rapid clearance during systemic delivery. After entering the blood stream nanopar-
ticles surface may experience nonspecific protein adsorption called as opsonization.
This process makes them more visible to phagocytic cells. These opsonized nanopar-
ticles could be easily cleared from the bloodstream through phagocytosis by the
mononuclear phagocyte system (MPS) in the liver and by spleen filtration. Factors
that govern the clearance and biodistribution of nanoparticles should be considered
before designing therapeutic nanoparticles. nanoparticle size plays an important role
in controlling circulation and biodistribution of nanoparticles during its journey
through physiological parameters such as hepatic filtration, tissue extravasation/diffu-
sion, and kidney excretion. Naoparticles size range <10 nm can be rapidly cleared by
the kidneys or through extravasation, while larger particles size may have higher ten-
dency to be cleared by cells of the mononuclear phagocyte system (MPS also referred
to as reticuloendothelial system, RES). It was also found that PEGylated spherical
nanoparticles (<100 nm, 100–200 nm, and >200 nm) showed different protein absorp-
tion rate since particle size influence its uptake by murine macrophages, and blood
clearance kinetics. It was reported that nanoparticles <100 nm remain in the blood for
long periods of time and experience reduced hepatic filtration. Additionally nanopar-
ticle size also affects their accumulation rate in tumor or its surroundings. This accu-
mulation is achieved through the EPR effect. Thus to take advantage of the EPR effect
and to efficiently escape from the physiological barriers, many studies advocate the
optimal nanoparticle size range of approximately 10–250 nm. Second factor that
could affect nanoparticles uptake by the MPS cells is their surface charge. Positively
charged nanoparticles generate a higher immune response compared to neutral or
negatively charged nanoparticle formulations. Similarly neutrally charged particles
have demonstrated much lower opsonization rates than charged particles. For reduced
phagocytosis and minimized nonspecific, it has been demonstrated optimal range of
nanoparticle is between −10 and +10 mV. Third factor, PEGylation, referred to the
surface modification of nanoparticles with PEG, which has favorable intrinsic physi-
cochemical properties which was found to reduce nanoparticle accumulation in off-
target organs. A hydrophobic or charged particles PEG shell on the nanoparticle,
leads to prolonged circulation half-life compared to non-PEGylated nanoparticles.
Several factors such as length, shape, and density of PEG chains on the nanoparticle
surface largely affect its surface hydrophilicity and phagocytosis. Brush configuration
in PEGylated nanoparticles would create more effective blocking or repulsion of
opsonins than the mushroom one. Fourth factor i.e. ligand functionalization is the
conjugation of targeting ligands to the surface of PEGylated nanoparticles which has
also been proven to affect their biodistribution. However targeting ligands could
improve the cell- or tissue-specific delivery of nanoparticles. They may compromise
the particle surface properties by masking the PEG layer and adversely affecting the
nanoparticles’ antibiofouling properties in vivo.
2.6 Types of Pharmaceutical Nanosystems 51
2.6 Types of Pharmaceutical Nanosystems
2.6.1 Carbon Based Structures
Carbon nano tubes are carbon based tubular structures that are discovered in 1991
[65]. These structures are arranged in fashion like a graphite sheet rolled up into a
cylinder and capped at one or both ends by a buckyball. These are hexagonal net-
works of carbon atoms having diameter of one nanometer and length from 1 to
100 nm. These carbon networks are arranged layer of graphite rolled up into a cylin-
der. There are two carbon based configuration that have received much attention
recently: single-walled nanotubes (SWNTs) and multiwalled nanotubes (MWNTs).
In addition to these types C60 fullerenes is also a part of common configurations.
These are hollow, carbon-based, cage-like architectures (nanotubes and fullerenes),
also known as bucky balls, which are differ in the arrangement of their graphite cyl-
inders. The size, geometry, and surface characteristics of these macromolecules
make them appealing for drug carrier usage and have remarkable physical proper.
SWNTs and C60 fullerenes have internal diameters range of 1–2 nm. This dimension
is equivalent to about half the diameter of the average DNA helix, whereas MWNTs
have diameters ranging from several nanometers to tens of nanometers with 0.36 nm
distance between layers of MWCNT, depending on the number of walls in the struc-
ture. Size may vary in their length ranging from 1 μm to a few micrometers [66]. As
far as their architecture is concerned fullerenes and carbon nanotubes are typically
fabricated using laser ablation, chemical vapor deposition, electric arc discharge, or
combustion processes. Characterization of these concentric forms is based on their
strength and stability so that they can be used as stable drug carriers. Cellular entry
of nanotubes may be mediated by endocytosis or by insertion through the cell mem-
brane. Fullerenes have also shown drug targeting capability. Tissue-selective target-
ing and intracellular targeting of mitochondria have been shown with use of fullerene
structures. Furthermore, experiments with fullerenes have also shown that they
exhibit antioxidant and antimicrobial behavior. Carbon nanotubes and their applica-
tions are highlighted in Table 2.3. Some of well known examples of carbon nantubes
and their respective applications are highlighted in Table 2.3.
Table 2.3 Carbon nanotubes and their applications [67]

Drug Type of disease Type of CNTs
Breast cancer MWCNTs
Amphotericin B Leishmania donovani (parasite) Not specified
Carboplatin Bladder cancer Not specified
Daunorubicin Leukemia SWCNTs
Doxorubicin Lymphoma SWCNTs
Gemcitabine Ovarian cancer SWCNTs
Methotrexate Breast cancer MWCNs
Paclitaxel Breast cancer SWCNTs
2.6.1.1 Applications
• Cell specificity
Enhancement of cell specificity by conjugating antibodies to carbon nanotubes
with fluorescent or radiolabelling [68]
• Internalization
Internalization within mammalian cells can be achieved by surface-functionalized
carbon nanotubes
• Vaccine delivery
Conjugation with peptides may be used as vaccine delivery structures
• Gene delivery
With the advancement in molecular dynamics simulations, the flow of water
molecules through surface-functionalized carbon nanotubes has been modeled in
such a way so that they can be conveniently utilized as small molecule transport-
ers in transporting DNA, indicating potential use as a gene delivery tool. The
ability of nanotubes to transport DNA across cell membrane is used in studies
involving gene therapy. During this therapy DNA can be attached to the tips of
nanotubes or can be incorporated within the tubes. It has been found that gene
therapy with β galactosidase marker gene nanotubes showed greater expression
compared to transfer of naked DNA. This assures the advantage of non immuno-
genicity in contrast to viral vectors used for gene transfer.
• Transport of peptides, nucleic acids and other drug molecules
Incorporation of carboxylic or ammonium groups to carbon nanotubes enhances
their solubility which makes them more suitable for the transport of peptides,
nucleic acids and other drug molecules. Pristine carbon nanotubes is a common
example of water insoluble forms having high in vitro toxicity compared to mod-
ified water dispersible forms of nanotubes. It has been also proven that the extent
of toxicity decreases with functionalization. However functionalization also
affects the elimination of the nanotube. Single-walled nanotubes without conju-
gation to monoclonal antibody have a high renal uptake. Whereas modest liver
uptake as compared to single-walled nanotubes with conjugation to monoclonal
antibody which is having higher liver uptake and lower renal uptake. In addition
it was also reported that carbon nanotubes, except acetylated ones, when conju-
gated with peptide produce a higher immunological reactions when compared to
free peptides. Such a property of inducing immunological responses can be uti-
lized in vaccine production to enhance the efficacy of vaccines.
• Reduced toxicity and increases the efficacy
Carbon nanotubes enhance drug delivery, efficacy and reduces the toxicity as
found in the case of Amphotericin B nanotubes. It has been found that
Amphotericin B nanotubes has shown enhanced drug delivery to the interior of
cells, increased antifungal efficacy and reduced toxicity to mammalian cells
when compared to amphotericin B administration without nanotubes [69]. The
efficacy of amphotericin B nanotubes was also effective on strains of fungi which
are usually resistant to amphotericin B alone [69].
• Gene silencing
Highly selective therapy is required for cancer therapy where tumor cells will be
selectively modulated. In this case gene silencing has been done with small inter-
fering RNA. This can be achieved by targeting functionalized single walled carbon
nanotubes with siRNA to silence targeted gene expression in the targeted cell [70].
• In diagnostics
It was reported that compounds that are bound to nanotubes enhance the effi-
ciency of diagnostic methods. This property of functionalization and high length
to diameter aspect ratio (which provides a high surface to volume ratio), assists
in designing the highly efficient biosensors [71].
Thus carbon nanotubes offer diverse advantages over other drug delivery and
diagnostic systems due to very interesting physicochemical properties such as
ordered structure with high aspect ratio, high electrical conductivity, high mechani-
cal strength, ultra-light weight, high thermal conductivity, metallic or semi-metallic
behavior and high surface area [72].
2.6.2 Fullerenes
They are also known as bucky balls, that are the carbon allotrope discovered in 1985
[72] having dimensions near around 7 Å in diameter and composed of 60 carbon
atoms that are arranged in a shape known as truncated icosahedrons [73]. Its shape
is quite similar to soccer ball with 20 hexagons and 12 pentagons and is highly sym-
metrical [74]. There are various types of fullerenes such as Alkali doped fullerenes,
endohedral fullerenes, endohedral metallofullerenes, exohedral fullerenes and het-
erofullerenes. Alkali doped fullerenes are the carbon allotropic structures that con-
tains alkali metal atoms in between fullerenes contributing valence electrons to
neighboring fullerenes [75]. Similarly endohedral fullerenes have another atom
enclosed inside the buckyball. If they are enclosed with metallic atom then they are
called as metallofullerenes [76, 77]. Owing to the very small size of C-60 fullerene,
it is difficult to synthesize endohedral C60 fullerenes. Therefore larger fullerenes
(C82 or C84) fullerenes are used for synthesizing endohedral fullerenes. Another type
of fullerenes called as exohedral fullerenes or fullerene derivatives or functionalized
fullerenes which are synthesized by chemical reaction between the fullerene and
other chemical groups. Last class of fullerene compounds are heterofullerenes
where one or more carbon atoms are replaced by other atoms like nitrogen or boron.
• Diagnostics
Endohedral metallofullerenes can be used for diagnostic purposes as radio con-
trast media in magnetic resonance imaging and other imaging procedures. Since
the radioactive metal is enclosed within the buckyball, these are less toxic and
safer. This method can also be employed for imaging organs as radioactive trac-
ers [77]. Animal studies with C60 fullerene conjugated with thyroglobulin have
produced a C60 specific immunological response which can be detected by
ELISA with IgG specific antibodies. This can be used to design methods of esti-
mation of fullerene levels in the body when used for therapeutic or diagnostic
purposes [78].
• Drug transport
Fullerenes are being investigated for drug transport of antiviral drugs, antibiotics
and anticancer agents [79–82].
• Free radical scavengers
Due to presence of high number of conjugated double bonds in the core structure
fullerenes can also be used as free radical scavengers. They also provide protec-
tion to the mitochondria against injury induced by free radicals [83], owing to
this property they can be used in cancer therapy [84].
• Photosensitizers
Fullerenes especially exohedral fullerenes can be used as photosensitizers in
photodynamic therapy against various types of malignancies. These fullerenes
potentially generate reactive oxygen species when stimulated by light and kills
the target cells. This method is now also being investigated for antimicrobial
property as these cause cell membrane disruption especially in Gram positive
bacteria and mycobacterium [79–82].
• Stimulate host immune response and production of antibodies
Fullerenes are efficient in stimulating host immune response and production of
fullerene specific antibodies.
2.6.2.2 Toxicity
After its parenteral administration through intravenous injection, these fullerenes get
distributed to various parts of the body and finally get excreted unchanged through
the kidney. In comparison to non soluble derivatives, soluble derivates of fullerenes
are safer and biocompatible. They are also having low toxic potential even at higher
doses [78]. Cost of fullerenes is dependent on its degree of purification. Purified
fullerenes are very expensive, restricting its application in medical field.
2.6.3 Quantum Dots
Quantumdots (QDs) are nanocrystals of semiconducting materials measuring

around 2–10 nm, consisting of a semiconductor inorganic core (CdSe), an aqueous
organic coated shell (e.g., ZnS) to improve optical properties, and can be made to
fluorescence when stimulated by light. Quantumdots bear a cap which enables them
in improving their solubility in aqueous buffers. They are neither atomic nor bulk
semiconductors. Core of the quantumdots determines the color emitted and outer
Table 2.4 Various examples of drugs that are delivered via Quantum Dots
Target cells/
Therapeutics diseases Type of QDs Efficacy
5-Fluorouracil Breast cancer ZnS QDs Targeting and controlled drug
delivery to cancer cells.
Daunorubicin Leukaemia CdTe QDs Enhanced drug uptake
Daunorubicin Leukemia K562 CdS QDs Inhibit multidrug resistance
cells
Doxorubicin Ovarian cancer Mucin1- aptamer Higher accumulation on target
QD
Saquinavir HIV-1 Carboxyl- High site-specificity and can cross
terminated QDs BBB
aqueous shell is available for conjugation with biomolecules. Biomolecular conju-

gation of the quantum dots can be modified according to target various biomarkers
[85]. Their properties originate from their physical size, which ranges from 2 to
10 nm in radius. Owing to the to their narrow emission, bright fluorescence, high
photostability and broad UV excitation QDs have been adopted for tracking of intra-
cellular process for longer time, for in vitro bioimaging and for real time monitoring
(Fig. 2.1). As far as the its applications are concerned QDs covers medical areas as
a diagnostic as well as therapeutic tool for in vitro and in vivo detection and analysis
of biomolecules, immunoassays, DNA hybridization, diagnostic tools (magnetic
resonance imaging, MRI), time graded fluorescence imaging of tissue, development
of non-viral vectors for gene therapy, labeling of cells, as therapeutic tools for can-
cer treatment and transport vehicles for DNA, protein, drugs or cells [86]. In addi-
tion they can be also tagged with biomolecules and used as highly sensitive probes.
Quantum dots and their therapeutic applications are highlighted in Table 2.4.
• Cancer therapy
In one report it was proven that quantum dots are accumulated in prostate cancer
developed in nude mice by enhanced permeability and retention [87]
• Bioconjugation with polymer
It was reported that its conjugation with polyethylene glycol (PEG) and antibody
and targeting to prostate specific membrane antigen enhances its accumulation
and retention [87] in the tumor tissue
• Imaging
They can also be utilized for imaging of sentinel node in cancer patients for
tumor staging and planning of therapy. This application assists in detecting suit-
able therapy and stage for various malignancies like melanoma, breast, lung and
gastrointestinal tumors [87]. In addition quantum dot probes provide real time
imaging of the sentinel node with Near Infra Red (NIR) fluorescence system
which is having the potential to produce reduced [88] background noise and
deeper penetration of rays into the biological sample.
2.6.3.2 Toxicity
QDs utilization in clinical practice is limited since it has serious elimination prob-
lems which cause extreme toxicity. After functionalization of the QDs size increases.
This size range is greater than the pore size of endothelium and renal capillaries,
thus reducing its elimination and resulting in toxicity. Additionally there are very
less reports available on the metabolism and excretion of quantum dots making their
utilization more difficult clinically [86].
2.6.4 Nanoshells
Nanoshells are the new modified forms of targeted therapy, having core of silica and
a metallic outer layer [89]. These thin coated core particles of different material
have gained considerable attention now days. The properties of nanoshells can be
altered by simply tuning the core to shell ratio. With the recent advancement in new
techniques it is now possible to synthesize these nanostructures in desired shape,
size and morphology. Nanoshells are synthesized to create novel structures with
different morphologies, since not possible to synthesize all the materials in desired
morphologies. For obtaining desirable morphology core particles of different mor-
phologies such as rods, wires, tubes, rings, cubes, etc. can be coated with thin shell
in core shell structures. These shells are inexpensive as precious materials can be
deposited on inexpensive cores. Therefore while synthesizing nanoshells expensive
material is required in lesser amount than usual. Targeting of nanoshells can be
achieved by using immunological methods. Nanoshells occupies variety of applica-
tions in diverse areas such as providing chemical stability to colloids, enhancing
luminescence properties, engineering band structures, biosensors, drug delivery,
etc. Synthesis of nanoshells can be useful for creating.
• Cancer therapy
This technology is being evaluated for cancer therapy. Nanoshells are tuned to
absorb infra red rays when exposed from a source outside the body and get
heated and cause destruction of the tissue. This has been studied in both in vitro
and in vivo experiments on various cell lines [89]
• Diagnostic purposes
They are useful for diagnostic purposes in whole blood immunoassays e.g. cou-
pling of gold nanoshells to antibodies to detect immunoglobulins in plasma and
whole blood
• Hydrogel mediated delivery
Nanoshells can be easily embedded in hydrogel polymer containing the drug.
Such type of delivery system can be used for targeting tumor cells. Mechanism
of action is based on the targeting of gel to tumor tissue by immunological meth-

ods and exposed under infrared laser beam to heat the polymer which facilitates
the release of the drug at the desirable site.
• Micro metastasis and diabetes
Nanoshells are currently studied for micro metastasis of tumors and also for
treatment of diabetes [90]
2.6.5 Nanobubbles
Nanobubbles (NBs) are nanoscaled bubble like structures that are generated in the
interface of hydrophobic surfaces in liquids. These nanobubbles remain stable at room
temperature and when heated to physiological temperature within the body coalesce to
form microbubbles. The mechanism of NB formation is based on the nucleation of gas
at the hydrophobic surface from a supersaturated solution, leading to trap atmospheric
gases. However the formation of NBs is thermodynamically forbidden, but the life
time of NBs is reached event to the orders of hours. There are four types of nanobub-
bles: bulk, interfacial, plasmonic and oscillating nanobubbles. Cancer therapeutic
drugs can be incorporated into these nanoscaled bubbles like structures. Nanobubbles
potentially exhibit advantages in targeting the tumor tissue and delivering the drug
selectively under the influence of ultrasound exposure. This may enhance the intracel-
lular uptake of the drug by the tumor cells. Additionally these nanobubbles can be
easily visualized in tumor by means of various ultrasound methods [91, 92].
• Delivery of drugs
NBs can be potentially utilized in delivery of drugs like doxorubicin in vitro and
in vivo. These NBs reach the tumor and get accumulated which is followed by
formation of microbubbles by coalescing of nanobubbles. Disruption of the
microbubbles occurs when the site is focused with high intensity focused ultra-
sound, which ultimately causes release of the drug. This may results in accumula-
tion of higher levels of drug in the target cells and reduced toxicity and increased
efficacy. This method needs further exploration for its utility in treatment of vari-
ous malignancies.
• Gene therapy
Liposomal nanobubbles and microbubbles are also being studied for effective
non viral vectors for gene therapy. Nanobubbles combined with ultrasound expo-
sure have shown improved transfer of gene in both in vitro and in vivo studies
[93, 94].
• Thrombolysis
Nanobubbles are also being investigated for removal of clot in vascular system
in combination with ultrasound. This process is called as sonothrombolysis. This
method is non invasive and causing less damage to endothelium [95].
• Toxicity
NBs are not that much toxic since the disruption of the microbubbles occurs only
at the targeted site when it’s being exposed to ultra sound waves. Therefore drug
is released at a particular site.
2.6.6 Paramagnetic Nanoparticles
Magnetic drug targeting is conceptualized with an objective to target magnetic drug

carrier particles at a specific site in the body using an externally applied magnetic field.
Magnetic nanoparticles are a class of particulate materials of less than 100 nm size that
can be manipulated under the magnetic field. These particles are composed magnetic
elements such as cobalt, nickel, iron and their respective oxides such as magnetite,
maghemite, cobalt ferrite and chromium dioxide. The classification of these particles is
based on their magnetic susceptibility which is defined as ratio of induced magnetiza-
tion to the applied field. Paramagnetic nanoparticles have a greater magnetic suscepti-
bility than conventional contrast agents. They are investigated for both diagnostic and
therapeutic purposes. For diagnostic purpose paramagnetic iron oxide nanoparticles are
used as contrast agents in magnetic resonance imaging. Targeting with paramagnetic
nanoparticles enables identification of specific organs and tissues [96].
• Cancer therapy
Conjugation of paramagnetic nanoparticles with antibodies and their expression in
breast cancer cells have been used with MRI to detect breast cancer cells in vitro
[97]. Moreover conjugation of paramagnetic nanoparticles with luteinizing hor-
mone (releasing hormone as breast cancer cells express LHRH receptors) studied
for the detection of breast cancer cells in vivo. Magnetic nanoprobes such as iron
nanoparticles coated with monoclonal antibodies are used for cancer therapy.
These nanoparticles are targeted towards tumor cells to generate high levels of heat
after their accumulation at the target site by means of an alternating magnetic field
applied externally. Such procedure kills the cancer cells selectively [98].
• Eliminate plasma opsonins and increase in circulation time
On intravenous administration of decoy of nanoparticle plasma opsonins can be
eliminated and reduces uptake of the nanoparticles. Moreover alteration in sur-
face charge of the nanoparticle to neutral by covalent coupling to chemicals
leads to an increase in circulation time
• For internalization
Paramagnetic nanoparticles internalization by macrophages can be overcome by
treatment with drugs like lovastatin which reduce macrophage receptor expres-
sion for the nanoparticle.
• Identification of proteins
Magnetic microparticle probes with nanoparticle probes have been used for
identification of proteins like prostate specific antigen. Here magnetic micropar-
ticles coated with antibodies together with nanoprobes with similar coating and
a unique hybridized DNA barcode are used [99]
• Imaging
Utilization of Iron oxide in MRI imaging faces limitations like specificity and
internalization by macrophages. Monocrystalline iron oxide nanoparticles have
been studied for magnetic resonance imaging of brain. These are rapidly taken up
by the tumor cells [100]. Hence give long lasting contrast enhancement of tumor.
The remaining nanoparticles are removed from the circulation by reticuloendothe-
lial system [100]
• Targeted action
Conjugation of antibodies with paramagnetic nanoparticles to direct the nanopar-
ticle to the target site helped to overcome problems with specificity of action.
2.6.7 Nanosomes
Nanosomes are currently being used for medical applications such as targeting,
diagnosis and therapy.
• Brain targeting
These nanosomes are being developed for treatment of various tumors (CNS
tumors) e.g. silica coated iron oxide nanoparticles coated with polyethylene gly-
col used to access specific areas of brain involved with tumor [101].
• Tumor targeting
Nanosomal delivery with magnetic resonance imaging and laser assist in target-
ing the nanoparticle specifically to the tumor cells and destroy the cells loaded
with these nanoparticles by the heat generated by iron oxide particles by absorb-
ing the infra red light.
• ROS production
Their stable integration with photocatalyst produces reactive oxygen species when
stimulated by light and destroy the target tissue. These nanoform exhibit advantages
over conventional drugs in being much safer without the adverse effects of can-
cerchemotherapy drugs and also the absence of development of drug resistance.
2.6.8 Pharmacyte
Pharmacyte is an ideal nanotechnology-based drug delivery system, which is a

self-powered, computer controlled medical nanorobot system capable of digitally
precise transport, timing, and targeted delivery of pharmaceutical agents to specific
cellular and intracellular destinations within the human body. This nanotechnology
may be constructed using future molecular manufacturing technologies such as

diamond mechanosynthesis. Pharmacytes will have many applications in nano-
medicine such as initiation of apoptosis in cancer cells and direct control of cell
signaling processes [102].
2.6.8.1 Niosome
Niosome is a class of molecular cluster formed by self-association of non-ionic

surfactants in an aqueous phase. The unique structure of niosome presents an effec-
tive novel drug delivery system (NDDS) with ability of loading both hydrophilic
and lipophilic drugs. Niosomes are vesicles composed of non-ionic surfactants,
which are biodegradable, relatively nontoxic, more stable and inexpensive, an alter-
native to liposomes. Niosomes behave in vivo like liposomes, prolonging the circu-
lation of entrapped drug and altering its organ distribution and metabolic stability.
As with liposomes, the properties of niosomes depend on the composition of the
bilayer as well as method of their production. It is reported that the intercalation of
cholesterol in the bilayers decreases the entrapment volume during formulation, and
thus entrapment efficiency. However, differences in characteristics exist between
liposomes and niosomes, especially since niosomes are prepared from uncharged
single-chain surfactant and cholesterol, whereas liposomes are prepared from
double-chain phospholipids (neutral or charged). The concentration of cholesterol
in liposomes is much more than that in niosomes. As a result, drug entrapment effi-
ciency of liposomes becomes lesser than niosomes. Besides, liposomes are expen-
sive, and its ingredients, such as phospholipids, are chemically unstable because of
their predisposition to oxidative degradation; moreover, these require special stor-
age and handling and purity of natural phospholipids is variable. Current opinions
for the utilization of niosomes in the delivery of biomolecules can be unsubstanti-
ated with a wide scope in encapsulating toxic drugs such as anti-AIDS drugs, anti-
cancer drugs, and anti-viral drugs. Niosomes offers a promising carrier system in
comparison with ionic drug carriers, which are relatively toxic and unsuitable.
However, the technology utilized in niosomes is still in pipeline. Therefore
researches are going on to develop a suitable technology for large production
because it is a promising targeted drug delivery system.
2.6.9 Dendrimers
Dendrimers are a unique class of polymers, are hyperbranched, tree-like structures,

whose size and shape can be precisely controlled and have compartmentalized
chemical polymer. Dendrimers are fabricated from monomers using either conver-
gent or divergent step growth polymerization. Size of these regular branching poly-
meric nanostructures is dependent on the number of branching which can be
controlled. These nanostructures arise several branches from the core in shape of a
spherical structure by means of polymerisation, resulting in formation of cavities
within the dendrimer molecule which can be used for drug transport. Free ends of
dendrimer can be utilized for conjugation or attachment to other molecule. These
end groups that can be tailored according to requirements. Such interconnecting
networks transport the attached molecules at desirable site and give dendrimers
various functional applications [103]. These well defined nanostructures are
equipped with surface functionalization capability, monodispersity of size, and sta-
bility properties that make them attractive drug carrier candidates. Incorporation of
drug molecule can be easily achieved via either complexation or encapsulation. As
far as the construction is concerned it contains three different basic regions: core,
branches, and surface (Fig. 2.1). Branches or end groups can be tailored or modified
into biocompatible compounds with low cytotoxicity and high biopermeability.
Such branches or networks assist in delivery of bioactive ranging from vaccines,
drugs, genes and metal to desired sites. Hollow networks present in dendrimers
presents space to incorporate drugs and other bioactive physically or by various
interactions to act as drug delivery vehicles. Dendrimers covers various distinct
applications mainly are solubilization, gene therapy, dendrimer based drug delivery,
immunoassay and MRI contrast agent. List of the various drugs that can be deliv-
ered through dendrimers are highlighted in Table 2.5. This hollow branched nano-
structure is an ideal carrier for drug delivery due to several advantages like:
• Can be modulated for target-specific drug delivery
• Feasibility to develop with defined molecular weight
• Good entrapment efficiency
• Offering surface for functionalization
• Very low polydispersity index
• Very low size (1–5 nm)
Variety of polymers (single or in combinations) are used for designing drug
delivery system in form of dendrimers:
• Andpoly(ethylene glycol)
• Chitin
• Melamine, poly(L-glutamic acid)
• Poly(propyleneimine),
• Polyamidoamine
• Polyethyleneimine
• Drug and gene delivery

Dendrimers are being investigated for both drug and gene delivery, as carriers for
penicillin, and for use in anticancer therapy.
• Imaging, targeting & diagnosis of disease
Complexes of dendrimers such as tectodendrimers with each dendrimer module
of the complex performing different functions such as targeting, diagnosis of
disease state, delivery of drug and imaging.
Table 2.5 List of drugs that can be delivered through Dendrimers [67]
Type of dendrimers/ Target cells/indications/ Advantages/
Drugs/therapeutics conjugates functions features
Boron EGF-carrying Neuron capture Intratumoral
PAMAM dendrimers technology injection or CED
Doxorubicin 2,2 Colon carcinoma cells of In vitro and in vivo,
bis(hydroxymethyl) rat dendrimer product
propanoic acid-based was ten times less
dendrimers toxic
Efavirenz Tuftsin-conjugated HIV Targeted delivery to
PPE dendrimers macrophages
EGFR siRNA Dendriworms Knockdown EGFR IV or CED
expression
Galactosylceramide Multivalent HIV-1 Higher stability and
analogues phosphorus- anti-viral property,
containing catanionic lower toxicity
dendrimers
Lamivudine Mannose-capped HIV Increased cellular
PPE dendrimers uptake, reduced
cytotoxicity
Plasmid pEGFP-N2 Angiopep-carrying Encode green IV
PEGylated PAMAM fluorescence protein
dendrimer G5.0
siRNA Amino-terminated Lymphocytes Reduced HIV
carbosilane infection, in-vitro
dendrimers
SN38 G3.5 PAMAM Hepatic colorectal cancer Increase oral
dendrimers cells bioavailability and
decrease
gastrointestinal
toxicity
Sulphated Polylysine HIV Higher activity due
oligosaccharides dendrimers to dendrimer
product
PAMAM Poly(amido amine), PPE poly (propyleneimine)
• Chemotherapy
Tectodendrimers are the nano device that acquires potential applications in can-
cer chemotherapy as a mode of targeted drug therapy [104]
• Gene therapy
Dendrimers can be used for gene therapy where these can replace conventional
viral vectors. They enter the cells by endocytosis and the DNA gets transported
into nucleus for transcription of the applied gene.
• Stimulation of immune reaction
The advantage of dendrimer based therapy is absence of stimulation of immune
reaction.
• Gene transfer
It was studied that the potential use of transferring conjugated gene transfer for
tumors of various tumors PEG modified polyamidoamine dendrimers and mag-
netic nanoparticle modified dendrimers for targeted gene delivery to the brain
and in transfer of antisense surviving oligonucleotides in tumor cell lines. These
methods provide an effective alternative to viral vectors of gene transfer for treat-
ment of various tumors [105]
• Transfection
Various dendrimer based DNA transfection kits (NanojuiceTM Transfection Kit
produced by EMD Chemicals Inc. and Superfect® Transfection Reagent of
Qiagen) are used for delivering DNA into the cell. These are claimed to have
improved transfection efficacy and low toxicity to cells [106]
• Antiretroviral therapy
Dendrimer based drugs are being tried for antiretroviral therapy. Some of the
dendrimer based drugs was found to successfully prevent simian HIV infection
• Treatment of cancer
Treatment of cancer by conjugating with anti-cancer drugs like cisplatin, adriamycin
or methotrexate [107]. PAMAM dendrimers can also be used in treatment of
cancer.
• Reduces the cytotoxicity
While antibacterial investigation it was observed that PEG coating of the den-
drimer reduces the cytotoxicity of unmodified PAMAM dendrimers. Hover
reduces the efficacy against Gram positive bacteria without change in efficacy
against Gram negative bacteria like Pseudomonas
• Contrast agents for imaging
Dendrimers are also used as contrast agents for imaging. The 1, 4-diaminobutane
core dendrimer and the PAMAM dendrimer are well studied commercially avail-
able dendrimers for imaging studies. Renal excretion is the main route of clear-
ance and is dependent on the size of the particle and more than 60 % of injected
DAB or PAMAM dendrimer is cleared from circulation within 15 min
• Rapid clearance
Smaller sized dendrimers undergo rapid renal clearance whereas dendrimers
with charged surface or hydrophobic surfaces are rapidly cleared by the liver.
Those dendrimers with a hydrophilic surface escape renal clearance and have a
greater circulation time
2.6.9.2 Toxicity
Toxicity profile of dendrimers renders them not very popular system for use as
delivery means. Cationic dendrimers have a greater potential to cause cytotoxicity
compared to anionic dendrimer or PAMAM dendrimers. It is proposed to cause cell
membrane instability and cell lysis. The toxicity of dendrimer is dependent on the
size of the particle and increase with size. It can be reduced by means of surface
modification of the dendrimers with incorporation of PEG or fatty acids
2.6.10 Nanopores
Nanopores were designed in 1977, consist of wafers with highly dense pore of size
20 nm (diameter). Main advantage of these nanopores that they doesn’t allow the
entry of oxygen glucose and other products. They can be potentially utilized to pro-
tect transplanted tissues from the host immune system.
2.6.10.1 Application
• DNA sequencing
Currently several researchers are working on modified nanopores that have the
ability to differentiate DNA strands based on differences in base pair sequences.
Nanopores are also being developed with ability to differentiate purines from
pyrimidines.
• Pharmacogenomics in drug development process
DNA sequencing via nanopores could possibly read a thousand bases per second
per pore. These can be used for low cost high throughput genome sequencing
which would be of great benefit for application of pharmacogenomics in drug
development process.
• Treatment for insulin dependent diabetes mellitus:
β cells of pancreas can be enclosed within the nanopore device and implanted in
the recipient’s body.
2.6.11 Microbivores
Function of these nano based hypothetical forms is to trap circulating microbes just
like the function of white blood cells in the blood stream. They are designed in such
a way so that they acquire greater efficacy than cellular blood cells in phagocytosis.
Their surface is arranged in such a fashion which can extend in length and secure
the microbe which gets in contact with it. Entrapped microbe will be gradually
transferred to the ingestion port and undergoes the process of morcellization and
enzymatic degradation. Degraded products are ultimately released as amino acids,
fatty acids, nucleotides and sugars.
2.6.11.1 Application
• Clear the blood circulation

Microbivores could theoretically clear the blood stream in septicaemia at a much
greater rate than the natural defense mechanism with antibiotics [108]
2.6.12 Nanocrystals and Nanosuspension
These are aggregated structures that are formed by the combination of various par-
ticles of drug in crystalline form coated with surfactant or combination of surfac-
tants. To achieve static and electrostatic surface stabilization a minimum quantity of
surfactants needs to be added in nanocrystals. These aggregated forms reduce limi-
tations of several drugs that are suffering from bioavailability and absorption prob-
lems. In addition problems of preparing the parenteral dosage form may be resolved
by formulation as nanocrystals. Loading capacity especially in carrier-based
nanoparticles is quite low however administration of high drug levels with depot
release can be achieved if dissolution is sufficiently slow. Nanocrystal technology
can be utilized for many dosage forms.
• Drugs in pipeline
Nanocrystals such as Rapamune®, containing sirolimus which is an immunosup-
pressant drug and Emend®, which contains aprepitant, MK 869, are in pipeline
• Favorable drug delivery system
Serve as a favorable delivery system for drugs like amphotericin B, tacrolimus, etc.
• Safe and effective passage
The size of nanocrystals allows for safe and effective passage through capillaries.
• Targeting
Nanoparticles offer the potential for targeting the mucosa of the gastrointestinal
tract after oral administration, and targeting the cells of the mononuclear phago-
cytic system (MPS) to treat infections of the MPS such as fungal mycobacterial
infections and leishmaniasis.
2.6.12.2 Toxicity
Since pure drug is used and no carrier is needed, eliminating potential toxicity
issues associated with the carrier molecule.
2.6.13 Solid Lipid Nanoparticles
Solid lipid nanoparticles were developed as an alternative carrier system to lipo-

somes, polymeric nanoparticles and emulsions as a colloidal carrier system for con-
trolled drug delivery. Solid lipid nanoparticles carry distinct advantages that make
them unique carriers systems than others like liposomes and polmeric nanoparticles.
This type of nanoparticles constitute solid lipid matrix with an average diameter
below 1 μm. Drug is normally incorporated in this matrix. These nanoparticles can
also be produced by high pressure homogenization. Different surfactants are used to

avoid aggregation and to stabilize the dispersion. These surfactants have an accepted
GRAS (Generally Recognized as Safe) status.
• Can be used for diverse route system

SLN have been developed and investigated for parenteral, pulmonal and dermal
application routes.
• Non-viral transfection
SLN have been considered as new transfection agents using cationic lipids for
the matrix lipid composition. Cationic solid lipid nanoparticles for gene transfer
can be formulated using the same cationic lipids as for liposomal transfection
agents. Cationic lipid composition seems to be more dominant for in vitro trans-
fection performance than the kind of colloidal structure it is arranged in. Hence,
cationic SLN extend the range of highly potent non-viral transfection agents by
one with favorable and distinct technological properties.
2.6.14 Silicon-Based Structures
These silicon-based structures can be fabricated by techniques such as etching, pho-

tolithography, and deposition commonly used in the manufacture of and microelec-
tromechanical systems and semiconductors. Among various silicon-based materials,
porous silicon and silica, or silicon dioxide are the most materials that are architec-
ture in form of calcified nanopores, platinum materials containing nanopores, porous
nanoparticles, and nanoneedles. Nanopores size (diameter) and density can be accu-
rately controlled to achieve a constant drug delivery rate through the pores. There are
various forms (porous hollow silica nanoparticles) that are fabricated in a suspension
containing sacrificial nanoscale templates. This followed by the addition of silica
precursors, such as sodium silicate, into the suspension, which is then dried and cal-
cinated. Template material is then dissolved further leaving behind the porous silica
shell. These nanoparticles mixed with the drug molecule and subsequently drying the
mixture to coalesce the drug molecules to the surface of the silica nanoparticles.
Various examples of therapies being studied for use with silicon-based delivery sys-
tems include
• For delivery of antitumor agent

Porous silicon embedded with platinum is reported
• Act as an artificial growth factor

Calcified porous silicon designed is reported
• For antibody delivery
Silicon nanopores are reported
• For antibiotics, enzymes, and DNA delivery
Porous silica nanoparticles are reported
2.6.15 Metallic Nanoparticles
Currently these nanoparticles are emerging as good delivery carrier for drug and
biosensor. For the synthesis of metallic nanoparticles diverse metals have been
explored though silver and gold nanoparticles are of prime importance for biomedi-
cal use (Fig. 2.1). Surface functionalization on these nanonarticles can easily been
done and various ligands have been decorated onto the surface. Variety of ligands
such as sugars, peptide, protein and DNA has been linked to nanoparticles.
Metallic nanoparticles have been used for active delivery of bioactive, drug discov-
ery, bioassays, detection, imaging and many other applications due to surface func-
tionalization ability, as an alternative to quantum dots.
2.6.16 Liposomes
Liposomes are lipid based vesicles that are extensively explored and most devel-
oped nanocarriers for novel and targeted drug delivery. Drugs that can deliver
through liposomal delivery system are highlighted in Table 2.6. These vesicles are
synthesized by hydration of dry phospholipids. Depending upon on their size and
number of bilayers they are classified into three basic types:
• Multilamellar vesicles
These vesicles consist of several lipid bilayers separated from one another by
aqueous spaces. These entities are heterogeneous in size, often ranging from a
few hundreds to thousands of nanometers in diameter.
• Small unilamellar vesicles
Small unilamellar vesicles consist of a single bilayer surrounding the entrapped
aqueous space having size range less than 100 nm.
• Large unilamellar vesicles
These vesicles consist of a single bilayer surrounding the entrapped aqueous
space having diameters larger than 100 nm.
Table 2.6 Liposomes and their respective model drugs [67]

Therapeutics Type of liposome Indications
Amiloride hydrochloride Small molecular liposome Cystic fibrosis
Budesonide Small molecular liposome Asthma
Doxorubicin + Verapamil Transferrin- (Tf-) conjugated MDR-leukemia
PEG-Liposome
Insulin Protein liposome Diabetes
Interleukin-2 Protein liposome Lung cancers
Irinotecan + Cisplatin Mixture of two liposomes Small-cell lung cancer
Ketotifen Small molecular liposome Asthma
siRNA + Doxorubicin PEG-Liposome MDR-breast cancer
Tobramycin Small molecular liposome Pulmonary infections
Topotecan + Vincristine PEG-Liposome Brain cancer
VEGF gene Gene liposme Pulmonary hypertension
VEGF vascular endothelial growth factor
Based on the physicochemical characteristics drug molecules can be entrapped

in the aqueous space or intercalated into the lipid bilayer of liposomes. Liposomes
are prepared with distinct structure, composition, size, flexibility with variety of
surface modification. Such availability of liposomes with enormous diverse proper-
ties makes them most intelligent carrier system for both active and passive delivery
of bioactive.
They have been successfully exploited in cancer therapy, carrier for antigens, pul-
monary delivery, leishmaniasis, ophthalmic drug delivery etc. Some of liposome-
based formulations are already in market (Table 2.5).
2.6.17 Polymeric Micelles
Polymeric micelles contains amphiphilic block copolymers assemble to form nano-

scopic supramolecular core-shell structures called as ‘polymeric micelles’. These
micelles are formed in solution as aggregates in which the component molecules are
generally arranged in a spheroidal structure with hydrophobic cores shielded from
water by a mantle of hydrophilic groups (Fig. 2.1). There are several examples of
component molecule such as Amphiphilic AB-type or ABA-type block copoly-
mers, where A and B are hydrophobic and Hydrophilic components, respectively.
These polymeric micelles are usually <100 nm and are used for the systemic deliv-
ery of water-insoluble drugs. Their hydrophilic surface of these dynamic systems
protects their nonspecific uptake by reticuloendothelial system. Polymeric micelle
carries advantage in trapping drugs or contrast agents physically within the hydro-
phobic cores or can be linked covalently to component molecules of the micelle.
Additionally they are proved as an excellent novel drug delivery system due to their
high stability in physiological conditions, high and versatile loading capacity, high
accumulation of drug at target site, possibility of functionalization of end group for
conjugation of targeting ligands and slower rate of dissolution.
2.6.18 Polymer Drug Conjugate
Polymer drug conjugate formed by the conjugation of low molecular weight drugs
with polymer. This interaction/conjugation causes drastic change in pharmacoki-
netic disposition of drug in whole body and at cellular level. They are designed to
increase the overall molecular weight, which facilitates their retention in cancer
cells through enhanced permeation and retention effect using passive delivery
approach.
2.6.19 Polyplexes/Lipopolyplexes
Polyplexes/Lipopolyplexes are the assemblies which are used in transfection proto-

cols. These assembies are formed by spontaneous interaction between nucleic acids
and polycations or cationic liposomes (or polycations conjugated to targeting
ligands or hydrophilic polymers). Usually composition and charge ratio of nucleic
acid to that of cationic lipid/polymer determines the shape, size distribution, and
transfection potential of these complexes. Current research offers various types of
polycations that have been used in gene transfer/therapy protocols:
• Cationic cyclodextrin
• Linear- and branched-poly (ethyleneimine)
• Poly (amidoamine)
• Poly-amino esters
• Poly-L-lysine
2.6.20 Respirocytes
These are hypothetical nanodevices or called as artificial red blood cells 51 and
function as red blood cells but with greater efficacy. Respirocytes are having higher
capacity to deliver oxygen to tissues. Their oxygen supplying capacity is 236 times
more oxygen per unit volume than natural red blood cells. Respirocytes equipped
with sensors on their surface which can detect changes in the environment. There is
also a provision to regulate the intake and output of the oxygen and carbon dioxide
molecules. According to past investigation an infusion of 1 L dose of 50 % respiro-
cytes saline suspension in a human can theoretically keep the patient oxygenated up
to four hours following cardiac arrest [109]. According to FDA these devices are
regulated under the provisions of the Medical Device Amendments of 1976, Safe
Medical Devices Act of 1990, and the Medical Device Amendments of 1992 [110].
2.6.21 Polymeric Nanoparticles
The main objective of our book is to explore the recent nano application of wide
array of natural polymers obtained from different sources. Natural polymers based
nano-conjugates and their advance applications are discussed in this chapter. In
addition various drug delivery and targeting based considerations are also discussed.
Natural polymer based nanoparticles are usually biocompatible and non toxic,
although often suffer from stability problems when delivered across the various
biological membranes. Such delivery exposed nanoparticles against various
pH. This variation in pH and certain other problems limit their use sometime.
Polymeric nanoparticles consist of a biodegradable polymer which is biocompat-
ible and non toxic. Feature such as biocompatibility is required for potential applica-
tion in tissue engineering, drug and gene delivery and new vaccination strategies.
Recently research explore some advance modification of natural polymers which
consists of synthetic polyesters like poly(D, L-lactide) or polycyanoacrylate and
related polymers like poly(lactide-co-glycolide) PLA or poly(lactid acid). Among
natural polymers the most widely used polymer which is used now days is chitosan.
In addition to chitosan many other such as gelatin, and sodium alginate overcome
some toxicological problems with the synthetic polymers. Natural polymer based
nanoparticles offers a significant improvement over traditional oral and intravenous
methods of drug delivery system in terms of efficiency and effectiveness. The vari-
ous natural polymers like gelatin, albumin and alginate are used to prepare the
nanoparticles. However they have some inherent disadvantages like poor batch-to
batch reproducibility, prone to degradation and potential antigenicity. Various poly-
meric nanoparticles and their respective model drugs are highlighted in Table 2.7.
Synthetic polymers used for nanoparticles preparation may be in the form of pre-
formed polymer e.g. polyesters like polycaprolactone (PCL), poly lactic acid (PLA)
or monomers that can be polymerized in situ e.g. polyalkyl cyanoacrylate. There are
many advantages of using polymeric nanoparticles in drug delivery:
• Biocompatable and biodregerable
• Increase the stability of any volatile pharmaceutical agents
• Less toxic
• They are easily cheaply fabricated in large quantities by a multitude of methods
• Have engineered specificity, allowing them to deliver a higher concentration of
pharmaceutical agent to a desired location
• Nonimmunogenicity and nontoxicity
Table 2.7 Different types of Polymer used for the preparation of nanoparticle [16]
Polymer Model drug Technique
Hydrophilic Albumin, Gelatin Hydrophilic and protein Desolvation and cross linking
affinity in water
Hydrophilic Albumin,Gelatin Hydrophilic Heat denaturation and cross
linking in w/o emulsion
Hydrophilic Alginates and chitosan Hydrophilic and protein Cross-linking in water
affinity
Hydrophilic Dextran Hydrophilic Polymer precipitation in an
organic solvent
Hydrophobic Hydrophilic Emulsion polymerization
Poly(alkylcyanoacrylates)
Hydrophobic Hydrophobic Interfacial O/W
Poly(alkylcyanoacrylates) polymerization
Polyesters Poly (lactic acid), Hydrophilic and Solvent extraction
poly(caprolactone) Hydrophobic Soluble in evaporation
polar solvent
Polyesters Poly (lactic acid), Poly Hydrophilic and Solvent displacement
(lactide-co-glycolide), Hydrophobic Soluble in
polar solvent
Polyesters Poly (lactic acid), Poly Soluble in polar solvent Salting out .
(lactide-co-glycolide)
Various polymers that have been used recently for the preparation of nanoparti-
cles are mentioned in Table 2.8.
Polymeric nanoparticles (Fig. 2.1) provide an alternative to abovementioned
nanosystems due to some inherent properties like biocompatibility, nonimmunoge-
nicity, nontoxicity and biodegradability. These are colloidal carrier, 10 nm−1 μm in
size, consisting of synthetic or natural polymers. Polymeric nanoparticles are a
broad class comprised of both vesicular systems (nanocapsules) and matrix systems
(nanospheres). Nanocapsules are systems in which the drug is confined to a cavity
surrounded by unique polymeric membrane whereas nanospheres are systems in
which the drug is dispersed throughout the polymer matrix. Polymeric nanoparti-
cles are considered as a matrix system in which the matrix in uniformly dispersed.
It should be mentioned, that besides of these spherical vesicular systems nanocap-
sules are also known, where a polymeric membrane surrounds the drug in a matrix
core. The candidate drug is dissolved, entrapped, attached or encapsulated through-
out or within the polymeric shell/matrix. The choice of polymer and the ability to
modify drug release from polymeric nanoparticles have made them ideal candidates
for cancer therapy, delivery of vaccines, contraceptives and delivery of targeted
antibiotics. Moreover, polymeric nanoparticles can be easily incorporated into other
activities related to drug delivery, such as tissue engineering, and into drug delivery
for species other than humans. Depending on the method of preparation, the release
characteristic of the incorporated drug can be controlled. Polymeric nanoparticulate
systems are attractive modules for intracellular and site specific delivery.
Table 2.8 Various examples of drugs those can be delivered through polymeric nanoparticles [67]
Type of polymer/
Therapeutics functionalization Indication/activity Effects
Amphotericin B PLA-b-PEG Neurodegenerative Improved transport
diseases across the BBB
Cisplatin Aptamer- PEG-PLGA Prostate cancer Higher efficiency
Doxorubicin + Cyclo- PACA Various cancers Synergistic effect.
sporine A
Lamivudine Methylmethacrylate- HIV/AIDS 100 % increased
sulfopropylmethacrylate BBB permeability
Nerve growth factor Polysorbate 80 coated Parkinsonism Improved transport
(NGF) PBCA across the BBB
Paclitaxel Aptamer- PEG-PLGA Gliomas Enhanced delivery
Stavudine Polybutylcyanoacrylate HIV/AIDS 8–20 times higher
(PBCA) Permeability
Vincristine + Vera- PLGA Hepatocellular Reduced multidrug
pamil carcinoma resistance
Zidovudine Poly (isohexyl cyanate) Targeting lymphoid Drug levels is four
tissue times higher
Zidovudine Polyhexylcyanoacrylate Targeting lymphoid Higher Zidovudine
tissue levels in the body
PACA Polyalkylcyanoacrylate, PLA-b-PEG Polysorbate 80 coated poly(lactic acid)-b-
poly(ethylene glycol), PLGA poly (lactide-co-glycolide)
Nanoparticles can be made to reach a target site by virtue of their size and surface
modification with a specific recognition ligand. Their surface can be easily modified
and functionalized. From the polymer chemistry viewpoint, there will be in the
future a challenging field to create new polymers matching hydrophilic and lipo-
philic properties of upcoming drugs for smart formulation.
2.6.22 Applications of Nanoparticulate Delivery Systems
Targeting of the drug to cells or tissue of choice is the potential area in drug delivery.
With the assistance of proficient drug targeting systems it’s now possible to decide
the fate of a drug entering in the body. Modern drug delivery systems and technolo-
gies are far away from the model of magic bullet (proposed by Paul Ehrlich) in
which the drug is precisely targeted to the exact side of action. Nanotechnology
present challenge to achieve this goal (to deliver the drug in the right place at the
right time) a bit closer [111]. Branch of nanotechnology is anticipated to bring a
fundamental transformation in manufacturing and have an enormous impact on Life
Sciences especially in delivery, diagnostics, nutraceuticals and the production of
biomaterials. In delivery systems targeting is the ability to direct the drug-loaded
system to desirable site. There are two major mechanisms (addressing the desired
sites for drug release) involved in this process (Table 2.9):
Table 2.9 Various applications of nanotechnology in the different field

Applied field Application
Agriculture Atomic force, microscopic and scanning tunnelling microscope
Chemical and Cosmetics Nanoscale chemicals and compounds, paints, coatings etc.
Electronics Semiconductors chips, memory storage, photonica,
optoelectronics
Environment and Energy Water and air purification filters, fuel cells, Photovoltaic
Food Sciences Processing, nutracetical food, nanocapsules
Materials Nanoparticles, carbon nanotubes, biopolymers, points, coatings
Military and Energy Biosensors, weapons, sensory enhancement
Nanomedicines Nano drugs, Medical devices, Tissue Engineering
Scientific Tools Atomic force, microscopic and scanning tunnelling microscope
2.6.23 Passive Targeting
Most popular example of passive targeting is the preferential accumulation of che-

motherapeutic agents in solid tumors. This result in to the enhanced vascular perme-
ability of tumor tissues compared with healthy tissue. In passive targeting
ligand–receptor interactions can be highly selective; hence precise targeting at the
site of interest [112] is possible. In this process targeting with nanoparticles encoun-
ters multiple obstacles on the way to their target. These include mucosal barriers,
nonspecific uptake of the particle and non-specific delivery of the drug (as a result
of uncontrolled release).
2.6.24 Active Targeting
Active targeting allows the surface functionalization of drug carriers with ligands
that are selectively recognized by receptors on the surface of the cells of interest.
Therefore, two most important aspects of nanoparticle drug delivery must be:
• Specific targeting of the diseased tissue with nanoparticles
Appropriate size and functionalization with antibodies or other means of selec-
tive binding provides means of enhanced delivery of drugs and reduced nonspe-
cific toxicity. This issue can be resolved by functionalization of the nanoparticles
with recognition elements on their surfaces towards receptors present on the par-
ticular diseased tissue. Conjugation with short chain variable fragments (scFvs)
or antibodies will provide selective binding to the specific cell’s surface, and
their endocytosis will be enhanced with suitably adjusted binding affinities.
• Timed release of the drug
To prevent nonspecific toxicity the drug must not diffuse out of the particle while
it is still in the circulatory system, and must remain encapsulated until the particle
binds to the target. For addressing this issue, nanoparticles with multilayeres can
be engineered, where each layer will contain one drug from the cocktail, and their
release will be sequenced in accordance with the appropriate timing of the delivery
of each drug for combination therapy.
Nanoparticles can be significantly used in targeted drug delivery at the site of
disease
• Improve the drug bioavailability
• Targeting of drugs to a specific site
• To improve the uptake of poorly soluble drugs
Chemotherapeutic agents such as dexamethasone, doxorubicin 5-fluorouracil and
paclitaxel have been successfully formulated using nanomaterials. To encapsulate
dexamethasone (a glucocorticoid with an intracellular site of action) polylactic/gly-
colic acid (PLGA) and polylactic acid (PLA) based nanoparticles have been used.
Dexamethasone potentially binds to the cytoplasmic receptors and the subsequent
drug-receptor complex is transported to the nucleus resulting in the expression of
certain genes that control cell proliferation [113]. Site-specific-targeted drug delivery
is important for such class of drugs in the therapeutic modulation of effective drug
dose and disease control. NPs have been reported for their potential use in targeting
to improve the bioavailability, reducing side effects, decreasing toxicity to other
organs. This less costly NP-based drug delivery is feasible in hydrophilic and hydro-
phobic states through variable routes of administration such as oral, vascular, and
inhalation. Advantages of using nanoparticles in drug development and discovery
• Nanoparticles can better deliver drugs to tiny areas within the body.
• Engineering on this scale enables researchers to exercise exquisite and previ-
ously unthinkable control over the physical attributes of polymers and other
biomaterials.
• Nanocarriers holds promise to deliver biotech drugs over various anatomic
extremities of body such as blood brain barrier [114]
• Nanoparticles aid in efficient drug delivery to improve aqueous solubility of
poorly soluble drugs that enhance Bioavailability for timed release of drug mol-
ecules, and precise drug targeting.
• Nanoparticles overcome the resistance offered by the physiological barriers in
the body
• Particle size and surface characteristics of nanoparticles can be easily manipu-
lated to achieve both passive and active drug targeting after parenteral
administration.
• Site-specific targeting can be achieved by attaching targeting ligands to surface
of particles or use of magnetic guidance.
• Targeted nano drug carriers reduce drug toxicity and provide more efficient drug
distribution.
• The surface properties of nanoparticles can be modified for targeted drug deliv-
ery for e.g. small molecules, proteins, peptides, and nucleic acids loaded nanopar-
ticles are not recognized by immune system and efficiently targeted to particular
tissue types.
• The system can be used for various routes of administration including oral, nasal,
parenteral, intra-ocular etc. [115]
• They control and sustain release of the drug during the transportation and at the
site of localization, altering organ distribution of the drug and subsequent clear-
ance of the drug so as to achieve increase in drug therapeutic efficacy and reduc-
tion in side effects because efficient delivery of drug to various parts of the body
is directly affected by particle size.
2.6.25 Tumor Targeting Using Nanoparticulate Delivery

Systems
The rationale of using nanoparticles for tumor targeting is based on one of the most
efficiency of nanoparticles is delivering drug in the area of the tumor targets via the
enhanced permeability and retention effect. This can also be achieved by active
targeting by ligands on the surface of nanoparticles
Nanoparticles limits the drug distribution to target organ, hence reduces the drug
exposure against healthy tissues. It was reported that mice treated with doxorubicin
based poly (isohexylcyanoacrylate) nanopsheres showed higher concentrations of
doxorubicin in the liver, spleen and lungs than in mice treated with free doxorubicin
[116]. It was also demonstrated that polymeric composition of nanoparticles such as
biodegradation profile of the polymer along with the associated drug’s molecular
weight, polymer type, its localization in the nanospheres and mode of incorporation
technique, adsorption or incorporation and hydrophobicity have a great influence on
the drug distribution pattern in vivo. In addition nanaoparticles are advantageous in
their rapid nanoparticles rate, within 1/2 h to 3 h, and it likely involves MPS and
endocytosis/phagocytosis process [117].
Earlier report suggested the biodistribution and pharmacokinetics (PK) pattern of
a cyclic RGD doxorubicin-nanoparticle formulation in tumor bearing mice [118].
During this biodistribution study it was revealed that drug concentrations over time in
the heart, lung, kidney and plasma was decreases and drug accumulation has been
found in the liver, spleen and tumor. Maximum of the injected dose was observed in
the liver (56 %) and only 1.6 % in the tumor at 48 h post injection. This study ensures
that nanoparticles have a great tendency to be captured by liver. This and several other
studies indicates the greatest challenge of using nanoparticles for tumor targeting is to
avoid particle uptake by mononuclear phagocytic system (MPS) in liver and spleen.
Such tendency of mononuclear phagocytic system for endocytosis/phagocytosis of
nanoparticles provides an opportunity to effectively deliver therapeutic agents to
these cells. This biodistribution can be of benefit for the chemotherapeutic treatment
of mononuclear phagocytic system rich organs/tissues localized tumors
• Brochopulmonary tumors
• Gynaecological cancers
• Hepatic metastasis arising from digestive tract
• Hepatocarcinoma,
• Mall cell tumors

• Myeloma and leukemia
• Primitive tumors and metastasis
According to earlier report it has been proven that the utilization of doxorubicin
loaded conventional nanoparticles was effective against hepatic metastasis model in
mice. Moreover it was also discovered that greater reduction in the degree of metas-
tasis than when free drug was used. This is possible due to the allocation of drug
reservoir to the malignant tissues and transfer of doxorubicin from healthy tissue,
resulting in increased therapeutic efficacy of the formulation [119]. Several other
parameters such as histological examination of tissue ensures considerable accumu-
lation of nanoparticles in the lysosomal vesicles of Kupffer cells, whereas nanopar-
ticles could not be clearly identified in tumoral cells [119].
Following a massive uptake of nanoparticles by phagocytosis, Kupffer cells,
potentially induce the release of doxorubicin, resulting in to drug concentration
gradient, favorable for a prolonged diffusion of the free and still active drug towards
the neighboring metastatic cells [119].
When conventional nanoparticles are used during chemotherapy, toxicity up to
certain extent against the Kupffer cells can be expected would result in deficiency of
Kupffer cells. This may finally resulted in to the reduced liver uptake and decreased
therapeutic effect [120]. In addition, conventional nanoparticles can also be a excel-
lent target for bone marrow. Bone marrow site is an important but unfavorable site
of action for most anticancer drugs since treatment with chemotherapeutic agents at
this site increase myelosuppresive effect. Thus potential of conventional nanoparti-
cles to improve anticancer drugs efficacy is limited to targeting tumors at the level
of mononuclear phagocytic system -rich organs. Furthermore, targeting anticancer
drug-loaded nanoparticles to other tumoral sites is not feasible if a rapid clearance
of nanoparticles occurs shortly after intravenous administration.
2.6.26 Long-Circulating and Target-Specific Nanoparticles
Nanoparticles are known to be the most successful way of delivering drug at

desirable site. They can be used to target tumors which are localized outside
mononuclear phagocytic system rich organs. Instantaneous identification of col-
loidal carriers (liposomes and polymeric nanospheres) from the blood by Kupffer
cells, has begin a surge of development for “Kupffer cell-evading” or long-circu-
lating particles. These carriers have major applications in vascular drug delivery
and release, site-specific targeting (passive as well as active targeting), as well as
transfusion medicine. So much effort has been done to develop so-called “stealth”
particles (PEGylated nanoparticles), which are invisible to macrophages or
phagocytes [121].
Utilization of hydrophilic polymers (poloxamines, poloxamers, polyethylene
glycol, and polysaccharides) has begun a major breakthrough in the nanotechnol-
ogy field to efficiently coat conventional nanoparticle surface produced an opposing

effect to the uptake by the mononuclear phagocytic system [122]. coating around
these nanoparticles provide a active “cloud” of hydrophilic and neutral chains at the
particle surface which repel plasma proteins [123], resulting in to the invisibility of
coated nanoparticles against mononuclear phagocytic system, therefore, remained
in the circulation for a longer period of time. Introduction of hydrophilic polymers
can be achieved in two ways, either by adsorption of surfactants or by use of block
or branched copolymers for production of nanoparticles.
Several studies also proved that PEG coated nanoparticles have a prolonged half-
life in the blood compartment. However they can be selectively extravasate in patho-
logical sites such as tumors or inflamed regions with a leaky vasculature, resulting in
increase in potential of long-circulating nanoparticles directly towards targeted tumors
located outside MPS-rich regions. Several characteristics such as size of the colloidal
carriers and surface characteristics are critical to the biological fate of nanoparticles.
Nanoparticle size (less than 100 nm) and surface characteristics (hydrophilic
surface) obligations are required in achieving the reduction of opsonisation reac-
tions and subsequent clearance by macrophages. Surface coating of conventional
nanoparticles with PEG or surfactants to obtain a long-circulating carrier has now
been used as a standard strategy for drug targeting in vivo. Various researches
have been contributed to achieve “active targeting” of nanoparticles in order to
deliver drugs to the right targets. This is particularly based on molecular recogni-
tion processes such as ligand-receptor or antigen-antibody interaction. Based on
earlier reports related with overexpression of folate receptors on the surface of
some human malignant cells and the cell adhesion molecules (selectins and inte-
grins), it was concluded that nanoparticles bearing specific ligands such as folate
may be used to target ovarian carcinoma while specific peptides or carbohydrates
may be used to target integrins and selectins [124]. In one more report it was sug-
gested that the benefits of folate ligand coating were to facilitate tumor cell inter-
nalization and retention of Gd-nanoparticles in the tumor tissue [125]. Small
ligands based targeting emerges more likely to be successful since they are easier
to handle and manufacture.
In addition they could be more significant when the active targeting ligands are
used in combination with the long-circulating nanoparticles. Such combination can
be used to maximize the likelihood of the success in active targeting of nanoparti-
cles. Since cancer cells are able to develop mechanisms of resistance, deterioration
of multidrug resistance anticancer drugs in tumor cells or in the tumor interstitium
occurs, resulting in to their limited efficacy against numerous solid tumors. Such
mechanism facilitates tumors to evade chemotherapy. One of the most serious prob-
lems in chemotherapy is multidrug resistance, mainly due to the over expression of
the plasma membrane pglycoprotein (Pgp), which is capable of extruding various
positively charged xenobiotics, including some anticancer drugs, out of cells.
Several strategies including the use of colloidal carriers have been applied in order
to restore the tumoral cells’ sensitivity to anticancer drugs by circumventing Pgp-
mediated MDR. The underlying principle behind the drugs association with colloi-
dal carriers (such as nanoparticles), against drug resistance derives from the fact that
Pgp probably recognizes the drug to be effluxed out of the tumoral cells. This can
be achieved only when this drug is present in the plasma membrane, and not when
it is located in the cytoplasm or lysosomes after endocytosis [126].
2.6.27 Nanoparticles for Oral Delivery of Peptides

and Proteins
Exploration of more antigenic substances in biotechnology and biochemistry field

persist the production of vaccines. Owing to the recent advancement biotechnology
various bio macromolecules and vaccines are explored. Thus there is an urgent
requirement of their suitable carriers system which still remains a challenge due to
the fact that bioavailability of these molecules is limited by the epithelial barriers of
the gastrointestinal tract and their susceptibility to gastrointestinal degradation by
digestive enzymes. Polymer based nanoparticles facilitates the encapsulation of bio-
active molecules and protect them against enzymatic and hydrolytic degradation
e.g. insulin-loaded polymeric nanoparticles have preserved insulin activity and pro-
duced blood glucose reduction in diabetic rats for up to 14 days following the oral
administration. It’s universally known that the surface area of human mucosa
extends to 200 times that of skin [127]. Protein or peptide based drug delivery
encountered a variety of physiological and morphological barriers:
• Bacterial gut flora
• Mucus layer and epithelial cell lining itself
• Proteolytic enzymes at the brush border membrane (endopeptidases)
• Proteolytic enzymes in the gut lumen like pepsin, trypsin and chymotrypsin
Histological feature of intestinal mucosa is designed in such a way to efficiently
prevent uptake of particulate matter from the environment. To overcome the gastro-
intestinal barrier, drug can be delivered in a colloidal carrier system (nanoparticles),
which can potentially enhance the interaction mechanisms of the drug delivery sys-
tem and the epithelia cells in the GI tract. Nanoparticles based targeting to epithelial
cells using ligands is an potential strategy to improve the interaction of nanoparti-
cles with adsorptive enterocytes and M-cells of Peyer’s patches in the GI tract. Such
type of targeting can be classified into those utilizing specific binding to ligands or
receptors and those based on nonspecific adsorptive mechanism. M cells display
cell-specific carbohydrates and enterocytes surface may serve as binding sites to
colloidal drug carriers containing appropriate ligands. Several glycoproteins and
lectins efficiently bind to this type of surface structure by specific receptor-mediated
mechanism. Lectins such as tomato lectin and bean lectin have been studied to
enhance oral peptide adsorption [128]. For an instance vitamin B-12 absorption
from the gut under physiological conditions (occurs via receptor-mediated endocy-
tosis) can be enhanced by covalent coupling with peptides such as granulocyte col-
ony stimulating factor, erythropoietin, resulting in enhancement of oral bioavailability
[129]. For making process more efficient and selective mucoprotein is required,
which is prepared by the mucus membrane in the stomach and binds specifically to
cobalamin. After reaching to the ileum mucoprotein resorption is mediated by
selective binding to specific receptors which can further enhance the absorption.
Absorption can also be enhanced by using non-specific interactions. Generally,
absorption of macromolecules and particulate materials in the gastrointestinal tract
is achieved by either paracellular route or endocytotic pathway. Less than 1 % of
mucosal surface area is utilized for the paracellular route of absorption of nanopar-
ticles having polymeric material such as starch or chitosan, poly(acrylate) [130–
132]. Such polymers enhance the paracellular permeability of macromolecules.
Absorption of nanoparticles mediated by endocytotic pathway can be accomplish
by receptor-mediated endocytosis (active targeting) or adsorptive endocytosis which
does not need any ligands. Existence of electrostatic forces (hydrogen bonding or
hydrophobic interactions) between the cell surface and absorbed material encour-
ages this whole process. Adsorptive endocytosis primarily dependent on the size
and surface properties of the material e.g. positive surface charged nanoparticles
provide an affinity to adsorptive enterocytes though hydrophobic, whereas negative
surface charged nanoparticles and hydrophilic shows greater affinity to adsorptive
enterocytes and M cells. So it has been concluded that of size, surface charge and
hydrophilicity play a major role in absorption of material.
2.6.28 Nanoparticles for Gene Delivery
Several vaccines based nanomedicines functions to deliver genes to host cells and
show their expression by production of antigenic protein to initiate immune
response. One of the recent example of polynucleotide vaccines work by delivering
genes encoding relevant antigens to host cells (where they are expressed) producing
the antigenic protein within the vicinity of professional antigen presenting cells to
initiate immune response. Such types of vaccines are responsible for the both
humoral and cell-mediated immunity since intracellular production of protein, as
opposed to extracellular deposition, stimulates both arms of the immune system.
Polynucleotide vaccines are composed of a key ingredient called as DNA, can be
produced economically and has much better storage and handling properties than
the ingredients of the majority of protein-based vaccines. Based on the potential
immunotherapy these polynucleotide vaccines are set to supersede many conven-
tional vaccines. Nevertheless these polynucleotides based vaccine suffers from sev-
eral issues which limit their application. These issues include efficient delivery of
the polynucleotide to the target cell population and its localization to the nucleus of
these cells, and ensuring that the integrity of the polynucleotide is maintained dur-
ing delivery to the target site are still in consideration. Owing to the rapid escape
from the degradative endo-lysosomal compartment to the cytoplasmic compart-
ment, plasmid DNA based nanoparticulate system serve as a potential sustained
release gene delivery system. Previous finding suggested the intracellular uptake
and endolysosomal escape of these nanoparticles offer sustained release of DNA
resulting in sustained gene expression. Such strategy could be utilized to facilitate

bone healing by using PLGA nanoparticles containing therapeutic genes such as
bone morphogenic protein [133, 134].
2.6.29 Nanoparticles for Drug Delivery into the Brain
Nervous system is one of the most delicate microenvironments of the body which is
protected by the blood–brain barrier (BBB) regulating its homeostasis. The blood–
brain barrier (BBB) is the most important factor limiting the development of new
drugs for the central nervous system. BBB is a highly complex structure that tightly
regulates the movement of ions of a limited number of small molecules and of an
even more restricted number of macromolecules from the blood to the brain, pro-
tecting it from injuries and diseases. The BBB is characterized by relatively imper-
meable endothelial cells with tight junctions, enzymatic activity and active efflux
transport systems. It effectively prevents the passage of water-soluble molecules
from the blood circulation into the CNS, and can also reduce the brain concentration
of lipid-soluble molecules by the function of enzymes or efflux pumps. BBB only
permits selective transport of molecules that are essential for brain function, conse-
quently, the BBB also significantly precludes the delivery of drugs to the brain, thus,
preventing the therapy of a number of neurological disorders. As a consequence,
several strategies are currently being sought after to enhance the delivery of drugs
across the BBB. For example polysorbate 80/LDL, transferrin receptor binding
antibody (such as OX26), lactoferrin, cell penetrating peptides and melano transfer-
rin have been shown capable of delivery of a self non transportable drug into the
brain via the chimeric construct that can undergo receptor-mediated transcytosis
[135–139]. It has been discovered that poly(butylcyanoacrylate) based nanoparti-
cles was able to deliver dalargin, hexapeptide, doxorubicin and other agents into the
brain which is significant because of the great difficulty for drugs to cross the
BBB. In addition to several reports which are based on the success of polysorbate
coated NPs, this system does have many shortcomings including rapid NP degrada-
tion, toxicity caused by presence of high concentration of polysorbate and desorp-
tion of polysorbate coating. In addition to some reports OX26 MAbs (anti-transferrin
receptor MAbs), the most studied BBB targeting antibody, have been used to
enhance the BBB penetration of lipsosomes. Presently, there are no effective thera-
pies for many diseases include neurodegeneration (e.g., amyotrophic lateral sclero-
sis, Alzheimer’s, Parkinson’s, Huntington disease, and Prion disease), genetic
deficiencies (e.g. lysosomal storage diseases, leukodystrophy), and several types of
brain cancer. Even if candidate drugs for therapy of such diseases may be already
available in line of principle, they cannot be currently utilized because of their insig-
nificant access to the central nervous system (CNS), due to the presence of the
blood–brain barrier (BBB) preventing the passage from blood to the brain. It is pos-
sible soon we will see these BBB specific molecules used for targeting nanoparti-
cles to the brain.
2.6.30 Anthrax Vaccine Uses Nanoparticles to Produce

Immunity
Anthrax is caused by the spore-forming, Gram-positive bacterium Bacillus anthra-

cis. The toxic effects of B. anthracis are predominantly due to an AB-type toxin
made up of the receptor-binding subunit protective antigen (PA) and two enzymatic
subunits called lethal factor and edema factor. Protective immunity to B. anthracis
infection is conferred by antibodies against PA, which is the primary component of
the current anthrax vaccine. A vaccine against anthrax that is more effective and
easier to administer than the present vaccine has proved highly effective in tests in
mice and guinea pigs, report University of Michigan Medical School scientists in
the August issue of Infection and Immunity. Although the vaccine is safe and effec-
tive, it requires multiple injections followed by annual boosters. The scientists were
able to trigger a strong immune response by treating the inside of the animals’ noses
with a “nanoemulsion” a suspension of water, soybean oil, alcohol and surfactant
emulsified to create droplets of only 200–300 nm in size. The oil particles are small
enough to ferry a key anthrax protein inside the nasal membranes, allowing immune-
system cells to react to the protein and initiate a protective immune response. That
primes the immune system to promptly fight off infection when it encounters the
whole microbe. It would take about 265 of the droplets lined up side by side to equal
the width of a human hair. The oil particles are small enough to ferry a key anthrax
protein inside the nasal membranes, allowing immune-system cells to react to the
protein and initiate a protective immune response. That primes the immune system
to promptly fight off infection when it encounters the whole microbe. Besides elimi-
nating the need for needles, the nanoemulsion anthrax vaccine has another advan-
tage, the researchers say: It is easy to store and use in places where refrigeration is
not available. An effective and easy-to-administer vaccine would be a valuable tool
for health authorities dealing with any future attack in which a terrorist might spread
anthrax microbes. The researchers say a nasal nanoemulsionbased anthrax vaccine,
if it proves effective in humans, could be given easily to people even after they are
exposed in an anthrax attack, along with antibiotics. With some diseases, vaccines
given after exposure are used to boost the speed of the immune response.
2.6.31 Stem Cell Therapy
Nanotechnology presents efficient tools for improving stem cell therapy. The syn-
ergy between size, structure and physical properties of NPs makes them key players
in revealing the fate and performance of stem cell therapy. Clearly NPs have much
to offer in stem cell research and therapy. Stem cell therapies offer great potentials
in the treatment for a wide range of diseases and conditions. With so many stem cell
replacement therapies going through clinical trials currently, there is a great need to
understand the mechanisms behind a successful therapy, and one of the critical
points of discovering them is to track stem cell migration, proliferation and differ-
entiation in vivo. To be of most use tracking methods should ideally be noninvasive,
high resolution and allow tracking in three dimensions. Magnetic resonance imag-
ing is one of the ideal methods, but requires a suitable contrast agent to be loaded to
the cells to be tracked, and one of the most wide-spread in stem cell tracking is a
group of agents known as magnetic nanoparticles. Researchers have successfully
used nanoparticles to improve stem cells potential in stimulating the regeneration of
damaged vascular tissue and reduce muscle degeneration in mice (published online
on October 5 in Proceedings of the National Academy of Sciences). In addition
researchers investigating stem cells role in stimulating new blood vessel formation.
This was investigated after their implantation into a living organism. Cells may not
continue to renew tissue effectively enough to keep the tissue alive long-term.
Hence cells can benefit from help with performance-enhancing genes, which pro-
mote growth in the target tissue. Researchers usually rely on viral vectors to deliver
these therapeutic genes to stem cells. It has been now investigated that (Chemistry
researchers at the University of Warwick) tiny nanoparticles can be utilized for
delivering this therapeutic gene since tiny nanoparticles could be twice as likely to
stick to the interface of two non mixing liquids than previously believed. This
research open gateways for the utilization of nanoparticles in living cells, polymer
composites, and high-tech foams, gels, and paints.
2.6.32 Gold Nanoparticles Detect Cancer
Metallic nanostructures are more flexible particles compared to other nanomateri-

als owed to the possibility of controlling the size, shape, structure, composition,
assembly, encapsulation and tunable optical properties. Between the metallic
nanostructures possible applied, AuNPs appears of great interest in the medical
field, 3showing great efficiency towards cancer therapy [140–143]. The continu-
ous interest in AuNPs is based in their tunable optical properties that can be con-
trolled and modulated for the treatment and diagnosis of diseases. Various
researchers have utilized gold nanoparticles as ultrasensitive fluorescent probes to
detect cancer biomarkers in human blood. High sensitivity of this approach sur-
pass the current methods by several orders of magnitude and make the process
more suitable for direct detection of viral or bacterial DNA. These nanoparticles
are promising probes for biomedical applications since they can be easily manu-
factured and, unlike other fluorescent probes (quantum dots or organic dyes), they
don’t get heated and burn out after long exposure to light. In one report, china
based researchers apply the particles to detect carcinoembryonic antigen (CEA)
and alpha foetal protein (AFP) - two important biomarkers in the diagnosis of
various cancers, including liver, breast and lung cancer. In this work they have
conjugated nanoparticles with antibodies to measure the amount of biomarker
levels present in the sample.
2.6.32.1 AuNPs in Cancer Therapy
• Photothermal Therapy
AuNPs presents tunable optical properties that allow the absorption of light at
near UV to near infrared, being the last one a characteristic that allows nanopar-
ticles to enter cells, constituting a major breakthrough for its application in pho-
tothermal therapy or hyperthermia [144].
• Radiotherapy
AuNPs have been review in radiotherapy experiments in order to overcome the
problems associated to the healthy tissue damage imposed by radiotherapy [144].
• Angiogenesis inhibition
The inhibition of angiogenesis, i.e. the formation process of new blood
vessels, is also a potent mechanism by which AuNPs can operate for cancer
therapy [144].
2.6.32.1.1 AuNPs as Delivery Systems
The well-known application of AuNPs in cancer therapy described above, lead to

further investigation of new potential therapeutic strategies and was verified that
AuNPs can be used in the design of delivery systems [145]. AuNPs as a potential
nanocarrier have the possibility to carry different payloads, such as small drug mol-
ecules for drug delivery or biomolecules like DNA, proteins and RNA (siRNAs),
being recognized as an attractive gene delivery system
• Specific targeting
The potency of such systems is achieved by the enhancement of cellular accumu-
lation of AuNPs by an active targeting to cancer cells compared to a free drug
that passively enters the cells, which simultaneously avoid the biological response
and biophysical barriers in vivo [146].
• AuNPs for drug/cargo delivery
The construction of DDSs depends on size, charge and surface functionalities of
the AuNPs, once they dictate the uptake capacity of such nanovectorization sys-
tems as well as its intracellular fate [147].
• AuNPs for gene therapy
Gene therapy is though as a hopeful strategy in cancer therapy being consid-
ered as a powerful treatment like chemotherapy and radiotherapy, however the
implementation of such systems is based in viral vectors that raise cytotoxic
and immune response problems [148]. When conjugated to AuNPs, siRNAs
have been shown to exhibit increased stability, cellular uptake and efficacy in
physiological conditions, retaining the ability to act through the RNAi
pathway
2.6.32.2 Toxicity of AuNPs
One major concern regarding AuNPs application in medical field relies in its toxic-
ity in the biological systems, i.e. the production of a general toxicity response not
only in cancer cells but also reaching healthy cells at the vicinity. Taken into account
the size, surface modifications and solubility in promoting biocompatibility of the
nanovectorization systems, they can be safer to apply in the medical field to the
treatment of cancer. In fact, nanoparticles size is an important feature because it
turns possible to circumvent the immune response and renal clearance, which main-
tains the therapeutic capacity of such systems [149].
2.7 Hazards and Toxicity Profile of Nanoparticles
Various reports are available on the toxicity of nanoparticles (Table 2.10) that are
originated from the inhalation toxicology including particulate matter with a size
below 10 nm.
2.7.1 Health Implication of Nanoparticles
It’s very essential to recognize and differentiate ‘free’ and ‘fixed’ nano particles. Free
nanoparticles exhibit serious health threat since they are more difficult to contain due
to airborne and can be inhaled. Nanoparticles can be entered in human body via
• Absorptions by the intestinal tract
• Absorptions by the skin [151]
• Lungs where a rapid translocation through the blood stream to vital organ is pos-
sible, including crossing the BBB and
Nanoparticles affect the following organs in several ways:
• Lungs
It has been already observed that titanium dioxide (TiO2) carbon black and the
diesel particles exhibit various adverse effects. Based on previous findings it has
been observed that the administration of ultrafine nanoparticles to the lung pro-
duce more potent adverse effect in the form of inflammation and subsequent
tumors compared with larger sized particles, of identical chemical composition
at equivalent mass concentration. Toxicity of these particles is dependent on their
surface charachterstics such as surface chemistry [152]
• Intestinal tract
To facilitate the absorption of the food particles, the epithelium of the small and large
intestinal is in close contact with ingested material. These food particles are converted
in to a mixture of disaccharides, peptides, fatty acids and monoglycerides generated
2.7 Hazards and Toxicity Profile of Nanoparticles 85
Table 2.10 Nanoparticles and their related toxicities

Type of
nanoparticles Toxicity
Carbon • MWCNT: Elicit proinflammatory responses in keretenocytes; Platelet
nanotubes aggregation
• On a dose per mass basis carbon nanotubes are more toxic then quartz
particles which are well known for their lung toxicity
• SWCNT: In vitro incubation of high dose of SWCNT with keratinocytes
and bronchial epithelial cells results in ROS generation, oxidative stress,
lipid peroxidation, mitochondrial dysfunction and changes in cell
morphology; Platelet aggregation; Intratracheal instillation of high doses
of nanotubes causes chronic lung inflammation, foreign body granuloma
formation, interstitial fibrosis; in vivo studies SWCNT induce lung
granuloma
Dendrimers • Albertazzi et al. [150] demonstrated the in vivo distribution and toxicity
of PAMAM dendrimers in the central nervous system depend on their
surface chemistry
• Limited clinical experience using dendrimers make it impossible to
designate any particular chemistry intrinsically “safe” or “toxic”
Fullerenes • Sonicated c-60 fullrenes LC50 was relatively found to be very high,
causes lipid peroxidation and related toxicity in brain
Gold • For gold nanorods the cytotoxicity is attributed to the presence of
nanoparticles stablizer CTAB
• Gold nanoparticlse can cause cell death in the presence of activated laser
light
Quantum dots • Cadmium-containing QDs can kill cells in culture
• QDs undergo design-dependent intracellular localization and they can
cause cytotoxicity by releasing free cadmium into solution and by
generating free radical species. In animal experiments, QDs
preferentially enter the liver and spleens following intravascular
injection, undergo minimal excretion if larger than 6 nm, and appear to
be safe to the animal
• In vitro and in vivo studies show an apparent discrepancy with regard to
toxicity. Dosing provides one explanation for these findings. Under
culture conditions, a cell experiences a constant QD dose, but the in vivo
QD concentration can vary, and the organ-specific dose may not be high
enough to induce detectable toxicity
• Surface coating of quantum dotes during in vitro studies might be toxic.
In contrast many studies also report that the surface modification
decrease the toxicity induced by naked quantum dots
Silica • For silica nanoparticles both in vitro toxic and non toxic responses have
nanoparticles been found
• Silica exposure results in an increased ROS levels indicating increase in
oxidative stress
• Cell with long doubling time is more toxic against silica nanoparticles
then with short doubling time
• Alveolar macrophage cell line is more susceptible against cytotoxicity
then lung epithelial cell line
however digestion in small intestine are further transformed and taken in the villi.
Particles having charge (e.g. like carboxylated polystyrene nano particles or those
composed of positively charged polymer) exhibit poor oral bioavailability through
electrostatic repulsions and means entrapment [153]. Smaller the size of particles
facilitate the faster penetration (within 2 mints,); 415 nm particles took 30 mints
whereas 1000 nm particles were not capable to translocate through this barrier [154].
• Skin
Particles having size range 500–1000 nm, theoretically afar from the area of
nanotechnology can infiltrate and reach the lower level of human skin. Size range
smaller than 128 are more likely penetrate deeper in to the skin [155].
• Blood and cardiovascular system
Cationic nanoparticles including gold and polystyrene have been shown to cause
hemolysis and blood clotting while anionic nanoparticle are non toxic.
Combustion and model nanoparticles can gain access to blood following inhala-
tion and can enhance the experimental thrombosis. High exposure to DEP by
inhalation cause altered heart rate in hypertensive rats. Inhalation of PM causes
atheromatous plaque and destablization in rabbits. Recent data showed that
Carbon derived nanomaterials induce platelet aggregation
• Brain
High concentrations of anionic and cationic nanoparticles are toxic to brain.
Nanoparticles have been shown to produce reactive oxygen species and oxida-
tive stress. This has been confirmed in the brain after inhalation of MNO2
nanoparticles. Oxidative stress induced by nanoparticles causes various neurode-
generative disease such as Parkinson and Alzheimer. In addition inhalation of
nanoparticles in balb/c mice to particulate matter showed the activation of pro-
inflammatory cytokines in the brain
References
1. Martin CR. Welcome to nanomedicine. Nanomedicine. 2006;1(1):5.

2. Lee CC, Gillies ER, Fox ME, Guillaudeu SJ, Fréchet JM, Dy EE, Szoka FC. A single dose of
doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas.
Proc Natl Acad Sci U S A. 2006;103:16649–54.
3. Goldberg DS, Vijayalakshmi N, Swaan PW, Ghandehari H. G3.5 PAMAM Dendrimers
Enhance Transepithelial Transport of SN38 while minimizing Gastrointestinal Toxicity.
J Control Release. 2011;150(3):318–25.
4. Lobenberg R, Maas J, Kreuter J. Improved body distribution of 14Clabelled AZT bound to
Mataraza nanoparticles in rats determined by radioluminography. J Drug Target.
1998;5(3):171–9.
5. Brewer E, Coleman J, Lowman A. Emerging technologies of polymeric nanoparticles in can-
cer drug delivery. J Nanomater. 2011;2011:1–10.
6. Liu Z, Fan AC, Rakhra K. Supramolecular stacking of doxorubicin on carbon nanotubes for
in vivo cancer therapy. Angew Chem Int Ed Eng. 2009;48:7668–72.
References 87
7. Samori C, Li-Boucetta H, Sainz R. Enhanced anticancer activity of multi-walled carbon

nanotube-methotrexate conjugates using cleavable linkers. Chem Commun (Camb). 2010,
46: 1494–6.
8. Mahajan SD, Roy I, Xu G, Yong K-T, Ding H, Aalinkeel R. Enhancing the delivery of anti-
retroviral drug “Saquinavir” across the blood brain barrier using nanoparticles. Curr HIV
Res. 2010;9:396–404.
9. Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded mannosyl-
ated poly(propyleneimine) dendrimer. Biochim Biophys Acta. 2007;1770(4):681–6.
10. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat
Biotechnol. 2006;24(10):1211–7.
11. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applica-
tions. Nat Rev Drug Discov. 2010;9(8):615–27.
12. Cai W, Chen X. Nanoplatforms for targeted molecular imaging in living subjects. Small.
2007;3:1840–54.
13. Davis ME, Chen Z. Shin DM Nanoparticle therapeutics: an emerging treatment modality for
cancer. Nat Rev Drug Discov. 2008;7(9):771–82.
14. Nahar M, Dutta T, Murugesan S, Asthana A, Mishra D, Rajkumar V, Tare M, Saraf S, Jain
NK. Functional polymeric nanoparticles: an efficient and promising tool for active delivery
of bioactives. Crit Rev Ther Drug Carrier Syst. 2006;23(4):259–318.
15. Hett A. Nanotechnology: small matters, many unknown. 2004.
16. Vyas SP, Khar RK. Targeted and controlled drug delivery.CBS publishers and distributers.
New Delhi. 2002;1:331–43.
17. Redhead HM, Davis SS, Illum LJ. Control. Release. 2001;70:353.
18. Betancor L, Luckarift HR. Trends Biotechnol. 2008;26:566. Dunne M, Corrigan.
19. DeAssis DN, Mosqueira VC, Vilela JM, Andrade MS, Cardoso VN. Release profiles and
morphological characterization by atomic force microscopy and photon correlation spectros-
copy of 99m Technetium—fluconazole nanocapsules. Int J Pharm. 2008;349:152–60.
20. Jores K, Mehnert W, Drecusler M, Bunyes H, Johan C, MAder K. Investigation on the stricter
of solid lipid nanopartuicles and oil-loaded solid nanoparticles by photon correlation spec-
troscopy, fieldflow fractionasition and transmission electron microscopy. J Control Release.
2004;17:217–27.
21. Molpeceres J, Aberturas MR, Guzman M. Biodegradable nanoparticles as a delivery system
for cyclosporine: preparation and characterization. J Microencapsul. 2000;17:599–614.
22. Muhlen AZ, Muhlen EZ, Niehus H, Mehnert W. Atomic force microscopy studies of solid
lipid nanoparticles. Pharm Res. 1996;13:1411–6.
23. Shi HG, Farber L, Michaels JN, Dickey A, Thompson KC, Shelukar SD, Hurter PN, Reynolds
SD, Kaufman MJ. Characterization of crystalline drug nanoparticles using atomic force
microscopy and complementary techniques. Pharm Res. 2003;20:479–84.
24. Polakovic M, Gorner T, Gref R, Dellacherie E. Lidocaine loaded biodegradable nanospheres.
II. Modelling of drug release. J Control Release. 1999;60:169–77.
25. Pangi Z, Beletsi A, Evangelatos K. PEG-ylated nanoparticles for biological and pharmaceuti-
cal application. Adv Drug Del Rev. 2003;24:403–19.
26. Scholes PD, Coombes AG, Illum L, Davis SS, Wats JF, Ustariz C, Vert M, Davies MC.
Detection and determination of surface levels of poloxamer and PVA surfactant on biode-
gradable nanospheres using SSIMS and XPS. J Control Release. 1999;59:261–78.
27. Kreuter J. Physicochemical characterization of polyacrylic nanoparticles. Int J Pharm.
1983;14:43–58.
28. Magenhein B, Levy MY, Benita S. A new in vitro technique for the evaluation of drug release
profile from colloidal carriers ultrafiltration technique at low pressure. Int J Pharm.
1993;94:115–23.
29. Kreuter J. Nanoparticles. In: Kreuter J, editor. Colloidal drug delivery systems. New York:
Marcel Dekker; 1994. p. 219–342.
30. Reverchon E, Adami R. Nanomaterials and supercritical fluids. J Supercrit Fluids.

2006;37:1–22.
31. Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, DeSimone JM. Direct fabrica-
tion and harvesting of monodisperse, shape-specific nanobiomaterials. J Am Chem Soc.
2005;127:10096–100.
32. Kompella UB, Bandi N, Ayalasomayajula SP. Poly (lactic acid) nanoparticles for sustained
release of budesonide. Drug Deliv Technol. 2001;1:1–7.
33. Ravi MN, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nano-
spheres as DNA carriers. Biomaterials. 2004;25:1771–7.
34. Li YP, Pei YY, Zhou ZH, Zhang XY, Gu ZH, Ding J, Zhou JJ. Gao, XJ, PEGylated polycya-
noacrylate nanoparticles as tumor necrosis factor-[alpha] carriers. J Control Release.
2001;71:287–96.
35. Kwon HY, Lee JY, Choi SW, Jang Y, Kim JH. Preparation of PLGA nanoparticles containing
estrogen by emulsification-diffusion method. Colloids Surf A Physicochem Eng Aspects.
2001;182:123–30.
36. Zambaux M, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso M, Labrude P, Vigneron
C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanopar-
ticles prepared by double emulsion method. J Control Release. 1998;50:31–40.
37. Song CX, Labhasetwar V, Murphy H, Qu X, Humphrey WR, Shebuski RJ, Levy RJ.
Formulation and characterization of biodegradables nanoparticles for intravascular local drug
delivery. J Control Release. 1997;43:197–212.
38. Jaiswal J, Gupta SK, Kreuter J. Preparation of biodegradable cyclosporine nanoparticles by
high-pressure emulsification solvent evaporation process. J Control Release. 2004;96:169–78.
39. Soppinath KS, Aminabhavi TM, Kulkurni AR, Rudzinski WE. Biodegradable polymeric
nanoparticles as drug delivery devices. J Control Release. 2001;70:1–20.
40. Tice TR, Gilley RM. Preparation of injectable controlledrelease microcapsules by solvent-
evaporation process. J Control Release. 1985;2:343–52.
41. Tabata J, Ikada Y. Protein pre-coating of polylactide microspheres containing a lipophilic
immunopotentiator for enhancement of macrophage phagocytosis and activation. Pharm Res.
1989;6:296–301.
42. Ueda H, Kreuter J. Optimization of the preparation of loperamide- loaded poly (l-lactide)
nanoparticles by high pressure emulsification solvent evaporation. J Microencapsul.
1997;14:593–605.
43. Allemann E, Gurny R, Doekler E. Drug-loaded nanoparticlespreparation methods and drug
targeting issues. Eur J Pharm Biopharm. 1993;39:173–91.
44. Bodmeier R, Chen H. Indomethacin polymeric nanosuspensions prepared by micro- fluidiza-
tion. J Control Release. 1990;12:223–33.
45. Koosha F, Muller RH, Davis SS, Davies MC. The surface chemical structure of poly
(-hydroxybutyrate) microparticles produced by solvent evaporation process. J Control
Release. 1989;9:149–57.
46. Lemarchand C, Gref R, Passirani C, Garcion E, Petri B, Muller R. Influence of polysaccha-
ride coating on the interactions of nanoparticles with biological systems. Biomaterials.
2006;27:108–18.
47. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparation of biodegradable nanopar-
ticles of water-soluble and insoluble drugs with D, Llactide/glycolide copolymer by a novel
spontaneous emulsification solvent diffusion method, and the drug release behavior. J Control
Release. 1993;25:89–98.
48. Vandervoort J, Ludwig A. Biodegradable stabilizers in the preparation of PLGA nano parti-
cles: a factorial design study. Int J Pharm. 2002;238:77–92.
49. Ubrich N, Bouillot P, Pellerin C, Hoffman M, Maincent P. Preparation and characterization
of propanolol hydrochloride nano particles: a comparative study. J Control Release.
2004;19:291–300.
50. Couvreur P, Dubernet C, Puisieux F. Controlled drug delivery with Nano particles: current
possibilities and future trends. Eur J Pharm Biopharm. 1995;41:2–13.
References 89
51. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JK, Kissel T. Biodegradable nano par-
ticles for oral delivery of peptides: is there a role for polymer to affect mucosal uptake? Eur
J Pharm Biopharm. 2000;50:147–60.
52. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E. Preparation techniques and mecha-
nism of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind
Pharm. 1998;24:1113–28.
53. Lambert G, Fattal E, Couvreur P. Nanoparticulate system for the delivery of antisense oligo-
nucleotides. Adv Drug Deliv Rev. 2001;47:99–112.
54. Takeuchi H, Yamamoto Y. Mucoadhesive nanoparticulate system for peptide drug delivery.
Adv Drug Del Rev. 2001;47:39–54.
55. Vargas A, Pegaz B, Devefve E, Konan-Kouakou Y, Lange N, Ballini JP. Improved photody-
namic activity of porphyrin loaded into nano particles: an in vivo evaluation using chick
embryos. Int J Pharm. 2004;286:131–45.
56. El-shabouri MH. Positively charged nano particles for improving the oral bioavailability of
cyclosporine-A. Int J Pharm. 2002;249:101–8.
57. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nano capsule formation by inter-
facial deposition following solvent displacement. Int J Pharm. 1989;55:R1–4.
58. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethyl-
ene oxide nanoprticles as protein carriers. J Appl Polym Sci. 1997;63:125–32.
59. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-
propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines.
Pharm Res. 1997;14:1431–6.
60. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcya-
noacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm.
2001;218:75–80.
61. Boudad H, Legrand P, Lebas G, Cheron M, Duchene D, Ponchel G. Combined hydroxypro-
pyl-[beta]- cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral admin-
istration of saquinavir. Int J Pharm. 2001;218:113–24.
62. Puglisi G, Fresta M, Giammona G, Ventura CA. Influence of the preparation conditions on
poly(ethylcyanoacrylate) nanocapsule formation. Int J Pharm. 1995;125:283–7.
63. Jung J, Perrut M. Particle design using supercritical fluids: literature and patent survey.
J Supercrit Fluids. 2001;20:179–219.
64. Sun Y, Mezian M, Pathak P, Qu L. Polymeric nanoparticles from rapid expansion of super-
critical fluid solution. Chemistry. 2005;11:1366–73.
65. Iijima S. Helical microtubules of graphitic carbon. Nature. 1991;354:56–8.
66. Reilly RM. Carbon nanotubes: potential benefits and risks of nanotechnology in nuclear
medicine. J Nucl Med. 2007;48:1039–42.
67. Saad MZH, Jahan R, Bagul U. Nanopharmaceuticals: a New perspective of drug delivery
system. Asian J Biomed Pharm Sci. 2012;2:14.
68. McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, et al.
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med.
2007;48:1180–9.
69. Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and dis-
covery. Acc Chem Res. 2008;41:60–8.
70. Zhang Z, Yang X, Zhang Y, Zeng B, Wang S, Zhu T, et al. Delivery of telomerase reverse
transcriptase small interfering RNA in complex with positively charged single-walled carbon
nanotubes suppresses tumor growth. Clin Cancer Res. 2006;12:4933–9.
71. Sinha N, Yeow JTW. Carbon nanotubes for biomedical applications. IEEE Trans
Nanobioscience. 2005;4(2):180–95.
72. Thakral S, Mehta RM. Fullerenes: an introduction and overview of their biological proper-
ties. Ind J Pharm Sci. 2006;68:13–9.
73. Kratschmer W, Lamb LD, Fostiropoulos K, Hoffman DR. Solid C 60: a new form of carbon.
Nature. 1990;347:354–8.
74. Taylor R, Hare JP, Abdul-Sada AK, Kroto HW. Isolation, separation and characterisation of
the fullerenes C60 and C70: the third form of carbon. J Chem Soc Chem Commun.
1990;20:1423–5.
75. Chandrakumar KR, Ghosh SK. Alkali-metal-induced enhancement of hydrogen adsorption
in C60 fullerene: an ab initio study. Nano Lett. 2008;8:13–9.
76. Fatouros PP, Corwin FD, Chen ZJ, Broaddus WC, Tatum JL, Kettenmann B, et al. Invitro and
invivo imaging studies of a new endohedral metallofullerene nanoparticle. Radiology.
2006;240:756–64.
77. Komatsu K, Murata M, Murata Y. Encapsulation of molecular hydrogen in fullerene C60 by
organic synthesis. Science. 2005;307:238–40.
78. Chen BX, Wilson SR, Das M, Coughlin DJ, Erlanger BF. Antigenicity of fullerenes: antibod-
ies specific for fullerenes and their characteristics. Proc Natl Acad Sci U S A.
1998;95:10809–13.
79. Mroz P, Pawlak A, Satti M, Lee H, WhartonT GH, et al. Functionalized fullerenes mediate
photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism. Free
Radic Biol Med. 2007;43:711–9.
80. Tegos GP, Demidova TN, Arcila-Lopez D, Lee H, Wharton T, Gali H, et al. Cationic fullerenes
are effective and selective antimicrobial photosensitizers. Chem Biol. 2005;12:1127–35.
81. Bosi S, Da RT, Castellano S, Banfi E, Prato M. Antimycobacterial activity of ionic fullerene
derivatives. Bioorg Med Chem Lett. 2000;10:1043–5.
82. Ji H, Yang Z, Jiang W, Geng C, Gong M, Xiao H, et al. Antiviral activity of nano carbon
fullerene lipidosome against influenza virus in vitro. J Huazhong Univ Sci Technolog Med
Sci. 2008;28:243–6.
83. Cai X, Jia H, Liu Z, Hou B, Luo C, Feng Z, et al. Polyhydroxylated fullerene derivative C(60)
(OH)(24) prevents mitochondrial dysfunction and oxidative damage in an MPP(+)-induced
cellular model of Parkinson’s disease. J Neurosci Res. 2008;86:3622–34.
84. Markovic Z, Trajkovic V. Biomedical potential of the reactive oxygen species generation and
quenching by fullerenes (C60). Biomaterials. 2008;29:3561–73.
85. Iga AM, Robertson JH, Winslet MC, Seifalian AM. Clinical potential of quantum dots.
J Biomed Biotechnol. 2007;2007:76087–97.
86. Bailey RE, Smith AM, Nie S. Quantum dots in biology and medicine. Physica E.
2004;25:1–12.
87. Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In-vivo cancer targeting and imaging with
semiconductor quantum dots. Nat Biotechnol. 2004;22:969–76.
88. Amiot CL, Xu S, Liang S, Pan L, Zhao JX. Near-infrared fluorescent materials for sensing of
biological targets. Sensors. 2008;8:3082–105.
89. West JL, Halas NJ. Applications of nanotechnology to biotechnology commentary. Curr Opin
Biotechnol. 2000;11:215–7.
90. Kherlopian AR, Song T, Duan Q, Neimark MA, Po MJ, Gohagan JK, et al. A review of imag-
ing techniques for systems biology. BMC Syst Biol. 2008;2:74–92.
91. Klibanov AL. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-
assisted drug-delivery applications. Invest Radiol. 2006;41:354–62.
92. Gao Z, Kennedy AM, Christensen DA, Rapoport NY. Drugloaded nano/microbubbles for
combining ultrasonography and targeted chemotherapy. Ultrasonics. 2008;48:260–70.
93. Negishi Y, Endo Y, Fukuyama T, Suzuki R, Takizawa T, Omata D, et al. Delivery of siRNA
into the cytoplasm by liposomal bubbles and ultrasound. J Control Release.
2008;132:124–30.
94. Suzuki R, Takizawa T, Negishi Y, Utoguchi N, Maruyama K. Effective gene delivery with
novel liposomal bubbles and ultrasonic destruction technology. Int J Pharm. 2008;354:49–55.
95. Iverson N, Plourde N, Chnari E, Nackman GB, Moghe PV. Convergence of nanotechnology
and cardiovascular medicine: progress and emerging prospects. BioDrugs. 2008;22:1–10.
96. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging impli-
cations of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006;107:
459–66.
References 91
97. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu
receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med.
2003;49:403–8.
98. Aduro Biotech. Berkeley: Oncologic and Triton BioSystems Merge to Form Aduro BioTech
Aduro to Focus on NT™ and TNT™ Systems for Solid Tumor Cancers. 2008. Available
from http://www.tritonsys. com/news/Aduro.pdf. Accessed 16 May 2009.
99. Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based biobar codes for the ultrasensitive
detection of proteins. Science. 2003;301:1884–6.
100. Moore A, Weissleder R, Bogdanov Jr A. Uptake of dextrancoated monocrystalline iron
oxides in tumor cells and macrophages. J Magn Reson Imaging. 1997;7:1140–5.
101. Xu H, Yan F, Monson EE, Kopelman R. Room-temperature preparation and characterization
of poly (ethylene glycol)-coated silica nanoparticles for biomedical applications. J Biomed
Mater Res A. 2003;66:870–9.
102. Freitas RA. Pharmacytes: an ideal vehicle for targeted drug delivery. J Nanosci Nanotechnol.
2006;6:2769–75.
103. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects.
FASEB J. 2005;19:311–30.
104. Baker JR, Quintana A, Piehler L, Banazak-Holl TD, Raczka E. The synthesis and testing of
anti-cancer therapeutic nanodevices. Biomed Microdevices. 2001;3:61–9.
105. Pan B, Cui D, Sheng Y, Ozkan C, Gao F, He R, et al. Dendrimermodified magnetic nanopar-
ticles enhance efficiency of gene delivery system. Cancer Res. 2007;67:8156–63.
106. Quiagen California: SuperFect Transfection Reagent. Available from http://www1.qiagen.com-
Products/Transfection/Transfection Reagents/SuperFectTransfectionReagent.aspx#Tabs = t1.
Accessed 3 May 2008.
107. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multipurpose nanodevices for oncology
drug delivery and diagnostic imaging. Biochem Soc Trans. 2007;35:61–7.
108. Freitas Jr RA. Microbivores: artificial mechanical phagocytes using digest and discharge
protocol. J Evol Technol. 2005;14:1–52.
109. Freitas Jr RA. Exploratory design in medical nanotechnology: a mechanical artifcial red cell.
Artif Cells Blood Substit Immobil Biotechnol. 1998;26:411–30.
110. Freitas Jr. RA. A mechanical artificial red cell: exploratory design in medical nanotechnology
[serial on the internet]. Available from http ://www.foresight.org/nanomedicine/
Respirocytes4.html#Sec610, Accessed 29 Sept 2008.
111. Kayser O, Lemke A, Hernández-Trejo N. The impact of nanobiotechnology on the develop-
ment of new drug delivery systems. Curr Pharm Biotechnol. 2005;6(1):3–5.
112. Kaparissides C, Alexandridou S, Kotti K, Chaitidou S. Recent advances in novel drug deliv-
ery systems; 2006.
113. Singh Suri S, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup
Med Toxicol. 2007;2:16.
114. Jahanshahi M, Babaei Z. Protein nanoparticle: a unique system as drug delivery vehicles. Afr
J Biotechnol. 2008;7(25):4926–34.
115. Rawat M, Deependra S, Saraf S, Saraf S. Nanocarriers: promising vehicle for bioactive
drugs. Biol Pharm Bull. 2006;29(9):1790–8.
116. Verdun C, Brasseur F, Vranckx H, Couvreur P, Roland M. Tissue distribution of doxorubicin
associated with polyhexylcyanoacrylate nanoparticles. Cancer Chemother Pharmacol.
1990;26:13–8.
117. Couvreur P, Kante B, Lenaerts V, Scailteur V, Roland M, Speiser P. Tissue distribution of
antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J Pharm Sci.
1980;69:199–202.
118. Bibby DC, Talmadge JE, Dalal MK, Kurz SG, Chytil KM, Barry SE, Shand DG, Steiert M.
Pharmacokinetics and biodistribution of RGD-targeted doxorubicinloaded nanoparticles in
tumor-bearing mice. Int J Pharm. 2005;293:281–90.
119. Chiannilkulchai N, Ammoury N, Caillou B, Devissaguet JP, Couvreur P. Hepatic tissue dis-
tribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M
5076 metastasis-bearing mice. Cancer Chemother Pharmacol. 1990;26:122–6.
120. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles:
theory to practice. Pharmacol Rev. 2001;53:283–318.
121. Storm G, Belliot S, Daemen T, Lasic D. Surface modification of nanoparticles to oppose
uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1995;17:31–48.
122. Torchilin V, Trubetskoy V. Which polymer can make nanoparticulate drug carriers long cir-
culating? Adv Drug Deliv Rev. 1995;16:141–55.
123. Jeon SI, Andrade JD. Protein—surface interactions in the presence of polyethylene oxide: II.
Effect of protein size. J Colloid Interf Sci. 1991;142:159–66.
124. Stella B, Arpicco S, Peracchia M, Desmaele D, Hoebeke J, Renoir M, d’Angelo J, Cattel L,
Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci.
2000;89:1452–64.
125. Oyewumi MO, Yokel RA, Jay M, Coakley T, Mumper RJ. Comparison of cell uptake, biodis-
tribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in
tumor-bearing mice. J Control Release. 2004;95:613–26. Drugs. Eur. J. Cancer Sci 2000.
11:265–83.
126. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered
intracellular distribution of anticancer agents. Pharmacol Ther. 2000;85:217–29.
127. Brandtzaeg P, Berstad A, Farstad I, Haraldsen G, Helgeland L, Jahnsen F, Johansen F, Natvig
I, Nilsen E, Rugtveit J. Mucosal immunity—a major adaptive defense mechanism. Behring
Inst Mitt. 1997;98:1–23.
128. Haltner E, Easson J, Lehr C. Lectins and bacterial invasion factors for controlling endo- and
transcytosis of bioadhesive drug carrier systems. Eur J Pharm Biopharm. 1997;44:3–13.
129. Hussain N, Jani PU, Florence AT. Enhanced oral uptake of tomato lectin-conjugated nanopar-
ticles in the rat. Pharm Res. 1997;14:613–8.
130. Schipper N, Olsson S, Hoogstrate J, de Boer A, Varum K, Artursson P. Chitosans as absorp-
tion enhancers for poorly absorbable drugs. 3: influence of mucus on absorption enhance-
ment. Eur J Pharm Sci. 1999;8:335–43.
131. Lehr C, Bowstra J, Tukker J, Junginer H. Intestinal transit of bioadhesive microspheres in an
in situ loop in the rat. J Control Release. 1990;13:51–62.
132. Bjork E, Isakkson U, Edman P, Artursson P. Starch microspheres induce pulsatile delivery of
drugs and peptides across the epithelial barrier by reversible separation of the tight junctions.
J Drug Target. 1995;6:501–7.
133. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of
poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery.
FASEB J. 2002;16:1217–26.
134. Hedley M, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cyto-
toxic T-cell responses. Nat Med. 1998;4:365–8.
135. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to
the brain. J Nanosci Nanotechnol. 2004;4:484–8.
136. Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev
Drug Discov. 2002;1:131–9.
137. Ji B, Maeda J, Higuchi M, Inoue K, Akita H, Harashima H, Suhara T. Pharmacokinetics and
brain uptake of lactoferrin in rats. Life Sci. 2006;78:851–5.
138. Scherrmann JM, Temsamani J. The use of Pep: trans vectors for the delivery of drugs into the
central nervous system. Int Cong Ser. 2005;1277:199–211.
139. Gabathuler R, Arthur G, Kennard M, Chen Q, Tsai S, Yang J, Schoorl W, Vitalis TZ, Jefferies
WA. Development of a potential protein vector (NeuroTrans) to deliver drugs across the
bloodbrain barrier. Int Cong Ser. 2005;1277:171–84.
140. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical prop-
erties and recent applications in cancer diagnostics and therapy. Nanomedicine.
2007;2(5):681–93.
141. Figueiredo S, Cabral R, Luís D, Fernandes AR, Baptista PV. Integration of gold nanoparticles
and liposomes for combined anti-cancer drug delivery. In: Seifalian A. (ed.) Nanomedicine.
University College London (UK); 2014. Chapter 3. Available from http://www.onecentral-
press.com/nanomedicine/#.
References 93
142. Cobley CM, Chen J, Cho EC, Wang LV, Xia Y. Gold nanostructures: a class of multifunc-
tional materials for biomedical applications. Chem Soc Rev. 2011;40(1):44–56.
143. Kumar A, Boruah BM, Liang XJ. Gold nanoparticles: promising nanomaterials for the diag-
nosis of cancer and HIV/AIDS. J Nanomater. 2011;31:1–17.
144. Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnos-
tics, therapies and toxicity. Chem Soc Rev. 2009;38(6):1759–82.
145. Wang J, Yao K, Wang C, Tang C, Jiang X. Synthesis and drug delivery of novel amphiphilic
block copolymers containing hydrophobic dehydroabietic moiety. J Mater Chem B.
2013;1(17):2324–32.
146. Dreaden EC, Mwakwari SC, Sodji QH, Oyelere AK, El-Sayed MA. Tamoxifen-poly(ethylene
glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast
cancer treatment. Bioconjug Chem. 2009;20(12):2247–53.
147. Lim ZZJ, Li JEJ, Ng CT, Yung LYL, Bay BH. Gold nanoparticles in cancer therapy. Acta
Pharmacol Sin. 2011;32(8):983–90.
148. Hunt KK, Vorburguer SA. Hurdles and hopes for cancer therapy. Science. 2002;
297(5580):415–6.
149. Conde J, Doria G, Baptista P. Noble metal nanoparticles applications in cancer. J Drug Deliv.
2012;2012:1–12.
150. Albertazzi L, Gherardini L, Brondi M, et al. In vivo distribution and toxicity of PAMAM
dendrimers in the central nervous system depend on their surface chemistry. Mol Pharm.
2013;10:249–60.
151. Hoet PMH, Brnske HI, Salata OR. Nano particles known and unknown health risk.
J Nanobiotecnol. 2004;2:12.
152. Lee KP, Kelly DP, Oneal FO, Kennedy GL. Lung response to ultrafine kertar aramid synthetic
fibrils following 2-year inhalation exposure in rats. Findam Appl Toxicol. 1998;11:1–20.
153. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticles uptake by the rat gastrointesti-
nal mucosa: quantitation and particle size dependency. J Pharm Pharmacol.
1990;42(12):812–26.
154. Jani P, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nano-
sphere and microsphere after oral administration to rats. J Pharm Pharmacol. 1989;41(12):
809–12.
155. Lademann J, Weigmann H, Rickmeyer C, Barthelmes H, Schaelmes H, Mueller G, Sterry W.
Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer
and the follicular orifice. Skin Pharmacol Appl Skin Physiol. 1999;12(5):247–56.
Chapter 3
Natural Polymers vs Synthetic Polymer
Abstract Polymers play an important role as excipients in any dosage form. They
influence drug release and should be stable, economic compatible, non-toxic, etc.
They are broadly classified as natural polymers and synthetic polymers. Synthetic
and natural based biodegradable polymers have received much more attention in the
last decades due their potential applications in the fields related to environmental
protection and the maintenance of physical health. Biodegradable materials are
used in agriculture, medicine packaging, and other areas. In recent years there has
been an increase in interest in biodegradable polymers. Two classes of biodegrad-
able polymers can be distinguished: synthetic or natural polymers. Synthetic poly-
mers are widely used in biomedical implants and devices because they can be
fabricated into various shapes. Natural polymers are basically polysaccharides so
they are biocompatible and without any side effects. In this chapter we have dis-
cussed various natural polymers, their advantages over synthetic polymers and role
of natural polymers in designing novel drug delivery systems.
Keywords Synthetic polymer • Natural polymer • Polysaccharide • Drug delivery

• Toxicity
3.1 Bioengineered Materials: Nano-Engines of Drug

Delivery Systems
Engineered materials have been employed for rising smart drug delivery systems.
Design and multi-functionalities synthesize efficient smart drug delivery systems
are vitally necessary for medicine and healthcare development. In the material sci-
ence field offers biodegradable, environment-responsive, biocompatible, and highly
effective novel polymeric system for targeted delivery. Nanotechnology offers bot-
tom-up and top-down nanofabrication with size controlled and multi-functionality
of particulate for targeted delivery. Novel materials invention and advanced technol-
ogy have been synergistically accomplished in drug delivery so far. The important
objectives of medical pharmacology to offer the right medicine, right dosage, and
right route at the right time to the right patient, so additional research required to
optimize the therapeutic efficacy of the drug. This is the most important principles

DOI 10.1007/978-3-319-41129-3_3
96 3 Natural Polymers vs Synthetic Polymer
Route of
administration
Nature of delivery Mechanism of drug

vehicle release
Nano-design
considerations
Ability to Drug
targeting Properties
Duration of delivery
Fig. 3.1 Considerations of various factors for simultaneous reflection to design a polymeric
nanoparticle for the smart drug delivery system
behind the smart drug delivery. A smart, controlled delivery system requires syner-
gistic consideration of a number of factors summarized in Fig. 3.1. It is not easy to
get all consideration factors in a smart controlled delivery system owing to other
influencing factors. Also high efficiency, quality, reliability, and reproducibility are
the most considerable issue while designing such a smart system.
3.2 Polymeric Nanoparticles
The polymeric nanoparticles are fabricated from biocompatible and biodegradable

polymers in size between 10–1000 nm where the drug is entrapped, dissolved, encap-
sulated or attached to a nanoparticle matrix. Depending upon the methodology of fab-
rication nanoparticles, nanospheres or nanocapsules can be obtained. Nanocapsules
are systems in which the drug is restricted to a cavity enclosed by a unique polymer
membrane, while nanospheres are matrix systems in which the drug is physically and
uniformly dispersed. The field of polymer nanoparticles (PNPs) is rapidly growing and
playing an significant role in a wide spectrum of disciplines ranging from electronics,
sensors, medicine, photonics, biotechnology, conducting materials, pollution control
and environmental technology. PNPs are promising vehicles for drug delivery by sim-
ple manipulation to fabricate carriers with the aim of delivering the drugs to particular
target, such an merit advances the drug safety. Polymer based nanoparticles efficiently
carry drugs, proteins, and DNA to target cells and organs. Their nanometer size encour-
ages effective permeation via cell membranes and stability in the blood stream.
Polymers are very suitable materials for the manufacture of countless and varied
molecular designs that can be integrated into exclusive nanoparticle constructs with
many potential medical applications. PNPs can be expediently fabricated either from
preformed polymers or by direct polymerization of monomers using classical polym-
erization or polyreactions. Methods like salting-out, dialysis solvent evaporation, and
supercritical fluid technology, encompassing the rapid expansion of a supercritical
3.3 Contemporary Methodologies for Fabrication of Polymeric Nanoparticles 97
Polymer Solvent evaporation Emulsion Monomer
Nanoprecipitation Microemulsion F
Polymeric
Salting out Microemulsion
nanoparticles
Dialysis Interfacial
Dispersion SCF C/LR Polymerization
Fig. 3.2 Plan illustration of different techniques for the preparation of polymeric nanoparticles
solution or rapid expansion of a supercritical solution into liquid solvent, can be

employed for the fabrication of polymeric nanoparticles from preformed polymers.
Alternatively, polymeric nanoparticles can be directly fabricated by the polymerization
of monomers using different polymerization techniques e.g. micro-emulsion, surfac-
tant-free emulsion, mini-emulsion, and interfacial polymerization. A representation of
various fabrication techniques for polymeric nanoparticles is mentioned in Fig. 3.2.
The selection of fabrication method is made on the basis of a number of factors such as
the type of polymeric system, area of application, size requirement and others.
3.3 Contemporary Methodologies for Fabrication

of Polymeric Nanoparticles
In recent times, the polymeric nanoparticles have appeared as a most potential and
viable technology platform for recognizing the targeted, environment-responsive
and, multi-functional with navigated controlled drug delivery system.
Polysaccharides in smart drug delivery is a fast rising new technological discipline
in which different therapeutic applications of nanoproducts are predictable to over-
come the patient complaints in healthcare. Smart delivery will offer new keys for
therapeutic interventions. There is immense interest from the commencement in
smart medicine of advanced and well-characterized bionanotechnological products
that will be particularly effective in fighting diseases like cardiovascular diseases,
aging, diabetes, cancer, some chronic metabolic syndrome and different degenera-
tive diseases and disorders. For an instance, the innovative smart polymers with
nanoparticulate drug-delivery systems can clearly advances in therapeutics by
directing the drugs to target cells and reducing the adverse-effect/side-effect on well
being. Presently, a number of smart polymer with multi-functioned nanoparticle
system strategies in clinical trials, and it demonstrate promising result. Definitely
the morbidity and mortality rate of disease affected patients could improve their
lifestyle by the initial course of smart therapeutic intervention. This smart
intervention can be achieved by developing high sensitivity and reliable smart drug
delivery. The quick development in the above course has been made with the initia-
tion and development of more advanced alternative nanofabrication techniques to
offer structures in various nano-scales level of controlled manners. Drug loaded
polymeric nanosystems can offer controlled release of both hydrophilic and hydro-
phobic drugs over a long period of time while reducing undesirable side effects in
the body. This encompass the fabrication of various novel biocompatible polymers
with well-defined nanometers to a few micro-meters structures using several mod-
ern techniques e.g. microfluidic systems, microelectromechanical systems,
microneedle based system, advanced high pressure homogenization, electrodrop-
ping system, interfacial emulsion polymerization and combined systems. Figure 3.3
explained the small number of modern techniques for polymeric nanoparticles fab-
rication with various concepts. The physiochemical features of polymeric nanopar-
ticles have to be optimized based on the specific application. A variety of
methodologies can be utilized to offer different nano-particulate systems with vari-
ous polymers. The multifunctional polymeric nanoparticles developments e.g. core-
shell nanoparticles, environment-responsive micelles, colloids, nano hydrogel,
nano-spheres and coreshell nano-spheres with layer-by-layer assembly for single/
dual or multi drug release have been achieved so far. So as to get the preferred fea-
tures, the mechanism of formulation method plays a vital role. Therefore, it is tre-
mendously beneficial to have synthesis mechanism at hand to approach
multi-functional polymeric nanoparticles with exact physiochemical properties for
a specific application.
3.4 Activation-Modulated Drug Delivery: Environmental

Activation/Stimuli Responsive Smart Delivery System
The smart drug delivery with activation-modulated system has been accomplished
by external or environmental stimuli. These environmental responsive smart deliv-
ery systems attained a lot more with double and multiple-responsive delivery sys-
tem. Different activation/stimuli responsive drug delivery vehicles have been
prepared and evaluated, in different particle sizes, ranges from nanometers to a few
micro-meters sized carriers for various routes of administration. The transdermal
electro-activated or electro-modulated drug delivery has been recognized as a com-
petent model. In this assembly of activation-modulated controlled drug delivery
system, the release of active agents from the systems is activated by some physical,
chemical, electrical, environmental condition or biochemical processes and/or facil-
itated by an energy supplied externally. The release profile has been regulated by the
input energy. Based on the activation/stimulation process applied or energy type
used, this activation-modulated controlled drug delivery system can be classified
into the different as mentioned in Fig. 3.4. These stimuli-responsive materials dis-
play variation in the physicochemical feature while the environmental condition
3.4 Activation-Modulated Drug Delivery: Environmental Activation/Stimuli… 99
a c
Monomers Monomers
homogeneous homogeneous
pump pump
Nano
Dialysis Polymer
solution
Buffer
Vesicles
Releases
b d
Organic
mixture
Transmission channels
Collection
Magnetic stirrer
Fig. 3.3 Schematic representation of the advanced techniques of preparation of polymeric

nanoparticles. (a) Core shell particulate system: in situ semi batch emulsion method. Size of the
core controlled via surfactant. Surfactant was removed via dialysis pH-responsive polymer core-
shell. (b) Sonication based system: mostly probe sonicator is used. Various optimization condi-
tions require ON/OFF cycle to reduce temperature. Ice bath to maintain the temperature. (c)
Electrodropping system: dual delivery using biocompatible care, homogeneous core shell, layer-
by layer assembly possible, difference of release profile possible. (d) Well controlled synthesis of
particles, tunable nanoparticles possible, reproducible synthesis, distinct nanoparticles for specific
target
changes. These variations in features can be entirely utilized in smart delivery sys-
tem, which definitely alike to the biological response behavior. Various sorts of
body organs, different tissues and various types of cellular compartments might
have vast dissimilarity in every stimulus with great response. Any definite behav-
ioral changes in the system results in phase transition, these transitions will be key
factors for the stimuli-responsive drug delivery system and some selected instances
of applications are explained in the Fig. 3.4.
Fig. 3.4 Plan illustration representing the activation-modulated drug delivery systems, which the
polymeric nanoparticles activated by different stimuli e.g. physical, chemical, biochemical, envi-
ronment, and/or a combination of two or more
3.5 Time to Move on Innovative Methods of Administration
Polymers are macromolecules having repeating structural units which are typically
connected by covalent chemical bonds. Synthetic and natural polymers are having
various applications specifically in the pharmaceutical sector because of their eco-
nomical, readily available and non-toxic nature. Additionally natural polymers are
capable of chemical modifications, potentially biodegradable and with few excep-
tions, also biocompatible. Various applications of natural and synthetic polymers
are mentioned in Fig. 3.5. Most of the pharmaceutical industries primarily manufac-
ture/dispense drugs orally (as solid pills and liquids) or as injectables.
Owing to the recent innovations in pharmaceutical sciences most of the manufac-
turers are focusing on different strategies for the production of formulations that
control the rate and period of drug delivery (i.e., time-release medications) and target
specific areas of the body for treatment have become increasingly common and com-
plex. Inclination of current researchers towards development of novel and potential
3.5 Time to Move on Innovative Methods of Administration 101
Types of polymerizations Hierarchical Characterization Techniques of Polymerization
Addition Polymerization Solution Polymerization

Condensation Polymerization Bulk (Mass) Polymerization
Metathesis Polymerization
Suspension Polymerization
Precipitation Polymerization
Emulsion Polymerization
Tissue Engineering, Drug Delivery, Biomedical
POLYMERS
Natural Polymers
Proteins and Poly(Amino Acids)
Hyaluronic Acid
Chondroitin Sulfate Fibrin-Based Biomaterials
Chitin and Chitosan Elastin-Based Biomaterials
Silk-Based Biomaterials
Applications
Alginic Acid
Cellulose Collagen-Based Biomaterials
Poly(Glutamic Acid)-Based
Biomaterials
Synthetic polymers Cyanophycin and Poly(Aspartic
Poly(α-ester)s Acid)- Based Biomaterials
Polyurethanes Poly-1-Lysine-Based
Poly(Ester Amide)s Biomaterials
Polyanhydrides
Polyphosphazenes
Pseudo Poly(Amino Acids) Chitosan as a Biomaterial
Polyacetals
Nucleic Acid Aptamers
Pseudo Poly(Amino Acids)

Composed of Amino Acids Dendrimers
Linked by Nonamide Bonds
such as Esters, Imino Citrate-Based
Citrate-Based
Carbonates, and Carbonates Biodegradable
Biodegradable
Elastomeric
Elastomeric
Polymers
Polymers
Fig. 3.5 Polymers and their diverse applications in tissue engineering, drug delivery and biomedi-
cal science
treatments and discoveries of bioactive molecules lead to exploration of mechanisms

and their assisted strategic methods of administration. The most complicated work
for current researchers is to design methods of drug delivery that exhibit specific
problems such as limited therapeutic effects of certain drugs or their partial degrada-
tion that occurs before they reach a desired target in the body. Accountability of fac-
tors which directly or indirectly influences the pathway(s) of drug assists in designing
the specified or targeted drug delivery system. Such systems not only deliver drug at
targeted site but also encourage time dependent release of medications which may
provide the relief from symptoms and protection from adverse events solely when
necessary. Focus can also be stretched towards development of injectables drugs
which could be manufactured less expensively and administered more conveniently
if they could simply be dosed orally. Nevertheless such an approach cannot be
achieved unless more advanced and scientific methods will be developed to safely
direct medications through specific areas of the body, such as the GIT, where pH
variation can destroy drug activity, or through an area where healthy bone and tissue
might be adversely affected. Objective of all complicated drug delivery systems is to
organize medications which can integrate to specifically targeted parts of the body
through a medium. Such medium can control the therapy’s administration by means
of either a physiological or chemical trigger. This objective can be achieved by

designing more advance micro- and nanotechnology in form of polymeric micro-
spheres, polymer micelles, and hydrogel-type materials. Such micro or nano scien-
tific based delivery system can be designed in such a way where it can promote drug
specificity, lower systemic drug toxicity, improves treatment absorption rates, and
provide protection for pharmaceuticals against biochemical degradation.
3.6 History of Drug Delivery from the Ancient to Date
Treatments obtained from plants and other natural sources were earlier delivered
either orally or topically. Various traditional system medicines (e.g. ayurvedic) and
their respective formulations were highly recommended in form of oral and topically
active preparations. It was later discovered that potential of these preparations is
based on the integumentary and gastrointestinal (GI) system integrity. Various natu-
ral extracts were supplemented to treat the disease e.g. cinchona tree powdered bark
containing quinine administered orally by native Brazilians to treat malaria [1].
Currently inspite of the development of resistant strains, quinine is still one of the
core treatments for malaria [2]. Traditional ayurvedic medicines in the form of gut-
tikas, churnas, leha, avleha, bhasmas, arishtas, asavas, and tailas form the foundation
of drug delivery system. According to an interview that a pharmacist historian gave
the LA Times [1], pills date as far back as 1500 BC. Earliest evidence to pills was
found on papyruses in ancient Egypt, and contained bread dough, honey or grease.
Pill name was introduced by Roman scholar Pliny (23–79 AD), he called them “pil-
ula,” later named as Pill. During medieval period people coated pills with slippery
plant substances and gilded them in gold and silver to facilitate their swallowing
more easily. The first concrete evidence of active table (sugar-coating and gelatin-
coating) was explored in the 1800s and during the same time the compressed tablet
also was invented in the 1800s by a Brit named William Brockedon. Later on it was
realize that these formulations require more advance, more efficient and effective
methods of drug delivery systems. Moreover significant role of drug delivery systems
in herbal medicines was explored. For the first in 1656, Sir Christopher Wren reported
the use of a syringe [3–5]. The earliest drug delivery systems, first introduced in the
1970s, were based on polymers formed from lactic acid. Later on in 1853, Scottish
physician Alexander Wood and French surgeon Charles Pravaz independently publi-
cized two extraordinary functional syringe designs [3–5]. This achievement explored
the potential of different types of injectables to directly inject medications with either
controlled or spontaneous rate. At last after the development of different designs of
injectables, in 1960s, disposable syringes were introduced [6]. This outstanding
achievement eliminated the need of boiling or sterilizing glass syringes, which
resulted in improved hygiene and convenience. Thus purpose of most of the earlier
delivery systems to deliver the therapeutic agent so that it will easily accumulated in
target cells in optimal concentrations for a prolonged period. Nevertheless potential
drug delivery via topical and systemic routes requires their transport through several
3.6 History of Drug Delivery from the Ancient to Date 103
physiological barriers [7, 8]. Till today enteral (entering the body via the GI tract) or
parenteral (entering the body by any route other than the GI tract) [7, 8] are the two
most primary drug delivery routes used to deliver medications. Most of the manufac-
tures designed different formula or delivery system for same medicines to control
their release at the desired site. In spite of the delivery route drug features such as
hydrophilic or hydrophobic nature plays an important role in determining the ulti-
mate fate during its transport across lipidic membranes. These membranes are most
permeable to lipophilic molecules nevertheless in order for a drug to dissolve in body
fluids and be transported, it must also be somewhat hydrophilic [9]. Some additional
factors such as low molecular weight and non-polarity improve drug transport across
membranes. Strategies were developed to design more advance drug delivery system.
In 1997, Glucose-sensitive hydrogel that could be used to deliver insulin to diabetic
patients using an internal pH trigger was synthesized by chemical engineers at Purdue
University in West Lafayette, IN, under the direction of Nicholas A. Peppas [10].
Development of different types of drug delivery system leads to the germination of
new sector where drug release rate can be controlled in a more systematic and effec-
tive fashion, exclude side effects and encourages safe delivery of medication. This
field is known as controlled drug delivery field began the founders who introduced
this exciting and important field, and the prominent researchers who came after them
[11]. This section is following the subsequent development phases of the field from
its origins in the 1960s to the 1970s and 1980s, when various macroscopic “con-
trolled” drug delivery devices and implants were developed for delivery as mucosal
inserts, as implants, as ingestible capsules, as topical patches, and were approved for
clinical use. Moreover these historical events section traces various phases of devel-
opment in the 1960s to the 1980s and 1990s when microscopic degradable polymer
depot DD systems (DDS) were commercialized [11]. Lastly the section objectives
were set to explore the currently very active and exciting nanoscopic era of targeted
nano-carriers, in a sense bringing to life Ehrlich’s imagined concept of the “Magic
Bullet”. In the 1970s nanoscopic period began with systems projected which were
first used in the clinic in the 1980s, and which came of age in the 1990s. These are
currently emerging as exciting and clinically successful products in the 2000s. Most
of these successful products are based on PEGylation and active targeting to specific
cells by ligands conjugated to the DDS, or passive targeting to solid tumors via the
EPR effect [11]. Key events and pioneers are highlighted in Table 3.1.
While this is of course one of the major reasons for the emergence of this field in
the 1960s and 1970s, to me the surge of the field in the last 35 years is a classic
example of an early form of “convergence to biomedical science”, the idea pro-
moted recently by Sharp and Langer [12]. ALZA Corporation was founded in 1967
by Alejandro Zaffaroni and immediately attracted a distinguished group of scien-
tists from the chemical and pharmaceutical fields. A result of the introduction of
mathematical models and molecular design principles in pharmaceutical formula-
tions was the development of a new field setting the foundations, mechanisms and
defining the principles of controlled release profiles. The founding of ALZA
Corporation of 1967 had a significant effect on the development of the field of “con-
trolled release”.
Table 3.1 Historical events occur in drug delivery

Year Event Researcher References
1960s Emergence of drug delivery field Sharp and Langer [12]
and “convergence to biomedical science”
1970s
1967 ALZA Corporation: Include the Alejandro Zaffaroni [12]
scientists from the chemical and
pharmaceutical fields to introduce
mathematical models and molecular
design principles in pharmaceutical
formulations
This was done for the development of a
new field setting the foundations,
mechanisms and defining the principles
of controlled release profiles
1967 ALZA Corporation had a significant Alejandro Zaffaroni [12]
effect on the development of the field of
“controlled release”
1961 The first pharmaceutical scientist to Takeru Higuchi (professor [13]
apply physical chemical principles to the at the University of
design of controlled release devices Wisconsin and then the
University of Kansas)
1960– His classic equation (metamorphosed Takeru Higuchi (professor
1985 several times by 1963 to be applied also at the University of
to porous systems with high or low drug Wisconsin and then the
solubility [4]) became the standard of University of Kansas)
design of drug delivery systems and
continues to be widely used in the design
of many ethical and generic products,
especially of the oral/transmucosal
delivery
1964 Developed systems of medical relevance Folkman and Long [14]
for the prolonged drug therapy of
patients
1981 Offered the first systematic, mechanism- Langer and Peppas [15]
based classification of controlled release
systems
1980 Design of drug delivery systems was a Ping Lee [16]
publication: provided simple but
accurate solutions and design equations
for drug delivery from matrices
1990 Developed the first successful Langer and Brem, working [17]
biodegradable systems for treatment of with researchers at MIT
brain tumors and Johns Hopkins
1976 Speiser was the father of pharmaceutical Speiser [18]
nanotechnology, having written about
nanoparticles in drug delivery as early as
1976 [16]
(continued)
3.6 History of Drug Delivery from the Ancient to Date 105

Year Event Researcher References
1986 Worked on the enhanced permeability Hiroshi Maeda [19]
and retention (EPR) effect that explained
the mechanisms of macromolecular
transport and accumulation to tumors
1960– Resulted in historical development of Contribution of Paul [20]
1970 nanoparticles Ehrlich and then by Ursula
Scheffel and colleagues
and the extensive work by
the group of Professor
Peter Speiser at the ETH
Zürich in the late 1960s
and early 1970s
3.6.1 Historical Role of Polymers as Plastics
The plastics industry is recognized having its beginning in 1868 with the synthesis
of cellulose nitrate. It all started with the shortage of ivory from which billiard balls
were made. The manufacturer of these balls, seeking another production method,
sponsored a competition. Johny Wesley Hyatt (in the U.S.) mixed pyroxin made
from cotton (a natural polymer) and nitric acid with camphor. The result was cel-
lulose nitrate which is called celluloid. It is on record; however that Alexander
Parkes, seeking a better insulating material for the electricity industry, had in fact
discovered that camphor was an efficient plasticizer for cellulose nitrate in 1862.
Hyatt, whose independent discovery of celluloid came later, was the first to take out
patents for this discovery. Cellulose nitrate is derived from cellulose a natural poly-
mer. The first truly man made plastic came from 41 years later (in 1909) when Dr.
Leo Hendrick Baekeland developed phenol-formaldehyde plastics (phenolics), the
source of such diverse materials as electric iron and cookware handles, grinding
wheels and electrical plugs. Other polymers-cellulose acetate (toothbrushes, combs,
eyeglass frames etc.), urea-formaldehyde (buttons, electrical accessories), poly(vinyl
chloride) (flooring, upholstery etc.) and nylon (toothbrush bristles, surgical sutures)
followed in the 1920s. It is obvious that the pace of development which was pain-
fully slow up to the 1920s picked up considerable momentum in the 1930s and the
1940s. The first generation of manmade polymers was the result of empirical activi-
ties; the main focus was on chemical composition with virtually no attention paid to
structure. However during the half of the twentieth century, extensive organic and
physical developments led to the first understanding of the structural concept of
polymers-long chains or a network of covalently bonded molecules. In this regard
the classic work of German chemist Hermann Staudinger on polyoxymethylene and
rubber and of the American chemists W.T. Carothers on nylon stand out clearly.
Staudinger, first proposed the theory that the polymers are composed of giant mol-
ecules and he coined the word macromolecule to describe them. Carothers discov-
ered nylon, and his fundamental research (through which actually nylon was
discovered) contributed considerably to the elucidation of the nature of polymers.

His classification of polymers as condensation or addition polymers persists today.
The years following World War II (1950s) witnessed great strides in the growth of
established plastics and the development of new ones. The Nobel Prize winning
development of stereo specific catalysis by professors Karl Ziegler of Germany and
Giulio Natta of Italy led to the ability of polymer chemists to order the molecular
structure of polymers. As a consequence, a measure of control over polymer proper-
ties now exists, polymers can be tailor made for specific purposes. In recent years as
a result of better understanding of polymer structure property relationship, introduc-
tion of new polymerization techniques and availability of new and low cost mono-
mers, the concept of a true tailor made polymer has become reality. In the years
ahead, polymers will continue to grow. The growth from all the indications will be
not only from the development of new polymers, but also from the chemical and
physical modification of existing ones.
3.7 Shift from Nature to Synthetic (Including the Merits

and Demerits of Synthetic Polymers)
Polymers have become a crucial part of life, especially biodegradable polymers are
of special interest since they do not accumulate in or nor harm the environment and
thus can be considered as green [21].
To date, due to versatility of polymeric materials, specifically biodegradable
ones, they are rapidly replacing other biomaterial classes, such as metals, alloys,
and ceramics for use in biomedical applications. In 2003 the sales of polymeric
biomaterials exceeded $7 billion, accounting almost 88 % of the total biomaterial
for that year. The global market for biodegradable polymers increased from 409
million pounds in 2006 to 3 % an estimated 541 million pounds by the end of 2007.
It should reach an estimated 1203 million pounds by 2012, a compound annual
growth rate of 17 [21].
Biodegradable polymers can be either natural or synthetic. In general synthetic
polymers great advantages over natural polymers since they can be tailored in such
a way to yield wide array of possibilities with different types of products. Some of
the natural polymers have important functional groups that are suitable for applica-
tions such as tissue engineering and less prone to produce toxic effects. Nevertheless
presence of such functional groups and contaminants present in the material of
natural origin may produce undesirable immunological effects [21]. On the other
hand synthetic polymers are available with wide range of chemical linkages that can
greatly affect the degradation and other derived properties. To obtain the intermedi-
ate property two or more polymers can be blended and or chemically linked (copo-
lymerized). This latter approach has basically attracted lot of attention because of
the possibility of generating polymers with desired properties without limitation
such as phase separation [21].
3.7 Shift from Nature to Synthetic (Including the Merits and Demerits… 107
Polymers are either naturally occurring or purely synthetic. All the conversion
process occurring in our bodies are due to the presence of enzymes. Life itself may
cease if there is a deficiency of these enzymes [22]. Enzymes, nucleic acid and pro-
teins are polymers of biologic origin. These structures are normally very complex
were not understood until very recently. Starch, cellulose and natural rubber are on
the other hand example of plant based natural polymers and have relatively simple
structure then those of enzymes or proteins. There are large numbers of synthetic
polymers consisting of various families: fibers elastomers, plastics, adhesives. Each
family itself has subgroups [22].
From last 10 to 15 years much attention has been given to the development of
synthetic polymers for drug delivery devices, especially polymers those are fabri-
cated from synthetic polymers that degrade under in vivo conditions. Various data-
bases, literature, and scientific reports in the field polymers science have
demonstrated that natural polymers to this field received far less publicity that the
synthetic polymers as they play major role in drug delivery science. Three broad
classes of natural polymers (proteins, polysaccharides and polyesters) derived from
hydroxyacids showed the variable candidates for drug delivery applications [23].
However Kopecek and Ulbrich correctly reported the certain advantages offered by
synthetic polymers over natural polymers. He has also suggested that the techniques
or methodologies employed to fabricate synthetic polymers simply cannot create
the well-designed molecular structures with unique properties featured by many
natural polymers [23]. This is the most important reason for considering the latter.
Protocol employed in the development of synthetic or natural polymers as drug car-
rier play a major role in deciding its ultimate applications in drug delivery.
Degradation by external factors such as biodegradability by enzymatic hydrolysis or
by other means is considered as the dominant feature of natural polymers. This type
of degradation eventually causes a molecular weight variation which ultimately
affects the molecular weight dependent biological activity of the natural polymer.
Process of degradation is more advantageous when the degradation products are the
part of normal metabolic process of the body. Potential of natural polymers to show
bioactivity offers interesting possibilities that are being explored to some degree,
but warrant further study [23]. In such cases, the carrier becomes an active partici-
pant in the therapeutic process. Nevertheless antigenicity, a form of bioactivity
exhibit by natural polymers like proteins can be very dangerous, though not consid-
ered as a major problem to date. Current research cited various references for appli-
cations of collagen based drug delivery devices. Consequently it’s suitable to review
nature for such applications. It is relevant to point out that collagen represent com-
plex family of numerous proteins [23]. Collagens are considered as the most impor-
tant protein for connective tissue and form a major part of the organic matrix of
bones. Although 11 type of collagens with varying features have been discovered
and according to researchers many more will be identified in future [23].
Biodegradable synthetic polymer offers a number of advantages for application
in tissue engineering and regenerative medicine [24]. The biomaterials can be easily
synthesized with reproducible quality and purity and fabricated in to various shapes
with desired bulk and surface properties [24]. Specific advantages include the abil-
ity to tailor the mechanical properties and degradation kinetics of these materials to
suit various applications. Poly-hydroxy acids such as poly(glycolic acid), poly(L-
lactic acid), and their copolymer poly(lactide-co-glycolide) are the most widely
used biodegradable synthetic polymers for tissue engineering applications. The
polymers have gained popularity due to their processing, consistency, adequate
mechanical properties and Biodegradability and they are already FDA approved for
human use in variety of applications including as sutures and in drug delivery sys-
tem [24]. The ester bond in these polymers degrades non enzymatic hydrolysis and
their non toxic degradation products are eliminated from the body in form of carbon
dioxide and water. The degradation rate of these polymers can be controlled by
alteration of their crystalline, initial molecular weight and the copolymer ratio of the
lactide and glycolide and the degradation times that can be achieved ranges from
several weeks to several months. Since these polymers are thermoplastics, they can
be configured in three dimensional structures with a desired microarchitecture,
shape and dimension, however synthetic polymer generally lacks intrinsic biologi-
cal activity and their degradation products may cause adverse effects or alter local
microenvironment in vivo. In addition the surface hydrophobicity of synthetic poly-
mer may mediate protein denaturation in the vicinity of the implant and induce
fibrous encapsulation [24]. A number of groups have begun to explore the synthesis
of biomaterials that unite the advantages of smart synthetic polymers with the bio-
logical activities of proteins at the same chemical level. The concept of smart poly-
mers was initially derived from the development of materials that show large
conformational changes in response to micro environmental stimuli such as tem-
perature, ionic strength, pH, or light. The responses of the polymer may include
precipitation or gelation, reversible adsorption on a surface, collapse of a hydrogel
or surface graft, and alteration between hydrophobic and hydrophobic state [24]. In
many cases change in the state of the polymer is reversible. Biological application
of this technology currently under development span diverse areas including biosep-
aration, drug delivery, reusable enzymatic catalysts, molecular switches, biosen-
sors, regulated protein folding, microfluides and gene therapy. Smart synthetic
polymers may offer promise for revolutionary improvements in tissue engineering
scaffolds. Beyond the physical properties of these polymers, a major goal is to
impart smart biomaterials with the specific properties of signaling proteins such as
growth factors. Natural polymers are oxygen-permeable and available in large quan-
tities from renewable sources, while synthetic polymers are produced from non
renewable petroleum resources.
Biodegradable synthetic polymer exhibit number of advantages such as easy to
process, bioactive molecules can be easily incorporated and mimic natural ECM
structure and function. However it also exhibits numerous disadvantages less bio-
compatible than natural polymer and easily degrades to form bio products. Naturally
derived materials are biocompatible, bioactive material can be easily incorporated,
mimic natural ECM structure and composition, however its difficult to control bio-
degradable rate and having poor mechanical stability. Additionally they are tem-
perature sensitive and transfer of pathogen is possible.
In contrast with natural polymers synthetic polymer enjoy the tremendous advan-
tage of versatility. Through creative polymer chemistry, the synthetic polymer can
be custom designed to meet specific needs. The toxicology of breakdown products
and tissue biocompatibility of the polymers are the major issue in deciding the suc-
cess of the devices. When intended as a long term delivery systems the cyto-toxicity
of degraded products may be less of a problem because of the slow degradation rate
and hence the low dose. Any acute inflammatory response to the implant may also
have the chance of being resolved as the polymer disappears. However other poten-
tial side effects such as carcinogenicity and teratogenicity are difficult to address
and evaluate. Nevertheless with the tremendous potential advantages, research in
this area is still rewarded with a high benefit to risk ratio.
3.7.1 Natural Polymers and Synthetic Polymers for Scaffolds
Recent report suggested the potential applications of polymers as biomaterials for

the fabrication of medical device and tissue-engineering scaffolds [25, 26]. The
most preferable features for suggesting the materials as biomaterials are molecular
weight, material chemistry, shape and structure, solubility, lubricity, hydrophilicity/
hydrophobicity, water absorption degradation, erosion mechanism and surface
energy. Owing to their distinctive properties such as high porosity with very small
pore size, biodegradation, high surface-to-volume ratio, and mechanical property,
polymeric scaffolds are considered for its potential biomedical applications. Their
unique characteristics represent distinct advantages of biocompatibility, versatility
of chemistry, and the biological properties which are significant in the application
of tissue engineering and organ substitution. According to reports various research-
ers have worked to culture skin and cartilage [27], bone and cartilage [28], liver
[29], heart valves and arteries [30], bladder [31], pancreas [32], nerves [33], corneas
[34], and various other soft tissues [35]. Depending on the intended use, scaffold
materials can be synthetic or biologic, degradable or nondegradable. Based on the
properties of polymers such as composition, structure, and arrangement of their
constituent macromolecules it can be classified into various types in terms of their
structural, chemical, and biological characteristics, for example, ceramics, glasses,
polymers, and so forth. In broad terms it can be classified in to naturally occurring
polymers, synthetic biodegradable, and synthetic nonbiodegradable polymers used
as biomaterials. According to earlier report natural polymers can be considered as
the first biodegradable biomaterials used clinically [36]. Since they exhibit bioactive
properties and have better interactions with the cells which allow them to enhance
the cells’ performance in biological system. Natural polymers can be broadly clas-
sified as polysaccharides (cellulose, amylose, dextran, chitin, and glycosaminogly-
cans), proteins (silk, collagen, gelatin, fibrinogen, elastin, keratin, actin, and
myosin), or polynucleotides (DNA, RNA) [37]. The most dominating feature of
synthetic polymer over natural polymers is that synthetic biomaterial direction pro-
vided by biomaterials may assist restoration of structure and function of damaged
or diseased tissues, thus highly considered in biomedical field. In addition their

properties (e.g., porosity, degradation time, and mechanical characteristics) can be
tailored for specific applications which may further encourage its utilization in bio-
medical field. In contrast with natural polymer, synthetic polymers are having broad
class with defined purity and properties. Additionally they often cheaper than bio-
logic scaffolds; it can be produced in large uniform quantities and have a long shelf
time. It has been observed that various commercially available synthetic polymers
show physicochemical and mechanical properties comparable to those of biological
tissues. As discussed above synthetic polymers correspond to the largest group of
biodegradable polymers, and they can be produced under controlled conditions and
exhibit, in general, predictable and reproducible mechanical and physical properties
such as tensile strength, elastic modulus, and degradation rate [38]. The most com-
monly used synthetic polymers in tissue engineering [39] are PLA, PGA, and PLGA
copolymers. Among various polymers, PHA (belongs to a class of microbial poly-
esters) is being increasingly considered for applications in tissue engineering [40].
In soft tissue engineering bioactive ceramics (such as HAP, TCP), and certain com-
positions of silicate and bioactive glasses (such as phosphate glasses) and glass-
ceramics (such as apatite-wollastonite) react with physiological fluids and through
cellular activity form tenacious bonds to hard [41]. Nevertheless the issues related
with their biocompatibility and biodegradability is often inadequate. This may limit
their potential use in the clinical side. Researchers are still working on overcoming
these issues by developing suitable blend of synthetic and natural polymers or by
exploring composite materials that improve the scaffold properties and thereby
allowing controlled degradation [42] and improving the biocompatibility in tissue
engineering applications [43]. For achieving mechanical and biological perfor-
mance in hard tissue the suitable blend of degradable polymers and inorganic bioac-
tive particles can be developed. This and many other alike approaches promote their
utilization in biomedical field [44].
3.7.2 Natural vs Synthetic Polymer (as Biomaterial)
Natural polymers can be found in living creatures and plants; for example, silk,
protein, cotton, linen, wool and DNA. Synthetic polymers, as their name indicates,
are synthesized in the lab through a series of chemical reactions. Examples of such
polymers are polyvinylchloride, polypropylene, chewing gum, rubber and nylon.
There are various biomedical applications of synthetic and natural polymers
(Table 3.2). Synthetic and natural polymers have diverse applications in drug deliv-
ery. Natural polymers faced many problems like instability, irreproducibility,
changes in aesthetics on storage, uncontrollable formulation characteristic etc.
therefore novel designs were required to develop in form of synthetic polymer by
some chemical processes like polymerization. Development of new structural
imprints could require solutions for some of the problems that are usually associ-
ated with natural polymers. Most of natural polymers are covered by gums such as
Table 3.2 Biomedical applications of synthetic and natural polymers

Polymer Biomedical applications
Poly (2-hydroxyethyl methacrylate) Contact lens
Poly(dimethyl siloxane) Breast implants, contact lenses, knuckle
replacements
Poly(ethylene) Orthopedic joint implants
Poly(ethylene glycol) Pharmaceutical fillers, wound dressings
Poly(ethylene terepthalate) Vascular grafts, sutures
Poly(e-caprolactone) Drug delivery devices, sutures
Poly(lactic-co-glycolic acid) Resorbable meshes, sutures
Poly(methyl-methacrylate) Bone cements, diagnostic contact lenses
Poly(tetrafluoroethylene) Vascular grafts, sutures
Poly(isoprene) Gloves
Poly(propylene) Sutures
Alginate Wound dressing
Chitosan Wound dressing
Collagen Orthopedic repair material,
Nerve repair matrices,
Tissue engineering matrices
Elastin Skin repair matrices
Fibrin Hemostatic products, tissue sealants
Glycosaminoglycan Orthopedic repair matrices
Hyaluronic acid Orthopedic repair matrices
acacia, tragacanth, guargum, xanthan, etc. these polysaccharides are having molec-
ular weight which sometime hinders its biological property. Natural polymers those
are derived from the animal origin carry antigenicity and therefore interfere with
function of model drug by inducing some immune reactions. Microbial based poly-
saccharides often carries the antigenic property which again interferes with in vivo
biological reactions induced by model drug, though they are still use for various
pharmaceutical applications. On the other hand synthetic polymers are either syn-
thesized from natural polymers or completely synthesized from synthetic mono-
mers. Synthetic derivatives like cellulose, acryl, vinyl polymers relatively address
these issues. In modern day formulations well engineered polymers are gradually
replacing the natural polymers. Natural polymers are less toxic, biodegradable and
don’t contain any synthetic chemical as synthetic polymers and derivatives con-
tains. Though the Synthetic polymers are more stable then the natural polymers
therefore synthetic polymers can be readily sterilized. Most of the natural polymers
tend to change color due to the process called as auto oxidation. This will lead to the
leaching of colorful substance in product which can interfere with the physic-chem-
ical properties of parent product. Therefore plasticizer supplementation is highly
recommended while fabricating natural polymer based formulation. Natural poly-
mers have the problem of short shelf life when compared with synthetic polymer.
Some of toxicities under in vivo and in vitro conditions were also highlighted in
some of the reports. There are various structural variable used to control
Table 3.3 Structural variable used to control biodegradable polymer properties [45]
Variables Effects Examples
Inco-operation of both May reduce/eliminate Nonimmunologic PGA and PLA
natural or non natural immunologic response often (vs collagen)
monomers found in natural derived
polymers
Inco-operation of labile Control kinetics of Hydrolysable ester bond in PGA
groups in polymer chain biodegradation
Inco-operation of Control chemical and physical Hydrophilic, hydrophobic and
functional groups in side properties of polymers amphiphilic polyphosphazenes
chains
Inco-operation of chiral Control chemical and Semi-crystalline I PLA,
centers in polymeric mechanical properties of amorphous di PLA
chains polymers
Possibility of utilizing Control properties of polymers Glycolic and lactic acids in
multiple monomers PLGA
Use of natural Biocompatible breakdown of Lactic acid in PLA
compounds as products
monomers
Use of different polymer Control chemical and Branched polymers lower
Architectures mechanical properties of viscosity
polymers
bio-degradable polymer properties (Table 3.3). Toxicity assessment of both syn-

thetic and natural polymers can be achieved by considering the biocompatibility and
biodegradability parameters which can be further assessed by in vivo and in vitro
cyto-toxicity (e.g. lactate dehydrogenase assay).
3.7.3 Natural vs Synthetic Polymer in Tissue Engineering
Natural based polymer can be derived from the sources within the body or outside the
body. One of the most common natural biomaterial found in the human body is the
protein collagen. Many different type of collagen exist in different tissues and several
of these particularly type I and II have been explored as biomaterials. Another protein
base biomaterial fibrin, results from the combination of blood clotting factors fibrino-
gen and thrombin. Both fibrin and collagen have been frequently used in tissue engi-
neering attempts to repair cartilage damage and other orthopedic applications.
In addition to proteins, naturally based polymers may be derived from sugars
(carbohydrates). Hyaluronic acid is an example of carbohydrate molecule occurring
in human tissue that is often employed as a biomaterial. However the source of other
carbohydrate derived materials may be non human. Chitosan, a sugar based sub-
stance found in arthropod exoskeletons, agarose which is formed by algae and algi-
nate derived from seaweed, are all currently being investigated as biomaterials for a
variety of applications. For example, combination of chitosan and alginate has been
examined for wound dressings.
There are advantages and disadvantages of both natural and synthetic polymer
and particularly materials may lend themselves to certain applications over others.
In many cases natural polymers have composition similar to tissues they are replac-
ing. Therefore they may be more fully integrated in to the surrounding tissue over
the time or more easily remolded in response to changes in tissue needs. However
concerns about the feasibility of findings large amount of some these materials for
clinical applications, their relatively low mechanical properties and the assurance of
pathogen removal. In addition regions of these molecules may be recognized as
foreign by the body immune system leading to a type of material rejection. Further
potential problem arise when the biomaterial is based on not a single naturally
occurring polymer, but decellularized tissue. Here unwanted calcification leading to
device failure is a particular concern.
In contrast synthetic polymer can be easily mass produced and sterilized so sup-
ply issues are not a problem at all. Additionally their physical, chemical, mechanical
and degradative properties can be tailored for specific applications. However unless
specifically treated, most synthetic materials do not interact with tissue in an active
manner and therefore cannot direct or aid in healing around the implant site. Also
few synthetic polymers have been approved by regulatory agencies for use in
humans in specific applications.
3.7.4 Natural vs Synthetic Polymer Hydrogels
Hydrogel can be prepared from natural or synthetic polymer using various methods.
Hydrogels made from natural sources can be derived from polymers such as colla-
gen, hyaluronic acid, fibrin, alginate, agarose, and chitosan. Many natural polymer
such as collagen HA and fibrin have been used in tissue engineering applications
because they are either components or have macromolecular properties similar to
the natural extracellular matrix. Collagens are composed of three polypeptide
strands twisted together to form a triple helix and are the main protein of mamma-
lian ECM. Likewise hyaluronic acid an anionic glycosaminoglycan polysaccharide,
is also found in nearly all adult animal tissues. Alternatively alginate, agarose and
chitosan are hydrophilic, linear polysaccharides derived from marine algae sources
(alginate and agarose) or crustaceans (chitosan). Another natural derived gel
Matrigel™, is derived from soluble basement membrane extract of mouse tumors.
Various natural polymers have specific utilities and properties based on their origin
and composition. Advantages of natural polymer based gels include inherent biode-
gradability and biologically recognizable moieties that support cellular activities.
Disadvantages of some of these hydrogels include mechanical weakness and the
possibility of evoking immune/inflammatory responses. Synthetic hydrogels are
appealing for tissue engineering due to amount of control scientists have over struc-
ture, such as cross-linking density and tailored properties such as bio-degradation,
mechanical strength, and chemical and biological response to stimuli. Synthetic
polymers such as poly(ethylene glycol) (PEG) and other PEG based polymers or
poly(vinyl alcohol) (PVA) can be reproducibly produced with specific molecular

weights, block structures, degradable linkages and cross linking density and
mechanical and degradation properties of the material. Hydrogels made from syn-
thetic polymers like PVA, PEG or their derivatives do not possess the inherent bio-
active properties that gels made from natural polymers do. However, they do have
well defined structures and are versatile templates for subsequent modifications that
yield taliorable degradability and functionality.
3.8 Natural Polymers (Reasons for Reverting to Nature)
Polymers derived from natural resources have been widely researched as biomateri-
als for a variety of biomedical applications including drug delivery and regenerative
medicine. These molecules have biochemical similarity with human ECM compo-
nents and hence are readily accepted by the body. Additionally these polymers
inherit several advantages including natural abundance, relative ease of isolation
and room for chemical modification to meet the technological needs. In addition
these polymers undergo enzymatic and hydrolytic degradation in the biological
environment with body friendly degradation bye products. Natural polymers include
the list of polysaccharides and animal derived proteins. Polysaccharides are an
important class of biomaterials with significant research interest for a variety of
drug delivery and tissue engineering applications due to their assured biocompati-
bility and bioactivity. Polysaccharides are often isolated and purified from renew-
able sources including plants, animals, and microorganisms. Essentially these
polymers have structural similarities, chemical versatilities and biological perfor-
mance similar to ECM components, which often mitigate issues associated with
biomaterials toxicity and host immune responses. The building block of carbohy-
drate monosaccharide’s are joined together by o-glycosidic linkages to form poly-
saccharide chains. Polysaccharides offer a diverse set of physicochemical properties
based on monosaccharide’s that constitutes the chain, its composition and source.
The popular list of polysaccharides used for a variety of biomedical applications
includes cellulose, chitin/chitosan, starch, alginates, HAs, pullulan, guar gum, xan-
than gum, and GAGs. In spite of many merits as biomaterials, these polysaccharides
suffer from various drawbacks including variation in the material properties based
on the source, microbial contamination, uncontrolled water uptake, poor mechani-
cal strength and unpredictable degradation pattern. These inconsistencies have lim-
ited their usage and biomedical applications related technology development.
Numerous synthetic polymers with well defined mechanical and degradation prop-
erties have been developed to meet the technological needs in the biomedical appli-
cations. However these polymers from the biological standpoint lack much desired
bioactivity and biocompatibility and may cause toxicity and immune response.
Polysaccharide structure offers freely available hydroxyl and amine functionalities
that make it possible to alter its physicochemical properties by chemically modify-
ing polysaccharide structure. For instance grafting synthetic monomers on the
3.8 Natural Polymers (Reasons for Reverting to Nature) 115
polysaccharide chains offer an easy way to control polymer solubility undesired

solvents, water uptake and degradation. These semi synthetic polymers offer best
feature of the both natural and synthetic polymers. Various cross linking techniques
to restrict the polysaccharide chain movement to control their water uptake, degra-
dation and mechanical properties have also been developed. Polysaccharides based
porous scaffolds, fiber matrices, hydrogels, and micro and nanoparticles have been
developed for variety of tissue regeneration and drug delivery applications. In the
recent years glycochemistry has gained research momentum for understanding car-
bohydrate biological functions and development of carbohydrate based drugs and
vaccines. Engineered carbohydrate based polymeric structures may serve as an
alternative material platform for a variety of regenerative medicine and drug deliv-
ery applications. A new nonpetroleum based biomaterial platform to meet the ver-
satile needs in biological science and biomedical engineering could be achieved by
collaborative efforts between academia, government and industry partnership. The
collaborative efforts should include bringing scientist working in different disci-
plines of chemistry, biology, polymers, materials sciences and engineering to work
toward these activities. The collaborative efforts could lead to the development of a
methodology for synthesis natural polymer based semi synthetic polymers and pro-
vide a greater depth of understanding of carbohydrate biological functions, polymer
structure, material properties degradation and mechanical properties. Further the
development of modeling tools to predict the structure, property and biological
activity of carbohydrates for biomedical applications is a step in this direction. The
goal of new initiatives should focus on the development of natural polymer based
orthopedic fixation devices, biomedical implants, drug delivery vehicles, carbohy-
drate based drugs, hydrogels, surfactants, coagulants, and absorbents for a variety of
biomedical applications. The research activities in this area could generate com-
mercially available technologies and product from the renewable resources and con-
tribute immensely toward economic development.
3.8.1 Need of Natural Polymers
• Biodegradable
Naturally occurring polymers produced by all living organisms. They show no
adverse effects on the environment or human being.
• Biocompatible and Non-Toxic
Chemically, nearly all of these plant materials are carbohydrates in nature and
composed of repeating monosaccharide units. Hence they are non-toxic.
• Economic
They are cheaper and their production cost is less than synthetic material.
• Safe and Devoid of Side Effects
They are from a natural source and hence, safe and without side effects.
• Easy Availability
In many countries, they are produced due to their application in many industries.
3.8.2 Disadvantages of Herbal Polymers
• Microbial Contamination
During production, they are exposed to external environment and hence, there
are chances of microbial contamination.
• Batch to Batch Variation
Synthetic manufacturing is controlled procedure with fixed quantities of ingredi-
ents while production of natural polymers is dependent on environment and vari-
ous physical factors.
• The Uncontrolled Rate of Hydration
Due to differences in the collection of natural materials at different times, as well
as differences in region, species, and climate conditions the percentage of chemi-
cal constituents present in a given material may vary [46].
• Slow Process
As the production rate is depends upon the environment and many other factors,
it can’t be changed, thus natural polymers have a slow rate of production.
• Heavy Metal Contamination
There are chances of Heavy metal contamination often associated with herbal
excipients [47].
References
1. Marino Jr R, Gonzales-Portillo M. Preconquest Peruvian neurosurgeons: a study of Inca and

pre-Columbian trephination and the art of medicine in ancient Peru. Neurosurgery.
2000;47(4):940–50.
2. Warrell DA. The 1996 Runme Shaw Memorial Lecture: malaria—past, present and future.
Ann Acad Med Singapore. 1997;26(3):380–7.
3. Paghdal KV, Schwartz RA. Topical tar: back to the future. J Am Acad Dermatol.
2009;61(2):294–302.
4. Thami GP, Sarkar R. Coal tar: past, present and future. Clin Exp Dermatol. 2002;27(2):99–103.
5. Feldmann H. History of injections. Pictures from the history of otorhinolaryngology high-
lighted by exhibits of the German History of Medicine Museum in Ingolstadt.
Laryngorhinootologie. 2000;79(4):239–46.
6. Kravetz RE. Hypodermic syringe. Am J Gastroenterol. 2005;100(12):2614.
7. Jain RK. Understanding barriers to drug delivery: high resolution in vivo imaging is key. Clin
Cancer Res. 1999;5(7):1605–6.
8. Wilding I. Site-specific drug delivery in the gastrointestinal tract. Crit Rev Ther Drug Carrier
Syst. 2000;17(6):557–620.
9. Zarowitz BJ. Pharmacologic consideration of commonly used gastrointestinal drugs in the
elderly. Gastroenterol Clin N Am. 2009;38(3):547–62.
10. Dorski CM, Doyle FJ, Peppas NA. Preparation and characterization of glucose sensitive
p(MAA-g-EG) hydrogels. Polym Mater Sci Eng Proc. 1997;76:281–2.
11. Hoffman AS. The origins and evolution of “controlled” drug delivery systems. J Control
Release. 2008;132(3):153–63.
12. Sharp PA, Langer R. Promoting convergence in biomedical science. Science. 2011;333:521–2.
13. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspen-
sions. J Pharm Sci. 1961;50:874–5.
References 117
14. Folkman J, Long DM. The use of silicone rubber as a carrier for prolonged drug therapy.
J Surg Res. 1964;4:139–42.
15. Langer RS, Peppas NA. Present and future applications of biomaterials in controlled drug
delivery systems. Biomaterials. 1981;2:201–14.
16. Lee PI. Diffusional release of a solute from a polymeric matrix. J Membr Sci. 1980;7:255.
17. Brem H. Polymers to treat brain tumors. Biomaterials. 1990;11:699–710.
18. Marty JJ, Oppenheim RC, Speiser P. Nanoparticles: a new colloidal drug delivery system.
Pharm Acta Helv. 1976;53:17.
19. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemo-
therapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent
SMANCS. Cancer Res. 1986;46:6387–92.
20. Kreuter J. Nanoparticles—a historical perspective. Int J Pharm. 2007;331(1):1–10.
21. Jain PJ, Ayen WY, Domb AJ, Kumar N. Biodegradable polymers in clinical use and clinical
development. NJ: Wiley; 2011.
22. Robert O. Ebewele polymer science and technology. Technology & engineering. Boca Raton,
FL: CRC Press; 2000. p. 6.
23. Tarcha PJ. Polymers for controlled drug delivery. Boca Raton, FL: CRC Press; 1990. p. 150.
24. Armiñán A, Sepúlveda P, Vicent MJ. Polymer therapeutics as nano-sized medicines for tissue
regeneration and repair. In: Pradas MM, Vicent MJ, editors. Polymers in regenerative
medicine: biomedical applications from nano- to macro-structures. Hoboken: Wiley; 2014.
doi:10.1002/9781118356692.ch8.
25. Piskin E. Biodegradable polymers as biomaterials. J Biomater Sci Polym. 1994;6:775–95.
26. Ghosh YJK, Shu XZ, et al. Electrospun three-dimensional hyaluronic acid nanofibrous scaf-
folds. Biomaterials. 2006;27(20):3782–92.
27. Eaglstein WH, Falanga V. Tissue engineering and the development of Apligraf a human skin
equivalent. Adv Wound Care. 1998;11(4):1–8.
28. Boyan BD, Lohmann CH, Romero J, Schwartz Z. Bone and cartilage tissue engineering. Clin
Plast Surg. 1999;26(4):629–45.
29. Mayer J, Karamuk E, Akaike T, Wintermantel E. Matrices for tissue engineering-scaffold
structure for a bioartificial liver support system. J Control Release. 2000;64(1–3):81–90.
30. Mayer JE, Shin'oka T, Shum-Tim D. Tissue engineering of cardiovascular structures. Curr
Opin Cardiol. 1997;12(6):528–32.
31. Oberpenning F, Meng J, Yoo JJ, Atala A. De novo reconstitution of a functional mammalian
urinary bladder by tissue engineering. Nat Biotechnol. 1999;17(2):149–55.
32. Tziampazis E, Sambanis A. Tissue engineering of a bioartificial pancreas: modeling the cell
environment and device function. Biotechnol Prog. 1995;11(2):115–26.
33. Mohammad J, Shenaq J, Rabinovsky E, Shenaq S. Modulation of peripheral nerve regenera-
tion: a tissue-engineering approach. The role of amnion tube nerve conduit across a 1-centimeter
nerve gap. Plast Reconstr Surg. 2000;105(2):660–6.
34. Germain L, Auger FA, Grandbois E, et al. Reconstructed human cornea produced in vitro by
tissue engineering. Pathobiology. 1999;67(3):140–7.
35. Diedwardo CA, Petrosko P, Acarturk TO, Dimilia PA, Laframboise WA, Johnson PC. Muscle
tissue engineering. Clin Plast Surg. 1999;26(4):647–56.
36. Nair LS, Laurencin CT. Biodegradable polymers as biomaterials. Prog Polym Sci.
2007;32(8–9):762–98.
37. Yannas IV. Classes of materials used in medicine: natural materials. In: Ratner BD, Hoffman
AS, Schoen FJ, Lemons J, editors. Biomaterials science: an introduction to materials in medi-
cine. San Diego, CA: Elsevier Academic Press; 2004. p. 127–36.
38. Gunatillake P, Mayadunne R, Adhikari R. Recent developments in biodegradable synthetic
polymers. Biotechnol Annu Rev. 2006;12:301–47.
39. Ma PX. Scaffolds for tissue fabrication. Mater Today. 2004;7(5):30–40.
40. Chen LJ, Wang M. Production and evaluation of biodegradable composites based on PHB-
PHV copolymer. Biomaterials. 2002;23(13):2631–9.
41. Hench LL. Bioceramics. J Am Ceram Soc. 1998;81(7):1705–27.
42. Cascone MG, Barbani N, Cristallini C, Giusti P, Ciardelli G, Lazzeri L. Bioartificial polymeric
materials based on polysaccharides. J Biomater Sci. 2001;12(3):267–81.
43. Ciardelli G, Chiono V, Vozzi G, et al. Blends of poly-(ε-caprolactone) and polysaccharides in
tissue engineering applications. Biomacromolecules. 2005;6(4):1961–76.
44. Roether JA, Boccaccini AR, Hench LL, Maquet V, Gautier S, Jérôme R. Development and
in vitro characterization of novel bioresorbable and bioactive composite materials based on
polylactide foams and Bioglass® for tissue engineering applications. Biomaterials.
2002;23(18):3871–8.
45. Atala A. Synthetic biodegradable polymer scaffolds. New York: Springer; 1997.
46. Kumbar S, Laurencin C, Deng M. Natural and synthetic biomedical polymers. Burlington:
Elsevier; 2014.
47. Jani GK, Shah DP, Prajapati VD, Jain VC. Gums and mucilages: versatile excipients for phar-
maceutical formulations. Asian J Pharm Sci. 2009;4(5):309–32.
Chapter 4
Plant Derived Polymers, Properties,
Modification & Applications
Abstract Current polymeric research has explored various applications in drug

delivery and its related biomedical applications. Natural polymers especially those
are derived from plant sources has evidenced for growing interest and attention in
biomedical and pharmaceuticals sectors. Owing to their relative abundance, low
cost, and biodegradable and eco-friendly profiles, plant derived polysaccharides are
more preferred over the synthetic polymers. Present work demonstrates the drug
delivery applications of plant based polysaccharides especially in nanotechnology
sector. Outstanding features of these polysaccharides attributed to its unique
physico-chemical properties. These plants polymer based nanomaterials used or
investigated as release retardant in sustained or controlled release drug delivery
systems. Nanomaterials of these plant based polysaccharide exhibit high water
content, functionality, biocompatibility, tunable size from submicrons to tens of
nanometers, large surface area for multivalent bioconjugation, and interior network
for the incorporation of therapeutics. These unique properties present great potential
for the utilization of polysaccharide-based microgels/nanogels in tissue biomedical
implants, engineering, bionanotechnology, and particularly, drug delivery.
Keywords Plant • Nanomaterials • Polysaccharides • Drug delivery • Biomedical •

Natural polymer • Nanotechnology • Nanoparticles
4.1 Introduction
Owing to their relative toxicity and stability issues under physiological environment
drugs are rarely administered as such since most of them are always formulated into
a desirable dosage form with the support of active excipients. Active excipients are
those excipients that may mask the toxic or undesirable effect of drug without
affecting its significant biological activity. Additionally most of the recent formula-
tions tend to enhance biological activity by increasing its stability profile especially
under in vivo environment. According to International Pharmaceutical Excipients
Council excipients are those substances, other than the active drug substances of
finished dosage form, though some excipients also exert similar or different biologi-
cal activity then active drug and sometime impart synergistic or cumulative effect

DOI 10.1007/978-3-319-41129-3_4
120 4 Plant Derived Polymers, Properties, Modification & Applications
to the active drug. Objectives of each and every excipients is to either aid the
processing of the drug delivery system through its manufacture, protect, bioavail-
ability, support or enhance stability, assist in product identification, or patient
acceptability, or enhance any other features of the general safety and efficiency of
the drug delivery system throughout storage or use [1]. Therefore excipients plays a
major role in deciding the final fate of drug under both in vitro and in vivo environ-
mental conditions. Currently a variety of excipients have been explored as binding,
flavoring, suspending, lubricating, gelling, sweetening and bulking agent among
others [2]. They also play an important role in preserving the efficiency, safety, and
stability of active drug and guarantying that they deliver their assured benefits to the
patients. One of the major advantages of excipients is that their utilization at opti-
mal concentration offers enhanced functionality, pharmaceutical manufacturers
with cost-savings in drug development and help in drug formulations innovation.
Since excipients are the largest components of any pharmaceutical formulation,
therefore its essential to determine their stability and toxicological parameters from
pre formulation studies. They can be obtained from natural or synthetic origin and
in contrast with natural excipients, synthetic excipients are more utilized in pharma-
ceutical dosage forms [3]. Owing to the exclusive properties and advantages over
naturally derived compounds, including a low sensitivity to various ingredients or
moisture, resulting in more efficient and effective pharmaceutical products, syn-
thetic and semi-synthetic products are preferred more [3]. Synthetic and semi-syn-
thetics excipients differentiated on the basis of their origin such as pure synthetic
organic chemical called as synthetic compound and substance that is naturally
derived but has been chemically modified is called as semi-synthetic.
Polymeric materials obtained from lipids, carbohydrates and protein covers a
broad class of excipients. Most of them are derived from natural polysaccharides
and their derivatives. Polysaccharides of plant origin endow a group of polymers
that are widely used in pharmaceutical formulations and play a significant role in
evaluating the underlying mechanism and rate of drug release from the dosage form.
Currently variety of plant based polysaccharides have been explored as excipients
in the formulation of solid, liquid and semisolid dosage forms in which they play
distinct functions as film formers, matrix formers or release modifiers, disintegrates,
binders, stabilizers, emulsifiers, suspending agents, thickeners or viscosity enhancers
and muco adhesives [4, 5]. Additionally plant based natural polymers can also be
used in the implants, micro particles, films, nanoparticles, beads, formulation and
manufacture of solid monolithic matrix systems, inhalable and injectable systems as
well as viscous liquid formulations [5–7]. These plant based polymers are not only
considered over synthetic polymers because of its significant features such as
biodegradability, biocompatibility, non toxic and low cost and relative abundance
compared to their and synthetic counter parts [8, 9], however also as natural
resources are renewable and provide constant supply of raw material if cultivated or
harvested in a sustainable manner [10]. The most popular plant based natural
polymers that are used in pharmacy and other fields are chitosan, ispaghula, acacia,
agar, guar gum, carrageenan, gelatin, shellac and gum karaya. These natural
polymers are extensively used in pharmaceutical industry as adjuvant, emulsifying
agent and adhesive in packaging; and also suitable for cosmetic and pharmaceutical
4.2 Sources of Plant Polymers 121
product development. Moreover various wide ranges of applications in drug delivery

have been explored since as polymers, they endow exclusive properties which so far
have not been exhibited by any other materials [11]. Natural polymers can be
conjugated with small molecular weight proteins, polypeptides, lipids, surfactants,
drugs, peptides, metals, nucleic acid, antibody, etc. They can be modified in such a
way so that large chains and functional groups can be conjugated with other low and
high molecular-weight materials to attain new materials with a variety of
physicochemical properties. To overcome their demerits, natural polymers are
tailored by chemical modification. Various physico-chemical modification reports
are also available on natural gums, mucilages and other polysaccharides suggesting
their potential role in pharmaceutical industry especially in drug delivery [12, 13].
Owing to the rising concern towards natural polymeric materials as pharmaceutical
excipients, it’s very difficult to document all the polymers at one platform, though
we tried to cover most of the plant based polymers with its physic-chemical
modifications and current applications in pharmaceutical industry.
4.2 Sources of Plant Polymers
Diversity of natural polymers in nature confers variation in their structural and gell-
ing properties. As a matter of fact native polymers show variability and versatility,
associated with their complex structures, not found in other classes of polymers.
Plant and algal derived polysaccharides are the precursors for the diverse polymers
which are widely used in drug delivery industry as advanced therapeutics. From a
view of commercial utilization plant derived polymers are at most priority, however
more researches are currently enduring on algal polysaccharides because of its com-
plex structure related gelling properties. Moreover mammalian and microbial poly-
saccharide is another foundation for the polymeric industries because of their unique
properties or because they provide a cheaper and superior alternative to other materi-
als derived from plant, animal, or synthetic sources. Throughout the whole literature
we found that usage of polysaccharides falls into three distinct areas: food applica-
tions, nonfood applications and biological purpose, whereas their growth and evalu-
ation requires considerable investment in time, money, and technology. Many of
these native polysaccharides for which potential industrial applications have been
claimed have not proved to be of commercial value. Thus latest tools are required for
their better study. Further discoveries in polymeric sciences furnish the continuous
supply of novel polysaccharide from novel origin which makes a trouble in covering
all the polymers under one platform. Combining together, here our attempt addresses
the nature’s broad class of polysaccharide from diverse origin with their current
advancements and contribution in the field of pharmaceutics. Exploration of exten-
sive class of plant based polysaccharides suitable for nanodelivery, chiefly from
natural sources with techniques to increase its development in pharmaceutics. Here
in this chapter we have covered the following set of objectives to explore the diverse
polysaccharides in pharmaceutical sciences.
• To cover the utmost diversity of natural polysaccharides with aim to distinguish

their commercial and medicinal utilization according to their structure related
gelling properties.
• Broad view of nano applications of these polymers
• Latest equipments and knowledge used in the structural interpretation and gelling
properties evaluation of diverse polysaccharides from different foundation.
Natural polysaccharides based polymers guarantee a new class of compounds for
the development of a variety of drug delivery systems. They are now distinguished
as valuable polymers for their significant pharmaceutical properties. These
renewable compounds are extremely advantageous as compared to synthetic
polymers in properties like non-toxic, biocompatible and show a number of peculiar
physico-chemical properties [14]. Polysaccharides have some common uniqueness
which are significant from a view of its applications; they have the ability to form
multiple hydrogen bonds implying the local stiffness of the molecules, generally
giving them the property of being water-soluble, but they also can be water-insoluble
when they form intermolecular hydrogen bonds with each other to give crystals or
large, high molecular weight, insoluble crystalline aggregates, granules, or fibers;
from this rigidity, they get a high thickener character [15]. Knowledge of solution
properties is needed to understand the polysaccharides’ behavior in different
applications. The main factors affecting the solution properties of polysaccharides
are the molecular structures of the polysaccharides themselves, for example, the
content of side galactose units and degree of substitution, molar mass, and
temperature, pH, and ionic strength circumstances [16].
Polysaccharides are present in all kind of organisms, mammals, plants and
microorganisms (Table 4.1). Because of its abundance it’s very difficult to furnish
absolute classification of polysaccharides. Polysaccharide derived from plants
polymers are nowadays of greatest interest. This interest is generated by the features
of these natural sources, such as being able to produce biodegradable and
biocompatible new products and as value-added materials [16]. Whereas algal
galactans like agar, alginate and carrageenan are the major hydrocolloids used as
texturing agents for food and non-food applications. Their extraordinary gelling and
thickening properties make them more complex then plant polysaccharides [17, 18].
In this context mammalian and microbial polysaccharides also play a great
contribution in pharmaceutical field [18–24]. More focusing event in studding the
polysaccharides is to establish a relationship between its structural and gelation
properties. Various chemical, physical and biochemical tools are now available for
their precise chemical and structural characterization.
Recently advance techniques and equipments have provided a more precise view
of the interaction between the structural and the gelling characteristics of these com-
plex polysaccharides. The quantitative estimation of all the constituent sugars, moe
specifically the acid labile 3,6-anhydyrogalactose can be done by methanolysis and
reductive acid hydrolysis procedures coupled to different chromatographic separa-
tions techniques. This advancement also presents the means of determining sugar
linkages, substitutions and sequences using chemical, enzymatic and spectroscopic
4.2 Sources of Plant Polymers 123
Table 4.1 Classification of polysaccharides

Plant Cellulose and its derivatives, starch (cyclodextrins and amylose) and its
polysaccharides derivatives, rosin, inulin, pectin, psyllium and arabinogalactans (larch)
Other polysaccharides from different sources like aloe, cereal, psyllium,
quince seed and oat brans also play some important role.
Gums and mucilages
Xanthan gum, gellan gum, konjac glucomannan, Xyloglucan, Guar gum
(guar beans), Karaya gum (Sterculia gum), Gum tragacanth (Astragalus
shrubs), Chicle gum (From Chicle tree), Konjac glucomannan (From
Konjac plant), Gum Arabic (Acacia tree), Gum ghatti (sap of Anogeissus
tree), Locust bean gum (carub tree), Cashew gum Mastic gum (mastic
tree), Tamarind kernel gum, Hakeagibbosa gum, Irvingiagabonensis,
Moringaoleifer gum, Kyaha gum, Okra, Grewia, mucilage gum, Mimosa
scabrella, Mimosa pudica, Albizia gum, Hupu gum, Lepidium sativum,
Gum Copal, Gum Damar, Bhara Gum, Moi gum, Cactus mucilage,
Cordia gum, Hakea, Karaya gum, Mucuna gum, Satavari mucilage,
Ocimum seed, Mucilage, Leucaena seed gum, Cassia tora, Cashew gum,
Asario mucilage, Bavchi mucilage, Abelmoschus mucilage,
galactomannans (locust bean, guar, fenugreek and tara gum,
hexofuranosides) Gum kondagogu, gum olibanum, Sida acuta gum
(SAG), Cashew-nut tree exudate gum, gum from Meryta sinclairii, peach
tree gum, angico gum, Laguncularia racemosa, Durian seed gums,
Lepidium perfoliatum, Flaxseed gum, Albizia lebbeck gum, seeds of
Gleditsia sinensis Lam gum, Mesquite gum (Prosopis spp.), Albizia
procera gum, Yanang (Tiliacora triandra) leaves, Mesona Blumes gum,
tamarind seed gum, Salvia macrosiphon) seed gum, hsian-tsao leaf gum,
flamboyant (Delonix regia) seed gum, Boswellia and Commiphora gum,
Angum gum, Gum karaya (Sterculia urens L.), Bael gum
Algal Brown algae: mannitol, Alginates and fucose/fucans/fucoidans,
polysaccharides sargassan, Laminaran, Polyuronan, alginic acid
Green algae: Ulvan Oligo-Ulvans
Red algae: Agar/Agarose (agarans), carrageenans, hypneans, porphyran,
furcellaran, funoran, dulsan, and iridophycan, mannans, crystalline
mannas and xylomannans, rhamnanns
Mirco alga: Spirulan, sacran
However certain green algae polysaccharides also play some important
role. Cyanobacteria (cyanobacterial polysaccharide) of the genera
Aphanocapsa, Cyanothece, Gloeothece, Synechocystis, Phormidium,
Anabaena and Nostoc are able to produce sulfated polysaccharides
containing uronic acids
Microbial Bacterial polysaccharide: Bacterial cellulose, dextran, bacterial
polysaccharides hyaluronic acid, xanthan, emulsan, β-d glucans, curdlan, alignate, gellan
and pullulan, Scleroglucan and Schizophyllan. Bacterial Hyaluronic
Acid, kefiran, exopolysacharide (EPS). xanthan gum, dextran, welan
gum, gellan gum, diutan gum and pullulan.
Fungal polysaccharides (Chitin, Scleroglucan, Lentinan, Schizophyllan
Krestin, galactofurinase)
Yeast polysaccharide: Zymosan, glucans, glycogen, mannan
Mammalian Glycosaminoglycans (Hyaluronic acid or hyaluronan, Chondroitin
polysaccharides sulphate), gelatin and heparin sulfate. Chitin and chitosan
Others β 1,3-Glucans derived from a variety of natural sources (such as yeasts,
grain, mushroom or seaweed), poly-gamma-glutamate (Aminoacid
polymer)
methods. Developments in multi- and low-angle laser-light diffusion detectors cou-

pled to high performance size exclusion chromatography now render the determina-
tion of molecular weight and molecular weight distribution of these galactans more
accessible. Moreover techniques like NMR, rheology, dissolution techniques, bioad-
hesion testing methods, DSC, desulfation methods, various carbohydrate determina-
tion methods, SEC, freeze-drying, scanning electron microscopy, colorimetry,
turbidimetry, X-ray diffraction method, plane polarized microscopy¸ fingerprinting
approaches, Chromatographic separations of the fragments by HPLC, HPAEC and/
or capillary electrophoresis and mass-spectrometric identification methods using the
recently developed ESI-MS-MS and/or MALDITOF-MS technologies. (high perfor-
mance size exclusion chromatography) coupled to multiple or low angle laser light
scattering detectors, various other hydrolysis and chemical modification methods,
establish a more clear link between structure and gelation of polysaccharides. From
the view of their applications and structural complexicity now a day’s polymers from
algal sources are getting more magnitude of concern then from plants, mammalian
and microbial resources. However here we have targeted certain gelling polysaccha-
rides of natural origin with a objective to study its broad pharmaceutical applications,
to testify their effectiveness in curing various human disorders and how current
research is employing different tools in studying and improving their native proper-
ties [18–32].
Carbohydrate-containing structures are amongst the most complex, heteroge-
neous, and abundant biomolecules on earth. Diversity of polysaccharides has given
germination to modern knowledge to understand its structure related gelling proper-
ties. It is essential to classify these compounds to distinguish their role and quality
in the drug delivery systems. Throughout our literature survey we comes to conclu-
sion that plant derived polysaccharides has wide applications in pharmaceutics
however algal or sulphated polysaccharides gives more advancement to the area of
polymeric sciences [5, 33]. Whereas mammalian polysaccharides are considered as
non toxic biomolecules having excellent mucoadhesive capacity and many impor-
tant applications in formulation of bioadhesive drug delivery systems. Besides its
mucoadhesive properties, it was found that this biopolymer may enhance the
absorption of drugs and proteins via mucosal tissues. Furthermore microbial poly-
saccharides are more economic and exclusive polymers provide an alternate source
to the current polymers exploiting industries.
4.3 Methods of Extractions
4.3.1 Cold Extraction
5 g of dried algal material was dissolved in 250 mL of distilled water and kept in
orbital shaking incubator for 12 h at 20–25 °C degree. To obtain polysaccharide
fraction the insoluble fraction was removed by centrifugation (15,000 rpm at 4 °C).
4.3 Methods of Extractions 125
The supernatant was separated and treated with ethanol (1:3 v/v). Ethanol precipi-
tated fraction was again dissolved in distilled water and dialyzed. The obtained
dialyzed sample was lyophilized weighed (0.38 g) and coded as EC [34].
4.3.2 Hot Extraction [Mild Acidic (EHA), Alkaline (EHB)

and Radical Hydrolysis (EHR)]
5 g of dried algal material was extracted with HCl (0.1 M) and maintained at 80 °C
with constant mechanical stirring for different periods of time. The acid solublized
fraction was separated by centrifugation (15,000 rpm at 4 °C) for 15 min. Similar
procedure was again repeated for alkaline hydrolysis using NaBH4 (0.1 M). Both
fractions were lyophilized and their yield was denoted as EHA and EHB. For all
the procedures the reaction time between sample and hydrolyzing agent was lim-
ited to 2 h.
Dry weight of Porphyran ( g )

% yield of POR = ´1000
Dry weight of Seaweed ( g )
4.3.3 Radical Hydrolysis (EHR)
Radical hydrolysis was conducted by using ascorbate (0.1 M) and H2O2 (0.1 M) at
25 °C for 5 g of dried algal sample and the lyophilized product was denoted as HER
[35–37]. The percentage yield was calculated on the basis of following equation:
Dry weight of Porphyran ( g )

% yield of POR = ´1000
Dry weight of Seaweed ( g )
4.3.4 Microwave Assisted Extraction (EM)
Domestic Microwave oven (CATA 2R, 140–700 W, Catalyst System, Pune, India)
equipped with closed vessel (100 mL), power sensor, temperature sensor and tem-
perature controller was used at conditions specified in the Table 4.1. 5 g of distilled
water dissolved algal sample was introduced in to the closed vessel followed by open-
ing of the vessel and cooling in an ice bath shortly to relieve the pressure. Subsequent
procedures were similar to those for hot extraction of polysaccharides [29].
4.3.5 Ultrasonic Extraction (EU)
5 g of algal sample was dissolved in distilled water and placed in a 250 mL beaker.
The beaker and its contents were placed in to 42 kHz bath (Branson Ultrasonic
cleaning bath unit, model 1510 DTH) and extracted under specified conditions
(Table 4.1). After this, the beaker was taken out of the sonication bath and subsequent
steps were followed as mentioned in Hot extraction for polysaccharides [38].
4.3.6 Enzymatic Hydrolysis (EE)
5 g of algal sample was treated with different percent of weighed amount of cellu-
lase in conditions as specified in Table 4.1. After the addition of distilled water pH
was adjusted (4.5). Rest procedure was followed in a similar manner as followed in
hot extraction method [39].
4.4 Chemical Composition Analysis
Chemical composition of polysaccharides can be determined by these methods.

Total sugar content, galactose and 3, 6 anhydrogalactose (AGR) contents were
estimated by phenol sulfate [40, 41] resorcinol methods. Furthermore sulfur and
protein content were determined by toluidine [42, 43] methods [40–43]. The organic
functional groups of the polysaccharides preparations can be identified by using an
FTIR spectrophotometer via the KBr 141 pressed-disc method.
4.5 Physical Properties
4.5.1 Determination of Gelling Strength (GS)
5 % polysaccharide solution can be prepared in an autoclave at 100 °C. Gel formation

took place in dark place at 25 °C after which the gel was kept at 10 °C overnight in
a refrigerator [44]. Strength of the gel was measured at 20 °C using a Model TA-XT2
Texture analyser (Stable Micro System, Surrey, UK).
4.5.2 Determination of Gelling Temperature (GT) and Melting

Temperature (MT)
The gelling and melting temperatures were measured according the method
described by Craigie and Leigh [45]. For measurement of gelling temperature,
10 mL solution of agar was allowed to cool gradually and a thermometer was
4.6 Physical-Chemical Modification of Plant Based Natural Polymers (PBNPS) 127
emerged in the sol. The temperature at which the thermometer was fixed to the gel
was noted. For melting temperature the gel was heated on a water bath and one iron
ball (ca. 1 g of weight) was placed on the surface of the gel. The temperature at
which the ball touched the bottom of the tube was noted.
4.5.3 Viscosity Measurement (VS)
Apparent Viscosity of polysaccharide can be measured by Brookfield Viscometer

(Synchrolectric Viscometer, Stoughton, MASS 02072). Spindle No. 1 at 60 rpm was
used for measuring apparent viscosities of agar samples (5 % in deionized water) at
60 °C.
4.5.4 Molecular Mass Determination (MM)
Owing to structural similarity with many polysaccharides, Agarose of known MW

was taken as standard. 5 % polysaccharide solution of all fractions (test samples)
and agarose (standard) was prepared in double distilled water. Flow time of the all
solutions (test and standard) and solvent (double distilled water) was determined by
using Cannon-Ubbeholde viscometer which gives the intrinsic viscosities [η] values
of all preparation. Viscosity average MWs were calculated from the intrinsic
viscosity using the Mark–Houwink equation for agarose, [η] = 0.07 M 0.72 where
[η] is mL/g [46, 47].
4.6 Physical-Chemical Modification of Plant Based

Natural Polymers (PBNPS)
In contrast with synthetic polymers plant based natural polymers have their dominant
features that can be physically or chemically modified for improvement in their
respective utilization and applications. Owing to the diverse class of natural
polymers it’s very difficult to cover each and every polymer therefore here in this
section we are more emphasizing on starch and cellulose based modification as an
ideal tool to endow the strategic platform for other PBNPs. PBNPs can also be
modified by grafting or conjugation on either linear or branched backbone or on its
active functional groups. This type of tailoring can be achieved by surface
modification, polymer-peptide conjugation, polymer-DNA conjugation, polymer-
siRNA conjugation, conjugation of polymer-surfactant, polymer-antibody, polymer-
gene and polymer-drug. These conjugates can be formulated in to nano or micro
forms for their delivery at suitable site.
4.6.1 Chemical Modifications of Plant Based Natural

Polymers (PBNPS)
Chemical modification of plant based natural polymer involves the polymer mole-
cules in its native form. Modification is generally achieved through derivatization
such as esterification, etherification and oxidation, crosslinking, cationization and
grafting. Nevertheless, there has been shortage of new methodologies in chemical
modifications since this type of modification endows issues concerning consumers
and the environment. Currently polymeric science is adopting combinational treat-
ment using various types of chemical treatments to create new kinds of modifica-
tions. In a similar way, chemical methods have been combined with physical
modifications such as microwave, radiation and extrusion to produce modified poly-
mer with specific functional properties. Overall merits of these modifications were to
reduce the time of modification and encourage production. Owing to the presence of
large amount of hydroxyl groups at the surface of PBNPs different chemical modifi-
cations have been attempted, including etherification, esterification, oxidation,
silylation, polymer grafting, etc. noncovalent Surface modification by adsorbing sur-
factants and polymer coating has also been reported. Chemical modifications of plant
based natural polymers (PBNPs) have been mainly conducted to alter their surface
energy characteristics which can further improve compatibility, particularly when
employed in conjunction with hydrophobic or nonpolar matrices in nanocomposites.
Additionally chemical modifications establish stable negative or positive electro-
static charges on the surface of PBNPs. This introduction of charge provides better
dispersion. Conducting this chemical modification or functionalization in a safe
mode i.e. only alter the surface characteristics of PBNPs by maintaining the unique
morphology. This step may avoid any polymorphic conversion and to preserve the
integrity of the crystal. Various polymers especially polysaccharides have been
chemically modified such as Kaur et al. [48] reported various surface modifications
of starch e.g. microwave radiation with lipase as catalyst [49, 50], hydrophobic reac-
tion of starch and alkenyl ketene dimer [51], esterification of starch nanoparticles
with lipase as a catalyst [52], dual modified crosslink-phosphorylated [53], cross-
linking coupled with osmotic pressure [54], starch-based hydrogels prepared by UV
photopolymerization [55], starch esterified with ferulic acid [56], microwave-assisted
synthesis of starch maleate and starch succinates [57, 58], microwave and ultrasound
irradiation [59], hydroxypropylation and enzymatic hydrolysis [60], Ozone-oxidised
starch [61–63].
4.6.1.1 Noncovalent Surface Chemical Modifications of Plant Based

Natural Polymers (PBNPS)
Noncovalent surface chemical modifications of plant based natural polymers

(PBNPs) are usually achieved by surface adsorption of surfactants. This was initially
studied by Heux et al. [64, 65] who employed surfactant consisting of the
mono- and di-esters of phosphoric acid bearing alkylphenol tails and the obtained
surfactant-coated CNs dispersed very well in nonpolar solvents [64]. it was further
observed that surfactant molecules formed a thin layer of about 15 Å at the surface
of the CNs [66]. Later on various surface modifier (ionic and non-ionic) were used
to accelerate the characteristics of whole CNs based formulation [67]. Recently
saccharide-based amphiphilic block copolymers were used to induce the surface
modification on CNs, which resulted in to the excellent dispersion abilities in
nonpolar solvents [68].
4.6.1.2 Tempo-Mediated Oxidation
At present, the more frequently used pre-treatment is TEMPOmediated oxidation.

Certainly, the TEMPO-oxidized cellulose nanofibers, confers a complete class of
nanocellulose valuable of consideration, in addition to PBNPs and MPBPs. This
oxidation based method is the most reliable method for altering the surface
modification of natural/raw cellulose, in which functional groups such as carboxylate
and aldehyde can be incorporated into solid native cellulose under suitable conditions
[69–74]. Additionally in contrast with energy consumption of repeated cycles of a
high pressure homogenizer (700–1400 MJ/kg), this oxidation based pre-treatment
considerably decline the consumption to values less than 7 MJ/kg [58, 60].
For chemical modification of plant based natural polymers (PBNPs)
(2,2,6,6-Tetramethylpiperidine-1-oxyl)-mediated (or TEMPO-mediated) oxidation
employed to convert the hydroxylmethyl groups present on their surface to their
carboxylic form. Advantage of this reaction is that the oxidation reaction is highly
selective for primary hydroxyl groups, thus the whole reaction is “green” and easy
to execute. This reaction encompass the application of stable nitroxyl radical, the
2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) in the presence of NaBr and NaOCl.
This TEMPO-Mediated Oxidation was initially explored by De Nooy et al. In his
study he observed that only the hydroxymethyl groups of polysaccharides were
oxidized, whereas the secondary hydroxyls remained unaffected. The whole method
is based on of pre-treatment consisting cellulose fibers oxidation via the addition of
NaClO to aqueous cellulose suspensions in the presence of 2,2,6,6-tetramethyl-1-
piperidinyloxy (TEMPO) and NaBr (at pH 10–11 at room temperature). During this
chemical reaction primary hydroxyl groups (C6) selectively transformed to
carboxylate groups by means of the C6 aldehyde groups. Additionally only the
NaOH and NaClO are consumed [73]. Owing to the presence of the repulsive forces
among the ionized carboxylates (which overpower the hydrogen bonds by holding
them together) nanofibrils within the fibers separate from each other [75]. Amount
of NaClO supplemented in reaction determines number of carboxylate groups
formed on the surface of the MPBPs i.e. more carboxylate groups when more
amount of NaClO is added. Similarly this supplementation of NaClO allows the
oxidation for extended time [76]. It was reported that enhancing the addition
concentration of NaClO (3.8–5.0 mmol/g) increases the carboxylate content from
0.2 to 0.3 mmol/g. Additionally this reaction extends the oxidation time period from
Table 4.2 Effectiveness of TEMPO based oxidation reaction in terms of oxidation efficiency of
their pre-treatment
Oxidation
Reaction Raw material efficiency Reference
TEMPO based oxidation reaction using Sulfite pulp 70–95 % [77]
NaClO at high concentration Cotton linters 62 %
Ramie 85 %
Spruce 96 %
holocellulose
40–45 min to 115–130 min. TEMPO based oxidation reaction is applied over vari-
ous sources such as cotton linters, tunicate, wood pulp, ramie, bacterial cellulose
and even spruce holocellulose [74, 77]. These researchers have described the
effectiveness of this reaction on the basis of their oxidation efficiency of their pre-
treatment [77] (Table 4.2).
One more TEMPO-mediated oxidation based methodology reported by Isogai
et al., Isogai et al., and Saito et al. [78–80] based on the same principle apart from
pH 7, NaClO instead and NaBr, and replacement of the primary oxidant NaClO
with NaClO2. In one review Isogai et al. [78, 79] already discussed the dissimilarity
among these two processes. During first process oxidation of C6-primary hydroxyls
of wood cellulose achieved by TEMPO/NaBr/NaClO system at pH 10 and at room
temperature, however very little amount of aldehyde groups (<0.08 mmol/g) are
present in the oxidized cellulose [78, 79]. On contrary no aldehyde groups is
obtained by the TEMPO/NaClO/NaClO2 system at pH 5–7, from oxidized wood
cellulose with a higher molecular weight. Moreover concentration of carboxylate
was found to be 0.8 mmol/g, and the optimum reaction time and temperature
required are higher [78, 79]. Recently TEMPO electro-mediated reaction discovered
by Isogai et al. [78, 79] was explored as an alternative method to oxidize the
C6-primary hydroxyls of cellulose. Electro-mediated oxidation with TEMPO at
pH 10, and 4-acetamido-TEMPO at pH 6.8 in a buffer solution were recently applied
to softwood bleached kraft pulp explored as new sustainable method to yield
MPBPs. Such MPBPs must be having carboxylate and aldehyde groups on its
surface so that and it could well replace the first two systems, however longer
oxidation times are required, resulting in to high yield more than 80 % and preserves
the main characteristics of TEMPO-oxidized MFC produced from bleached
softwood kraft pulp [78, 79]. This procedure of pre-treatment with TEMPO
oxidation is followed by mechanical treatment, which can be achieved using a
cooking blender or an ultra turax system. To remove the partial fibrillated MPBPs,
generally centrifugation is employed separation on a laboratory scale. However now
day’s sonication is employed inspite of blending in order to separate the TEMPO
oxidized pulp and it was observed that the sonication time influences the yield of
nanofibrils [75, 81]. TEM characterization confirmed the transformation of 97.5 %
of the fiber suspension into MPBPs with a width of 3–5 nm. On contrary Li and
Renneckar [82], measured an average thickness value of 1.38 nm and a length of
580 nm with the help of AFM after 30 min of sonication. Various researchers estab-
lished apparent relationship between sonication time and its significant impact on
the nanofibril dimensions. It has been reported that with longer sonication time
thickness decreased to 0.74 nm and the length to 260 nm.
It was observed that when this TEMPO-mediated oxidation was employed for
oxidation of CNs only half of the accessible hydroxymethyl groups are available to
react, whereas the other half is buried within the crystalline particle. Araki et al. [83]
demonstrated CNs maintained their initial morphological integrity and formed a
homogeneous suspension when dispersed in water after the TEMPOmediated
oxidation. This is due to the presence of the newly installed carboxyl groups that
imparted negative charges at the CN surface and thus induced electrostatic
stabilization. Later on similar observations were reported by Montanari et al. [71].
In his study he has observed that excessive TEMPO-mediated oxidation decreases
crystal size which results in to the partial delamination of cellulose chains. Similarly
various authors have investigated the degrees of oxidation that can be examined by
using specific amounts of the primary oxidizing agent (NaOCl). Such an investigation
was based on supramolecular structure, morphology, and crystallographic
parameters of the CNs. It was observed that many TEMPO-oxidized or carboxylated
natural polymers such as CN suspensions when dispersed in water give display
birefringence patterns and do not show flocculation or sedimentation. This occurs
due to the polyanionic character carried by the negative charges on the CNs surfaces.
4.6.1.3 Cationization of Plant Based Natural Polymers
During this process positive charges are introduced on the surface of plant based
natural polymers (PBNPs) e.g. weak or strong ammonium containing groups, such
as epoxypropyltrimethylammonium chloride can be grafted onto the plant based
natural polymers (PBNPs) surfaces [84]. This can be achieved by the nucleophilic
addition of the alkali-activated cellulose hydroxyl groups to the epoxy moiety of
epoxypropyltrimethylammonium chloride. Ultimately aforementioned step resulted
in stable aqueous suspensions of PBNPs such as CNs with unexpected thixotropic
gelling properties. Shear birefringence was reported in some reports while no liquid
crystalline chiral nematic phase separation was observed which may lead to high
viscosity of the suspension.
4.6.1.4 Esterification, Silylation and Other Surface Chemical

Modifications of Plant Based Natural Polymers
Sassi and Chanzy have reported homogeneous and heterogeneous acetylation of

plant based natural polymers such as CNs. In this study they have induced
homogeneous and heterogeneous acetylation by using acetic anhydride in acetic
acid [85]. After TEM and X-ray diffraction analysis of acetylated samples, only a
limited reduction in CN length was observed. This was happened because of limited
reduction in CN length was observed, which was further explained by nonswelling

mechanism which only affects the cellulose chains localized at the crystal surface.
The partially acetylated molecules instantaneously partition into the acetylating
medium as they adequately solublize during homogeneous acetylation whereas the
cellulose acetate stay insoluble due to the presence of unreacted cellulose chains in
surrounded the crystalline core. In some cases of natural plant based polymers
concurrent occurrence of hydrolysis and acetylation has been also reported e.g. as
found in the case of cellulose. Application of some prominent simultaneous
esterification/hydrolysis based reactions were also explored in the case Fischer
esterification of amorphous cellulose chains as a viable one-pot reaction methodology
that allows isolation of acetylated CNs in a single-step process [86, 87]. Yuan et al.
[88] has recently explored the environmentally friendly CN surface acetylation
which involves low reagent consumption and simple-to-apply procedure. Another
reaction which is recently employed on cellulose matrix was based on alkenyl
succinic anhydride (ASA), development of ASA-CA emulsion, to yield acylated
CNs with high hydrophobic features. Highly substituted CN esters were recently
developed by Berlioz et al. via highly efficient method (fatty acid chains based on
dried CNs via a gas-phase process) for an almost complete surface esterification of
CNs proceeded from the surface of the substrate to the crystal core. This method
yielded fully reacted (esterified) CN without change in its native morphological
features. Reaction of natural plant based polymers with organic fatty acid chlorides
[having different lengths of the aliphatic chain (C12 to C18)], was also reported
which resulted in high density of C18 fatty acid, advantageous enough for further
grafting on such lengthy aliphatic chain (C12 to C18) [89]. Silylated based PBNPs
modification was observed in case of cellulose whiskers. This has been resulted
from acid hydrolysis of tunicate which have been partially silylated by a series of
alkyldimethylchlorosilanes. This reaction yielded a product with the carbon
backbone of the alkyl moieties ranging from a short carbon length to longer lengths
[90]. Degree of silylation (DOS) plays an important role in deciding solubility of
cellulose and its dispersion in solvent e.g. DOS between 0.6 and 1, encourages
dispersion in solvents of low polarity leading to stable suspensions with preserved
morphological integrity whereas at time when DOS >1 leads to deeper silylation
(chains in the core of the crystals became silylated) which can further resulted in to
disintegration of the crystals and ultimately the loss of original morphology
characteristics. However some highly silylated CN was investigated by Roman and
Winter as nanocomposites [91]. Lastly, it has been observed that N-octadecyl
isocyanate based modification assist in improving the stiffness and ductility of the
resultant nanocomposites [92].
4.6.1.5 Carboxymethylation and Acetylation
Carboxymethylation is another chemical pre-treatment which increases the anionic

charges in the formation of carboxyl groups on the surface of the MPBPs. In
previous work carboxymethylated MPBPs was compared its dimensions with
non-pretreated MPBPs [93] and it was observed that carboxymethylation treatment

makes the fibrils highly charged and easier to liberate. Moreover it was observed
that net specific energy consumption required after carboxymethylation was 2.2
MWh/t per pass through a microfluidizer, whereas 5.5 MWh/t per pass was required
to obtain MPBPs without pre-treatment [94]. Zimmermann’s research group
developed acetylation process in which grafting of acetyl moieties intend to reduce
the hydrophilicity of MPBPs and increase the chemical affinity between MPBPs
and a nonpolar solvent. For improving compatibility with the PLA matrix Tingaut
et al. [95] developed PLA/MFC biocomposites with acetylated MPBPs. Further
they observed that concentration of an acetyl content above 4.5 % encourages
significant alteration in the crystalline structure of MPBPs. In this study acetylation
was done in the inner crystalline regions of the MPBPs and prevents hornification
upon drying. Modification with acetyl groups reduces the chances of hydrogen
bonding between MPBPs and therefore facilitates improved dispersibility in an
apolar polymeric matrix. It was later discovered that MPBPs especially MFC can be
stored in a dry form which allow its possible industrial-scale production.
4.6.1.6 Polymer Grafting of Plant Based Natural Polymers
Two main approaches, specifically, the “grafting-onto” and “grafting-from” has

been carried on the surface of plant based natural polymers during polymer grafting.
First strategy involve the grafting on to the open ends hydroxyl groups at the PBNPs
surface of presynthesized polymer chains by using a coupling agent. In second
strategy “grafting-from” in situ surface-initiated polymerization (from immobilized
initiators on the substrate) has been carried out to form the polymeric chains. First
approach was initially utilized by Ljungberg et al. [96]. In his work he has grafted
maleated polypropylene onto the surface of tunicate-extracted CNs, which was
resulted in to nanocrystals with good compatibility and high adhesion when
dispersed in atactic polypropylene. Grafting of amine terminated polymers on the
surface of TEMPO-mediated oxidized was investigated by Araki et al. [83] and
Vignon et al. [97] Similarly grafting of DNA oligomers on the surface of CNs was
studied by Mangalam et al. [98] All of these researchers reported high grafting
density that was enough for grafted chains to crystallize at the surface of CNs.
Cocrystallization phenomenon was first reported by Cao et al. [99] to yield grafted
CNs polymer. This research has further promoted cocrystallizations of the free
chains of the respective polymer matrices during CN-based nanocomposite pro-
cessing. Additionally this phenomenon of cocrystallization significantly enhances
the interfacial adhesion by inducing the formation of a co-continuous phase
between the matrix and filler, resulted in to the highly improved mechanical
strength of the resulting nanocomposites. Second approach known as “grafting
from” was first reported by Habibi et al. [100], who has utilized stannous octoate
(Sn(Oct)2) as a grafting and polymerization agent to graft polycaprolactone onto
the surface of CNs via ring-opening polymerization. Pranger et al. [101] studied in
situ polymerization of furfuryl alcohol from the surface of cellulose whiskers.
Later on various researchers produced thermoresponsive substrates by the polymer-

ization of vinyl monomers from the surface of CNs [102].
4.6.2 Procedure for the Development of Microfibrillated Plant

Based Polymers (MPBPS) by Physical Modification
MPBPs is currently fabricated from a number of different natural sources e.g. wood,
bleached kraft pulp (starting material for MPBPs production) [73, 76, 94, 103–105],
and bleached sulfite pulp [106, 107] (Figs. 4.1 and 4.2). Still various sources are
needed to explore to fulfill the demand for such raw materials offering environmental
benefits owing to their renewable nature and their low energy consumption in pro-
duction [108]. Considering cellulose, Eucalyptus sulfite wood pulp, Bleached Luffa
cylindrica fibers, Bleached sulfite pulp, Bleached sisal pulp, Sisal fibers (Agave
sisalana), Elemental chlorine free bleached hardwood kraft pulp from Birch, Mixture
of pine and spruce pulps (Betula pendula), Bleached and unbleached kraft hardwood
pulps, Softwood sulfite pulp of spruce (Picea abies) and white fir (Abies alba),
Wheat straw (Triticum sp.) Refined fibrous wheat straw (Vitacel, Rettenmaier &
Sohne GmbH & Co.KG), Refined beech wood (Fagus sylvatica) (Mikro-Technik
GmbH & Co. KG), Refined fibrous beech wood pulp (Arbocel, Rettenmaier & Sohne
GmbH & Co. KG), Bleached sulfite softwood (Domsjo ECO Bright), Elemental
chlorine free bleached hardwood kraft pulp from Birch (Betula pendula), Domsjo
dissolving plus (Sweden), Softwood dissolving pulp (Domsjo), Wood pulp, Softwood
dissolving pulp (Domsjo), Softwood dissolving pulp (Domsjo), Bleached kraft bam-
boo (P. pubescens), Domsjo dissolving plus (Sweden), Bleached sulfite pulp, Sisal
fibers (Agave sisalana), are the main sources as reported by Lavoine et al. [109].
MPBPs present in micro meter range
MPBPs production
Enzymatic treatment
MPBPs present in nano meter range
Mechanical treatment Mechanical treatment Fiber suspension
TEMPO
Dialysis
Nanocrystal production
Pre treatment
Nanocrystals
Fig. 4.1 Schematic representation of production of microfibrillated natural polymers

Fig. 4.2 Illustration demonstrating microfibrillated plant based polymers and their arrangement in
plants
Irrespective of the source, natural polymers are manufactured from a pulp suspen-
sion mainly using a mechanical treatment. There are several types of equipments
available to defibrillate the pulp and obtain nanopolymer. Various physical methods
have been applied to transform the raw cellulose in micrometer size in to suspension
or nano crystal form in nanometer size. Various physical methods that can be applied
for this purpose are mentioned below.
4.6.2.1 Mechanical Treatments
Homogenizer and Microfluidizer
With the help of Gaulin homogenizer, Turbak et al. [110], for the first time applied
mechanical treatment produce to manufacture all kinds of microfibrillated cellulose
[93, 103, 111–115]. During this type of modification slurry of selected natural poly-
mer is forced at elevated pressure and fed via a spring-loaded valve assembly. Fibers
are subjected to a huge pressure dive under elevated shearing forces. This was car-
ried out by allowing the valve to open and close in quick progression. Combined
force aggravates high degree of fibrillation of the cellulose fibers [115]. Equipment,
Gaulin homogenizer most frequently used the microfluidizer since it makes it pos-
sible to obtain more uniformly sized fibers [111]. This equipment function when the
masses of wood pulp passes through thin z-shaped chambers under high pressure
[116] which results in the formation of very thin cellulose nanofibers. During this
mechanical process chambers of different sizes are employed to increase the degree
of fibrillation. This equipment used various time supplementation of raw material
passage from chamber which consequently increases the number of passes. This fac-
tor limits the likely scaling-up of production and consequently creates negative envi-
ronmental force with high energy consumption.
Grinding Process
Transformation of raw micro natural polymer in to fibrillated polymer can also be

achieved by grinding process. There are various equipments used for grinding raw
plant based polymer. Using equipment known as grinder, Masukoc was the first
researcher to build and sell apparatus. Grinder generates shearing forces that help in
breakdown of the cell wall structure. During this process raw material in form of
pulp is passed through a static grind stone and a rotating grind stone revolving at
about 1500 rpm. Grinder promotes separation of microfibrill by breakdown the cell
wall which contains nanofibers in a multilayer structure. This step encourages
individualized nanofibers from the pulp when material passes from the grinder after
multiple attempts. It has been observed that multiple passes of raw fibers from Pinus
radiate influence MPBPs morphology. After sequential one to three passes,
maximum raw material turned into sub-micron-size and nano-sized fibers, whereas
after five passes, most of the fibers became nanosized fibers. No significant changes
were observed in the fiber morphology after passing raw material from grinder at
higher number thus it was concluded after that five passes through the grinder the
fibrillation of pulp fibers was roughly complete. In contrast with homogenization
process, this grinding require only few passes to obtain plant based fibrillated
natural polymer in micro or nano range. No. of passing usually determine the size
or dimension of cellulose fiber. Nevertheless pulp degradation caused by grinding
process in terms of reduction in length might affect the strengthening and physical
properties of PNMPs [117]. As discussed above its very difficult to determine the
length and suitable analysis of related characteristics therefore they cannot be
monitored in comprehensive manner. Several authors have attempted to evaluate the
chain length which was based on the results obtained from the intrinsic viscosity in
cupriethylene diamine. Pohler et al. [118] proven that microfluidizer reduces the
chain length more than the grinder. Couple of years before Uetani and Yano [115]
used blender (with an ABS-BU motor, Vita Mix, and a CAC90B X-TREME 2 L
bottle, WARING) with a well equipped tamper to produce microfibrillated cellulose.
This equipment has efficiency to defibrillated different wood fiber suspensions
(0.1–1.5 wt%) at different stirring speeds, from 5000 to 37,000 rpm. However it’s
difficult to deduce best mechanical treatment since product obtain from this blender
is not very homogeneous, even it doesn’t acquire the capacity to transform whole
plant based raw fibers in to micro fibrils. It was reported that it induces less damage
then grinder treatment but still it’s difficult to conclude which treatment can known
to be the best treatment.
Cryocrushing
One rarely used and the most expensive method which cannot be scale up called as
cryocrushing as suggested by Dufresne et al. [119]. He has crushed frozen pulp with
liquid nitrogen [120, 121]. Owing supercritical nature of nitrogen, liquid nitrogen
enter inside the cell, this penetration cause the crystallization of cell (Ice crystals
within the cells are then formed), and eventually mechanical crushing is employed
to breakdown the cellular wall and release wall fragments. So far this method is
applied over many pulps and other plant material (sugar beet pulp, wheat straw and
soy hulls, flax, hemp, and rutabaga fibers and soybean stock) to yield microfibrill
polymer with varying nano dimensions [120–122].
Electrospinning
In contrast to all these methods electrospinning methods can be employed to obtain

fibrillated PNMPs process of cellulose regeneration. However this process require
more fundamental studies are currently dedicated to this method [123–126].
Energy Consumption and New Processes
Above mentioned methods require mechanical treatments with high energy

utilization. Energy consumption (70,000 kWh/t) in case of homogenizer estimated
was initially estimated by Eriksen et al., whereas energy consumption in case of
microfluidizer estimated by Zimmermann et al., reaches up to 8.5 kWh [127, 128].
As discussed above in case of microfluidizer fibrillation depends on the number of
times raw material passes through the assembly therefore for 10 L of PBNPs pulp it
takes about 15 min to pass through a microfluidizer once and let there are overall
four passes during this process then consumed energy can be calculated accordingly
(8.5 kW, and its value increased to 14,875 kW with only three passes more). Since
the most difficult thing that need further research is variation in mass during each
pass (i.e. mass doesn’t remain ideal) so for estimating single pass energy each time
mass should be calculated. Process become more difficult when pulp solution
obtained is less homogenous. Later on various authors’ studied the factors (e.g.
number of passes, the pressure, and the speed) that influence the rate of formation
of microfibrills and films, mainly the nature of material (bleached and unbleached
kraft hardwood pulps) on consumption of energy [129, 130]. These authors’ have
done the comparative study of the energy consumption and physical properties of
MFC produced by different processing methods, namely a homogenizer, a
microfluidizer, and a grinder. From this study it was deduced that, in spite of its high
energy consumption, homogenizer resulted in MFC with the highest specific surface
area and films with the lowest water vapor transmission rate. Furthermore films
produced during both process (microfluidizer and a grinder) offered better optical,
physical, and water interaction properties. This unique features obtained from these
processes suggested that these materials could be created with additional cost-
effective approach for packaging purposes. Alternatively exploration of other less
energy-consuming disintegration methods also turn into precedence in protecting
the industrialization of MPBPs production. Presently combinations of various pre-
treatments and mechanical methods have been employed to yield suitable
microfibrill. Additionally in order to obtain MFC with low energy consumption or
via a faster process, every year new equipment is being studied or developed.
Heiskanen, Harlin, Backfolk, and Laitinen [131] has modified the process and
tested with extrusion. Later on SUNPAP (2009), Papiertechnische Stiftung (PTS) in
Germany, developed commercial process, Cavitron®. Recently novel fractionation
devices have been developed to classify different MPBPs qualities [132].
4.6.3 Pre-treatment
Various approaches have been employed in order to obtain fibers that are less stiff
and cohesive. These approached help in reducing the energy required for fibrillation.
Among these approaches three approaches (avoiding the hydrogen bonds, adding a
repulsive charge, reducing the DP or the amorphous link between individual
PNMPs) are more preferred during pre-treatment. Protocols that are more favorable
according to these considerations are:
4.6.3.1 Enzymatic Pre-treatment
Enzymatic modification has mainly used hydrolyzing enzymes in its modification

and one of its products is syrup be it glucose syrup or high fructose corn syrup. With
research, there are more enzymes being identified for use in modification of polymer.
Combinational treatment is employed by combining enzymatic hydrolysis with
mechanical shearing and high pressure homogenization (105 and 170 MPa) to
obtain PNMPs in desirable nano range. Paakko et al. [133] conducted the whole
process by introducing the enzymatic treatment with endoglucanase between two
refining steps. Step is achieved by before passing the pulp slurry through the
microfluidizer. Main positive point of enzymatic hydrolysis than acid hydrolysis it
is less aggressive and allows selective hydrolysis of the non-crystalline cellulose,
which facilitates the mechanical disintegration [133, 134]. Enzyme supplementation
promotes cell wall degradation and prevents the blockage in Z-shaped chamber of
microfluidizer [135]. It has been observed that in some cases more specific enzymatic
treatment is required e.g. pre-treatment with C-type endoglucanase enzyme studied
by Henriksson et al. [135], to treat some disorder in the structure in order to attack
the cellulose and attain its conformation that encourage its desirable properties.
After the mechanical treatment with Gaulin homogenizer, these researchers
examined non-pretreated PNMPs in contrast with enzyme-pretreated MFC, as well
as enzyme-pretreated PNMPs. This pre-treatment with endoglucanase allows the
disintegration of cellulosic wood fiber pulp by enhancing its swelling in water,
additionally this eco-friendly pretreatment present more favorable structure on the
MFC, since it decreases the fiber length and enhances the amount of fine material,
in contrast to end product obtained from acid hydrolysis pre-treatment. It was also
studied that pretreatment with endoglucanase appeared to be a very promising
method for industrial applications and important for first pilot production of PNMPs
[134].
4.6.4 Post-treatments
In addition to the pretreatment, post-treatments in combination with pretreatment

are progressively carried out in order to increase the features of microfibrillated
natural polymer. In contrast with various pre-treatment approaches utilization of
post-treatment still remains small. Goal of these two protocols are very distinctive
since the primary objective of pre-treatment is to decrease the energy consumption
of PNMPs production, while the post-treatment mainly aims to improve the PNMPs
or to incorporate new features, from the viewpoint of new probable applications. In
order to develop PNMPs films with good barrier properties, Rodionova et al. [136]
carried out the acetylation of MFC from kraft pulp. Based on results [136], it was
observed that hydroxyl groups replacement by acetyl groups occurs at surface of the
PNMPs as well as amorphous regions for long reaction times. Later on it was
studied that acetylation is an essential tool for bacterial cellulose to improve the
optical properties of nanocomposite films [137]. Nogi et al. [138] studied that
acetylation was also used to improve the thermal properties. In order to obtain
hydrophobic MFC, Andresen et al. [139] modified the surface of MFC by means of
silylation with chlorodimethyl isopropylsilane. It has been seen among some natural
polymers that when the silylation conditions were too strong, PNMPs lost its
microfibrillar structure and consequently it was concluded that with a degree of
surface silylation (between 0.6 and 1), some natural polymer e.g. MFC could be
dispersed into an organic solvent without losing its characteristics or properties.
Some post-treatments among PNMPs e.g. MFC, encourage nanocomposite
applications after their grafting with suitable coupling agents. Most of the post-
treatments (Table 4.3) provide MFC with a hydrophobic character in order to
improve its compatibility with non-polar polymers and thus play a major role in the
elaboration of nanocomposites. However some post-treatments emerge to endow
Table 4.3 Post-treatments among MFC

Coupling agents Purpose & applications References
MFC+ titanate To enhance the adhesion between [140]
MFC and epoxy resin matrix
Titanate + MFC MFC with enhanced hydrophobic [106]
surface property
MFC oxidation with cerium IV MFC with a hydrophobic surface [106]
layer, nanoscale electronic and
optoelectronic devices
Grafting of hexamethylene diisocyanate. MFC with more hydrophobic [106]
surface layer, nanoscale electronic
and optoelectronic devices
Succinic and maleic acids coupled to the MFC with a hydrophobic surface [106]
MFC layer, nanoscale electronic and
optoelectronic devices
N-octadecyl isocyanate onto MFC To improve the MFC’s [92]
compatibility with
polycaprolactone, using an in situ
solvent exchange
N-octadecyl isocyanate onto MFC To improve the MFC’s [141, 142]
compatibility with
polycaprolactone
Grafting cellulose with octadecyldimethyl MFC films with antibacterial [143]
(3-trimethoxysilylpropyl) ammonium property
chloride (ODDMAC)
microfibrillated cellulose with some new functionality. Owing to the unique features
MFC that are attractive in different fields. Primary aim of this work is to reduce the
energy consumption of MFC production so as to fulfill with a political agenda and
gain market interest and second goal is to improve MFC properties in order to
endorse a novel biomaterial with unique characteristics that can compete against the
current non-biopolymers.
4.6.5 Dual Modifications
Recommendation for physical modification is sometime preferred over chemical

since it can be safely used as a modification process in food products as it does not
involve any chemical presence which some causes harm to biological tissue. Various
physical methods have been employed for different plant based natural polymer
using a combination of chemical and physical or chemical and enzymatical methods
(Table 4.4).
Owing to the diverse class of PBNPs, here in this section we have only discussed
the starch based physical or chemical modifications. Deetae et al. [53] combined
methodology (physical as well as chemical) using crosslinking with sodium trimeta-
Table 4.4 Physical methods Treatments References

reported for starch
Corona electrical discharges [144]
modifications
Deep freezing [145, 146]
Instantaneous controlled pressure [147, 148]
drop (DIC) process
Iterated syneresis [149]
Mechanical activation-with stirring [150]
ball mill
Micronization in vacuum ball mill [151]
Multiple deep freezing and thawing [146]
Osmotic-pressure treatment [152]
Pulsed electric fields treatment [153]
Superheated starch [154]
Thermally inhibited treatment [151, 155, 156]
(dry heating)
phosphate and phosphorylation on rice starch, provided modified rice starch with
good freeze-thaw stability. Whole procedure was conducted in the presence of
osmotic-pressure enhancing salts [53]. These salts caused an increase final viscosity
with a sharp decline in breakdown. It has been observed that trigger in osmotic pres-
sure enhances the activity of the crosslinking agent [157]. UV induced polymeriza-
tion is used to prepare starch-based hydrogels. During this procedure polymerization
performed by treatment acryloylated starch with zwitterionic monomer 3-dimethyl
(methacryloyloxyethyl) ammonium propane sulfonate (DMAPS). It was observed
that this type of polymerization induces a unique salt-tolerant swelling behavior in
modified starch [55]. Ou et al. [56] developed modified starch via esterification with
ferulic acid which yielded in to starch ferulate. In contrast to native, starch ferulated
starch exhibited higher water holding capacity, lower viscosity and much less retro-
gradation during low storage temperature [56]. Similarly Xing et al. [57] developed
efficient method in esterifying starch, microwave-assisted esterification, to produce
starch maleate using the dry method had a reaction efficiency of up to 98 %. Jyothi
et al. [58] developed efficient method of producing succinylated cassava starch with
microwave assistance to decrease the use of chemicals and enhance production.
Later on it was observed that microwave and ultrasound irradiation can be employed
for the esterification of carboxymethyl cold-water-soluble potato starch with octe-
nylsuccinic anhydride which consequently shorten the esterification time from a
few hours to a few minutes. Derivates produced during this process present out-
standing emulsifying and surfactant performance properties [59]. For achieving
more successful dual modification process, Karim et al. [60] utilized native starch
in form of corn and mung bean starch. Native starch was modified by partial enzy-
matic treatment followed by hydroxypropylation with propylene oxide. Modified
starch proved to have significant functional properties in contrast with hydroxypro-
pyl starch prepared with untreated native starch [60].
4.6.6 Ozonation
In addition to above mentioned methods various other methods such as ozonation

have been developed with more development in polymeric sciences and its allied
fields. This process carries extra oxygen atom therefore act as powerful oxidant and
can be applied for process of ozonation. According to previous reports this process
enhances the carboxyl and carbonyl contents and concentration keep on increasing
with time of exposure to ozone. In contrast hypochlorite oxidation process where
large amount of salts are produced this powerful oxidant (ozone) is a clean and
leaves no residues behind unlike [61].
Chan et al. [62] observed that there was a difference in the rate of starch oxidation
among starches from various sources. An and King [63] found that starch those are
produced in the presence of amino acids were more suitable alternatives in contrast
to highly chemically oxidized starch and found useful as thickening agents.
As mentioned above physical modifications are safer for processing of food
products since it does not involve any chemical presence. Owing to the diversity of
plant based polymers, here in this section we have only discuss starch based modi-
fication. Some new strategies developed in physical modification for PBNPs are
highlighted in Table 4.4. Pukkahuta et al. [152] utilized “Osmotic-pressure treat-
ment” (OPT) in the presence of high salt solutions to obtain a uniform starch sus-
pension and heat distribution. After treatment with the gelatinization temperatures
potato-starch treated changed from a B to a A type. A uniform heat distribution is
an advantage of this method in contrast to heat-moisture treatment which helps in
production of modified starch at large scale. Similarly Szymonska et al. [145]
reported the deep freezing and thawing of moistened starch to increase the crystal-
linity of the granules, however Szymonska et al. [146] also reported that multiple
deep freezing and thawing caused an irreversible disruption of the crystalline
order. Process of deep freezing and thawing was repeated until the moisture con-
tent in the solid phase was less than 20 %. It was observed that most of the starch
showed conversion towards B-type X-ray diffraction pattern suggesting a disrup-
tion of the crystalline property [149]. Since there is no involvement of any type of
chemicals therefore there is no concern for the effect on the environment and safety
issues to be addressed. Process called as iterated syneresis was similar to multiple
deep freezing and thawing. Other physical modification including instantaneous
controlled pressure drop and DIC lead to increase in gelatinization transition tem-
peratures and enzymatic hydrolysis while gelatinization enthalpy decreased after
treatment. During this procedure saturated steam at a fixed pressure and predeter-
mined time was injected before it drops towards vacuum to pursue the short pres-
surization. Other mechanical actions such as collision, friction, impingement,
shear, etc can also be employed to modify the crystalline structures and properties
of the starch granule. This process is called as mechanical activation or microniza-
tion. During this process large particle breakdown to form smaller particles how-
ever the tiny particles agglomerate and form large particles, resulting in to the
decrease in gelatinization temperature and viscosity of the treated sample [150,
4.7 Genetic/Biotechnology Modification 143
151]. Han et al. [153] reported the pulsed electric field (PEF) technology (non-
thermal food preservation method) to study the effect of the treatment on starch.
They have observed that starch molecules rearranged and destructed resulting in to
the constant decrease in gelatinization properties, viscosity and crystallinity.
Nemtanu and Minea [144] also reported that with increase of exposure time to
corona electrical discharges, solubility, gel consistency and clarity of starches
decreased. Dehydration of starch is done to achieve thermal inhibition which is
carried out (a) by dehydrating starch until it becomes anhydrous, (b) treating it to
a temperature of hundred degree Celsius for a period of time. The effect of heating
can also be increased by an alkaline condition. Chiu et al. [155] suggested that
pastes obtained from theses starches had increased resistance to viscosity break-
down and a non-cohesive texture. Ionic gums such as sodium alginate, CMC and
xanthan act as crosslinking agents to form graft copolymers through ester forma-
tion. Such type of gums induced thermal inhibition [156]. Production of spreadable
particle gels with spherulite morphology and creamlike texture upon cooling can
be obtained by heating a starch solution to a temperature between 180 and 220° to
form superheated starches. It was observed that in contrast with native starch dry
superheated starches when mix with cold water gives immediate gel-like texture
[154]. Two processes fluidized bed heating and extrusion heating were applied
over on amaranth starch-rich fraction. Treatment with fluidized bed heating lead to
some loss in crystallinity but granule integrity was preserved whereas extrusion
heating caused a high degree of granule disruption and almost complete loss of
crystallinity [158].
4.7 Genetic/Biotechnology Modification
Development in genetic engineering allows genetic modification of various natural

plant based polymers probably by targeting the enzymes of the biosynthetic path-
ways of the respective NPBPs. Owing to the diverse classification of PBNPs, here in
this section we have only discussed starch which can present the better ideology/
platform for the modification of others. Current development in genetic engineering
science allows transgene technology to produce genetically modified starches which
can prevent the environmentally harmful post-harvest chemical or enzymatic modi-
fication [159]. It was observed that activity of these enzymes plays an important role
in affecting the functionality, reactivity and applicability in non food and food appli-
cations of these modified starches. Traditional plant-breeding techniques or modern
biotechnology can be applied to accomplish genetic modification in a more success-
ful way [160]. Some of the key modifications of starches that have been done geneti-
cally are mentioned below. For alteration of specific structural motifs in potato
starch, repression of starch phosphorylating enzyme R1 was used in the of potato
starch [161]. Similarly modification for potato cell lines was achieved by treatment
with an Escherichia coli glg B encoding a glycogen branching enzyme [162]. Starch
obtained after this treatment contains higher amount of short amylopectin chains
with lower content of phosphate which can be used to give hard and adhesive gels.
Alike to potato cell line total cassava root biomass can be treated with ADP-glucose
pyrophosphorylase for enhancing the total cassava root biomass by 2.6 fold [163].
Modification of starch was also investigated when a full length cDNAs encoding a
second starch branching enzyme isoform was isolated and an antisense starch branch-
ing enzyme A RNA was produced on transgenic potato plants. During this study
complete reduction in starch branching enzyme A was observed. The average chain
length of amylopectin was greater in modified starch and it was observed that the
composition and structure of the potato starch was completely altered. Additionally
higher levels of phosphorous were also reported [164]. Similarly Safford et al. [165]
reported the same study by the modification of starch obtained from potato (showed
altered amylopectin branch patterns). Verhoeven et al. [166] explored the tree muta-
genised grains of the diploid oat (Avena strigosa): mutants lam-1, lam-2 and sga-1. It
was investigated that two mutagens (lam-1 and lam-2) lacked in GBSS activity and
amylose component thus endow mutations of the waxy type [166].
4.8 Applications of Plant Based Polysaccharides
Plant based polysaccharides are having various established applications in

biomedical, tissue engineering, pharmaceutical sciences and other areas. Our
current concern is to cover plant based natural polymers and their nanotechnologi-
cal applications in different field. Table 4.5 covered various modifications of natural
polymers and its nanotechnological application in different drug delivery systems.
4.8.1 Cellulose
In 1838 French chemist Anselme Payen discovered cellulose by isolating it from

plant matter and determined its chemical formula. Cellulose is a linear unbranched
organic polysaccharide with the molecular formula (C6H10O5)n, consisting of
β(1 → 4) linked D-glucose units from several hundred to over ten thousand (Fig. 4.3).
Among all plant cell wall polysaccharides e.g. hemicelluloses, pectin, cellulose
forms a vital structural component in higher plants and corresponds to the most
abundant organic polymer [359, 360]. Linearly arranged various parallel cellulose
molecules form crystalline microfibrils which are mechanically strong and highly
resistant to enzymatic attack and are aligned with each other to provide structure to
the cell wall. This organic polysaccharide is insoluble in water and indigestible by
the human body [361, 362], however digested by herbivores and termites. Fibrous
materials (such as wood and cotton) derived cellulose such as wood and cotton, can
be mechanically treated (disintegrated) to produce powdered cellulose. This
powdered form has been used in the pharmaceutical industry as filler in tablets.
Treatment of high quality powdered cellulose with hydrochloric acid produces
Table 4.5 Various modification of plant based natural polysaccharides and its nano applications
Polymer Modification Nano applications Drug delivery applications References
Cellulose (a) Sulfonation (a) Nanocrystalline cellulose (NCC) (a) Multi-particulate drug delivery of [167–187]
(b) Oxidation by TEMPO (b) Nano-fibrils Aphidicolin nanosuspension
(c) Ester linkages via acid chlorides (c) Nano fibrillar cellulose matrices (b) Transversal drug delivery of
(d) Cationization via epoxides (d) Au, Ag, Pt, Fe2O3, Cds, PbO NPs primaquine cellulose based niosomes
(e) Ester linkages via acid anhydrides (e) CA/TiO2 hybrid membranes (c) Various cellulose based
(f) Urethane linkages via isocyanates (f) Micrometer-long hybrid nanofibers (CdS formulations:
(g) Silylation NPs/bacterial cellulose hybrid nanofibers) PQ/- Eudragit®
(h) SURFUNCELL (Surface functionalisation (g) Hybrid Fe3O4@Amino cellulose NPs RL 100-, ethyl cellulose polymers
of cellulose with noble metals NPs through a (h) Ag–Pd alloy nanoparticles with various penetration enhancers,
selective nucleation) (i) Cellulose whiskers PQ/ethyl cellulose polymer mixed
(j) Magnetic NPs with Mygliol® 840 plus the
(k) pH-sensitive core–shell NPs antioxidant alpha-tocopherol)
(l) Cellulose-chitosan NPs
(m) Fluorescent CMC NPs
(n) Cellulose based semiconductors NCs
Xyloglucan (a) Degalatosylation (a) pH dependent xylogucan nano aggregates Xyloglucan mucoadhesive polymer is [188–195]
(b) β-galactosidase degradation (b) Self-assembled polystyrene/xyloglucan suitable for anti-protozoal and
(c) Synthesizing thiolated xyloglucan (TXG) nanospheres antimicrobial drug delivery
Galactomannan Enzymic oxidation on the C-6 of the (a) Galactomannan and chitosan Nps Lichen galactomannan and its [196–204]
galactose side units (b) Gold Nps vanadyl (IV) complex on peritoneal
(a) Oxidation (TEMPO or TEMPO-NaBr- (c) Guar gum Nps (Cationic, carboxymethyl, macrophages and leishmanicidal
NaClO system) hydroxylpropyl, and activity.
(a) Etherification, (b) Esterification, (c) carboxymethylhydroxypropyl galactomannans)
hydroxypropylation, (d) carboxymethylation
(continued)
konjac (e) Phosphorylated (f) glucomannan (a) Mannose receptors targeted GM Nps [205–208]
glucomannan (g) By alkali and sodium (h) (b) Galactomannan and chitosan (protein
KGM carboxymethylcellulose (enzymatic, alkali particular carrier) (KGM, KGM-KOH, KGM-
and acid hydrolysis) CMC and KGM-CMC-KOH)
(i) Hydrogen bonds formation (c) Conjugate with kappa carrageenan, acetan
(j) Number of junction zones Length of (xylinan), gellan gum, alginate and chitosan
connecting chains
(k) Deacetylation process
Rosin Polymerized rosin (PR) Rosin NPs(hydrocortisone) Rosin transparent wax preparation [209–212]
Cyclodextrin (a) Aqueous organometallic catalysis in (a) Meglumine antimoniate-beta-cyclodextrin (a) Oral delivery of meglumine [213–233]
aqueous media (hydrogenation, conjugates antimoniate-beta-cyclodextrin
hydroformylation, oxidation, reduction and (b) Paclitaxel loaded Nonsurfactant Cyclodextrin complex
carbon-carbon coupling reactions) Nanoparticles (b) Beta-cyclodextrin as an
(b) α-cyclodextrin-dodeca (2, 3) benzoate (c) Enhanced antiviral activity of Acyclovir absorption enhancer of the water-
(c) hexakis (6-amino-6-deoxy)-α-cyclodextrin loaded into β- cyclodextrin -poly(4- soluble drug meglumine antimoniate
hexahydrochloride acryloylmorpholine) conjugate nanoparticles (c) Meglumine antimoniate-beta-
(d) hexakis (6-amino-6-deoxy)-dodeca (2, (d) aminated β-cyclodextrin silver nanoparticles cyclodextrin conjugates
3)-O-methyl-α-cyclodextrin (e) cyclodextrin–poly(anhydride) nanoparticles
hexahydrochloride (f) β-cyclodextrin-modified TiO2 nanoparticles
(e) hexa (6)-O-methyl-α-cyclodextrin (f) Tamoxifen citrate loaded amphiphilic
(f) heptakis (6-azido-6-deoxy)-β-CD- β-cyclodextrin nanoparticles
tetradeca (2, 3)acetate (g) Camptothecin loaded amphiphilic
β-cyclodextrin nanoparticles
(h) Cyclodextrin-covered gold nanoparticles
Starch Microwave radiation with lipase as catalyst (a) Starch-Stabilized Silver Nanoparticles Primaquine-Conjugated Gum Arabic [52,
a) Hydrophobic reaction of starch and (b) Hydroxyl propyl starch NPs Microspheres oxidized starch imine 234–240]
alkenyl ketene dimer (c) starch-coated iron oxide nanoparticles derivatives
b) Esterification of starch nanoparticles with (d) Nasal starch insulin NPs starch capped water
lipase as a catalyst soluble copper
c) Dual modified crosslink-phosphorylated (e) idarubicin propylated starch NPs
d) Crosslinking coupled with osmotic (f) supramagnetic carboxymethyl starch NPs
pressure (g) amylomaize coenzyme Q10 NPs
e) Starch-based hydrogels prepared by UV
photopolymerization
f) Starch esterified with ferulic acid
g) Microwave-assisted synthesis of starch
maleate and starch succinates
h) Microwave and ultrasound irradiation
i) Hydroxypropylation and enzymatic
hydrolysis
j) Ozone-oxidised starch
Xanthan gum α-Galactosidase enzyme treatment Starch–xanthan gum Amphotericin B-Gum [241–249]
Modified with formaldehyde to improve the Chitosan/xanthan Gum/montmorillonite Arabic Conjugates
dissolution rate. nanocomposites To improve the bioavailability of
Konjac glucomannan/xanthan gum Berbrine, antiprotozoal drug
Colon targeted metanidazole by
xanthan gum
Guar gum Silanization of guar gum (trimethylsilyl Polyacrylamide/guar gum graft copolymer silver Guar gun for Acyclovir delivery [201, 241,
chloride) derivatization, grafting and network nanoparticles Colon targeted metanidazole by guar 250–261]
formation Tamoxifen loaded Guar gum gum
Carboxymethylation Acrylic acid grafted guargum–nanosilica
(continued)
Arabinogalactan With 5-amino salicyclic acid with isonicotinic gold nanocomposites (Au, Ag, Pd, and Pt Efficacious treatment of experimental [241,
acid hydrazide protected by natural polymer arabinogalactan) leishmaniasis with amphotericin 262–294]
Core-shell colloidal structure of B-arabinogalactan water-soluble
nanobiocomposites of gold nanoparticles derivatives.
Deaxtran and arabinogalactan
conjugates
Inulin Tosylated and azidated inulins Hydroxyapatite Nps (carboxymethyl inulin [295–309]
O-(aminoethyl)inulin derivative)
β-hydroxyalkyl ethers of inulin Inulin multi-methacrylate
inulin with amidoxime groups and (IMMA) Nps
coordination with copper(II) ions Inulin PEG-ylated Nps
poly(acrylic acid) grafted inulin
carboxy methylation of inulin
Modified inulin 2 6
using tetramethylsilane (TMS)
Locust beam β-mannanase, β-mannosidase and Locust bean based polymer-lipid NPs [310–314]
α-galactosidase cleavage
carboxyl, hydroxyl, and phosphate derivatives
of these polymers
Gum tragacanth Using Fabricated silver nanoparticles Binding agent in antiprotozaol drug [272–277,
epichlorhydrine. delivery 279, 280]
Effect of gamma irradiation
Lactose addition
Mechanical degradation (microfluidization)
Gum Arabic Methylation Nanoparticles with affinity ligands specific for Amphotericin B-gum arabic [241, 281,
β-D-mannanase degradation antibodies conjugates 282,
acetylation Magnetic nanoparticles with oleylamine Self-gelling primaquine-gum arabic 284–289,
Addition Maltose and gum arabic hybrid gold conjugate for primaquine 291, 294,
of monovalent metal nanoparticles 315, 316]
Silver nanoparticles in gum arabic based
semi-IPN hydrogen
Gum khatti Methylation Size-controlled silver nanoparticles Trichostatin as an antiprotozoal agent [317–322]
Acylation Insulin nanoparticles using chitosan and Arabic
deionized water treatment gum
Microwave assisted synthesis of Noble metal nanoparticles
polyacrylamide grafted gum ghatt Beta-lactoglobulin-polysaccharide nanoparticles
Pectin Pectins except glycine Methyl ester Thiolated pectin nanoparticles Metronidazole loaded pectin [323–341]
(glycylglycinemodified pectin) pectin-based nanoparticles for poorly soluble microspheres
Deesterified by base, plant or fungal pectin drugs Nystatin, clotrimazole, amphotericin
esterase or esterified inacid methanol β-lactoglobulin–pectin nps B, miconazole, ketoconazole or
Arabinase, pectin esterase and pectin acetyl pectin–iron oxide magnetic nanocomposite griseofulvin oral pectin based
esterase degradation Formation of nano-hydroxyapatite crystal in situ delivery
UV irradiation in chitosan–pectin polyelectrolyte complex Zn/pectin beads with a eudragit
Heat inactivated pectin methylesterase and network coating
NaCl
Endo-arabinanase and
α-L-arabinofuranosidase
Modification in their degrees of methylation
and acetylationCalcium binding efficacy
modification
Citrus pecin (potassium pectate), were
modified with a low amount of UV-absorbing
substituents
Protease, arabinanase/galactanase mixture,
polygalacturonase structural modifications
(continued)
Gellan Methacrylated Gellan Gum Gellan gel beads containing magnetic Swellable gellan gum for acyclovir [342–358]
(ion activated esterified Gellan Gum nanoparticle deliver
gelling polymer) Gellan gum grafted cinnamate photo Gellan gum blended PEI nanocomposites Gellan gum for antiprotozaol drug
crosslinkable polymer delivery
Fermentation mediated esterification Chitosan and gelln gum based
Ionotropic gelation of gellan with trivalent delivery of clindamycin
Al + 3 ions and covalent cross-linking with In situ gellan gum gel for secnidazole
glutaraldehyde (GA) for Al + 3/gellanbeads delivery
Peptide- modification of gellan gum
Gellan gum films with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide
cross-linker
Gellan gum and egg albumin preparation
Microwave assisted synthesis of acrylamide
grafted gellan
Monovalent cation salts addition for
Commercial gellan preparation
TEMPO oxidation
Deacylation of gellan
Gellan forms coupled networks with konjac
glucomannan and tamarind xyloglucan,
Phase-separated networks with kappa
carrageenan and calcium alginate
Interpenetrating networks with agarose and
gelling maltodextrin
Complex coacervates with gelatin under
acidic conditions
(2,2,6,6-Tetramethylpiperidine-1-oxyl)-mediated (orTEMPO-mediated)
4.8 Applications of Plant Based Polysaccharides 151
Fig. 4.3 Chemical

structure of a powdered OH OH
OH
cellulose (n ≈ 500) or O HO HO OH
HO O O OH
microcrystalline cellulose O
HO O O O
(n ≈ 220) OH HO OH
OH OH
n
Fig. 4.4 Chemical

structure of OR
hydroxypro- H2C OR
RO
pylmethylcellulose O
O O
RO O
OR CH2
OR n
Where R is H, CH3 or [CH3CH(OH)CH2].
Cellulose
Microcrystalline Esterification Etherification Crosslinking and graft

cellulose copolymerization
Hydroxypropyl- Cellulose nitrate

methylcellulose
Carboxy- Cellulose acetate pthalate

methylcellulose
Cellulose acetate
Fig. 4.5 Derivatization and modification of cellulose
microcrystalline cellulose. Microcrystalline cellulose is preferred over powdered

cellulose because it is more free-flowing containing non-fibrous particles and there-
fore used in the pharmaceutical industry as a diluent/binder in tablets for both the
granulation and direct compression processes [363]. Derivatization of cellulose can
be achieved by replacing/modifying open hydroxyl moieties on the D-glucopyra-
nose units of the cellulose polymer to give a variety of derivatives (Fig. 4.5). This
process involves various physical/chemical modification which are fixed according
to post and pre treatment procedures during which chief chemical reactions such as
etherification, esterification, cross-linking or graft copolymerization are conducted.
Esterification results in derivatives which include cellulose nitrate, cellulose acetate
and cellulose acetate phthalate whereas etherification yields derivatives such as
hydroxyl-propyl-methylcellulose and carboxyl-methyl-cellulose. These all chemi-

cal products have outstanding application in membrane controlled release systems
or monolithic matrix systems such as film or enteric coating and the use of semi-
permeable membranes in osmotic pump delivery systems. Partly O-methylated and
O-(2-hydroxypropylated) cellulose ether derivative known as hydroxypropylmeth-
ylcellulose has been extensively studied as an excipient in controlled release drug
delivery systems due to its gel forming ability. These derivatives are having wide
use and applications in monolithic matrix systems. Various reports and investiga-
tions have proven their potential to sustain the release of medicaments and most of
these derivatives have been employed for this purpose [364].
4.8.2 Hemicellulose
A hemicellulose is a heteropolymer (matrix polysaccharides), such as arabinoxylans,

consisting xyloglycans, xylans, mannans and glucomannans, and β-(1 → 3,
1 → 4)-glucans (Fig. 4.4) [365].
4.8.2.1 Arabinoxylans
These polysaccharides are bound to the surface of cellulose microfibrils which

themselves do not form micro fibrils can be extracted from the plant cell wall with
the aid of strong alkali. In contrast with cellulose (crystalline, unbranched strong,
and resistant to hydrolysis), hemicellulose has a random, amorphous structure with
little strength. Unlike cellulose, hemicelluloses have β-(1 → 4)-linked backbones
with an equatorial configuration, consists of shorter chains—500–3000 sugar units.
In addition, hemicellulose is a branched polymer, while cellulose is unbranched.
Though the xyloglycans have alike backbone as cellulose, they contain xylose
branches on 3 out of every 4 glucose monomers, while the β-1,4-linked D-xylan
backbone of arabinoxylan contains arabinose branches [366].
4.8.2.2 Glucomannans
Glucomannan is mainly a straight-chain hydrocolloidal polysaccharide of the

mannan family, consisting of β-1,4 linked D-mannose and D-glucose monomers
(with acetyl side branches on some of the backbone units), with about 8 % branching
through β-(1 → 6)-glucosyl linkages. The component sugars are β-(1 → 4)-linked
D-mannose and D-glucose in a ratio of 1.6:1, but the mannose:glucose ratio may
differ depending on the source [367]. The acetyl groups contribute to its solubility
and swelling capacity of the glucomannans and enhance the solubility of the
glucomannans by supporting glucomannans in making a soluble natural
polysaccharide with the highest viscosity and water-holding capacity. It is diversely
present very in nature and specifically derived from tubers, softwoods, roots and
plant bulbs. Glucomannan is called as konjac Glucomannan as it is the most com-
monly used type of Glucomannan which is extracted from the tubers of
Amorphophallus konjac (Ulmaceae) and act as a potential excipient in controlled
release drug delivery devices in combination with other polymers or by modifying
its chemical structure. As mentioned, it is a very promising polysaccharide for
incorporation into drug delivery systems. According to previous investigation
konjacglucomannan and xanthan in combination efficiently slow down drug release
by stabilization of the gel phase of the tablets. Stabilization is achieved by a network
of intermolecular hydrogen bonds between the two polymers [368].
4.8.3 Starches
Starch or amylum (Fig. 4.6) is a storage and structural polysaccharide consisting of

a large number of glucose units joined together by glycosidic bonds, chiefly present
in plants as energy source. Various sources of starches have been used for
pharmaceutical purpose such as maize (Zea mays), rice (Oryza sativa), wheat
(Triticum aestivum), and potato (Solanum tuberosum) [369]. Generally starch
present in two forms modified and native starch. Starch whether in the native or
modified form has been used as one of the key pharmaceutical excipients in
pharmaceutical tablet and capsule formulations. Modified Starch is evaluated as
pregelatinized starch product in directly compressible controlled-release matrix
systems which can be prepared by enzymatic degradation of potato starch followed
by precipitation (retrogradation), filtration and washing with ethanol whereas native
starch may not be suitable in controlled release drug delivery systems due to
substantial swelling and rapid enzymatic degradation resulting in too fast release of
b OH
HO
O
HO
OH
HO
a O
OH O
HO
OH HOH2C HO
O O O HOH C
OH O 2 O
HO O O
OH O HO
O OH O O
HO OH O HO OH O
n OH O OH O
HO HO
Fig. 4.6 Chemical structure of starch, with (a) amylose and (b) amylopectin
many drugs. Owing to this derivatives of native starch that are more resistant to
enzymatic degradation as well as crosslinking and formation of co-polymers.
Moreover most of them serve various functions such as binder, aiding drug delivery,
bulking or disintegrant. Currently starch based micro-capsulated delivery systems
can be used to deliver proteins or peptidic drugs orally [369]. Recently starch was
modified using interfacial cross-linking agent, terephthaloyl chloride, to form
starch/bovine serum albumin mixed walled microcapsules. During this procedure
native or amino-protected aprotinin was loaded in microcapsules by supplementing
protease inhibitors in the aqueous phase. This procedure was performed with the
help of cross linking agent. Modified starch in form of microcapsules showed
protective effect for bovine serum albumin. It was observed that acetylation of
starch significantly reduces its swelling and enzymatic degradation [370]. According
to previous findings, acetylation of potato starch considerably delay drug release
compared to that of natural potato starch film. During the investigation on Amylose-
rich maize starch (Hylon VII™) for tablet film coating it was observed that the
temperature of the coating pan did not influence the roughness of the coated tablet
at low spray rates, whereas at high spray rates increases the temperatures, resulted
in to the smooth films. This was resulted in to the rapid dissolution rate Hylon VII™
coated tablets in an acid medium (releasing 75 % of the drug). Various other reports
on the amylose and native starches as film forming agent were explored [371–375].
In another work ethyl-cellulose was employed with amylase in combination to
generate aqueous and non-aqueous based coatings for colon drug delivery has been
reported [376].
4.8.4 Pectin
Pectin (Fig. 4.7) is the purified non-starch, linear polysaccharides extracted from the
plant cell walls especially by acid hydrolysis from the inner portion of the rind of
citrus peels i.e. Citrus Simon or Citrus Aurantium, (Rutaceae). This water soluble
linear galacturonic acid polysaccharide mainly composed of α-1,4-linked
Dgalacturonic acid residues interrupted by 1,2-linked L-rhamnose residues with a
few hundred to about one thousand building blocks per molecule, equivalent to an
average molecular weight of about 50,000 to about 1,80,000 [377]. since galacturonic
acid polysaccharides contains different neutral sugars such as arabinose, rhamnose,
xylose, glucose, and galactose, therefore composition of pectin varies according to
the botanical source, e.g. pectin from citrus contains lower amount of neutral sugars
and has a lesser molecular size in comparison to the pectin obtained from apples
[378, 379]. Owing to its water solubility, this polysaccharide is not able to protect
its drug load efficiently for the period of its passage from the stomach and small
intestine [377]. Against this pH variable in vivo environment, drug core should be
protected with significant thickness or layers of polymer, thus the whole center of
attention was inclined to the progress of low water soluble pectin derivatives which
get degraded by the colonic micro flora. Derivatization or modification of pectin
reduces their solubility e.g. calcium derivatives of pectin were found to reduce the
Fig. 4.7 Chemical

structure of pectin HO2C
O H3CO2C
HO O
OH O O
HO OH
n
solubility by forming an eggbox configuration. Ethyl-cellulose was also examined

as a coating material for colon-specific drug delivery. This combination was devel-
oped to overcome the drawback of high solubility of pectin and provide colon spe-
cific degradation properties of pectin with the protective properties of the water
insoluble ethyl cellulose [380]. Pectin based hydrogels widely investigated used as
controlled-release matrix tablets. Pectin in form of high-methoxy-pectin showed
their potential in controlled-release matrix formulations and the drug release from
compressed pectin based matrix tablets can be modified by altering the concentration
and nature of pectin in the matrix tablets. It was observed pectinic acid (degree of
methoxylation 4 %) with retarded solubility was suitable as an excipient for
pelletisation by extrusion/spheronisation. According to previous work presence of
20 % pectinic acid in formulations is suitable for the formation of approximately all
spherical beads which were mechanically stable and showed drug release at
physiological pH 6.8 [381]. Pectin based micro particulate polymeric delivery
systems have been investigated as a possible approach to improve the low
bioavailability characteristics [382]. Spray dried pectin microspheres of piroxicam
showed a considerable improvement of piroxicam bioavailability when compared
with marketed piroxicameye drops. Modification of pectin such as amidated pectin
was investigated to mask the bitter taste of chloroquine when orally administered
[383]. Study showed potential applications of pectin-chloroquine patch matrix for
the transdermal delivery of chloroquine. Similarly calcium pectinate nanoparticles
were prepared to deliver insulin in colon [384]. Additionally pectin gel formulations
has wide application in cosmetics for the prolonged release of cosmetic compounds
such as citronellal responsible for the fragrance and proved as promising materials
for controlled fragrance release [385].
4.8.5 Inulin
Inulin (Fig. 4.8) is a naturally occurring storage polysaccharide obtained from

Dehlia, Inula Helenium (Compositae), Saussurea lappa (Compositae) or chicory
roots, Dendelion, Taraxacum officinale (Compositae). Burdock root, Cichonium
intybus (Compositae) [386]. This polysaccharide contains mixture of oligomers and
belongs to the group of gluco-fructans, widely present in plants such as artichoke,
garlic, onion, and chicory. As far as structural features are concerned inulin
molecules contain from two to more than 60 fructose molecules linked by β-2,1-
bonds. According to previous investigation inulin is not digested properly in the
upper gastrointestinal tract, however this polysaccharide hydrolyzed by colonic
Fig. 4.8 Chemical

structure of inulin
microflora [387, 388]. For delivering drug or any other therapeutic substance in
gastric and intestinal fluids, inulin with a high degree of polymerization was used in
combination with Eudragit® RS (that could withstand break down by the gastric and
intestinal fluids) to prepare biodegradable colon-specific films [387]. In an alike
study it was reported that using the combination of two different grades of Eudragit®
RS and Eudragit® RL when mixed with inulin showed better swelling and permeation
properties in colonic medium rather than other gastrointestinal media [389]. Earlier
investigation on inulin based hydrogels for colon-specific drug delivery systems
proven that methylated inulin hydrogels exhibit comparatively high rate of water
uptake and anomalous dynamic swelling behavior pH sensitive hydrogel by UV
irradiation were investigated by derivatization of inulin with methacrylic anhydride
and succinic anhydride [388]. This pH sensitive hydrogel system exhibit exhibited
a reduced swelling and low chemical degradation in acidic medium. However it
shows good swelling and degradation properties in simulated intestinal fluid espe-
cially in the presence of its specific enzyme called inulinase [295].
4.8.6 Rosin
Rosin (Fig. 4.9) also called colophony or Greek pitch (Pix græca), is a low molecular
weight (400 Da) natural polymer obtained from the oleoresin of various Pinus sp.
by heating fresh liquid resin to vaporize the volatile liquid terpene components. It
contains abietic and pimaric acids and exhibit excellent film-forming properties.
According to recent report, Rosin and its derivatives investigated as potential
biopolymer for various pharmaceutical applications such as film-forming and
coating properties, matrix materials in the tablets for sustained and controlled
release and microencapsulation [390]. Recent report explored its improved drug
release properties matrix tablets and pellets [391] when its synthesized by a reaction
with polyethylene glycol 200 and maleic anhydride. This work lead to the
Fig. 4.9 Structure of

Rosin
development of potential derivatives which can be suitable for sustain release of the
tablets. Similarly high polymerization of rosin films showed excellent potential as
coating materials for the development of sustained release dosage forms [392].
Various investigations on rosin derivatives (glycerol ester of maleic rosin) and their
film forming and coating properties established their potential as potential coating
materials for pharmaceutical products as well as in sustained release drug delivery
systems. It was observed that rosin concentration has profound effect on the release
of the hydrocortisone from rosin based nanoparticles which has demonstrated its
potential as effective nanoparticulate drug delivery systems [209].
4.8.7 Plant Based Gums
Plant has its own established mechanism to secrete viscous, sticky fluid exudate
gums in order to seal-off infected sections of the plant and prevent loss of moisture
due to physical injury or fungal attack [393]. These exudates have their own unique
property to convert in to brittle, translucent, glassy, hard mass. This property recently
explored as a potential tool in retaining various drugs and other therapeutic
candidates for their sustained, controlled or specified release from the desired
dosage forms. There are various types of gums (mentioned below) secreted by
plants currently investigated for their pharmaceutical applications.
4.8.7.1 Gum Arabic
Acacia gum or gum Arabic is the dried gummy exudation obtained from the Acacia
arabica (Leguminosae) and other related African species of acacia [241, 394]. The
gum has been recognized as a branched molecule of 1, 3-linked β-D-galactopyranosyl
units. It is an acidic polysaccharide containing D-galactose, L-arabinose, L-rhamnose,

and D-glucuronic acid and is mainly used in oral and topical pharmaceutical
formulations as a suspending and emulsifying agent. Previous study has explored
gum Arabic as a matrix microencapsulating agent for the enzyme, endoglucanase
[394], shown the slow release endoglucanase from the formulation. Gum Arabic
was used as an osmotic suspending and expanding agent to prepare a monolithic
osmotic tablet system. The optimum system delivered the water-insoluble drug,
naproxen, at a rate of approximately zero order for up to 12 h at a pH of 6.8.58
Sustained release of ferrous sulphate was achieved for 7 h by preparing gum Arabic
pellets. An increase in the amount of gum Arabic in the pellets decreased the rate of
release.
4.8.7.2 Tragacanth Gum
This gum is obtained from the branches of Astragalus gummifer (Leguminosae). 22

and anionic carbohydrate which consists of two major fractions: tragacanthin
(water-soluble) and bassorin (water-swellable) [395]. Tragacanthic acid is composed
of D-galacturonic acid, D-xylose, L-fructose, D-galactose, and other sugars. It’s very
difficult to understand the clear physical or chemical relationship between
tragacanthin and bassorin since both fractions can be easily separated. As far as the
chemical nature and composition are concerned bassorin and tragacanthin differ
mainly in terms of their uronic acid and methoxyl content [396]. It has been
demonstrated that bassorin is a complex structure of polymethoxylated acids and on
demethoxylation, perhaps yields tragacanthin [397]. Tragacanth when employed as
the carrier in the formulation of 1- and 3-layer matrices produced suitable release
prolongation either alone or in combination with other polymers. It has been
suggested that supplementation of tragacanth in aqueous media results in the
improvement of rheological behavior at very low concentration, thus considered as
potential as a suspending agent, stabilizer, and emulsifier [398]. Only few reports
have been explored on the functional properties of gum tragacanth and its application
in various fields. Recent investigation has demonstrated the flow behavior of Iranian
gum tragacanth at different concentration dispersions, showed that all of the gum
dispersions had shear-thinning natures and exhibit significant physicochemical
properties [399].
4.8.7.3 Mucilage Gums
Recently various mucilage gums have been explored from seed by different
extraction procedures such as guar gum from the ground endosperms or seeds of the
plant Cyamopsistetragonolobus (Fam. Leguminosae) and locust bean gum from the
endosperms of the hard seeds of the locust bean tree (Carob tree), Ceratoniasiliqua
(Fam. Caesalpiniaceae) [400]. These polysaccharides have been investigated for
their potential role in drug delivery and other pharmaceutical applications.
4.8.7.4 Locust Bean Gum
Locust bean gum (Fig. 4.10) or carob gum, irregularly shaped molecule with
branched β-1, 4-D-galactomannan units, derived from the seeds of the carob,
Ceratoniasiliqua Linn (Fam. Caesalpiniaceae). For achieving full solubility with
complete hydration and highest viscosity this neutral charged polymer requires
heat. This feature encourages its coating strength and imparts protection to several
drug candidates against several degradation factors in vivo. Colon-specific drug
delivery systems based on polysaccharides using locust bean gum and chitosan was
developed. It was observed that when these coating materials was applied over core
tablet it endow better shielding affect by protecting the drug from being released in
the physiological environment of stomach and small intestine. Additionally it also
provides protection against colonic bacterial enzymatic actions with resultant drug
release in the colon.
4.8.7.5 Guar Gum
Guar gum (Fig. 4.11), high molecular weight hydrocolloidal polysaccharide consist
of linear chain of β-D-mannopyranosyl units linked (1 → 4) with single member α-D-
galacto-pyranosyl units occurring as side branches. This Cyamposistetragonolobus
endosperms derived polysaccharide contains glycosidic linked galactan and mannan
Fig. 4.10 Chemical OH OH

structure of locust bean
gum HO O
HO
OH O
HO HO HO
O O HO
O O O O
HO O HO O
HO
HO
OH OH
Fig. 4.11 Chemical structure of guar gum

units and shows degradation in the large intestine due the presence of microbial
enzymes. Guar gum has high molecular weight with high apparent viscosity in solu-
tion and shows solubility in cold water with its complete swift hydration to yield
viscous pseudo plastic solutions. However it was observed that its shear-thinning
usually have better low-shear viscosity than other hydrocolloids. This high viscosity
and molecular weight dependent gelling property delays the drug from its dosage
form, and become more vulnerable against susceptible to degradation in the colonic
environment. This galactomannan based non-ionic polysaccharide that abundantly
present in nature and endow many significant properties desirable for drug delivery
applications. Nevertheless owing to its elevated swelling features in water, the utili-
zation of this galactomannan based polysaccharide is limited. Recently various
physico-chemical methods have been employed to improve its property such as
derivatiztion, grafting and network formation. Such modification allows its more
utilization for biomedical applications. Additionally this plant based natural polymer
can be exploited in various forms such as matrix tablets, hydrogels, nano/micro par-
ticles and coatings can be exploited as potential carriers for targeted drug delivery
[401]. One report suggested the significant role of guar gum in oral controlled drug
delivery systems for highly water-soluble metroprolol as a carrier in the form of a
three-layer matrix tablet. During this study it was observed that three-layer guar gum
matrix tablets provide the desirable release rate for metoprolol tartrate formulations
with no change either in physical appearance, drug content or in dissolution pattern
and did not show any possibility of metoprolol tartrate/guar gum interaction with the
formulation excipients used in the study [402]. Same results were obtained in guar
gum based three layer tablet of tri-metazidinedihydrochloride controlled release for-
mulation [403]. In another report where guar gum potential was explored as a carrier
for colon-specific drug delivery in form of a novel tablet formulation for oral admin-
istration using indo-methacin as a model drug. It was observed that this galactoman-
nan based polysaccharide protects the drug from being released entirely in the
physiological environment of stomach and small intestine. Based on these investiga-
tions it was concluded that 4 % w/v of rat caecal contents in PBS offers the best
conditions for in vitro assessment of guar gum [404]. In one more investigation guar
gum was modified by using acrylamide grafting in which amide groups of these
grafted copolymers were transformed into carboxylic functional groups and finally
tablets were prepared by incorporating diltiazem hydrochloride. Based on in-vitro
drug release data it was observed that that the drug release dissolution was controlled
in case of unhydrolyzed copolymer in contrast with hydrolyzed copolymers, drug
release was swelling-controlled at first, however at later stage, it became dissolution-
controlled. This report suggested potential role of pH sensitive hydrolyzed pAAm-
g-GG matrices for intestinal drug delivery [405].
4.8.7.6 Grewia Gum
Grewia genus which was formerly categorized under linden Family (Tiliaceae) or
the Spermamanniaceae and has been now merged into the Malvaceae [406]. Its
increasing citations in International Pharmaceutical Abstracts database, EBSCO
and in PubMed augment its interest on Grewia mollisas as a potential pharmaceutical

excipient [407]. In concern with its polysaccharide based pharmaceutical evaluation,
the first report was documented in the early 2000s [408–416], in which researchers
have explored some physicochemical and rheological characteristics as well as
water vapor permeability of the aqueous-based films. During this investigation
effect of gum derived from Grewia mollisas, on the binding properties in sodium
salicylate tablets [413] and its influence on the granulating fluid on the release
profile of drug [414] were evaluated. Later on in a study researchers have observed
that method of incorporating the gum into tablet formulation had significant effect
on tablet properties. Additionally it was discovered that introduction by activation
with water produced improved tablet properties than when incorporate by wet
granulation or direct compression [415]. It was observed that acidic hydrolysis of
the gum and some chemical modifications showed reduced viscosity and improved
drug release from tablets [416–418]. In recent work some workers have explored
the significant role of gum in binding in contrast with both untreated gum and
gelatin in paracetamol tablet formulations [419]. It was observed that tablet
formulations containing treated grewia gum exhibited low onset of plastic
deformation, enhanced friability was found with increase in acid concentration and
treatment time and decrease in crushing strength, disintegration and dissolution
times with increase in acid concentration and treatment time was observed. Other
researchers concluded that acid treated grewia gum, depending on the desired onset
of action of medicament, can be used in formulation of conventional tablets
especially if the formulation does not require sustained release [420]. With the
advancement in analytical tools it’s now possible to characterize the natural
polymers in much better way then the conventional technologies. Technologies such
as gel permeation chromatography, gas chromatography, differential scanning
calorimetry, scanning electron microscopy, thermo gravimetric analysis, 1H and
13
C-NMR, solid-state nuclear magnetic resonance, Fourier transformed infrared,
x-ray photoelectron spectroscopy, and NIR techniques have been utilized to
characterize the gum [421, 422]. Based on the analysis it was observed that
polysaccharide gum is a normally amorphous polysaccharide gum containing
rhamnose, glucose, arabinose, galactose, and xylose as neutral sugars with an
average molecular weight of 5925 kDa expressed as the pullulan equivalent. As far
as its physical properties are concerned gum gradually hydrated in water. This
dispersion swells to form a highly viscous dispersion having pseudo plastic flow
behavior. Technique like centrifugation gives better molecular weights range
between 230 and 235 kDa of gum when centrifuged successively at 4500 rpm for
30 min. Such processes improve the aqueous solubility and useful in delivering
more solids to the substrate when used as a film coating agent [422].
4.8.7.7 Okra Gum
Okra gum is obtained from plant which is widely cultivated and grown in most
tropical part of Nigeria known as Abelmoschusesculentus (Fam. Malvaceae). This
plant is widely consumed as food in Asia and Africa and therefore considered as
subject of research in agriculture [423, 424]. Okra is popular for its viscous
mucilaginous solution which is formed when heated and extracted in water [425].
This high molecular weight polysaccharide gum is reported as pharmaceutical
excipient in various reports as a suspending [425–427], control release [428], film
coating [429], binder [430, 431], and bio-adhesive [432] agent. Okra gum is
documented as controlled-release agent in modified release matrices, in contrast
with sodium carboxymethylcellulose and hydroxyl-propyl-methyl-cellulose, using
Paracetamol as a model drug. Results showed that an okra gum matrix was useful in
the formulation of sustained-release tablets for up to 6 h [428].
4.8.7.8 Kyaha Gum
Recent report explored the relative binding effects of khaya gum obtained from
Khayasenegalensis and Khayagrandifoliola (Fam. Meliaceae) in paracetamol tablet
formulation were evaluated [433]. In one report mechanical properties of the tablets
using khaya gum were assessed using the tensile strength, brittle fracture index and
friability of the tablets while the drug release properties were evaluated by means of
disintegration and dissolution times. It was observed that the brittle fracture index
and friability decreased whereas tensile strength, disintegration and the dissolution
times of tablets increased with the increase in binder concentration. It was also
concluded that gum obtained from K. senegalensis produced strong tablets with
extended disintegration and dissolution times in contrast with those obtained from
K. grandifoliola gum. Based on reports it was finally suggested that gums obtained
from K. senegalensis will be more suitable as a binding agent than K. grandifoliola
when high mechanical strength and slow release profiles of tablets are required.
4.8.7.9 Moringaoleifer Gum
Moringaoleifera derived gum was investigated for its physical features such as loss
on drying, swelling index, solubility, and pH in form of gel based formulations
using Diclofenac sodium as model. It was studied that 8.0 % mucilage gels prepared
were found to be ideal and equivalent with a marketed preparation [434].
4.8.7.10 Irvingiagabonensis
Seeds of Irvingia gabonensis, commonly known as ‘African mango’ or ‘bush

mango’ contains large amount of lipids and polymeric constituents [423, 435–440]
which are very important to pharmaceutical scientists as excipients. Mucilage
isolated from the kernel is of great pharmaceutical significance and has been used
as binding agent in tablet formulation [441], as emulsifying and suspending agent
[442]. Moreover the lipid has been employed in sustained release ingredient
[443–445], as suppository base [446–448], tableting as lubricant, microencapsula-

tion [449], and as a part of film coating process [446]. Polysaccharide extraction can
be achieved by using aqueous dispersion in petroleum ether or diethyl ether [450],
however simultaneous extraction processes for both lipis and polysaccharide content
has not been reported yet [451]. Irvingiagabonensis mucilage was investigated for
use as suspending and emulsifying agent and its rheological behavior was evaluated
against tragacanth. It was observed that formulated suspensions of Irvingia mucilage
at all concentrations gave higher final sedimentation height and sedimentation
volume values. Furthermore it was also documented that 2.0 % w/v Irvingia
mucilage (as an emulsifying agent) when compared against tragacanth and acacia
gum showed stability throughout the 6 weeks of study. This observation led to
conclusion that Irvingia mucilage presents superior properties than acacia and
tragacanth. This performance was found to be much better, even at lower
concentrations in the formulation of emulsions and suspensions. Iirvingia lipid
based suppository base has also been investigated and it was observed that irvingia
fat can be actively employed as suppository base. Furthermore the potential binding
effects of mucilage on sustained release tablets, metronidazole tablets and as
lubricating potential in tablet formulations have been investigated.
4.8.7.11 Hakeagibbosa Gum
This water-soluble gum is obtained from Hakeagibbosa (hakea), having considerable

muco adhesive and sustained-release properties especially for the formulation of
buccal tablets. Hakeagibbosa gum is recently investigated in flat-faced tablets using
chlorpheniramine maleate as model drug [452]. It was observed that hakea coated
tablet significantly extend the in vitro release up to several hours and characterization
results suggested the absence of chemical interactions. Additionally force of
detachment for directly compressed and wet granulated tablets was increased as the
amount of hakea per tablet was increased. Researchers also reported that hakea,
might not only be employed to prolong the chlorpheniramine maleate release from
a buccal tablet, however it also displayed excellent mucoadhesive properties. The
underlying mechanism behind this is the slow relaxation of the hydrated hakea
which can cause chlorpheniramine maleate release in a sustained manner.
4.8.7.12 Psyllium Mucilage
Mucilage derived from Psyllium, has been investigated for its tablet binding
properties [453]. This mucilage is derived from the seed coat of Plantagoovata
(Fam. Plantaginaceae) [454]. Isolation is achieved by milling of the outer layer of
the seeds yield smooth texture mucilage. Psyllium hydrogels were investigated by
insulin as model drug and N, N’-methylene-bis-acryl-amide as cross-linker.
Formulation showed controlled release of the active ingredient [455].
4.8.7.13 Miscellaneous Gums and Mucilage
Various gums have been explored for pharmaceutical significance such as

Colocassiaesculenta [456], seeds of Linumusitatissimum [457], malva nut gum
[458] and Sterculiafoetida gum for swelling and erosion modulator in controlled
release matrix tablets of diltiazem hydrochloride.
References
1. IPECFED. The world unites for safer medicines, 2011.

2. Parrott EL. Pharmaceutical technology: fundamental pharmaceutics. Minneapolis: Burgess
Publishing Company; 1971.
3. Russell R. Synthetic excipient challenge all-natural organics offer advantages/challenges to
developer and formulators. Pharm Tech. 2004;27:38–50.
4. Guo J, Skinner GW, Harcum WW, Barnum PE. Pharmaceutical applications of naturally
occurring water-soluble polymers. Pharm Sci Technol Today. 1998;1:254–61.
5. Beneke CE, Viljoen AM, Hamman JH. Polymeric plant-derived excipients in drug delivery.
Molecules. 2009;14:2602–20.
6. Pandey R, Khuller GK. Polymer based drug delivery systems for mycobacterial infections.
Curr Drug Deliv. 2004;1:195–201.
7. Chamarthy SP, Pinal R. Plasticizer concentration and the performance of a diffusion-
controlled polymeric drug delivery system. Colloids Surf A Physiochem Eng Asp.
2008;331:25–30.
8. Malafaya PB, Silva GA, Reis RL. Natural-origin polymers as carriers and scaffolds for bio-
molecules and cell delivery in tissue engineering applications. Adv Drug Deliv Rev.
2007;59:207–33.
9. Malviya R, Srivastava P, Kulkarni GT. Applications of mucilages in drug delivery – a review.
Adv Biol Res. 2011;5:1–7.
10. Perepelkin KE. Polymeric materials of the future based on renewable plant resources and
biotechnologies. Fibre Chem. 2005;37:417–30.
11. Raizada A, Bandari A, Kumar B. Polymers in drug delivery: a review. Int J Pharm Res Dev.
2010;2:9–20.
12. Verbeken D, Dierckx S, Dewettinck K. Exudate gums: occurrence, production and applica-
tions. Appl Microbiol Biotechnol. 2003;63:10–21.
13. Maneesh K, Gaurav S, Ravinder K, Kapil K, Paramjot K, et al. Applications of novel excipi-
ents in the allopathic and herbal formulations. J Chem Pharm Res. 2010;2:851–60.
14. Paulsen BS. Biologically active polysaccharides as possible lead compounds. Phytochem
Rev. 2002;1:379–87.
15. Coviello T, Matricardi P, Marianecci C, Alhaique F. Polysaccharide hydrogels for modified
release formulations. J Control Release. 2007;119:5–24.
16. Robyt JF. General properties, occurrence, and preparation of carbohydrates. In: Reid BF, Tatsuta
K, Thiem J, editors. Glycoscience. Berlin: Springer; 2008. 10.1007/978-3-540-30429-6_2.
17. Lahaye M. Developments on gelling algal galactans, their structure and physico-chemistry.
J Appl Phycol. 2001;13:173–84.
18. Cardozo KHM, Guaratini T, Barros MP, Falcao VR, Tonon AP, Lopes NP, Campos S, Torres
MA, Souza AO, Colepicolo P, Pinto E. Metabolites from algae with economical impact.
Comp Biochem Physiol C Toxicol Pharmacol. 2007;146:60–78.
19. Holst O, Loennies SM. Microbial polysaccharide structures. Borstel: Research Center
Borstel-Leibniz-Center for Medicine and Biosciences; 2007.
References 165
20. Sutherland IW. Bacterial exopolysaccharides. Edinburgh: Edinburgh University; 2007.

21. McDonald JA, Camenisch TD. Hyaluronan: genetic insights into the complex biology of a
simple polysaccharide. Glycoconj J. 2003;19:331–9.
22. Kogan G, Soltes L, Stern R, Gemeiner P. Hyaluronic acid: a natural biopolymer with a broad
range of biomedical and industrial applications. Biotechnol Lett. 2007;29:17–25.
23. Girish KS, Kemparaju K. The magic glue hyaluronan and its eraser hyaluronidase: a
biological overview. Life Sci. 2007;80:1921–43.
24. Harrington JC, Morris ER. Conformational ordering and gelation of gelatin in mixtures with
soluble polysaccharides. Food Hydrocoll. 2009;23:327–36.
25. Velde FV, Knutsen SH, Usov AI, Rollemay HS, Cerezo AS. 1H and 13C high resolution NMR
spectroscopy of carrageenans: application in research and Industry. Trends Food Sci Technol.
2002;13:73–92.
26. Kazłowski B, Pan CL, Ko YT. Separation and quantification of neoagaro- and agaro-
oligosaccharide products generated from agarose digestion by b-agarase and HCl in liquid
chromatography systems. Carbohydr Res. 2008;343:2443–50.
27. Jones C, Mulloy B. The application of nuclear magnetic resonance to structural studies of
polysaccharides. In: Jones C, Mulloy B, Thomas AH, editors. Spectroscopic methods and
analyses NMR – Mass spectrometry, and metalloprotein techniques, Methods in molecular
biology, vol. 17. Totowa, NJ: Humana Press; 1993. p. 6.
28. Tuvikene R, Truus K, Kollist A, Volobujeva O, Mellikov E, Pehk T. Gel-forming structures
and stages of red algal galactans of different sulfation levels. J Appl Phycol. 2007;20:527–35.
doi:10.1007/s10811-007-9229-9.
29. Navarro DA, Flores ML, Stortz CA. Microwave-assisted desulfation of sulfated polysaccha-
rides. Carbohydr Poly. 2007;69:742–7.
30. Chou BAM, Koenig JL. A review of polymer dissolution. Prog Polym Sci.
2003;28:1223–70.
31. Talukdar MM, Vinckier I, Moldenaers P, Kinget R. Rheological characterization of Xanthan
Gum and hydroxypropylmethyl cellulose with respect to controlled-release drug delivery.
J Pharm Sci. 1996;85:5.
32. Phillips HM, Craig DQM, Royall PG, Hill VL. Characterisation of the glass transition of
HPMC using modulated temperature differential scanning calorimetry. Int J Pharm.
1999;180:83–90.
33. Rinaudo M. Seaweed polysaccharides. Grenoble: Centre de Recherches sur les Macromole´
cules Ve´ ge´ tales, CNRS; 2007.
34. Maciel JS, Chaves LS, Souza BWS, Teixeira DIA, Freitas ALP, Feitosa JPA, et al. Structural
characterization of cold extracted fraction of soluble sulfated polysaccharide from red
seaweed Gracilaria birdiae. Carbohydr Polym. 2008;71(4):559–65.
35. Zhao T, Zhang Q, Qi H, Zhang H, Niu X, Xu Z, et al. Degradation of porphyran from
Porphyra haitanensis and the antioxidant activities of the degraded porphyrans with different
molecular weight. Int J Biol Macromol. 2006;38:45–50.
36. Noseda MD, Viana AG, Duarte MER, Cerezo AS. Alkali modification of carrageenans. Part
IV. Porphyrans as model compounds. Carbohydr Polym. 2000;42:301–5.
37. Karlsson A, Singh SK. Acid hydrolysis of sulphated polysaccharides. Desulphation and the
effect on molecular mass. Carbohydr Polym. 1999;38:7–15.
38. Zhou C, Yu X, Zhang Y, He R, Ma H. Ultrasonic degradation, purification and analysis of
structure and antioxidant activity of polysaccharide from Porphyra yezoensis Udea.
Carbohydr Polym. 2012;87:2046–51.
39. Denis C, Jeune HL, Gaudin P, Fleurence J. An evaluation of methods for quantifying the
enzymatic degradation of red seaweed Grateloupia turuturu. J Appl Phycol.
2009;21(1):153–9.
40. Dubois M, Gilles K, Hamilton JK, Rebers PA, Smith F. A colorimetric method for the deter-
mination of sugars. Nature. 1951;168:167.
41. Yaphe W, Arsenault GP. Improved resorcinol reagent for the determination of fructose, and
of 3, 6-anhydrogalactose in polysaccharides. Anal Biochem. 1965;13:143–8.
42. Nader HB, Dietrich CP. Determination of sulfate after chromatography and toluidine blue
complex formation. Anal Biochem. 1977;78:112–8.
43. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol
reagent. J Biol Chem. 1951;193(1):265–75.
44. Hutardo-Ponce AQ, Umezaki I. Physical properties of agar gel from Gracilaria (Rhodophyta)
of the Philippines. Botanica marina. 1988;31:171–4.
45. Craigie JS, Leigh C. Carrageenans and agars. In: Hellebust JA, Craigie JS, editors. Hand
book of phycological methods. Cambridge: Cambridge University Press; 1978. p. 109–31.
46. Rochas C, Lahaye NI. Average molecular weight and molecular weight distribution of aga-
rose and agarose-type polysaccharide. Carbohydr Polym. 1989;10:289–98.
47. Kilp T, Guillet JE. A rapid procedure for the determination of viscosity – MW relations.
Macromolecules. 1977;10:90–4.
48. Kaur B, Ariffin F, Bhat R, Karim AA. Progress in starch modification in the last decade.
Food Hydrocoll. 2012;26:398–404.
49. Rajan A, Prasad VS, Abraham TE. Enzymatic esterification of starch using recovered coco-
nut oil. Int J Biol Macromol. 2006;39:265–72.
50. Rajan A, Sudha JD, Abraham TE. Enzymatic modification of cassava starch by fungal lipase.
Ind Crops Prod. 2008;27:50–9.
51. Qiao L, Gu Q-M, Cheng HN. Enzyme-catalyzed synthesis of hydrophobically modified
starch. Carbohydr Polym. 2006;66:135–40.
52. Chakraborty S, Sahoo B, Teraoka I, Miller LM, Gross RA. Enzyme catalyzed regioselective
modification of starch nanoparticles. Macromolecules. 2005;38:61–8.
53. Deetae P, Shobsngob S, Varanyanond W, Chinachoti P, Naivikul O, Varavinit S. Preparation,
pasting properties and freeze-thaw stability of dual modified crosslink-phosphorylated rice
54. Varavinit S, Paisanjit W, Tukomane T, Pukkahuta C. Effects of osmotic pressure on the cross-
linking reaction of tapioca starch. Starch/Stärke. 2007;59:290–6.
55. Li JM, Zhang LM. Characteristics of novel starch-based hydrogels prepared by UV photopo-
lymerization of acryloylated starch and a zwitterionic monomer. Starch/Stärke.
2007;59:418–22.
56. Ou S, Li A, Yang A. A study on synthesis of starch ferulate and its biological properties. Food
Chem. 2001;74:91–5.
57. Xing GX, Zhang SF, Ju BZ, Yang JZ. Microwave-assisted synthesis of starch maleate by dry
method. Starch/Stärke. 2006;58:464–7.
58. Jyothi AN, Rajasekharan KN, Moorthy SN, Sreekumar J. Microwave assisted synthesis and
characterization of succinate derivatives of cassava (Manihot esculenta Crantz) starch. Starch/
Stärke. 2005;57:556–63.
59. Cízová A, Sroková I, Sasinková V, Malovíková A, Ebringerová A. Carboxymethyl starch
octenylsuccinate: microwave- and ultrasound-assisted synthesis and properties. Starch/
Stärke. 2008;60:389–97.
60. Karim AA, Sufha EH, Zaidul ISM. Dual modification of starch via partial enzymatic hydro-
lysis in the granular state and subsequent hydroxypropylation. J Agric Food Chem.
2008;56:10901–7.
61. Kesselmans RPW, Bleeker IP. Method for oxidizing dry starch using ozone. World Intellectual
Property Organization, WO/1997/032902, 1997.
62. Chan HT, Bhat R, Karim AA. Physicochemical and functional properties of ozone-oxidized
starch. J Agric Food Chem. 2009;57:5965–70.
63. An HJ, King JM. Using ozonation and amino acids to change pasting properties of rice
starch. J Food Sci. 2009;74:278–83.
64. Heux L, Chauve G, Bonini C. Nonflocculatingand chiral-nematic self-ordering of cellulose
microcrystals suspensions in nonpolar solvents. Langmuir. 2000;16:8210.
65. Heux L, Bonini C. International Patent WO 2000/077088, 2000.
66. Bonini C, Heux L, Cavaille JY, Lindner P, Dewhurst C, Terech P. Rodlike cellulose whiskers
coated with surfactant: a small-angle neutron scattering characterization. Langmuir. 2002;
18:3311.
References 167
67. Rojas OJ, Montero GA, Habibi Y. J Appl Polym Sci. 2009;113:927.
68. Zhou Q, Brumer H, Teeri TT. Macromolecules. 2009;42:5430.
69. Gert EV, Torgashov VI, Zubets OV, Kaputskii FN. Preparation and properties of enterosor-
bents based on carboxylated microcrystalline cellulose. Cellulose. 2005;12(5):517–26.
70. Kitaoka T, Isogai A, Onabe F. Chemical modification of pulp fibers by TEMPO-mediated
oxidation. Nordic Pulp Paper Res J. 1999;14(4):279–84.
71. Montanari S, Roumani M, Heux L, Vignon MR. Topochemistry of carboxylated cellulose
nanocrystals resulting from TEMPO-mediated oxidation. Macromolecules. 2005;38(5):
1665–71.
72. Saito T, Isogai A. TEMPO-mediated oxidation of native cellulose. The effect of oxidation
conditions on chemical and crystal structures of the water-insoluble fractions.
Biomacromolecules. 2004;5(5):1983–9.
73. Saito T, Isogai A. Introduction of aldehyde groups on surfaces of native cellulose fibers by
TEMPO-mediated oxidation. Colloids Surf A Physicochem Eng Asp. 2006;289(1–3):
219–25.
74. Saito T, Nishiyama Y, Putaux JL, Vignon M, Isogai A. Homogeneous suspensions of indi-
vidualized microfibrils from TEMPO-catalyzed oxidation of native cellulose.
75. Eichhorn SJ, Dufresne A, Aranguren M, Marcovich NE, Capadona JR, Rowan SJ, et al.
Review: Current international research into cellulose nanofibres and nanocomposites. J Mater
Sci. 2010;45(1):1–33.
76. Saito T, Kimura S, Nishiyama Y, Isogai A. Cellulose nanofibers prepared by TEMPO-
mediated oxidation of native cellulose. Biomacromolecules. 2007;8(8):2485–91.
77. Saito T, Okita Y, Nge TT, Sugiyama J, Isogai A. TEMPO-mediated oxidation of native cel-
lulose: microscopic analysis of fibrous fractions in the oxidized products. Carbohydr Polym.
2006;65(4):435–40.
78. Isogai A, Saito T, Fukuzumi H. TEMPO-oxidized cellulose nanofibers. Nanoscale.
2011;3(1):71.
79. Isogai T, Saito T, Isogai A. Wood cellulose nanofibrils prepared by TEMPO electro-mediated
oxidation. Cellulose. 2011;18(2):421–31.
80. Saito T, Hirota M, Tamura N, Kimura S, Fukuzumi H, Heux L, et al. Individualization of
nano-sized plant cellulose fibrils by direct surface carboxylation using TEMPO catalyst
under neutral conditions. Biomacromolecules. 2009;10(7):1992–6.
81. Johnson RK, Zink-Sharp A, Renneckar SH, Glasser WG. A new bio-based nanocomposite:
fibrillated TEMPO-oxidized celluloses in hydroxypropylcellulose matrix. Cellulose.
2008;16(2):227–38.
82. Li Q, Renneckar S. Molecularly thin nanoparticles from cellulose: isolation of sub-
microfibrillar structures. Cellulose. 2009;16(6):1025–32.
83. Araki J, Wada M, Kuga S. Langmuir. 2001;17:21.
84. Hasani M, Cranston ED, Westmana G, Gray DG. Soft Matter. 2008;4:2238.
85. Sassi JF, Chanzy H. Cellulose. 1995;2:111.
86. Braun B, Dorgan JR. Biomacromolecules. 2009;10:334.
87. Sobkowicz MJ, Braun B, Dorgan JR JR. Green Chem. 2009;11:680.
88. Yuan H, Nishiyama Y, Wada M, Kuga S. Biomacromolecules. 2006;7:696.
89. Junior de Menezes A, Siqueira G, Curvelo AAS, Dufresne A. Extrusion and characterisation
of functionalised cellulose whiskers reinforced polyethylene nanocomposites. Polymer.
2009;50:4552.
90. Gousse C, Chanzy H, Excoffier G, Soubeyrand L, Fleury E. Polymer. 2002;43:2645.
91. Grunnert M, Winter WT. Polym Mater Sci Eng. 2000;82:232.
92. Siqueira G, Bras J, Dufresne A. Biomacromolecules. 2009;10:425.
93. Aulin C, Ahola S, Josefsson P, Nishino T, Hirose Y, Osterberg M, et al. Nanoscale cellulose
films with different crystallinities and mesostructures—their surface properties and
interaction with water. Langmuir. 2009;25(13):7675–85.
94. Taipale T, Osterberg M, Nykanen A, Ruokolainen J, Laine J. Effect of microfibrillated cel-

lulose and fines on the drainage of kraft pulp suspension and paper strength. Cellulose.
2010;17(5):1005–20.
95. Tingaut P, Zimmermann T, Lopez-Suevos F. Synthesis and characterization of bionanocom-
posites with tunable properties from poly(lactic acid) and acetylated microfibrillated cellu-
lose. Biomacromolecules. 2009;11(2):454–64.
96. Ljungberg N, Bonini C, Bortolussi F, Boisson C, Heux L, Cavaille JY. Biomacromolecules.
2005;6:2732.
97. Vignon M, Montanari S, Habibi Y. (Centre National de la Recherche Scientifique CNRS, Fr.)
FR 2003/5195, 2004.
98. Mangalam AP, Simonsen J, Benight AS. Biomacromolecules. 2009;10:497.
99. Cao X, Habibi Y, Lucia LAJ. Mater Chem. 2009;19:7137.
100. Habibi Y, Goffin AL, Schiltz N, Duquesne E, Dubois P, Dufresne AJ. Mater Chem.
2008;18:5002.
101. Pranger L, Tannenbaum R. Macromolecules. 2008;41:8682.
102. Zoppe J, Habibi Y, Rojas OJ. Abstr. Pap., ACS Natl. Meet. 2008, 235, CELL-057.
103. Iwamoto S, Nakagaito AN, Yano H, Nogi M. Optically transparent composites reinforced
with plant fiber-based nanofibers. Appl Phys A. 2005;81(6):1109–12.
104. Spence KL, Venditti RA, Habibi Y, Rojas OJ, Pawlak JJ. The effect of chemical composition
on microfibrillar cellulose films from wood pulps: mechanical processing and physical
properties. Bioresour Technol. 2010;101(15):5961–8.
105. Spence KL, Venditti RA, Rojas OJ, Habibi Y, Pawlak JJ. The effect of chemical composition
on microfibrillar cellulose films from wood pulps: water interactions and physical properties
for packaging applications. Cellulose. 2010;17(4):835–48.
106. Stenstad P, Andresen M, Tanem BS, Stenius P. Chemical surface modifications of microfibril-
lated cellulose. Cellulose. 2007;15(1):35–45.
107. Ahola S, Osterberg M, Laine J. Cellulose nanofibrils-adsorption with poly(amideamine) epi-
chlorohydrin studied by QCM-D and application as a paper strength additive. Cellulose.
2007;15(2):303–14.
108. Alemdar A, Sain M. Biocomposites form wheat straw nanofibers: morphology, thermal and
mechanical properties. Compos Sci Technol. 2008;68(2):557–65.
109. Lavoine N, Desloges I, Dufresne A, Bras J. Microfibrillated cellulose – its barrier properties
and applications in cellulosic materials: a review. Carbohydr Polym. 2012;90:735–64.
110. Turbak AF, Snyder FW, Sandberg KR. Micro-fibrillated cellulose and process for producing
it. Patent CH 648071 (A5), 1985.
111. Aulin C. Novel oil resistant cellulosic materials (Pulp and paper technology). Stockholm:
KTH Chemical Science and Engineering; 2009.
112. Dinand E, Maureaux A, Chanzy H, Vincent I, Vignon MR. Microfibrillated cellulose and
process for making the same from vegetable pulps having primary walls, especially from
sugar beet pulp. Patent EP 0726356 B1, 2002.
113. Leitner J, Hinterstoisser B, Wastyn M, Keckes J, Gindl W. Sugar beet cellulose nanofibril-
reinforced composites. Cellulose. 2007;14(5):419–25.
114. Nakagaito AN, Yano H. The effect of morphological changes from pulp fiber towards nano-
scale fibrillated cellulose on the mechanical properties of high-strength plant fiber based
composites. Appl Phys A. 2004;78(4):547–52.
115. Uetani K, Yano H. Nanofibrillation of wood pulp using a high-speed blender.
116. Siqueira G, Bras J, Dufresne A. Cellulosic bionanocomposites: a review of preparation, prop-
erties and applications. Polymer. 2010;2(4):728–65.
117. Iwamoto S, Nakagaito AN, Yano H. Nano-fibrillation of pulp fibers for the processing of
transparent nanocomposites. Appl Phys A. 2007;89(2):461–6.
118. Pohler T, Lappalainen T, Tammelin T, Eronen P, Hiekkataipale P, Vehniainen A, et al.
Influence of fibrillation method on the character of nanofibrillated cellulose (NFC). Presented
References 169
at the TAPPI international conference on nanotechnology for the forest products industry,
Espoo, 2010.
119. Dufresne A, Cavaille JY, Vignon MR. Mechanical behavior of sheets prepared from sugar
beet cellulose microfibrils. J Appl Polym Sci. 1997;64(6):1185–94.
120. Chakraborty A, Sain M, Kortschot M. Cellulose microfibrils: a novel method of preparation
using high shear refining and cryocrushing. Holzforschung. 2005;59(1):102–7.
121. Alemdar A, Sain M. Isolation and characterization of nanofibers from agricultural residues –
wheat straw and soy hulls. Bioresour Technol. 2008;99(6):1664–71.
122. Bhatnagar A, Sain M. Processing of cellulose nanofiber-reinforced composites. J Reinforced
Plastics Compos. 2005;24(12):1259–68.
123. Huang ZM, Zhang YZ, Kotaki M, Ramakrishna S. A review on polymer nanofibers by elec-
trospinning and their applications in nanocomposites. Compos Sci Technol.
2003;63(15):2223–53.
124. Li D, Xia Y. Electrospinning of nanofibers: reinventing the wheel? Adv Mater.
2004;16(14):1151–70.
125. Diez I, Eronen P, Osterberg M, Linder MB, Ikkala O, Ras RHA. Functionalization of
nanofibrillated cellulose with silver nanoclusters: fluorescence and antibacterial activity.
Macromol Biosci. 2011;11(9):1185–91.
126. Walther A, Timonen JVI, Diez I, Laukkanen A, Ikkala O. Multifunctional high-performance
biofibers based on wet-extrusion of renewable native cellulose nanofibrils. Adv Mater.
2011;23:2924–8.
127. Zimmermann T, Bordeanu N, Strub E. Properties of nanofibrillated cellulose from different
raw materials and its reinforcement potential. Carbohydr Polym. 2010;79(4):1086–93.
128. Eriksen O, Syverud K, Gregersen OW. The use of microfibrillated cellulose produced from
kraft pulp as strength enhancer in TMP paper. Nordic Pulp Paper Res
J. 2008;23(3):299–304.
129. Spence KL, Venditti RA, Rojas OJ, Habibi Y, Pawlak JJ. A comparative study of energy
consumption and physical properties of microfibrillated cellulose produced by different
processing methods. Cellulose. 2011;18(4):1097–111.
130. Spence KL, Venditti RA, Rojas OJ, Pawlak JJ, Hubbe MA. Water vapor barrier properties of
coated and filled microfibrillated cellulose composite films. Bioresources.
2011;6(4):4370–88.
131. Heiskanen I, Harlin A, Backfolk K, Laitinen R. Process for production of microfibrillated
cellulose in an extruder and microfibrillated cellulose produced according to the process.
Patent No WO 2011051882, 2011.
132. Tanaka A, Sneck A, Seppanen V, Houni J, Pirkonen P. Possibilities to characterize NFC: NFC
fractionation. Presented at the SUNPAP Workshop 2011.
133. Paakko M, Ankerfors M, Kosonen H, Nykanen A, Ahola S, Osterberg M, et al. Enzymatic
hydrolysis combined with mechanical shearing and high-pressure homogenization for
nanoscale cellulose fibrils and strong gels. Biomacromolecules. 2007;8:1934–41.
134. Engstrom A, Ek M, Henriksson G. Improved accessibility and reactivity of dissolving pulp
for the viscose process: pretreatment with monocomponent endoglucanase.
135. Henriksson M, Henriksson G, Berglund LA, Lindstrom T. An environmentally friendly
method for enzyme-assisted preparation of microfibrillated cellulose (MFC) nanofibers. Eur
Polym J. 2007;43(8):3434–41.
136. Rodionova G, Lenes M, Eriksen O, Gregersen O. Surface chemical modification of microfi-
brillated cellulose: improvement of barrier properties for packaging applications. Cellulose.
2010;18(1):127–34.
137. Ifuku S, Nogi M, Abe K, Handa K, Nakatsubo F, Yano H. Surface modification of bacterial
cellulose nanofibers for property enhancement of optically transparent composites:
dependence on acetyl-group DS. Biomacromolecules. 2007;8(6):1973–8.
138. Nogi M, Ifuku S, Abe K, Handa K, Nakagaito AN, Yano H. Fiber-content dependency of the
optical transparency and thermal expansion of bacterial nanofiber reinforced composites.
Appl Phys Lett. 2006;88(13):133124.
139. Andresen M, Johansson LS, Tanem BS, Stenius P. Properties and characterization of hydro-
phobized microfibrillated cellulose. Cellulose. 2006;13(6):665–77.
140. Lu J, Askeland P, Drzal LT. Surface modification of microfibrillated cellulose for epoxy com-
posite applications. Polymer. 2008;49(5):1285–96.
141. Missoum K, Belgacem MN, Bras J. Ionic liquids: green process for modifying nanofibrillated
cellulose surface chemistry. Presented at the SUNPAP Workshop, Espoo, 2011.
142. Missoum K, Belgacem N, Krouit M, Martin C, Tapin-Lingua S, Bras J. Influence of fibrilla-
tion degree & surface grafting of micro-fibrillated cellulose on their rheological behavior in
aqueous suspension. Presented at the 2010 TAPPI nanotechnology conference for the forest
product industry, Espoo, 2010.
143. Andresen M, Stenstad P, Moretro T, Langsrud S, Syverud K, Johansson LS, et al. Nonleaching
antimicrobial films prepared from surface-modified microfibrillated cellulose.
144. Nemtanu MR, Minea R. Functional properties of corn starch treated with corona electrical
discharges. Macromol Symp. 2006;245–246:525–8.
145. Szymonska J, Krok F, Tomasik P. Deep-freezing of potato starch. Int J Biol Macromol.
2000;27:307–14.
146. Szymonska J, Krok F, Komorowska Czepirska E, Rebilas K. Modification of granular potato
starch by multiple deep-freezing and thawing. Carbohydr Polym. 2003;52:1–10.
147. Zarguili I, Maache-Rezzoug Z, Loisel C, Doublier JL. Influence of DIL hydrothermal process
conditions on the gelatinization properties of standard maize starch. J Food Eng.
2006;77:454–61.
148. Maache-Rezzoug Z, Maugard T, Zarguili I, Bezzine E, El Marzouki MN, et al. Effect of
instantaneous controlled pressure drop (DIC) on physicochemical properties of wheat, waxy
and standard maize starches. J Cereal Sci. 2009;49:346–53.
149. Lewandowicz G, Soral Smietana M. Starch modification by iterated syneresis. Carbohydr
Polym. 2004;56:403–13.
150. Huang ZQ, Lu JP, Li XH, Tong ZF. Effect of mechanical activation on physico-chemical
properties and structure of cassava starch. Carbohydr Polym. 2007;68:128–35.
151. Che LM, Li D, Wang LJ, Chen XD, Mao ZH. Microniation and hydrophobic modification of
cassava starch. Int J Food Properties. 2007;10:527–36.
152. Pukkahuta C, Shobsngob S, Varavinit S. Effect of osmotic pressure on starch: new method of
physical modification of starch. Starch/Stärke. 2007;58:78–90.
153. Han Z, Zeng X, Zhang B, Yu S. Effect of pulsed electric fields (PEF) treatment on the proper-
ties of corn starch. J Food Eng. 2009;93:318–23.
154. Steeneken PAM, Woortman AJJ. Superheated starch: a novel approach towards spreadable
particle gels. Food Hydrocoll. 2009;23:394–405.
155. Chiu CW, Schiermeyer E, Thomas DJ, Shah MB. Thermally inhibited starches and flours and
process for their production. U.S. Patent 5,725,676, 1998.
156. Lim ST, Han JA, Lim HS, BeMiller JN. Modification of starch by dry heating with ionic
gums. Cereal Chem. 2002;79:601–6.
157. Vartiainen J, Pohler T, Sirola K, Pylkkanen L, Alenius H, Hokkinen J, et al. Health and envi-
ronmental safety aspects of friction grinding and spray drying of microfibrillated cellulose.
Cellulose. 2011;18(3):775–86.
158. González R, Carrara C, Tosi E, Añón MC, Pilosof A. Amaranth starch rich fraction properties
modified by extrusion and fluidized bed heating. LWT Food Sci Technol. 2007;40:136–43.
159. Davis JP, Supatcharee N, Khandelwal RL, Chibbar RN. Synthesis of novel starches in planta:
opportunities and challenges. Starch/Stärke. 2003;55:107–20.
160. Johnson LA, Baumel CP, Hardy CL, White PJ. Identifying valuable corn quality traits for
starch production. A project of the Iowa Grain Quality Initiative Traits Task Team. Ames, IA:
Center for Crops Utilization Research, Iowa Agriculture & Home Economics Experiment
Station, Iowa State University; 1999.
References 171
161. Viksø-Nielsen A, Blennow A, Jørgensen K, Jensen A, Møller BL. Structural, physicochemi-

cal, and pasting properties of starches from potato plants with repressed r1-gene.
Biomacromolecules. 2001;23:836–43.
162. Wischmann B, Blennow A, Madsen F, Jørgensen K, Poulsen P, Bandsholm O. Functional
characterisation of potato starch modified by specific in planta alteration of the amylopectin
branching and phosphate substitution. Food Hydrocoll. 2005;19:1016–24.
163. Ihemere U, Arias-Garzon D, Lawrence S, Sayre R. Genetic modification of cassava for
enhanced starch modification. Plant Biotechnol J. 2006;4:453–65.
164. Jobling SA, Schwall GP, Westcott RJ, Sidebottom CM, Debet M, Gidley MJ, et al. A minor
form of starch branching enzyme in potato (Solanum tuberosum L.) tubers has a major effect
on starch structure: cloning and characterization of multiple forms of SBE A. Plant
J. 1999;18:163–71.
165. Safford R, Jobling SA, Sidebottom CM, Westcott RJ, Cooke D, Tober KJ, et al. Consequences
of antisense RNA inhibition of starch branching enzyme activity on properties of potato
166. Verhoeven T, Fahy B, Leggett M, Moates G, Denyer K. Isolation and characterisation of
novel starch mutants of oats. J Cereal Sci. 2004;40:69–79.
167. Lam E, Male KB, Chong JH, Leung ACW, Luong JHT. Applications of functionalized and
nanoparticle-modified nanocrystalline cellulose. Trends Biotechnol. 2012;30(5):283–90.
168. Kayser O. Nanosuspensions for the formulation of aphidicolin to improve drug targeting
effects against Leishmania infected macrophages. Int J Pharm. 2000;196(2):253–6.
169. Valo H, Kovalainen M, Laaksonen P, Häkkinen M, Auriola S, Peltonen L, Linder M, Järvinen
K, Hirvonen J, Laaksonen T. Immobilization of protein-coated drug nanoparticles in
nanofibrillar cellulose matrices—enhanced stability and release. J Control Release.
2011;156(3):390–7.
170. Boufi S, Ferraria AM, Rego AMB, Battaglini N, Herbst F, Vilar MR. Surface functionalisation
of cellulose with noble metals nanoparticles through a selective nucleation. Carbohydr
Polym. 2011;86(4):1586–94.
171. Bilbao-Sainz C, Bras J, Williams T, Sénechal T, Orts W. HPMC reinforced with different
cellulose nano-particles. Carbohydr Polym. 2011;86(4):1549–57.
172. Liu S, Tao D, Zhang L. Cellulose scaffold: a green template for the controlling synthesis of
magnetic inorganic nanoparticles. Powder Technol. 2012;217:502–9.
173. Abedini R, Mousavi SM, Aminzadeh R. A novel cellulose acetate (CA) membrane using
TiO2 nanoparticles: preparation, characterization and permeation study. Desalination.
2011;277(1–3):40–5.
174. Gutierrez J, Tercjak A, Algar I, Retegi A, Mondragon I. Conductive properties of TiO2/
bacterial cellulose hybrid fibres. J Colloid Interface Sci. 2012;377(1):88–93.
175. Yang J, Yu J, Fan J, Sun D, Tang W, Yang X. Biotemplated preparation of CdS nanoparticles/
bacterial cellulose hybrid nanofibers for photocatalysis application. J Hazard Mater.
2011;189(1–2):377–83.
176. Zhang Y, Jin Q, Zhao J, Wu C, Fan Q, Wu Q. Facile fabrication of pH-sensitive core–shell
nanoparticles based on HEC and PMAA via template polymerization. Eur Polym
J. 2010;46(7):1425–35.
177. Kaihara S, Suzuki Y, Fujimoto K. In situ synthesis of polysaccharide nanoparticles via poly-
ion complex of carboxymethyl cellulose and chitosan. Colloids Surf B Biointerfaces.
2011;85(2):343–8.
178. Li S, Yang W, Chen M, Gao J, Kang J, Qi Y. Preparation of PbO nanoparticles by microwave
irradiation and their application to Pb(II)-selective electrode based on cellulose acetate.
Mater Chem Phys. 2005;90(2–3):262–9.
179. Generalova AN, Sizova SV, Oleinikov VA, Zubov VP, Artemyev MV, Spernath L, et al.
Highly fluorescent ethyl cellulose nanoparticles containing embedded semiconductor
nanocrystals. Colloids Surf A Physicochem Eng Asp. 2009;342(1–3):59–64.
180. Aswathy RG, Sivakumar B, Brahatheeswaran D, Raveendran S, Ukai T, Fukuda T, Yoshida
Y, et al. Multifunctional biocompatible fluorescent carboxymethyl cellulose nanoparticles.
J Biomater Nanobiotechnol. 2012;3:254–61.
181. Fidale LC, Nikolajski M, Rudolph T, Dutz S, Schacher FH, Heinze T. Hybrid Fe3O4@amino
cellulose nanoparticles in organic media – heterogeneous ligands for atom transfer radical.
J Colloid Interface Sci. 2013;390:25–33.
182. Guilminot E, Gavillon R, Chatenet M, Berthon-Fabry S, Rigacci A, Budtova T. New
nanostructured carbons based on porous cellulose: elaboration, pyrolysis and use as platinum
nanoparticles substrate for oxygen reduction electrocatalysis. J Power Sources.
2008;185(2):717–26.
183. Liu H, Wang D, Shang S, Song Z. Synthesis and characterization of Ag–Pd alloy nanoparticles/
carboxylated cellulose nanocrystals nanocomposites. Carbohydr Polym. 2011;83(1):38–43.
184. Dorlo TPC, Balasegaram M, Beijnen JH, Vries PJ. Miltefosine: a review of its pharmacology
and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother.
2012;67:2576–97.
185. Mayorga P, Puisieux F, Puisieux F, Couarraze G. Formulation study of a transdermal delivery
system of primaquine. Int J Pharm. 1996;132(1–2):71–9.
186. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int
J Pharma. 1998;172(1–2):33–70.
187. Murambiwa P, Masola B, Govender T, Mukaratirwa S, Musabayane CT. Anti-malarial drug
formulations and novel delivery systems: a review. Acta Trop. 2011;118(2):71–9.
188. Jó TA, Petri DFS, Beltramini LM, Lucyszyn N, Sierakowski MR. Xyloglucan nano-
aggregates: physico-chemical characterisation in buffer solution and potential application as
a carrier for camptothecin, an anti-cancer drug. Carbohydr Polym. 2010;82(2):355–62.
189. Lubambo AF, Lucyszyn N, Petzhold CL, Camargo PC, Sierakowski MR, Schreiner WH, Saul
CK. Self-assembled polystyrene/xyloglucan nanospheres from spin coatingevaporating
mixtures. Carbohydr Polym. 2011;84:126–32.
190. Itoh K, Yahaba M, Takahashi A, Tsuruya R, Miyazaki S, Dairaku M, et al. In situ gelling
xyloglucan/pectin formulations for oral sustained drug delivery. Int J Pharm.
2008;356(1–2):95–101.
191. Miyazaki S, Suisha F, Kawasaki N, Shirakawa M, Yamatoya K, Attwood D. Thermally
reversible xyloglucan gels as vehicles for rectal drug delivery. J Control Release.
1998;56(1–3):75–83.
192. Mahajan HS, Tyagi VK, Patil RR, Dusunge SB. Thiolated xyloglucan: synthesis,
characterization and evaluation as mucoadhesive in situ gelling agent. Carbohydr Polym.
2013;2:618–25.
193. Freitas RA, Busato AP, Mitchell DA, Silveira JLM. Degalatosylation of xyloglucan: effect on
aggregation and conformation, as determined by time dependent static light scattering.
HPSEC–MALLS and viscosimetry. Carbohydr Polym. 2011;83(4):1636–42.
194. Lubambo AF, Lucyszyn N, Petzhold CL, Camargo PC, Sierakowski MR, Schreiner WH, Saul
CK. Mucoadhesive xyloglucan-containing formulations useful in medical devices and in
pharmaceutical formulations. U.S. Patent Application 20120088726, 2012.
195. Lubamboa AF, Lucyszynb N, Petzhold CL, Camargo PC, Sierakowski MR, Schreinera WH,
Saula CK. Self-assembled polystyrene/xyloglucan nanospheres from spin coating evaporating
mixtures. Carbohydr Polym. 2011;84(1):126–32.
196. Cao Y, Gu Y, Ma H, Bai J, Liu L, Zhao P, He H. Self-assembled nanoparticle drug delivery
systems from galactosylated polysaccharide-doxorubicin conjugate loaded doxorubicin. Int
J Biol Macromol. 2010;46(2):245–9.
197. Noleto GR, Mercê AL, Iacomini M, Gorin PA, Soccol VT, Oliveira MB. Effects of a lichen
galactomannan and its vanadyl (IV) complex on peritoneal macrophages and leishmanicidal
activity. Mol Cell Biochem. 2002;233(1-2):73–83.
198. Il’ina AV, Mestechkina NM, Kurek DV, Levov AN, Semenyuk PI, Orlov VN, Shcherbukhin
VD, Varlamov VP. Preparing, studying, and prospects of using nanoparticles based on
chitosan and galactomannan. Nanotechnol Russia. 2011;6(1–2):154–60.
199. Lesnichaya MV, Aleksandrova GP, Feoktistova LP, Sapozhnikov AN, Sukhov BG, Trofimov
BA. Formation kinetics of gold nanoparticles in the galactomannan polysaccharide matrix.
Doklady Chem. 2011;440(2):282–5.
References 173
200. Cerqueira MA, Bourbon AI, Pinheiro AC, Martins JT, Souza BWS, Teixeira JA, Vicente
AA. Galactomannans use in the development of edible films/coatings for food applications.
Trends Food Sci Technol. 2011;22:662–71.
201. Soumya RS, Ghosh S, Abraham ET. Preparation and characterization of guar gum nanopar-
ticles. Int J Biol Macromol. 2010;46(2):267–9.
202. Sierakowski MR, Milas M, Desbrieres J, Rinaudo M. Specific modifications of
galactomannans. Carbohydr Polym. 2000;42:51–7.
203. Srivastava M, Kapoor VP. Seed galactomannans: an overview. Chem Biodivers.
2005;2(3):295–317.
204. Silveira JLM, Bresolin TMB. Pharmaceutical use of galactomannans. Quim Nova.
2011;34(2):292–9.
205. Matji JA et al. Products for receptor mediated activation and maturation of monocyte-derived
dendritic cells by a phosphorylated glucomannane polysaccharide. U.S. Patent Application
20080171002, 2008.
206. Cheng LH, Abd Karim A, Norziah MH, Seow CC. Modification of the microstructural and
physical properties of konjac glucomannan-based films by alkali and sodium
carboxymethylcellulose. Food Res Int. 2002;35(9):829–36.
207. Alonso-Sande M, Teijeiro-Osorio D, Remuñán-López C, Alonso MJ. Glucomannan, a
promising polysaccharide for biopharmaceutical purposes. Eur J Pharm Biopharm.
2009;72:453–62.
208. Xu J, Hou Z, Li T. Novel sample preparation method of polymer emulsion for SEM observa-
tion. Microsc Res Tech. 2007;70(10):847–50.
209. Lee CM, Lim S, Kim GY, Kim DW, Joon HR, Lee KY. Rosin nanoparticles as a drug delivery
carrier for the controlled release of hydrocortisone. Biotechnol Lett. 2005;27:1487–90.
210. Baek W, Nirmala R, Barakat NAM, El-Newehy MH, Al-Deyab SS, Kim HY. Electrospun
cross linked rosin fibers. Appl Surf Sci. 2011;258(4):1385–9.
211. Do HS, Park JH, Kim HJ. UV-curing behavior and adhesion performance of polymeric
photoinitiators blended with hydrogenated rosin epoxy methacrylate for UV-crosslinkable
acrylic pressure sensitive adhesives. Eur Polym J. 2008;44(11):3871–82.
212. Gupta SK. Transparent cold-wax and hot-wax depilatory compositions with three-dimen-
sional suspended particles. U.S. Patent 7,438,897, 21 Oct 2008.
213. Demicheli C, Ochoa R, da Silva JB, Falcão CA, Rossi-Bergmann B, de Melo AL, Sinisterra
RD, Frézard F. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for
treatment of leishmaniasis. Antimicrob Agents Chemother. 2004;48(1):100–3.
214. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments
in the last 10 years. Clin Infect Dis. 1997;24(4):684–703.
215. Martins PS, Ochoa R, Pimenta AM, Ferreira LA, Melo AL, da Silva JB, Sinisterra RD,
Demicheli C, Frézard F. Mode of action of beta-cyclodextrin as an absorption enhancer of the
water-soluble drug meglumine antimoniate. Int J Pharm. 2006;325(1-2):39–47.
216. Salem II, Düzgünes N. Efficacies of cyclodextrin-complexed and liposome-encapsulated
clarithromycin against Mycobacterium avium complex infection in human macrophages. Int
J Pharm. 2003;250(2):403–14.
217. Chattopadhyay A, Jafurulla M. A novel mechanism for an old drug: amphotericin B in the
treatment of visceral leishmaniasis. Biochem Biophys Res Commun. 2011;416:7–12.
218. Ribeiro RR, Ferreira AW, Martins SP, Neto LR, Rocha GO, Moyec L, Demicheli L, Frezard
CF. Prolonged absorption of antimony(V) by the oral route from non-inclusion meglumine
antimoniate-beta-cyclodextrin conjugates. Biopharm Drug Dispos. 2010;31:109–19.
219. Date AA, Joshi MD, Patravale VB. Parasitic diseases: liposomes and polymeric nanoparticles
versus lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):505–21.
220. Bricout H, Hapiot F, Tilloy APS, Monflier E. Chemically modified cyclodextrins: an attrac-
tive class of supramolecular hosts for the development of aqueous biphasic catalytic pro-
cesses. Sustainability. 2009;1:924–45.
221. Badi P, Guégan P, Legrand FX, Leclercq L, Tilloy S, Monflier E. B-Cyclodextrins modified
by alkyl and poly(ethylene oxide) chains: a novel class of mass transfer additives for aqueous
organometallic catalysis. J Mol Catal A Chem 2010;318:8–14.
222. Cavalli R, Donalisio M, Civra A, Ferruti P, Ranucci E, Trotta F, Lembo D. Enhanced antiviral
activity of Acyclovir loaded into β-cyclodextrin-poly(4-acryloylmorpholine) conjugate
nanoparticles. J Control Release. 2009;137(2):116–22.
223. Gerebern Petrus Roger Vandecruys. Pharmaceutical compositions comprising a basic drug, a
cyclodextrin, a polymer and an acid. EP0998304 B1, 2003.
224. Abou-Okeil A, Amr A, Abdel-Mohdy FA. Investigation of silver nanoparticles synthesis
using aminated β-cyclodextrin. Carbohydr Polym. 2012;89(1):1–6.
225. Agüeros M, Areses P, Campanero MA, Salman H, Quincoces G, Peñuelas I, Irache
JM. Bioadhesive properties and biodistribution of cyclodextrin–poly(anhydride)
nanoparticles. Eur J Pharm Sci. 2009;37(3–4):231–40.
226. Shown I, Masaki U, Imae T. Sensitizing of pyrene fluorescence by β-cyclodextrin-modified
TiO2 nanoparticles. J Colloid Interface Sci. 2010;352(2):232–7.
227. Memisoglu-Bilensoy E, Vural I, Bochot A, Renoir JM, Duchene D, Hincal AA. Tamoxifen
citrate loaded amphiphilic β-cyclodextrin nanoparticles: in vitro characterization and
cytotoxicity. J Control Release. 2005;104(3):489–96.
228. Çirpanli Y, Bilensoy E, Lale DA, Çaliş S. Comparative evaluation of polymeric and
amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur J Pharm
Biopharm. 2009;73(1):82–9.
229. Kwon TK, Kim JC. In vitro skin permeation of monoolein nanoparticles containing
hydroxypropyl β-cyclodextrin/minoxidil complex. Int J Pharm. 2010;392(1–2):268–73.
230. Badruddoza AZM, Hidajat K, Uddin MS. Synthesis and characterization of β-cyclodextrin-
conjugated magnetic nanoparticles and their uses as solid-phase artificial chaperones in
refolding of carbonic anhydrase bovine. J Colloid Interface Sci. 2010;346(2):337–46.
231. Kim JW, Nichols WT. Hierarchically assembled titania-cyclodextrin nano-networks. Mater
Lett. 2012;67(1):11–3.
232. Nielsen AL, Steffensen K, Larsen KL. Self-assembling microparticles with controllable
disruption properties based on cyclodextrin interactions. Colloids Surf B Biointerfaces.
2009;73(2):267–75.
233. Kanwar JR, Long BM, Kanwar RK. The use of cyclodextrins nanoparticles for oral delivery.
Cyclodextrin-covered gold nanoparticles for targeted delivery of an anti-cancer drug. J Mater
Chem. 2009;19(16):2310–5.
234. Park C, Youn H, Kim H, Noh T, Kook YH, Oh ET, Park HJ, Kim C. J Mater Chem.
2009;19:2310–5.
235. Fanta GF, Kenar JA, Felker FC, Byars JA. Preparation of starch-stabilized silver nanoparti-
cles from amylose-sodium palmitate inclusion complexes. Carbohydr Polym.
2012;92:260–8.
236. Santander-Ortega MJ, Stauner T, Loretz B, Ortega-Vinuesa JL, Bastos-González D, Wenz G,
Schaefer UF, Lehr CM. Nanoparticles made from novel starch derivatives for transdermal
drug delivery. J Control Release. 2010;141(1):85–92.
237. Ernest V, Shiny PJ, Mukherjee A, Mukherjee A, Chandrasekaran N. Silver nanoparticles: a
potential nanocatalyst for the rapid degradation of starch hydrolysis by α-amylase. Carbohydr
Res. 2012;352:64.
238. Cole AJ, David AE, Wang J, Galbán CJ, Hill HL, Yang VC. Polyethylene glycol modified,
cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting.
Biomaterials. 2011;32(8):2183–93.
239. Valodkar M, Rathore PS, Jadeja RN, Thounaojam M, Devkar RV, Thakore S. Cytotoxicity
evaluation and antimicrobial studies of starch capped water soluble copper nanoparticles.
J Hazard Mater. 2012;201–202:244–9.
240. Jain R, Dandekar P, Loretz B, Melero A, Stauner T, Wenz G, Koch M, Lehr CM. Enhanced
cellular delivery of idarubicin by surface modification of propyl starch nanoparticles
employing pteroic acid conjugated polyvinyl alcohol. Int J Pharm. 2011;420(1):147–55.
References 175
241. Nishi KK, Antony M, Mohanan PV, Anilkumar TV, Loiseau PM, et al. Amphotericin B-Gum
arabic conjugates: synthesis, toxicity, bioavailability, and activities against Leishmania and
fungi. Pharm Res. 2007;24:971–80.
242. Nishi KK, Jayakrishnan A. Preparation and in vitro evaluation of primaquine-conjugated
gum Arabic microspheres. Biomacromolecules. 2004;5(4):1489–95.
243. Ferreira EI, Cruz ML, Korolkovas A. Latentiation of chemotherapeutic agents. Part 1: syn-
thesis of oxidized starch imine derivatives and antimalarials. Starch/starke. 1992;44:21–4.
244. Saboktakin MR, Maharramov A, Ramazanov MA. Synthesis and characterization of
superparamagnetic nanoparticles coated with carboxymethyl starch (CMS) for magnetic
resonance imaging technique. Carbohydr Polym. 2009;78(2):292–5.
245. Kim EA, Kim JY, Chung HJ, Lim ST. Preparation of aqueous dispersions of coenzyme Q10
nanoparticles with amylomaize starch and its dextrin. Food Sci Technol. 2012;47(2):493–9.
246. Comba S, Sethi R. Stabilization of highly concentrated suspensions of iron nanoparticles
using shear-thinning gels of xanthan gum. Water Res. 2009;43(15):3717–26.
247. Liu H, Nakagawa K, Chaudhary D, Asakuma Y, Moses O. Tadé Freeze-dried macroporous
foam prepared from chitosan/xanthan gum/montmorillonite nanocomposites. Chem Eng Res
Des. 2011;89(11):2356–64.
248. Mundargi RC, Patil SA, Agnihotri SA, Aminabhavi TM. Development of polysaccharide-
based colon targeted drug delivery systems for the treatment of amoebiasis. Drug Dev Ind
Pharm. 2007;33(3):255–64.
249. Vuddanda PR, Chakraborty S, Singh S. Berberine: a potential phytochemical with multispec-
trum therapeutic activities. Expert Opin Investig Drugs. 2010;19:10.
250. Sarmah JK, Bhattacharjee SK, Mahanta R, Mahanta R. Preparation of cross-linked guar gum
nanospheres containing tamoxifen citrate by single step emulsion in situ polymer cross-
linking method. J Incl Phenom Macrocycl Chem. 2009;65(3–4):329–34.
251. Mahantab JKSR, Mahantac SKBR, Deyd A, Guhad P, Biswa A. In-vitro cytotoxicity analysis
of tamoxifen citrate loaded cross-linked guar gum nanoparticles on jurkat (human t-cell
leukemia) cell line. J Drug Deliv Ther. 2012;2(2).
252. Giri A, Bhunia T, Mishra SR, Goswami L, Panda AB, Pal S, Bandyopadhyay A. Acrylic acid
grafted guargum–nanosilica membranes for transdermal diclofenac delivery. Carbohydr
Polym. 2013;91(2):492–501.
253. Sarmah JK, Mahanta R, Bhattacharjee SK, Mahanta R, Biswas A. Controlled release of
tamoxifen citrate encapsulated in cross-linked guar gum nanoparticles. Int J Biol Macromol.
2011;49(3):390–6.
254. Mao CF, Zeng YC, Chen CH. Enzyme-modified guar gum/xanthan gelation: an analysis
based on cascade model. Food Hydrocoll. 2012;27(1):50–9.
255. Su L, Ji WK, Lan WZ. Chemical modification of xanthan gum to increase dissolution rate.
Carbohydr Polym. 2003;53(4):497–9.
256. Alvarez-Manceñido F, Landin M, Lacik I, Martínez-Pacheco R. Konjac glucomannan and
konjac glucomannan/xanthan gum mixtures as excipients for controlled drug delivery
systems. Int J Pharm. 2008;349(1–2):11–8.
257. Dodi G, Hritcu D, Popa MI. Carboxymethylation of guar gum: synthesis and characterization.
Cellulose Chem Technol. 2011;45(3-4):171–6.
258. Zhang J, Chen G. Silanization of guar gum to improve the temperature resistance. Heterocycl
Lett. 2011;1(4):329–33.
259. Krishnan PN, Saraswathi R, Dilip C, Rama Rao N, Sambasiva Rao KRS, Raghvendra.
Formulation and evaluation of acyclovir microcapsules using biodegradable and non-
biodegradable polymers. Der Pharm Lett. 2010;2(5):83–94.
260. Tiraferri A, Chen KL, Sethi R, Elimelech M. Reduced aggregation and sedimentation of
zero-valent iron nanoparticles in the presence of guar gum. J Colloid Interface Sci.
2008;324(1–2):71–9.
261. Abdel-Halim ES, El-Rafie MH, Al-Deyab SS. Polyacrylamide/guar gum graft copolymer for
preparation of silver nanoparticles. Carbohydr Polym. 2011;85(3):692–7.
262. Badykova LA, Mudarisova RK, Khamidullina GS, Aminev KK, Monakov
YB. Arabinogalactan with isonicotinic acid hydrazide. Chem Nat Compounds.
2008;44(3):279.
263. Mudarisova RK, Badykova LA, Tolstikova TG, Aleksandrova GP, Borisov IM, Monakova
YB. Modification of arabinogalactan and its oxidized fractions with 5-aminosalicylic acid.
Russian J Appl Chem. 2005;78(10):1691–4.
264. Gasilova E, Galina A. Core-shell colloidal structure of nanobiocomposites of gold nanopar-
ticles capped with natural polysaccharide arabinogalactan. J Nanomed Nanotechnol. 2012;3.
265. Smith JP. Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator
against drug-resistant tuberculosis. Yale J Biol Med. 2011;84(4):361–9.
266. Golenser J, Frankenburg S, Ehrenfreund T, Domb AJ. Efficacious treatment of experimental
leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob
Agents Chemother. 1999;43(9):2209–14.
267. Mucalo MR, Bullen CR, Manley-Harris M, McIntire TM. Arabinogalactan from the Western
larch tree: a new, purified and highly water-soluble polysaccharide-based protecting agent for
maintaining precious metal nanoparticles in colloidal suspension. J Mater Sci.
2002;37(3):493–504.
268. Nikolaeva MN, Aleksandrova GP, Martynenkov AA. Effect of electrization on molecular
mobility in gold nanocomposites based on arabinogalactan. Russian J Phys Chem A.
2012;86(5):812–5.
269. Gasilova E, Aleksandrova G, Sukhov B, Trofimov B. Colloids of gold nanoparticles pro-
tected from aggregation with arabinogalactan. Macromol Symp. 2012;317–318(1):1–6.
270. Light Gasilova ER, Toropova AA, Bushin SV, Khripunov AK, Grischenko LA, Aleksandrova
GP. Scattering from aqueous solutions of colloid metal nanoparticles stabilized by natural
polysaccharide arabinogalactan. J Phys Chem B. 2010;114(12):4204–12.
271. Kora AJ, Beedu SR, Jayaraman A. Size-controlled green synthesis of silver nanoparticles
mediated by gum ghatti (Anogeissus latifolia) and its biological activity. Org Med Chem Lett.
2012;2(1):17.
272. Silvestri S, Gabrielson G. Degradation of tragacanth by high shear and turbulent forces dur-
ing microfluidization. Int J Pharm. 1991;73(2):163–9.
273. Starz KA, Goia D, Koehler J, Bänisch V. Noble metal nanoparticles, a process for preparing
these and their use. Patent Number 8071259, 2011.
274. Hatami M, Nejatian M, Mohammadifar MA. Effect of co-solute and gelation temperature on
milk protein and gum tragacanth interaction in acidified gels. Int J Biol Macromol.
2012;50(4):1109–15.
275. Hatami M, Nejatian M, Mohammadifar MA, Alijani S, Balaghi S, Mohammadifar MA. Effect
of gamma irradiation on rheological properties of polysaccharides exuded by A. fluccosus and
A. gossypinus. Int J Biol Macromol. 2011;49(4):471–9.
276. Borisy A, Keith C, Foley MA, Stockwell BR. Combinations of chlorpromazine and pentami-
dine for the treatment of neoplastic disorders. U.S. Patent Number 6,569,853, 2003.
277. Skeiky Y, Brannon M, Guderian J. Heterologous fusion protein constructs comprising a
Leishmania antigen. U.S. Patent Application 20030175294, 2003.
278. Chenlo F, Moreira R, Pereira G, Silva C. Rheological modelling of binary and ternary sys-
tems of tragacanth, guar gum and methylcellulose in dilute range of concentration at different
temperatures. Food Sci Technol. 2009;42(2):519–24.
279. Beverley SM, Zhang K. Compositions and methods for inhibiting protozoan growth.
U.S. Patent Application 20080119483, 2008.
280. Chenlo F, Moreira R, Silva C. Rheological behaviour of aqueous systems of tragacanth and
guar gums with storage time. J Food Eng. 2010;96(1):107–13.
281. Batalha IL, Hussain A, Roque AC. Gum Arabic coated magnetic nanoparticles with affinity
ligands specific for antibodies. J Mol Recognit. 2010;23(5):462–71.
282. Wilson Jr OC, Blair E, Kennedy S, Rivera G, Mehl P. Surface modification of magnetic
nanoparticles with oleylamine and gum Arabic. Mater Sci Eng C. 2008;28(3):438–42.
References 177
283. Livney YD. Beta-lactoglobulin-polysaccharide nanoparticles for hydrophobic bioactive

compounds. Patent Application Number 20110038942, 2011.
284. Avadi MR, Sadeghi AMM, Mohammadpour N, Abedin S, Atyabi F, Dinarvand R, Rafiee-
Tehrani M. Preparation and characterization of insulin nanoparticles using chitosan and
Arabic gum with ionic gelation method. Nanomedicine. 2010;6(1):58–63.
285. Gils PS, Ray D, Sahoo PK. Designing of silver nanoparticles in gum arabic based semi-IPN
hydrogel. Int J Biol Macromol. 2010;46(2):237–44.
286. Fent GM, Casteel SW, Kim DY, Kannan R, Katti K, Chanda N, Katti K. Biodistribution of
maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile
swine. Nanomedicine. 2009;5(2):128–35.
287. Roque ACA, Wilson Jr OC. Adsorption of gum Arabic on bioceramic nanoparticles. Mater
Sci Eng C. 2008;28(3):443–7.
288. Williams DN, Gold KA, Holoman TRP, Ehrman SH, Wilson Jr OC. Surface modification of
magnetic nanoparticles using gum Arabic. J Nanopart Res. 2006;8(5):749–53.
289. Wu CC, Chen DH. Facile green synthesis of gold nanoparticles with gum arabic as a stabiliz-
ing agent and reducing agent. Gold Bull. 2010;43(4):234–40.
290. Mahmoud AE. Viscosity modification of gum Arabic as a means of enhancing marketability.
M.Sc. Thesis, Faculty of Forest Products, Virginia Polytechnic Institute and State University,
Blacksburg; 1983.
291. Dhar S, Reddy EM, Shiras A, Pokharkar V, Prasad BL. Natural gum reduced/stabilized gold
nanoparticles for drug delivery formulations. Chemistry. 2008;14(33):10244–50.
292. Hinrichs WLJ, Manceñido FA, Sanders NN, Braeckmans K, Smedt SCD, Demeester J,
Frijlink HW. The choice of a suitable oligosaccharide to prevent aggregation of PEGylated
nanoparticles during freeze thawing and freeze drying. Int J Pharm. 2006;311(1–2):237–44.
293. Bibby DC, Talmadge JE, Dalal MK, Kurz SG, Chytil KM, Barry SE, Shand DG, Steiert
M. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles
in tumor-bearing mice. Int J Pharm. 2005;293(1–2):281–90.
294. Chockalingam AM, Babu HKRR, Chittor R, Tiwari JP. Gum arabic modified Fe3O4 nanopar-
ticles cross linked with collagen for isolation of bacteria. J Nanobiotechnol. 2010;8:30.
295. Castelli F, Sarpietro MG, Micieli D, Ottim S, Pitarresi G, Tripodo G, Carlisi B, Giammona
G. Differential scanning calorimetry study on drug release from an inulin-based hydrogel and
its interaction with a biomembrane model: pH and loading effect. Eur J Pharm Sci.
2008;35:76–85.
296. Öner M, Uysal U. Synthesis of hydroxyapatite crystals using carboxymethyl inulin for use as
a delivery of ibuprofen. Mater Sci Eng C Mater Biol Appl. 2013;33:482–9.
297. Morros J, Levecke B, Infante MR. Chemical hydrophobic modification of inulin in aqueous
media: synthesis of β-hydroxyalkyl ethers of inulin. Carbohydr Polym. 2010;81(3):681–6.
298. Izawa K, Hasegawa T. Tosylated and azidated inulins as key substrates for further chemical
modifications to access inulin-based advanced materials: an inulin-based glycocluster. Bioorg
Med Chem Lett. 2012;22(2):1189–93.
299. Ren J, Wang P, Dong F, Feng Y, Peng D, Guo Z. Synthesis and antifungal properties of
6-amino-6-deoxyinulin, a kind of precursors for facile chemical modifications of inulin.
300. Morros J, Levecke B, Infante MR. Hydrophobically modified inulin from alkenyl succinic
anhydride in aqueous media. Carbohydr Polym. 2011;84(3):1110–6.
301. Ren J, Liu J, Dong F, Guo Z. Highly efficient synthesis and antioxidant activity of
O-(aminoethyl)inulin. Carbohydr Polym. 2011;83(3):1240–4.
302. Pitarresi G, Giacomazza D, Triolo D, Giammona G, San Biagio PL. Rheological character-
ization and release properties of inulin-based hydrogels. Carbohydr Polym. 2012;88(3):
1033–40.
303. Ren J, Liu J, Dong F, Guo Z. Synthesis and hydroxyl radicals scavenging activity of
N-(aminoethyl)inulin. Carbohydr Polym. 2011;85(1):268–71.
304. Ronkart SN, Paquot M, Deroanne C, Fougnies C, Besbes S, Blecker CS. Development of
gelling properties of inulin by microfluidization. Food Hydrocoll. 2010;24(4):318–24.
305. Verraest DL, Peters JA, Kuzee HC, Raaijmakers HWC, Bekkum H. Modification of inulin
with amidoxime groups and coordination with copper(II) ions. Carbohydr Polym.
1998;37(3):209–14.
306. Kim Y, Faqih MN, Wang SS. Factors affecting gel formation of inulin. Carbohydr Polym.
2001;46(2):135–45.
307. Fares MM, Salem MS, Khanfar M. Inulin and poly(acrylic acid) grafted inulin for dissolution
enhancement and preliminary controlled release of poorly water-soluble Irbesartan drug. Int
J Pharm. 2011;410(1–2):206–11.
308. Stevens CV, Meriggi A, Booten K. Chemical modification of inulin, a valuable renewable
resource, and its industrial applications. Biomacromolecules. 2001;2(1):1–16.
309. Gupta H, Sharma A. Ion activated bioadhesive in situ gel of clindamycin for vaginal applica-
tion. Int J Drug Deliv. 2009;1:32–40.
310. Braz L, Grenha A, Ferreira D, Rosa da Costa A, Sarmento B. Locust bean gum derivatives for
nanometric drug delivery. Rev Port Farm. 2011;52:127–8.
311. Dionísio M, Grenha A. Locust bean gum: exploring its potential for biopharmaceutical
applications. J Pharm Bioallied Sci. 2012;4:175–85.
312. Braz L, Grenha A, Sarmento B, Costa AR. XVIII Novel locust bean gum nanoparticles for
protein delivery. In: International Conference on Bioencapsulation, Porto, Portugal, 2, 2010.
313. Ngwuluka N, Pillay V, Choonara YE, Claire Du TL. Polymeric matrix of polymer-lipid
nanoparticles as a pharmaceutical dosage form. WIPO Patent WO/2012/070031, 2012.
314. Braz L, Grenha A, Ferreira D, Rosa da Costa AM, Luis Braz BS et al. Locust bean gum based
nanoparticles for oral antigen delivery. Pharm Anal Acta 3:1. 2nd International Conference on
Pharmaceutics & Novel Drug Delivery Systems 3, 1 – 115 Pharm Anal Acta, 2012 San
Francisco Airport Marriott Waterfront, USA.
315. Livney YD. Beta-lactoglobulin-polysaccharide nanoparticles for hydrophobic bioactive
compounds. Patent Application Number, 20110038942, 2011.
316. Mahmoud AE. Viscosity modification of gum Arabic as a means of enhancing gum quality.
In Proceedings of the Meetings of the National Crop Husbandry Committee 40th, 2005,
226–236.
317. Kang J, Cui SW, Guo Q, Chen J, Wang Q, Phillips GO, Nikiforuk J. Structural investigation
of a glycoprotein from gum ghatti. Carbohydr Polym. 2012;89(3):749–58.
318. Deshmukh AS, Setty CM, Badiger AM, Muralikrishna KS. Gum ghatti: a promising polysac-
charide for pharmaceutical applications. Carbohydr Polym. 2012;87(2):980–6.
319. Kang J, Cui SW, Chen J, Phillips GO, Wu Y, Wang Q. New studies on gum ghatti (Anogeissus
latifolia). Part I: Fractionation, chemical and physical characterization of the gum. Food
Hydrocoll. 2011;25(8):1984–90.
320. Omura S, Oiwa R. Trichostatin as an antiprotozoal agent. U.S. Patent 4,218,478, 1980.
321. Kang J, Cui SW, Phillips GO, Chen J, Guo Q, Wang Q. New studies on gum ghatti (Anogeissus
latifolia). Part II: Structure characterization of an arabinogalactan from the gum by 1D, 2D
NMR spectroscopy and methylation analysis. Food Hydrocoll. 2011;25(8):1991–8.
322. Rani P, Sen G, Mishra S, Jha U. Microwave assisted synthesis of polyacrylamide grafted gum
ghatt. Carbohydr Polym. 2012;89:275–81.
323. Vaidya A, Jain A, Khare P, Agrawal RK, Jain SK. Metronidazole loaded pectin microspheres
for colon targeting. J Pharm Sci. 2009;98(11):4229–36.
324. Majumdar S, Roy S, Ghosh B. Design and gamma scintigraphic evaluation of colon specific
pectin-EC pellets of secnidazole prepared by powder layering technology. Pharmazie.
2011;66(11):843–8.
325. Ding D, Zhou Y, Zhang YK, Zhang YK, Plattner JJ, Plattner JJ, Zhou H. Boron-containing
small molecules as antiprotozoal agents. Patent Application Number, 20110207701, 2011.
326. Andremont A, Huguet HC. Colonic delivery using zn/pectin beads with a eudragit coating.
EP2081557 A1, 2009.
References 179
327. Newsham EA, Forrester JW, Rowley DJ. Moistureless oral drug delivery formulation and
method for preparing same. Patent Number 4867970, 1989.
328. Kurita O, Miyake Y, Yamazaki E. Chemical modification of citrus pectin to improve its
dissolution into water. Carbohydr Polym. 2012;87(2):1720–7.
329. Buchholt HC, Christensen TMIE, Fallesen B, Ralet MC, Thibault JF. Preparation and proper-
ties of enzymatically and chemically modified sugar beet pectins. Carbohydr Polym.
2004;58(2):149–61.
330. Schmelter T, Wientjes R, Vreeker R, Klaffke W. Enzymatic modifications of pectins and the
impact on their rheological properties. Carbohydr Polym. 2002;47(2):99–108.
331. Matthew JA, Howson SJ, Keenan MHJ, Belton PS. Improvement of the gelation properties of
sugarbeet pectin following treatment with an enzyme preparation derived from Aspergillus
niger. Comparison with a chemical modification. Carbohydr Polym. 1990;12(3):295–306.
332. Kowalonek J, Kaczmarek H, Dąbrowska A. Air plasma or UV-irradiation applied to surface
modification of pectin/poly(vinyl alcohol) blends. Appl Surf Sci. 2010;257(1):325–31.
333. Schmelter T, Vreeker R, Klaffke W. Characterisation of a novel gel system containing pectin,
heat inactivated pectin methylesterase and NaCl. Carbohydr Polym. 2001;45(3):277–84.
334. Ngouémazong DE, Kabuye G, Fraeye I, Cardinaels R, Loey AV, Moldenaers P, Hendrickx
M. Effect of debranching on the rheological properties of Ca2 + –pectin gels. Food Hydrocoll.
2012;26(1):44–53.
335. Ralet MC, Crépeau MJ, Buchholt HC, Thibault JF. Polyelectrolyte behaviour and calcium
binding properties of sugar beet pectins differing in their degrees of methylation and
acetylation. Biochem Eng J. 2003;16(2):191–201.
336. Morris GA, Hromádková Z, Ebringerová A, Malovı́ková A, Alföldi J, Harding
SE. Modification of pectin with UV-absorbing substituents and its effect on the structural and
hydrodynamic properties of the water-soluble derivatives. Carbohydr Polym. 2002;
48(4):351–9.
337. Funami T, Nakauma M, Ishihara S, Tanaka R, Inoue T, Phillips GO. Structural modifications
of sugar beet pectin and the relationship of structure to functionality. Food Hydrocoll.
2011;25:221–9.
338. Sharma R, Ahuja M, Kaur H. Thiolated pectin nanoparticles: preparation, characterization
and ex vivo corneal permeation study. Carbohydr Polym. 2012;87(2):1606–10.
339. Jones OG, Lesmes U, Dubin P, McClements DJ. Effect of polysaccharide charge on forma-
tion and properties of biopolymer nanoparticles created by heat treatment of β-lactoglobulin–
pectincomplexes. Food Hydrocoll. 2010;24(4):374–83.
340. Gong JL, Wang XY, Zeng GM, Chen L, Deng JH, Zhang XR, Niu QY. Copper (II) removal
by pectin–iron oxide magnetic nanocomposite adsorbent. Chem Eng
J. 2012;185–186(15):100–7.
341. Li J, Zhu D, Yin J, Liu Y, Yao F, Yao K. Formation of nano-hydroxyapatite crystal in situ in
chitosan–pectin polyelectrolyte complex network. Mater Sci Eng C. 2010;30(6):795–803.
342. Narayana RC, Harish NM, Gulzar AM, Prabhakara P, Singh AK, Subrahmanyam
EV. Formulation and in vitro evaluation of in situ gels containing secnidazole for vaginitis.
Yakugaku Zasshi. 2009;129(5):569–74.
343. Survase SA, Annapure US, Singhal RS. Gellan gum as immobilization matrix for production
of cyclosporin A. J Microbiol Biotechnol. 2010;20(7):1086–91.
344. Morrisa ER, Nishinarib K, Rinaudoc M. Gelation of gellan – a review. Food Hydrocoll.
2012;28(2):373–411.
345. Britten N. Pharmaceutical dosage form for mucosal delivery. EP1471890 B1. 27 Sept 2006.
346. Coutinho DF, Sant SV, Shin H, Oliveira JT, Gomes ME, Neves NM, Khademhosseini A, Reis
RL. Modified gellan gum hydrogels with tunable physical and mechanical properties.
Biomaterials. 2010;31(29):7494–502.
347. Silva NA, Cooke MJ, Tam RY, Sousa N, Salgado AJ, Reis RL, Shoichet MS. The effects of
peptide modified gellan gum and olfactory ensheathing glia cells on neural stem/progenitor
cell fate. Biomaterials. 2012;33(27):6345–54.
348. Hamcerencu M, Desbrieres J, Khoukh A, Popa M, Riess G. Synthesis and characterization of

new unsaturated esters of Gellan Gum. Carbohydr Polym. 2008;71(1):92–100.
349. Dreveton E, Monot F, Lecourtier J, Ballerini D, Choplin L. Influence of fermentation hydro-
dynamics on gellan gum physico-chemical characteristics. J Fermentation Bioeng.
1996;82(3):272–6.
350. Maiti S, Ranjit S, Mondol R, Ray S, Biswanath SA. Al+3 ion cross-linked and acetalated gel-
lan hydrogel network beads for prolonged release of glipizide. Carbohydr Polym.
2011;85(1):164–72.
351. Lee MW, Tsai HF, Wen SM, Huang CH. Photocrosslinkable gellan gum film as an anti-
adhesion barrier. Carbohydr Polym. 2012;90(2):1132–8.
352. Lee MW, Chen HJ, Tsao SW. Preparation, characterization and biological properties of
Gellan gum films with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide cross-linker.
353. Kulkarni RV, Mangond BS, Mutalik S, Sa B. Interpenetrating polymer network microcap-
sules of gellan gum and egg albumin entrapped with diltiazem–resin complex for controlled
release application. Carbohydr Polym. 2011;83(2):1001–7.
354. Bar-Shalom D, Slot L, Fischer G, Hemmingsen PH. Swellable dosage form comprising
gellan gum. Patent Application Number 20120039969, 16 Feb 2012.
355. Vijan V, Kaity S, Biswas S, Isaac J, Ghosh A. Microwave assisted synthesis and characteriza-
tion of acrylamide grafted gellan, application in drug delivery. Carbohydr Polym.
2012;90(1):496–506.
356. Doner LW, Douds DD. Purification of commercial gellan to monovalent cation salts results
in acute modification of solution and gel-forming properties. Carbohydr Res. 1995;273(2):
225–33.
357. Rana V, Rai P, Tiwary AK, Singh RS, Kennedy JF, Knill CJ. Modified gums: approaches and
applications in drug delivery. Carbohydr Polym. 2011;83(3):1031–47.
358. Redouan E, Emmanuel P, Christine B, Bernard C, Josiane C, Cédric D. Development of new
ulvan-like polymer by regioselective oxidation of gellan exopolysaccharide using TEMPO
reagent. Carbohydr Polym. 2010;80:485–90.
359. Nishiyama Y, Langan P, Chanzy H. Crystal structure and hydrogen-bonding system in cel-
lulose Iβ from synchrotron X-ray and neutron fiber diffraction. J Am Chem Soc.
2002;124(31):9074–82.
360. Scheller HV, Jensen JK, Sørensen SO, Harholt J, Geshi N. Biosynthesis of pectin. Physiol
Plant. 2007;129:283–95.
361. Aquilera JM, Stanley DW. Microstructural principles of food processing and engineering.
Aspen: Springer; 1999. p. 99–103.
362. Cosgrove DJ. Growth of the plant cell wall. Nat Rev Mol Cell Biol. 2005;6:850–61.
363. Dumitriu S. Cellulose and its derivatives: structures, reactions and medical uses. In: Hon
DNS, editor. Polysaccharides in medicinal applications. New York, NY: Marcel Dekker, Inc;
1996. p. 87–106.
364. Hon DNS. Cellulose and its derivatives: structures, reactions and medical uses. New York,
NY: Marcel Dekker; 1996.
365. Scheller HV, Ulvskov P. Hemicelluloses. Annu Rev Plant Biol. 2010;61:263–89.
366. Lerouxel O, Cavalier DM, Liepman AH, Keegstra K. Biosynthesis of plant cell wall polysac-
charides – a complex process. Curr Opin Plant Biol. 2006;9:621–30.
367. Katsuraya K, Okuyamab K, Hatanakab K, Oshimab R, Satoc T, et al. Constitution of konjac
glucomannan: chemical analysis and 13C NMR spectroscopy. Carbohydr Polym.
2003;52:183–9.
368. Fan J, Wang K, Liu M, He Z. In vitro evaluations of konjac glucomannan and xanthan gum
mixture as the sustained release material of matrix tablet. Carbohydr Polym.
2008;73:241–7.
369. Larionova NV, Ponchel G, Duchene D, Larionova NI. Biodegradable cross-linked starch/
protein microcapsules containing proteinase inhibitor for oral protein administration. Int
J Pharm. 1999;189:171–8.
References 181
370. Tuovinen L, Peltonen S, Jarvinen K. Drug release from starch-acetate films. J Control
Release. 2003;91:345–54.
371. Krogars K, Antikainen O, Heinamaki J, Laitinen N, Yliruusi J. Tablet film coating with amy-
lose-rich maize starch. Eur J Pharm Sci. 2002;17:23–30.
372. Milojevic S, Newton JM, Cummings JH, Gibson GR, Botham RL, et al. Amylose, the new
perspective in oral drug delivery to the human large intestine. STP Pharma Sci.
1995;5:47–53.
373. Milojevic S, Newton JM, Cummings JH, Gibson GR, Botham RL, et al. Amylose as a coating
for drug delivery to the colon: preparation and an in vitro evaluation using 5-aminosalicylic
acid pellets. J Control Release. 1996;38:75–84.
374. Milojevic S, Newton JM, Cummings JH, Gibson GR, Botham RL, et al. Amylose as a coating
for drug delivery to the colon: preparation and in vitro evaluation using glucose pellets.
J Control Release. 1996;38:85–94.
375. Palviainen P, Heinamaki J, Myllarinen P, Lahtinen R, Yliruusi J, et al. Corn starches as film
formers in aqueous-based film coating. Pharm Dev Technol. 2001;6:351–61.
376. Siew LF, Basit AW, Newton JM. The potential of organic based myloseethylcellulose film
coatings as oral colon specific drug delivery systems. AAPS PharmSciTech. 2000;1, E22.
377. Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm.
2001;224:19–38.
378. Fry SC. Primary cell wall metabolism, tracking the careers of wall polymers in living plant
cells. New Phytol. 2004;161:641–75.
379. Cárdenas A, Goycoolea FM, Rinaudo M. On the gelling behaviour of ‘nopal’ (Opuntia ficus
indica) low metholoxyl pectin. Carbohydr Polym. 2008;73:212–22.
380. Sungthongjeen S, Pitaksuteepong T, Somsiri A, Sriamornsak P. Studies on pectins as poten-
tial hydrogel matrices for controlled release drug delivery. Drug Dev Ind Pharm.
1999;25:1271–6.
381. Tho I, Sande SA, Kleinebudde P. Pectinic acid: a novel excipient for production of pellets by
extrusion/spheronisation: preliminary studies. Eur J Pharm Biopharm. 2002;54:95–9.
382. Giunchedi P, Conte U, Chetoni P, Saettone MF. Pectin microspheres as ophthalmic carriers
for piroxicam: evaluation in vitro and in vivo in albino rabbits. Eur J Pharm Sci.
1999;9:1–7.
383. Musabayane CT, Munjeri O, Matavire TP. Transdermal delivery of chloroquine by amidated
pectin hydrogel matrix patch in the rat. Ren Fail. 2003;25:525–34.
384. Cheng K, Lim LY. Insulin-loaded calcium pectinate nanoparticles: effects of pectin molecular
weight and formulation pH. Drug Dev Ind Pharm. 2004;30:359–67.
385. Liu L, Chen G, Fishman ML, Hicks KB. Pectin gel vehicles for controlled fragrance delivery.
Drug Deliv. 2005;12:149–57.
386. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. 22nd ed. India: Nirali Prakashan;
2003. p. 133–66.
387. Vervoort L, Kinget R. In vitro degradation by colonic bacteria of inulin HP incorporated in
Eudragit RS films. Int J Pharm. 1996;129:185–90.
388. Vervoort L, Van den Mooter G, Augustijns P, Kinget R. Inulin hydrogels, I. Dynamic and
equilibrium swelling properties. Int J Pharm. 1998;72:127–35.
389. Akhgari A, Farahmand F, Garekani H, Sadeghi F, Vandamme TF. Permeability and swelling
studies on free films containing inulin in combination with different polymethacrylates aimed
for colonic drug delivery. Eur J Pharm Sci. 2006;28:307–14.
390. Satturwar PM, Fulzele SV, Dorle AK. Biodegradation and in vivo biocompatibility of rosin:
a natural film-forming polymer. AAPS Pharm Sci Tech. 2003;4:1–6.
391. Nande VS, Barabde UV, Morkhade DM, Patil AT, Joshi SB. Synthesis and characterization of
PEGylated derivatives of rosin for sustained drug delivery. React Funct Polym.
2006;66:1373–83.
392. Fulzele SV, Satturwar PM, Dorle AK. Polymerized rosin: novel film forming polymer for
drug delivery. Int J Pharm. 2002;249:175–84.
393. Izydorczyk M. Understanding the chemistry of food carbohydrates. Boca Raton, FL: Taylor
and Francis; 2006.
394. Ramakrishnan A, Pandit N, Badgujar M, Bhaskar C, Rao M. Encapsulation of endoglucanase
using a biopolymer gum arabic for its controlle lease. Bioresour Technol. 2007;98:368–72.
395. Aspinall GO, Baillie J. Gum tragacanth. Part I: Fractionation of the gum and the structure of
tragacanthic acid. J Chem Soc (Resumed). 1963:1702–14.
396. Anderson DMW, Bridgeman MME. The composition of the proteinaceous polysaccharides
exuded by astragalus microcephalus, A. Gummifer and A. Kurdicusâ—the sources of Turkish
gum tragacanth. Phyto Chem. 1985;24:2301–04.
397. Anderson DMW, Grant DAD. The chemical characterization of some Astragalus gum exu-
dates. Food Hydrocoll. 1988;2:417–23.
398. Philips GO, Williams PA. Handbook of hydrocolloids. New York: CRC; 2000.
399. Sima B, Mohammad AM, Azizollaah Z. Physicochemical and rheological characterization of
gum tragacanth exudates from six species of Iranian Astragalus. Food Biophys.
2010;5:57–71.
400. Parija S, Misra M, Mohanty AK. Studies of natural gum adhesive extracts - an overview.
Polym Rev. 2001;4:175–97.
401. Prabaharan M. Prospective of guar gum and its derivatives as controlled drug delivery sys-
tems. Int J Biol Macromol. 2011;49:117–24.
402. Krishnaiah YS, Karthikeyan RS, Satyanarayana V. A three-layer guar gum matrix tablet for
oral controlled delivery of highly soluble metoprolol tartrate. Int J Pharm. 2002;241:
353–66.
403. Krishnaiah YS, Karthikeyan RS, Gouri Sankar V, Satyanarayana V. Three-layer guar gum
matrix tablet formulations for oral controlled delivery of highly soluble trimetazidine
dihydrochloride. J Control Release. 2002;81:45–56.
404. Prasad YV, Krishnaiah YSR, Satyanarayana S. In vitro evaluation of guar gum as a carrier for
colon-specific drug delivery. J Control Release. 1998;51:281–7.
405. Toti US, Aminabhavi TM. Modified guar gum matrix tablet for controlled release of diltia-
zem hydrochloride. J Control Release. 2004;95:567–77.
406. Heywood VH, Brummitt RK, Culham A, Seberg O. Flowering plant families of the world.
Richmond Hill, ON: Firefly Books; 2007.
407. Wikipedia, Grewia, Wikipedia encyclopedia 2010.
408. Wikipedia, Carl Linnaeus, Wikipedia encyclopedia, 2010.
409. Sprague TA. The section microcos of Grewia in Africa. Bull Miscellaneous Inf (Royal
Botanic Gardens, Kew). 1909;1909:66–8.
410. Onwuliri FC, Mawak JD, Wonang DL, Onwuliri EA. Phytochemical toxicological and histo-
pathological studies of some medicinal plants in Nigeria. Int J Nat Appl Sci. 2006;2:225–9.
411. Okafor IS. Characterization and application of grewia gum in tabletting, Pharmaceutics.
Nsukka: University of Nigeria; 2001.
412. Okafor IS. The rheological properties of grewia gum. Nigeria J Polym Sci Technol.
2001;2:169–75.
413. Okafor IS, Chukwu A. Water vapor permeability of aqueous-based grewia gum film. Nigeria
J Polym Sci Technol. 2003;3:178–85.
414. Okafor IS, Chukwu A. The binding property of grewia gum in sodium salicylate tablets. West
Afr J Biol Sci. 2003;14:9–21.
415. Okafor IS, Chukwu A, Udeala OK. Some physicochemical properties of grewia gum. Nigeria
J Polym Sci Technol. 2001;2:161–8.
416. Okafor IS, Danat IM. The influence of granulating solvents on drug release from tablets
containing grewia gum. J Pharm Bioresour. 2004;1:76–83.
417. Audu-Peter JD, Gokum BG. Effect of methods of incorporating grewia gum as binder on
tablet properties. Nigerian J Pharm Res. 2005;4:68–73.
418. Audu-Peter JD, Isah S. Evaluation of grewia gum as binder in paracetamol tablet. J Pharm
Bioresour. 2007;4:68–73.
References 183
419. Emeje M, Isimi C, Kunle O. Effect of Grewia gum on the mechanical properties of
Paracetamol tablet formulations. Afr J Pharm Pharmacol. 2008;2:1–6.
420. Muazu J, Musa H, Musa KY. Compression, mechanical and release properties of paracetamol
tablets containing acid treated Grewia gum. J Pharm Sci Technol. 2009;1:74.
421. Nep EI, Conway BR. Characterization of grewia gum, a potential pharmaceutical excipient.
J Excip Food Chem. 2010;1:30–40.
422. Ogaji I. Characterization and application of grewia gum as a film coating agent in theophyl-
line hydrochloride tablets. Pharm Pharm Technol. 2011;308.
423. Ndjouenkeu R, Akingbala J, Oguntimein G. Emulsifying properties of three African food
hydrocolloids: okra (Hibiscus esculentus), dika nut (Irvingia gabonensis) and khan
(Belschmiedia sp.). Plant Foods Hum Nutr. 1997;51:245–55.
424. Udayasekhara Rao P. Chemical composition and biological evaluation of Okra (Hibiscus
esculentus) seeds and their kernels. Plant Foods Hum Nutr. 1985;35:89–396.
425. Nasipuri RN, Igwilo CI, Brown AS, Kunle OO. Mucilage from Abelmoschus esculentus
(okra) fruits: a potential pharmaceutical raw material; part I; physicochemical properties.
J Pharm Res Dev. 1996;1:22–8.
426. Ogaji I. Some physicochemical properties of acetaminophen pediatric suspensions formu-
lated with okra gums obtained from different extraction processes as suspending agent. Asian
J Pharm. 2011;5:15–20.
427. Femi-Oyewo MN, Adedokun MO, Olusoga TO. Evaluation of the suspending properties of
Albizia zygia gum on sulphadimidine suspension. Trop J Pharm Res. 2004;3:279–84.
428. Kalu VD, Odeniyi MA, Jaiyeoba KT. Matrix properties of a new plant gum in controlled drug
delivery. Arch Pharm Res. 2007;30:884–9.
429. Ogaji I, Nnoli O. Film coating potential of okra gum using paracetamol tablets as a model
drug. Asian J Pharm. 2010;4:130–4.
430. Tavakoli N, Ghasemi N, Taimouri R, Hamishehkar H. Evaluation of okra gum as a binder in
tablet dosage forms. Iranian J Pharm Res. 2004;2:47.
431. Momoh MA, Akikwu MU, Ogbona JI, Nwachi UE. In vitro study of release of metronidazole
tablets prepared from okra gum, gelatin gum and their admixture. Bio-Research.
2009;6:339–42.
432. Attama AA, Adikwu MU, Amorha CJ. Release of indomethacin from bioadhesive tablets
containing Carbopol 941 modified with Abelmuschus esculentus (Okra) gum. Boll Chim
Farm. 2003;142:298–302.
433. Adenuga YA, Odeku OA, Adegboye TA, Itiola OA. Comparative evaluation of the binding
properties of two species of Khaya gum polymer in a paracetamol tablet formulation. Pharm
Dev Technol. 2008;13:473–80.
434. Singh AK, Panner Selvam R, Sivakumar T. Isolation, characterisation and formulation prop-
erties of a new plant gum obtained from mangifera indica. Int J Pharm Biomed Res.
2010;1:35–41.
435. Eka O. Proximate composition of bush mango tree and some properties of dika fat. Nigerian
J Nutr Sci. 1980;1:33–6.
436. Giami SY, Okonkwo VI, Akusu MO. Chemical composition and functional properties of raw,
heat-treated and partially proteolysed wild mango (Irvingia gabonensis) seed flour. Food
Chem. 1994;49:237–43.
437. Amubode FO, Fetuga BL. Amino acid composition of seeds of some lesser known tree crops.
Food Chem. 1984;13:299–307.
438. Lewkowitsch J. Dika fat. Analyst. 1905;30:394–5.
439. Meara ML, Patel CB. The component acids and glycerides of dika fat. J Sci Food Agric.
1950;1:48–51.
440. Abdurahman EM, Rau PP, Shok M, Olurinola PF, Laakso I. Analysis of the fatty acid com-
position of the seed fat of two varieties of Irvingia gabonensis by high resolution gas chroma-
tography. J Pharm Res Dev. 1996;1:48–9.
441. Odeku OA, Patani B. Evaluation of dika nut mucilage (Irvingia gabonensis) as a binding
agent in metronidazole tablet formulation. Pharm Dev Technol. 2005;10:439–46.
442. Isimi CY, Kunle OO, Bangudu AB. Some emulsifying and suspending properties of the muci-
lage extracted from kernels of Irvingia gabonensis. Boll Chim Farm. 2000;139:199–204.
443. Ofoefule SI, Chukwu A. Effects of polyethyleneglycol 4000 and sodium lauryl sulphate on
the release of hydrochlorothiazide embedded in the dika fat matrix. Acta Pharm.
2001;51:233–9.
444. Ofoefule SI, Chukwu A, Okore VC, Ugwah MO. Use of dika fat in the formulation of sus-
tained release frusemide encapsulated granules. Boll Chim Farm. 1997;136:646–50.
445. Umekoli GC, Onyechi JO, Udeala OK. Use of dika fat in the formulation of sustained release
theophylline tablets and capsules. Bio-Research. 2009;7:456–60.
446. Okore VC. Evaluation of dika fat as a suppository base: factors which affect the drug release
from dika fat-based suppositories. Acta Pharm. 1998;48:39–46.
447. Okore VC. Evaluation of dika fat as a suppository base II: thermal and release characteristics
of blended dika fat suppositories. Drug Dev Ind Pharm. 1994;20:93–100.
448. Megwa SA. Evaluation of dika fat as a suppository base. Drug Dev Ind Pharm. 1987;13:
2731–48.
449. Udeala OK, Aly SAS. The effects of microencapsulation with dika wax on the degradation
and dissolution of aspirin tablets. Drug Dev Ind Pharm. 1986;12:397–421.
450. Dudu PO, Okiwelu SN, Lale NES. Attractancy of diethyl ether extracts of Arachis hypogaea
(Linnaeus) (Papilionaceae), Citrullus lanatus (Thunberg) (Cucurbitaceae) and Irvingia
gabonensis var. excelsa (Baillon) (Irvingiaceae) to Oryzaephilus mercator (Fauvel)
(Coleoptera: Silvanidae). J Stored Prod Res. 1998;34:237–41.
451. Ogaji I, Anjan N, Hoag SW. A novel extraction method and some physicochemical proper-
ties of extractives of irvingia gabonensis seeds. J Young Pharm. 1996;23:45–9.
452. Alur HH, Pather SI, Mitra AK, Johnston TP. Evaluation of the gum from Hakea gibbosa as a
sustained-release and mucoadhesive component in buccal tablets. Pharm Dev Technol.
1999;4:347–58.
453. Tyler VE, Brady LR, Robers JE. Plant gums and mucilage. 8th ed. Philadelphia: Lea and
Febiger; 1981.
454. Kulkarni GT, Gowthamrajan K, Rao BG, Suresh B. Evaluation of binding properties of plan-
tago ovate and Trigonella foenum graecum mucilages. Indian Drugs. 2002;38:422–5.
455. Singh B, Chauhan N. Modification of psyllium polysaccharides for use in oral insulin deliv-
ery. Food Hydrocoll. 2009;23:928–35.
456. Chukwu KI, Udeala OK. Binding effectiveness of Colocassia esculenta gum in poorly com-
pressible drugs-paracetamol and metronidazole tablet formulations. Boll Chim Farm.
2000;139:89–97.
457. Baveja SK, Ranga Rao KV, Arora J. Examination of natural gums and mucilages as sustain-
ing materials in tablet dosage forms. Indian J Pharm Sci. 1988;50:89–92.
458. Somboonpanyakul P, Wang Q, Cui W, Barbut S, Jantawat P. Malva nut gum. (Part I):
Extraction and physicochemical characterization. Carbohydr Polym. 2006;64:247–53.
Chapter 5
Marine Polysaccharides Based Nano-Materials
and Its Applications
Abstract Marine polysaccharides and its associated nano-materials are currently

considered as an excellent source for nano-technological applications. These appli-
cations are broadly categorized in the field of cancer therapy, wound dressing, drug
delivery, gene delivery, tissue engineering, water treatment and biosensor.
Promising biological functions are due to their structure and physicochemical
characteristics, which certainly depend on the source of the organism. Production
of marine polysaccharides based nano-materials is simple, economical, biodegrad-
able, and well suggested to be used in the large-scale production of bio-nanomate-
rials. These polysaccharides are highly biocompatible, biodegradable, nontoxic,
low cost, stable, safe, and abundant. Nevertheless the majority of the commercial
applications are still at the laboratory level. Moreover in vivo investigations and
clinical applications are required to develop industrial nanoproducts. In addition to
these applications marine polysaccharide-based nano-materials have various appli-
cations biomedical sciences, fabric and food industries, and pharmaceutical
industries.
Keywords Marine • Nanomaterial • Nanoparticle • Polysaccharide • Polymer •

Alga
5.1 Introduction
Marine polysaccharides especially derived from algal sources offers various poten-
tial applications in modern medicine and nanobiotechnology field. These polysac-
charides have several applications in drug delivery, gene delivery, wound dressing
and tissue engineering [1]. Algae especially seaweeds present an array of therapeu-
tic compounds with diverse structures and remarkable biological activities. These
bioactive compounds contain rich source of sulfated polysaccharides such as por-
phyran, agarose, alginate, fucoidan, carrageenan, and ulvan. Sulfated polysaccha-
rides are derived from various sources as mentioned in Fig. 5.1. In addition to algal
sources exoskeleton of marine crustaceans offer some bioactive polysaccharides

DOI 10.1007/978-3-319-41129-3_5
186 5 Marine Polysaccharides Based Nano-Materials and Its Applications
Sulphated
polysaccharides
Natural Synthetic
Complete Sulfation of
Plant Animal Microbial
synthesis neutral PS
Algae Mammals Fungi
Marine Bacteria
Marine plants
invertebrates
Fig. 5.1 Various sources of sulphated polysaccharides
such as chitosan (CS), chitin, and oligosaccharides [2]. Various marine organisms
produce exopolysaccharides (EPS) as an approach for growth adhering to solid sur-
faces and to survive in adverse conditions. These marine microorganisms producing
EPS are a complex mixture of biopolymers chiefly comprised of polysaccharides as
well as lipids, proteins, nucleic acids and humic substances [3]. Owing to the vari-
ous advantages such as nanotoxicity, biocompatibility, low cost, biodegradability,
and abundance offered by marine polysaccharide-based nanomaterials they endow
significant applications in biomedical and chemical research [4]. Currently pharma-
ceuticals based on marine bionanoparticles of polymers such as nanomaterials, lipo-
somes, dendrimers, metals or metaloxides or micelles are mainly investigated for
fighting against different diseases, including cancer and bacterial infections and for
drug delivery, gene delivery, wound healing and tissue engineering [5]. Sulfated
polysaccharides and EPS are easily developed in to various nano and micro
(nanoparticles, nanofibers, microparticles) membranes, gels, scaffolds, beads, and
sponge forms. There pharmaceuticals have been used for variety of biomedical
applications in drug delivery, tissue engineering, cancer therapy, wound dressing,
biosensors, and water treatment in the area of nanobiotechnology (Table 5.1) [7].
This chapter highlights marine polysaccharide-based nanomaterials for nanotech-
nological and biomedical applications.
5.2 Polysaccharides Derived from Marine Sources
Among all living organisms marine polysaccharides derived from various

resources such as marine algae, crustaceans, and microorganisms [4] forms one of
the major components and considered as the most abundant source of
Table 5.1 Description of various sulphated polysaccharides highlighting their own biological
activity and applications [6]
Marine organisms
Polysacchari-des (source) Class Biological properties Applications
Heterofucans Canistrocarpus Chromophyta Anticoagulant, Vaccines for
cervicornis Dictyotales antioxidant; anti- immunotherapy
a.k.a. Dictyota cervicornis proliferative, Production of
Dictyopteris delicatula anti-thrombotic, antiviral nanofibers
S-fucans Canistrocarpus Chromophyta Anti-proliferative, Gluing and soft
cervicornis Dictyotales antiviral, anti- tissue closure after
a.k.a. Dictyota cervicornis Ectocarpales inflammatory, surgery
Dictyopteris delicatula Fucales antiadhesive, Lubricants for bone
P. tetrastromatica Antitumor, joints
Cladosiphon okamuranus immunomodulator, Nanotechnology
a.k.a. Okinawa mozuku angiogenic,
Spatoglossum schröederi gastroprotective,
Ascophyllum nodosum Cardioprotective,
Fucus spp. restenosis preventive
F. vesiculosus
Hizikia fusiforme
a.k.a. Sargassum
fusiforme
Sargassum spp.
S-galactofucans D. menstrualis Chromophyta Anti-thrombotic;
Lobophora variegate Dictyotales Peripheral
Spatoglossum schröederi Ectocarpales anti-nociceptive;
Adenocystis utricularis Laminariales Anti-proliferative,
Costaria costata anti-adhesive,
L. japonica antioxidant
a.k.a. Saccharina japonica
Undaria pinnatifida
LMW-S-fucans Nemacystus decipiens Fucales Anticoagulant
P. canaliculata Ectocarpales
S-fucoidan C. novae-caledoniae Fucales Antitumor
Saccharina cichorioides Ectocarpales
a.k.a. Laminaria
cichorioides
Laminaria spp.
S. horneri
S. henslowianum
Fucoidans Eisenia bicyclis Fucales Anticoagulant
Lessonia vadosa
S-galactofucans Undaria pinnatifida Fucales Antiviral, anticoagulant,
Fucoidan antitumor, anti-
proliferative,
immunomodulatory,
anti-inflammatory
induced osteoblastic
differentiation
LMW-fucoidan S. patens Fucales Antiviral
S-laminaran Laminaria sp. (or Fucales Antitumor, anticoagulant,
Saccharina) decreases liver
triglyceride, cholesterol
and
phospholipid levels; serum
hypocholesterolaemic,
hypotensive,
antibacterial,
immunomodulator
(continued)
Marine organisms
Laminarans Eisenia bicyclis Fucales Anti-proliferative, Wound healing
antitumor, anticoagulant; Burn-wound
Antitumor, serum dressings
hypocholesterolaemic, Tissue regeneration
hypotensive,
antibacterial,
immunomodulator
S-galactan Porphyra spp. Antitumor, hypotensive, Cell encapsulation
porphyran regulates Scaffolds for tissue
blood cholesterol engineering
Porphyran P. yezoensis Rhodophyta Antitumor, Wound healing and
P. haitanensis Bangiales immunomodulatory, dressings
hypolipidaemic Revascularization
S-agarans Bostrychia montagnei Rhodophyta Antiviral

Cryptopleura ramose Bangiales
Digenea simplex Ceramiales
Gloiopeltis complanata Cryptonemiales
Aghardiella tenera G.
corticata
LMW-PS Corallina sp. Corallinales Antiviral;
C. ocellatus Gigartinales Antitumor
Furcellaria lumbricalis
Hypnea charoides
Soliera chordalis
Agaroid- G. furcata Cryptonemiales
carrageenan
di-S-galactan Gelidium crinale Gelidiales
Hybrid Pterocladia capillacea Gigartinales
DL-galactans Gymnogongrus torulosus
S-λ-carrageenan Chondrus crispus Gigartinales Anticoagulant,
E. spinosa antithrombotic
G. skottsbergii
Phyllophora brodiei
Stenogramme interrupta
LMW-PS Hypnea charoides Immunostimulant
LMW-S- Kappaphycus striatus Antitumor,
carrageenans immunomodulator
sPS Gracilaria caudate Gracilariales Antiviral,
G. verrucosa Chlorophyta anti-inflammatory,
U. conglobata Bryopsidales immunomodulator,
U. fasciata Ulvales anti-proliferative,
U. lactuca Diatoms prevention
U. rigida Chlorophytes of tumour cell growth
C. cupressoides Prasinophyte
Prymnesiophyte/
haptophyte
S-galactans G.corticata Ulvales Anticoagulant,
Grateloupia indica Rhodymeniales antithrombotic
Schizymenia dubyi Nematomatales
S. binderi Halymeniales
U. lactuca Gracilariales
Caulerpa spp. Gigartinales
Aghardiella tenera
Euchema cottonii
Pterocladia capillacea
(continued)
5.2 Polysaccharides Derived from Marine Sources 189

Marine organisms
S-mannans Nemalion helminthoides Ulotrichales Antiviral Drugs carriers
Capsosiphon fulvescens Nemaliales Immunomodulator Encapsulation,
Xylogalactans Nothogenia fastigiata Nemaliales Antiviral, anticoagulant Scaffolds for
S-xylomannans ligaments and tissue
engineering
di-S-galactan Botryocladia occidentalis Rhodymeniales Anticoagulant, Regeneration of
LMW-sPS Champia feldmannii anti-venom tissues
S-xylomannans Sebdenia polydactyla Nemaliales Antiviral Moulding in
S-arabinogalactans Codium spp. Chlorophyta Anticoagulant, dentistry
Bryopsidales antithrombotic, antiviral Wound healing and
dressings
S-pyrulylated- C. isthmocladum Chlorophyta Antioxidant,
galactans Bryopsidales anticoagulant,
anti-proliferative
S-rhamnans and Monostroma latissimum Ulotrichales Anticoagulant,
LMW-S- M. nitidum antithrombotic,
rhamnans Enteromorpha hepatoprotective,
Rhamnans intestinalis antitumor,
immnunomodulator
S-ulvans and E. prolifera Ulvales Antioxidant,
Derivatives, U. pertusa anti-proliferative,
LMW-S-ulvan or Hypocholesterolaemic
otherwise
modified
EPS Haslea ostrearia Diatoms Antiviral, antibacterial,
Nitzschia closterium Chlorophytes prevention of tumour
Skeletonema costatum Cyanobacteria Cell growth
Chaetoceros spp.
Amphora sp.
Dunaliella salina
Ankistrodesmus angustus
Botryococcus braunii
s-Spirulan Arthrospira platensis Cyanobacteria Anti-proliferative,
anti-adhesive,
Anti-metastatic
polysaccharides (Table 5.2) (Figs. 5.2 and 5.3). These polysaccharides exhibit
various biological and biomedical applications, namely [8], antiangiogenic [9],
antimetastatic [10], and anticoagulant [11], antioxidant [11], anti-inflammatory,
immunomodulating [8], antiproliferative [11], antitumor [12], antiparasitic antivi-
ral [8] properties. Among all class sulphated polysaccharides have been of great
interest because of the presence of sulphur group and their potential to generate
new bioactive compounds [10].
190
Table 5.2 Chief sources of polysaccharides and its description

5
Sources Description Name Bio-prop. Biopolymer Application

Green algae (1-3(6))-Linked galactose,(1-3 (4))-linked Green algae, Antiviral activity Ulvan Tissue engineering
sulfated arabinose,(1-4)- linked glucose and Caulerpa (herpes simplex
polysaccharides terminal,(1-4)-linked xylose residues. racemosa virus type 1 and 2)
Sulfation soccuron O6 of galactose and O3
of arabinose. Sulfate ester content: 9 %
(1-2)-Linked L-rhamnose residues with Green algae, Anticoagulant
sulfate groups substitute dat positions of C3 Monostroma activity
and/or C4. Sulfate ester content: 23 %/25 % latissimum
Brown algae Fucan: (1-3)-linked α-L-fucopyranosyl Brown algae, Antiviral activity Alginate Drug delivery,
sulfated backbone, mostly sulfated atC4, and Adenocystis (herpes simplex Anti-tubercular and
polysaccharides branched at C2 with non-sulfated utricularis virus type 1 and antifungal,
fucofuranosyl and fucopyranosyl units, and 2), Antiretroviral Antitumor
2-sulfated fucopyranosyl units. Galactan: activity (HIV-1)
D-galactopyranose units linked on C3 and
C6, and sulfation mostly on C4. Sulfate ester
content: 30–34 %/21–24 %
Mainly composed of fucose (82 %), Brown algae, Antiproliferative
galactose (14 %), and small amounts of Ecklonia cava activity, anticancer
xylose and mannose Sulfate ester content: activity
92 %
Fucose, galactose. Sulfations occur on Brown algae, Anti-inflammatory Algal fucoidan Cytotoxic activity,
position-2 and-3. Sulfate ester content: Ecklonia cava activity anticancer
41–92 %
Marine Polysaccharides Based Nano-Materials and Its Applications
Red algae Red algae, Antioxidant Agarose & porphyran Cytotoxic activity
5.2
Backbone of alternating β-(1-3)- linked

sulfated D-galactosyl units and α- (1-4)-linked Porphyra activities, Antibacterial
polysaccharides L-galactosyl,(1-6)- sulfate or3,6-anhydro-α- haitanensis anticoagulant activity Drug
(porphyran) L-galactosyl units. Sulfate ester content: activities delivery
17 %
Shrimp and crab Biopolymer family of lin-ear polysaccharide Shrimp and Gene delivery, Chitosan Drug delivery
that is composed of glucosamine and crab Antimicrobial
N-acetyl glucosamine units via ˇ-(1 → 4) activity, Tissue
linkages randomly or block-spread engineering,
throughout the polymer chain, depending on Anticancer
the extraction pro-cedures to derive CS from activity, Wound
chitin dressing
Water-soluble anionic derivative of chitin Wound dressing, Chitin Drug delivery
containing carboxyl groups Antibacterial (Carboxymethyl
activity, Drug chitin)
delivery
COS, a low molecular weight Anticancer Chitooligosaccharide Drug delivery
Polysaccharides Derived from Marine Sources
depolymerization product of CS,

191
Marine polys accharide

sources
Algal sources Chitin Marine microorganisms
Red algae Exos keletons of marine

Marine microbial EPS
(Rhodophyceae) crustaceans
Carrageenans,agarose, Shrimp, crab,lob ster Cyanobacteria,

porphyran shells, cell walls of actinobacteria, fungi
marine fungi
Brown algae (Phaeo-

phyceae) Chitos an
Laminarin, fucoidan, N-deacetylation of

alginates chitin
Green algae
Chitooligosaccharides
(Chlorophyceae)
Ulvan Depolymerization
products of chitin or
chitosan
Fig. 5.2 Marine based polysaccharides and its sources
5.2.1 Marine Algae Based Polysaccharides
Marine algae polysaccharides especially sulfated polysaccharides received a greater

importance as natural resources of marine natural products. Owing to the potential
properties of seaweed and other marine sources derived polysaccharides they have
received considerable attention in the cosmeceutical, nutraceutical, and pharmaceu-
tical fields [13]. Marine algae chiefly classified in to three: green algae
(Chlorophyceae), brown algae (Phaeo-phyceae) and red algae (Rhodophyceae)
(Fig. 5.2).
From the research and commercial point of view there are some prominent
sources (such as carrageenans, agarose, and porphyran) of sulfated polysaccharides
extracted from red seaweeds [14], ulvan is a natural polysaccharide isolated from
green algae [15] and laminarin, fucoidan, and alginates are chiefly derived from
marine brown algae.
5.2
Polysaccharides Derived from Marine Sources
Fig. 5.3 Various types of sulfated polysaccharides and their applications in nanobiotechnology
193
5.2.2 Marine Crustaceans Derived Polysaccharides
5.2.2.1 Chitin
Among all the polysaccharides chitin is reported as one of the most abundant natu-
ral polymers and chiefly found in the exoskeletons of marine crustaceans and cell
walls of marine fungi [5]. Shrimp, crab, and lobster shells are the major sources
chitin and form the existing waste products of the seafood industry. According to
present research this polymers can be easily modified in to chitosan and other forms
whereas both unmodified as well as modified forms can be easily processed into
microparticles, nanoparticles, nanofibers, scaffolds, sponge forms, beads, gels, and
membranes. There maximum utilization in biomedical field is based on excellent
low toxicity, high biodegradability and biocompatibility [16]. Such properties
endow various biomedical applications such as wound dressing, targeted drug
delivery, tissue engineering and gene delivery, and offer significant applications in
nanotechnology [17].
5.2.2.2 Chitosan and Chitooligosaccharides
Modification of chitin helps in improving its various properties such as improve-

ment in molecular weight, biocompatibility and toxicity profile. Chitosan, a natu-
rally occurring polysaccharides isolated by the N-deacetylation of chitin has now
become the most highlighted polymer in chemical, nutraceutical and pharmaceuti-
cal industries [18]. One more modification which has been now highlighted for its
excellent properties is chitooligosaccharides obtained by the depolymerization
products of chitin or chitosan by enzymatic and acidic hydrolysis methods. These
methods significantly affect the molecular weight and ease of control and safety.
Additionally such modification methods impart excellent properties such as high
water solubility nonotoxicty, good biocompatibility, excellent biodegradability and
low cost [19]. Chitosan and chitooligosaccharides are now recently considered for
its great promising application in biomedical science, such as hypocholesterolemic
effects [20], wound healing [21], drug delivery [22], tissue engineering [23], antitu-
mor effects [24], and antimicrobial activity [25].
5.2.2.3 Marine Microorganisms
Among the potential class of marine based polysaccharides microbial polysaccha-

rides especially
EPS are abundantly present in various marine sources such as fungi [26], bacte-
ria [27], actinobacteria [28], and cyanobacteria [29]. Currently, EPS presents vari-
ous interesting applications in cosmeceutical, nutraceutical and pharmaceutical
industries. Additionally EPS also plays an important role in wastewater treatment
and detergent applications [30]. All marine based microbial polysaccharide offers
an increasing attention for biological activities such as antitumor, antiviral, anti-
5.3 Nanomaterials Derived from Marine Sources 195
inflammatory properties [31]. According to previous reports extremophilic bacterial

polysaccharide, mauran (MR), explored as novel biocompatible and stable biomate-
rial and therefore becomes more favorable for its utilization in nanotechnology,
pharmaceutics and biomedical field [1]. Previous findings also suggested the role of
Streptomyces sp. based polysaccharides in the production of polysaccharide-based
bioflocculant for the green synthesis of silver nanoparticles [32]. These NPs can be
treated as choice for the advancement in novel bactericidal bio-nanomaterials espe-
cially for several biotechnological applications and wastewater treatment.
5.3 Nanomaterials Derived from Marine Sources
Owing to high biodegradability, good biocompatibility, nontoxic nature, low cost

and other features, marine polysaccharide-based nanomaterials are considered as
most suitable novel carriers in nanotechnology science [33]. Because of their unique
physicochemical properties these polysaccharides have attracted considerable
attention for imaging and therapeutic agents. Some special features such as its abun-
dance, hydrophilic, biocompatible, biodegradable, inexpensive, nontoxic, safe,
hydrophilic and biocompatible nature they are of particular importance in the area
of nanotechnology and have a promising future as biomaterials. Recent research on
polysaccharides based nanomaterials offers various biomedical application such as
drug delivery, antimicrobial activity, tissue engineering, gene delivery, cancer ther-
apy, and wound dressing [34–36].
5.3.1 Nano Scaffolds Derived from Fucoidan
Brown seaweeds derived sulfated polysaccharide known as Fucoidan (1) is an

excellent drug candidate for pharmaceutical applications. Similarly fucan sulfates
were obtained from marine invertebrates are having excellent pharmaceutical appli-
cations [37]. Fucoidan in the presence of formamide, pyridine and acetic anhydride
yields acetylated nanoparticles. Whole process is conducted at room temperature
for 24 h (Fig. 5.4, Table 5.3). Fucoidan is considered as an excellent candidate for
various biological applications such antiproliferative properties, immunomodulat-
ing properties [47], anticoagulant [48], antiviral [47], antiangiogenic, antitumor,
anti-inflammatory, [49], antioxidant [50]. Previous findings suggested that com-
pounds such as fucoidans are now considered as the novel bioactive agents espe-
cially for nanotechnology and biomedical applications [38]. Recent research has
investigated the role of fucoidans in the biosynthesis of metalnanoparticles, cancer
treatment and drug delivery. Synthesis and characterization of fucoidan-coated poly
(isobutylcyanoacrylate) nanoparticles was reported by Lia et al. [51]. Polymerization
and redox radical emulsion polymerization were used to prepare of isobutylcyano-
acrylate using fucoidan as a novel coating biomaterial. These nanoparticles exhibit
potential in vitro cytotoxic effect against different fibroblast cell lines. Nanoparticles
Fig. 5.4 Synthesis of acetylated fucoidan NPs from natural fucoidan

Table 5.3 Various advancement and applications of fucodain in nanoparicle drug delivery
[38–46]
Polysaccharides Modifications Nanoaprticles Drug delivery applications
Fucodain Oversulphated, Cytotoxicity and Suppressive effect of
acetylated and fucoidan-coated fucoidan on an attachment
benzoylated fucoidan nanoparticles of Cryptosporidium
Phosphorylated and Stromal cell-derived parvum
aminated derivatives factor-1 released from Fucoidan cures infection
offucoidan chitosan/ with both antimony-
Radical degradation tripolyphosphate/ susceptible and -resistant
Polyethylene fucoidan nanoparticles strains of Leishmania
terephthalate (PET) Carboxymethylated- donovani
polymer surface curdlan and fucoidan Growth-inhibitory effect of
attachment Green synthesis of a fucoidan
Fucosidase,enzyme silver nanoparticles On Plasmodium parasites
degradation and Chitosan/Fucoidan pH Asexual growth inhibiton
microvate associated Sensitive of Babesia bovis
degradation Nanoparticles
Degraded fucoidans Fucoidan-Stabilized
were coupled with Gold Nanoparticles
several hydrophobic
groups (oligofucose-
dodecylaniline
combination)
prepared by anionic emulsion polymerization nanoparticles showed IC50 at 2 g/

mL. As far as the sources are concerned fucoidans are derived from various sources
two of marine algae such as Cladosiphon okamuranus and Kjellamaniellacrassifolia.
Recent research showed its potential application in green synthesis of gold nanopar-
ticles [52]. Previous findings on production of silver nanoparticles using carboxy-
methylated curdlan or fucoidan as reducing and stabilizing agents has opened
gateway for the synthesis of metallic nanoparticles [39]. C. okamuranus derived
fucoidan encapsulated in nanoparticles using liposomes as nanocarriers showed
potential in vitro anticancer activity against osteosarcoma [53]. It was observed that
hydrophobically modified fucoidan (synthesized by the acetylation of fucoidan)
was required to prepare the chemotherapeutic agent loaded nanoparticles e.g. acety-
lated fucoidan nanoparticles was used to encapsulate Doxorubicin.
5.3.2 Alginate Nanoparticles
Owing to excellent properties such as low cost, low toxicity, biocompatibility and
mild gelation, alginate ‘a natural polysaccharide’ derived from brown seaweeds has
been widely investigated and used for biomedical applications [54]. Previous find-
ings have explored various functionalization and modification steps for alginate to
yield modified alginate with improved physic-chemical and biological properties
(Fig. 5.5). Current research on alginate-based nanoparticles offers various
198
5
Fig. 5.5 Various functionalization and modification steps recently explored to yield modified alginate
Marine Polysaccharides Based Nano-Materials and Its Applications
applications in insulin delivery [55] and antifungal and antitubercular drugs [56].
Alginate based nanoparticles have raised greater interest in the medical field e.g.
[55] insulin-loaded nanoparticles using alginate ionotropic pre-gelation followed by
CS polyelectrolyte complexation. This has proven the elastic nature of alginate to
hold and shield drug by polyelectrolyte complexation with chitosan. During this
study it was observed that insulin-loaded nanoparticles using alginate showed load-
ing capacity of 14.3 %. Similarly loading of insulin in alginate–dextran nanospheres
through nanoemulsion dispersion resulted in increase in encapsulation efficiency up
to 82.5 %. Various methods like irradiation method was also reported for the prepa-
ration of gold nanoparticles using alginate as a stabilizer. Utilization of effective
methods such as irradiation method for the preparation of gold nanoparticles using
alginate as astabilizer was also reported. During this study it was observed that
irradiation technique is suitable for the production of alginate-stabilized gold
nanoparticles with controllable size and high purity. This technique yields alginate-
stabilized gold nanoparticles which are spherical in nature having particle size rang-
ing from 5 to 40 nm [57]. Recently hydrothermal synthesis of silver nanoparticles
using sodium alginate as a reducing and stabilizing agent was studied by Yang and
Pan [58]. During this study it was observed that incubation time and temperature of
the reaction played an important role under suitable effective sodium alginate con-
centrations and Ag+ precursor in the development of silver nanoparticles with desir-
able shapes. So generally triggering the temperature and incubation time of reaction
were favorable for the formation of nanoplates whereas low temperature and short
incubation time of reaction were shown to result in the formation of nanospheres. In
one report the role of alginate in DOX-loaded glycyrrhetinic acid-modified alginate
nanoparticles was suggested by determining liver-targeting efficiency, and antitu-
mor activity. It was observed that nanoparticles showed strong liver-targeting effi-
ciency, reduced cardiac toxicity and improved antitumor activity of DOX against
liver tumors [59, 60]. One of the major causes of therapeutic failure of anti-
tuberculosis medicines is patient non-compliance. This happens due to the multi-
drug administration for at least 6 months. Delivery systems such as nano formulations
are more suitable for co-bacterial infections (such as tuberculosis) [61]. An alginate-
encapsulated anti-tubercular drugs such as isoniazid, rifampicin, pyrazinamide, and
ethambutol was studied by Ahmad et al. [62]. During their oral administered to mice
it was observed that all the encapsulated drugs in nano forms showed better anti-
tubercular effects. Additionally these nanoparticles showed high encapsulation effi-
ciency with average particle size. Various nanoparticle applications and its recent
modification/functionalization of alginate are mentioned in Table 5.4.
5.3.3 Carrageenan Based Nanoparticles
Red algae such as Kappaphycus sp. and Eucheuma sp are the chief source of car-
rageenan. This natural polymer is having D-galactose and anhydro-galactose units
joined by glycosidic linkages and ester sulfate groups. Carrageenan on the basis of
Table 5.4 Alginate modifications and its recent nanparticulate forms [57, 63–124]
Polymer Modification Nano applications Drug delivery applications
Aliginate • Modification of hydroxyl groups of alginate include oxidation, • Alginate/Chitosan nanoparticles Aliginate based leishmani
reductive-amination, sulfation, copolymerization and coupling of • Insulin-loaded alginate nanoparticles vaccine
cyclodextrin units • Chitosan/alginate nanoparticles encapsulating Alginate-Capped
• Methods used for modification of carboxyl groups include antisense oligonucleotides Amphotericin B Lipid
esterification, use of the Ugi reaction, and amidation. • Alginate–AgNPs composite sponge Nanoconstructs Against
• Surface modification of sphalerite with sodium alginate • Paraquat-loaded alginate/chitosan nanoparticles Visceral Leishmaniasis
• Degradation by epimerases • Chitosan or N-trimethyl chitosan and a cisplatin– Acyclovir-loaded alginate
• Ionotropic gelation of sodium alginate using N,N′- alginate complex NPs mucoadhesive
methylenebisacrylamide and carboxy-methylcellulose • Superparamagnetic iron oxide nanoparticles stabilized microspheres
• Covalent modification of alginate with polyethylene glycol– by alginate
conjugated anthracene molecules has the potential to both stabilize • Thiolated alginate-albumin nanoparticles
the alginate and act as a photosensitive crosslinker • Silica/alginate nanoparticles as Hybrid Magnetic
• Chemoselective cross-linking of alginate with thiol-terminated Carriers
peptides for tissue engineering applications • Magnetite nanoparticles,
• Modification of alginate through partial crosslinking with a matrix • Alginate–quaternary ammonium NPs
metalloproteinase (MMP) • Alginate stabilized gold nanoparticles,
• By simple covalent modifications • Silica/alginate nanoparticles as Hybrid Magnetic
• Novel crosslinking reagent (alginate dialdehyde) for biological Carriers
tissue fixation • Lipid nanoparticles into calcium alginate beads
• Thermo-sensitive alginate-based injectable hydrogel for tissue • Chitosan–sodium alginate microcapsules containing
engineering ZnS nanoparticles
• Alginate dialdehyde for biological tissue fixation • Maghemite nanoparticles for Pb(II) removal in
• Modification of alginate by grafting of N-vinyl-2-pyrrolidone aqueous solution
• The effects of peptide-based modification of alginate • Inhalable alginate nanoparticles
• Modification of alginate through the grafting of • Superparamagnetic iron oxide nanoparticles stabilized
2-acrylamidoglycolic acid by alginate
• Effect of gamma radiation on the physico-chemical properties of • Layer by layer chitosan/alginate coatings on
alginate poly(lactide-co-glycolide) nanoparticles
• Hydrophobically modified alginate • Barium alginate caged Fe3O4@C18 magnetic
• Modification of alginate degradation properties using orthosilicic nanoparticles
acid • Alginate/Fe@Fe3O4 core/shell structured
• Calcium alginate nanoparticles
• Sodium alginate sulfates • Multifunctional alginate microspheres
• Modification of PVA–alginate as a suitable immobilization matrix • Curcumin in alginate-chitosan-pluronic composite
nanoparticles
extraction procedures and resources is further classified in to three types kappa,

iota, and lambda (Fig. 5.6). Major difference between these types is that they all
having sulphur group which is differing in the substitution degree. From gelling
point of view, kappa and iota show high gelling efficiency whereas delta carra-
geenan is a non gelling polysaccharide [125]. Among these kappa carrageenan is
rigid and firm whereas iota carrageenan elastic and soft in nature [126]. Using these
all types Daniel-da-Silva et al. [127] studied the biosynthesis of magnetite nanopar-
ticles and examined for their particle size morphology and chemical stability.
Carrageenan has various applications in nanotechnological, biological and pharma-
ceutical field (Table 5.5). Additionally carrageenan also exhibit various food and
non-food applications. Six types of sulfated polysaccharides from marine brown
and red seaweeds was isolated and investigated for their respective antioxidant
activities by DeSouza et al. [128]. It was observed that carrageenan and fucoidan
exhibit strong antioxidant activity. In an another study inhibitory effects of delta
carrageenan and a mixture of sulfated polysaccharides derived from red seaweeds
against feline herpesvirus-1 under in-vitro was investigated [129]. Delta-carrageenan
showed IC50 5 μg/mL against feline herpes virus -1. Carrageenan and chitosan
nanoparticles were investigated by Grenha et al. [130]. These nanoparticles were
produced by hydrophilic conditions using very mild protocol and preventing the use
of organic solvents and other intensive chemical conditions. This protocol yields
suitable nanoparticles that can present sustained and controlled form of drug deliv-
ery system and can be treated as excellent candidates for biomedical applications.
Additionally it has been studied that these nanoparticles were proved for their low
toxicity against fibroblast cell lines as well as superior biocompatibility and high
Iota
carrageenan
OSO3-
H H
CH2OH H
H O O
HO
O
H
H O OSO3-
H OH H
H H
H
Lambda O Kappa
OH carrageenan O carrageenan
H OSO3-
CH2OH -O SO OSO3- H
R 3 H H
H CH2OH O
O H O
HO
H O
O H
H H -O SO
H O
3 H OH
O H OH H
H H H H H
Fig. 5.6 Types of carrageenan

Table 5.5 Marine organisms derived sulfated polysaccharides with nanotechnological, biological
and pharmaceutical applications
Biological and pharmaceutical
Type of SPS Nanotechnology application applications
Carrageenans Capping agent for biomineralizing metal oxides Anti-coagulant activity
Composite gels Anti-oxidant activity
Composite nanoparticles Anti-viral activity
Drug encapsulation and delivery Free radical scavenging
Gelling agent activity
Hydrogels Microbicidal activity
Microbeads for controlled release Prevention of sexually
Stabilizing agent transmitted diseases
Stabilizing micelles Vaginal gel formulation
Thickening agent
Fucoidans Stabilizing agent Anti-angiogenic activity
Fucospheres or microspheres Anti-coagulant activity
Anti-inflammatory activity
Anti-oxidant activity
Anti-proliferative activity
Anti-tumor activity
Anti-viral activity
Immunomodulating property
Treating dermal burns in rabbit
Ulvan Nanofibrous scaffolds Resist attack of necrotic
pathogens in plants
Antifungal activity
safety. CS, carrageenan, and cross linking agent tripolyphosphate based nanoparti-
cles was investigated by Rodrigues et al. [131] for their stability smaller size and
strong positive surface. In this study prepared nanoparticles were used for purpose
in mucosal delivery of macromolecules. Metallic nanoparticles for gastrointestinal
release using modified kappa-carrageenan was investigated to study the effect of
genipin cross-linking and it was proved that metallic nanoparticles seem signifi-
cantly improve gastrointestinaltract-controlled drug delivery [132]. Salgueiro et al.
[133] studied the influence of introducing spherical and rod-shaped gold nanopar-
ticles in the microstructure and thermomechanical properties of delta-carrageenan
hydrogels. Moreover he has also investigated the effect of these nanoparticles in the
release kinetics and mechanism of methylene blue from kappa-carrageenan nano-
composites. It was observed that hydrogel nanocomposites demonstrated enhanced
viscoelastic properties in contrast with neat kappa-carrageenan, at the time they
used with either with gold nanospheres and gold nanorods.
5.3.4 Agarose Nanoparticles
3,6 anhydro galactose based natural polymer known as Agarose (Fig. 5.7) derived
from red seaweeds, Gracilaria sp. and Gelidium sp. This 3,6 anhydro galactose
based natural polymer is a linear polysaccharide made up of repeating units of
OH
OH
O
O
O
O OH
H O
OH
OH
Agarose n
Fig. 5.7 Structure of agarose
agarobiose, which is a disaccharide made up of D-galactose. Agarose is having vari-

ous applications in biotechnology biochemistry and molecular biology field espe-
cially in different types of electrophoresis techniques (for the separation of nucleic
acids). This red seaweed derived polysaccharide usually used for its gel-forming
property to create semiconductor and metal nanoparticles. It was observed that this
type of nanoparticle exhibit strong antibacterial activity against Escherichia coli. It
has been also discovered that the agarose composite films can be rapidly transformed
to carbon metal composites by carbonizing the films in nitrogen atmosphere [134].
Previous finding suggested the application of agarose-stabilized gold nanoparticles
for the detection of micromolar concentrations of DNA nucleosides via surface-
enhanced Raman spectroscopic detection [135]. Results suggested that agarose-
stabilized goldnanoparticles yield higher surface-enhanced Raman spectroscopic
detection for DNA nucleosides, which is used for on-chip biosensing applications.
5.3.5 Porphyran Based Nanoparticles
Porphyran (Fig. 5.8) 3,6-anhydro galactose is a natural sulphated polysaccharides

obtained from marine red seaweed, Porphyra vietnamensis [136]. Porphyran is a
hot-water-soluble fraction of the cell wall having the similar characteristics like
agar. It is the major constituent (40–50 %) of the marine P. vietnamensis and has
nutritional value. It’s a anionic disaccharide units consisting of 3-linked D-galactosyl
residues alternating with 4-linked 3,6-anhydro-L-galactose and 6-sulfate residues.
Porphyran can be extracted from various species of Porphyra and having some
important pharmaceutical properties reported in various structural and functional
studies.
Bhatia et al 2009 described biological properties emphasizing the role of por-
phyran in pharmaceutical world [137–143]. Bhatia et al (2010) demonstrated the
structure based gelling and emulsifying properties of porphyran. Molecular weight
based antioxidant property of porphyran was described by Bhatia et al. (2011)
[137–143]. Further molecular weight dependent potential immunomodalation
Fig. 5.8 Structure of

Porphyran OSO3-
HO
HO OH
H H
O O
O
H HO
H H
OH HO
H OH H OH
effect of porphyran was investigated by Bhatia et al. (2013). Porphyran molecular

weight was modified and immunomodulation effects of modified and natural sam-
ple were investigated [137–143]. It was observed that alkali treated sample showed
better immunomdulation effects then natural one. Bhatia et al. (2013) has exam-
ined the role of porphyran in development of oral amphotericin B loaded nanopar-
ticles to reduce its toxicity and other associated problems [137–143]. In this study
Amphotericin B was packed between two oppositely charged ions (chitosan and
porphyran) by polyelectrolyte complexation technique with TPP as a crosslinking
agent. Formulation was optimized using three-factor three-level (33) central com-
posite design. High concentration of POR in NPs was confirmed by sulfated poly-
saccharide assay [137–143]. Degradation and dissolution studies suggested the
stability of NPs over wide pH range. Hemolytic toxicity data suggested the safety
of prepared formulation. In vivo and in vitro antifungal activity data suggested the
high antifungal potential of optimized formulation when compared with standard
drug and marketed formulations. Hence, these experimental oral NPs may repre-
sent an interesting carrier system for the delivery of AmB. Bhatia et al. (2015)
investigated the factors influencing the molecular weight of porphyran and its
associated antifungal activity. During this study various extraction methodologies
have been employed to derive porphyran from high tide and low tide samples of P.
vietnamensis. Results suggested that P. vietnamensis collected during low tide
yields high percentage of porphyran with relatively low molecular weight and high
sulfate content than the high tide sample. Among various extraction methodologies
alkali modified POR yield slow molecular weight polysaccharide but surprisingly
with high sulfate content which have shown improved physico-chemical and anti-
fungal properties than chitosan without any toxicological affects. Bhatia et al.
(2015) has established the relationship between structural features and pharmaceu-
tical properties of porphyran [137–143]. This polysaccharide exhibit molecular
weight dependent activity as highlighted in reports on the anticancer and antioxi-
dant activities of porphyran [144]. Biosynthesis of gold nanoparticles using a por-
phyran and subsequent loading of Doxorubicin was investigated [145]. Toxicological
data of porphyran-reduced gold nanoparticles was performed on normal monkey
kidney cell line, which showed a non-toxic nature of nanoparticles [146].
5.3.6 Nanofibers of Ulvan
Ulvan (Fig. 5.9) is obtained from the cell walls of marine green algae (Ulvales,
Chloro-phyta). It’s a complex anionic sulfated polysaccharide contains sulfated,
xylose, rhamnose, glucuronic, and iduronicacids. Ulvan is abundantly present in
green algae especially Ulva rigida and have a low cost of production. These poly-
saccharides are still under-exploited and have been investigated as an antitumor,
anticoagulant, antioxidant, and immune modulator [15]. Current utilization of ulvan
in nanotechnology is especially towards preparation of nanofibers with the special
interest in the biomedical engineering field because of their potential applications in
tissue engineering, drug delivery and wound dressing. Due to some physicochemi-
cal and biological properties ulvan becomes good candidate for nanofiber produc-
tion and has been successfully explored into nanobiotechnology for presenting
novel promising biomaterials in biomedical applications, including drug delivery
systems, wound dressing, and tissue engineering. Earlier report suggested that spin-
nability of U. rigida based polysaccharide can be used for the fabrication of nanofi-
bers which imply that spinnability plays an important role in improving the
properties of ulvan [147].
5.3.7 Mauran Based Nanoparticles
Just like other sulphated polysaccharides, mauran is Halomonas maura (halophilic

bacterium) derived sulfated polysaccharide with high sulfate, phosphate, and uronic
acid content. Moreover it has been also reported that mauran constitute mannose,
glucose, galactose, and glucuronic acid. Recent research has explored the utilization
of mauran for the biosynthesis of metal nanoparticles and their well known visco-
elastic properties. Previous finding suggested the role of sulfated polysaccharide-
based nanoparticles as a good biocompatible material for bioimaging, drug delivery
and anticancer activity [1]. Additionally thixotropic and pseudoplastic properties of
mauran make it a supreme molecule for material science applications [148].
+
NaOOC
O H3C
O O O
HO
OH HO
OH
Ulvan
Fig. 5.9 Structure of Ulvan

5.3.8 Chitin and Its Nanoparticles
Chitin (Fig. 5.10) is one of the abundantly present biopolymer in nature [149], iso-
lated from the various marine sources crab, shrimp, and lobster shells and their by-
product in the seafood industry. Million tons of chitin per annum generated as waste
by the seafood industry [150]. There are several methods involved in the production
of chitin such as enzymatic methods, hydrolytic methods using boiling HCl and
methods applied using chitin whiskers. Various applications of chitin in nanosci-
ence are mentioned in Table 5.6.
5.3.9 Chitosan Based Nanoparticles
Chitosan is a naturally occurring linear polysaccharide which is composed of glu-

cosamine and N-acetylglucosamine units via β-(1 → 4) linkages. These linkages
are randomly or block-spread all over the polymer chain. Arrangement or distribu-
tion of these linkages is dependent on the extraction procedures to derive chitosan
from chitin. Degree of deacetylation is known as the parameter that define molar
ratio of glucosamine to N-acetyl glucosamine. Degree of deacetylation signifi-
cantly determines the physicochemical properties and industrial applications of
chitosan [126]. Once the chitosan get deactylated it can be easily dissolved in an
acidic medium and develop into the only sulfated polysaccharide that possesses a
Fig. 5.10 Structure features of chitin and chitosan

5.3
Table 5.6 Chitin and its nano-applications

Type of chitin Method NPs Applications Uses/benefits References
Chitin Ion cross linking agent Chitin NPs Reinforcing fillers in polymeric [151]
matrices
Carboxy-methyl chitin – CMC NPs Wound-healing dressings, Nontoxic, water-soluble [152]
exhibits good bio-compatibility anionic derivative
Carboxymethyl chitin Cross-linking approach CMC NPs Controlled drug delivery Nontoxic, water-soluble [153]
with FeCl3 & CaCl2 applications, anionic derivative
in vitro cyto-toxicactivity against
mouse L929 cell lines, NPs
showed strong antibacterial
activity against Staphylococcus.
Nanomaterials Derived from Marine Sources
Amorphous chitin Ionic cross-linking Paclitaxel loaded For colon cancer drug delivery Hemo-compatible & [154]
approach using amorphous chitin in vitro drug release
pentasodium nanoparticles exhibited a sustained
tripolyphosphate release,
enhanced efficacy
Amorphous chitin Ionic cross-linking Rifampicin-loaded Intracellular delivery of Sustained drug delivery [155]
amorphous chitin rifampicin inside could reduce dosing
polymorphonuclear leukocytes, frequency, lower toxicity,
anti-bacterial activity enable long-term
treatment, & prevent
potential side effects
related to the free drug
207
high density of positive charges. This positive charge is due to the protonation of
amino groups on its backbone. In addition to its unique features chitosan has been
reported to have various other essential properties such as good biocompatibility
and biodegradability and non-toxicity [156]. There are different protocol reported
for the preparation of various derivatives of chitosan (Figs. 5.11 and 5.12).
Currently chitosan has offered significant applications (Table 5.7) in nanotechno-
logical area especially in biomedical sector such as drug delivery [168], nutrition
[169], and tissue engineering [170].
N-methyl-2-
Chitin pyrollidinone
deacetylase
N-N-N-
Chitin Chitosan Schiff base trimethyl
chitosan
Isopropanaol Glyoxalic
Isopropanol acid
O- N, N,
Carboxymethyl
Carboxymethyl Carboxymethyl
chitin
chitin chitin
Fig. 5.11 Steps involved in the chemical modification of chitin/chitosan
Fig. 5.12 Protocol for the preparation of various chitosan derivatives

5.3
Table 5.7 Applications of chitosan nanoparticles

NPs type Method Model drug Application References
CS- and CS-gold Ionic gelation method Salmon leutinizing hormone Showed considerable reproductive [157]
nanoconjugates releasing hormone efficacy in female fish (Cyprinus carpio)
CS-dextran sulfate NPs Ionic gelation method Doxorubicin Anticancer activity (increase cytotoxicity [158]
activity)
Dextran-DOX encapsulated Reverse micro-emulsion Doxorubicin Improved antitumor activity in murine [159]
in CS nanoparticles tumor models
CS NPs Immuno-suppressive peptide Targeted delivery of drugs to the ocular [160]
cyclosporin A mucosa,
CS AOT/n hexane – Particle size of CS NPs was mainly [161]
NPs reversemicellar system influenced by the degree of cross-linking
cross-linked- glutaraldehyde
Nanomaterials Derived from Marine Sources
CS NPs Copper Anti-antibacterial activity against [162]

Cu-loaded CS NPs pathogenic microorganisms
CS–TPP-NPs polyanion-initiated gene or protein Delivery of gene or protein [163]
elation macromolecules macromolecules
CS NPs Ionic gelation method siRNA Good vehicles for siRNA delivery [164]
CS–TPP-NPs Ionic gelation method siRNA CS–TPP-NPs proved as good vehicles [165]
for siRNA delivery then CS NPs
Hydrophobically modified Camptothecin Substantial enhancement of antitumor [165]
glycol chitosan NPs activity
CS and silver-loaded CS NPs Silver Antimicrobial textile applications, [166]
silver-loaded CS NPs exhibited
synergistic antibacterial activity
CS NPs Blank Hemolytic activity [167]
209
Table 5.8 Various applications of COS nanoparticles

Nanoparticles (NPs) Applications/advantages References
Hydrophobically modified Drug delivery in cancer therapy by [172]
amphiphilic COS derivatives for improving the solubility of insoluble
self-assembled polymeric NPs drugs, drug targeting, and absorption
Iron oxide loaded magnetic Colloidally stable in water and buffer [173]
COS NPs & attractive for biomedical applications
CS oligosaccharide-stabilized Efficient heat nano-mediator for cancer [174]
ferri-magnetic iron oxide nanocubes hyperthermia & exhibited strong
antitumor activity without toxicity.
Multidentate dithiolanelipoic acid and Used for bio-logical various [175]
phosphorylcholine conjugated CS applications
oligosaccharide derivative to stabilize
gold NPs
COS NPs polyelectrolyte complexes Showed strong inhibition of the [176]
proliferation of HeLa & B16
melanoma cells.
COS-based multidentate NPs Ultrastable, cytotoxicity & [177]
biocompatible
5.3.10 Chitooligosaccharide Based Nanoparticles
Chitooligosaccharide is low molecular weight polymer obtained by depolymeriza-

tion of CS and offers various superior features such as biocompatiblity, water-
solublity, biodegradablity and nontoxicity in nature. Chitosan has various
applications in biomedical and pharmaceutical sectors and also exhibit unique bio-
logical activities such as immune-enhancing, antimicrobial, and antitumor activi-
ties. Recently this oligosaccharide is exploited for its polymer-drug conjugate
applications. This is because of its accessibility for coupling with the primary amino
groups and hydroxyl groups of each polymer subunit. Further the cationic nature of
COS allows ionic crosslinking [171]. Different applications of COS are mentioned
in Table 5.8.
5.4 Marine Polysaccharide-Based Nanomaterials and Its

Biomedical and Biotechnological Applications
Marine polysaccharides especially algal polysaccharides based nanomaterials are

considered as nanomedicine offering high possibilities for diagnosis and therapeuti-
cal applications. Current researches on these nanomaterails have attracted attention
of all the researchers in the field of biotechnological and biomedical science [178].
Current researchers are working on the structural features of these polysaccharides
to synthesize more potential derivatives that are suitable for various applications.
Recent innovations in polymeric sciences lead to the production of potential lower
molecular weight oligosaccharide derivatives which have shown to possess a
5.4 Marine Polysaccharide-Based Nanomaterials and Its Biomedical… 211
variety of biomedical applications. We have traced some of the important nanobio-

technological applications of these biopolymer based nanomaterials in the field of
antimicrobial activity, drug delivery, gene delivery, tissue engineering, cancer ther-
apy, wound dressing biosensors, and water treatment.
5.4.1 Biomedical Applications of Marine Polysaccharides
5.4.1.1 Antimicrobial Activity
Marine organism has their potential antimicrobial activities since they live in such
a dampish environment where moisture promotes the growth of microorganisms.
Such type of organisms are usually found on intertidal zone. Antimicrobial therapy
has been evolved in recent years with development of more resistance of pathogenic
microorganisms against different types of antimicrobial agents. Prevailing resis-
tance of many infectious microorganisms contributes a serious problem in clinical
practice, therefore limits the development of novel drugs to fight against them [179].
Explorations of those substances which can prevent the development of resistant
pathogenic species of microorganisms are more preferred nowadays. Potential
effects of certain inorganic agents have been recently explored and it was found that
these candidates can act effectively against resistant strains of microorganisms
[180]. Among these candidates, silver compounds and their derivatives are exten-
sively studied for antimicrobial activity. Moreover recent research is exploring
these compounds and their derivatives in form of nanoparticles using marine poly-
saccharides as biopolymer, to enhance their antimicrobial potential more effectively
[181, 182]. A report suggested the role of agar as biopolymer (derived from the red
alga Gracilaria dura) in the synthesis of silver nanoparticles and nanocomposite
material [182]. It was found that these silver loaded NPs showed potential antibac-
terial effect with 99.9 % reduction of bacteria over the control value. These types of
nanocomposites may considered as effective antibacterial activity and may offer
various applications in food preservation and wound dressing. Previous finding on
green synthesis of silver nanoparticles using marine polysaccharide derived from
red algae, P. vietnamensis suggested the dose-dependent effect of biosynthesized
silver nanoparticles. This report has explored the effective anti-bacterial activity
against Gram-negative bacteria compared with Gram-positive bacteria [183].
5.4.1.2 Marine Based Nanomaterials and Its Drug Delivery Applications
Development in nano-biotechnology allows the medicines to be administered in a

more convenient and safe way. This can be achieved by the development of more
efficient and advance drug delivery systems to diagnose, cure or to treat any disor-
der. Current research is more emphasizing on the safe and targeted delivery of many
bioactive compounds for cancer treatment. Innovations in biomedical sciences are
paying attention towards nanomaterials for reducing dosing frequency, their
Table 5.9 Applications of algal based NPs in drug delivery system (DDS)
Nanoparticles (NPs) Applications in DDS References
CS NPs As novel drug delivery system for the [185]
ocular mucosa
CS NPs Topical ocular route drug delivery system [186]
DOX-loadedgold NPs using Strong cytotoxicity on LN-229 cell line [187]
porphyran
Berberine-loaded CS/Fucodain– Oral delivery of berberine (Ber). [187]
taurine complex NPs
toxicity, and avoiding potential side effects however they do not recognize that
delivery systems themselves may impose risks to the patient [184]. Various applica-
tions of algal based polysaccharides are mentioned in Table 5.9.
5.4.1.3 Genetic Transformation
Developments in biotechnology endow different alternatives to treat the disease e.g.

gene therapy can be utilized for correcting genetic disorders by use of genes itself.
Genetic transformation can be successfully achieved by plasmid DNA. In this pro-
cess plasmid DNA which carries gene of interest is introduced into the target cells.
The introduced plasmid DNA should get transcribed and further the genetic infor-
mation should finally be translated into the respective protein. There are number of
obstacles to be overcome by the gene delivery device during this genetic transfor-
mation [171]. According to current research nucleic acids are being functionally
utilized for both vaccination and therapeutic gene expression and chitosan nanopar-
ticles have been suggested as promising non viral gene carriers. Chitosan-alginate
NPs (core-shell structured) were fabricated using water-in-oil reverse microemul-
sion template and utilized to encapsulate a plasmid DNA for gene delivery through
the cell endocytosis pathway [188]. Nevertheless it has been already reported that
chitosan-DNA NPs can be easily fabricated by complex coacervation between the
positively charged amine groups on CS and negatively charged phosphate groups
on DNA [189]. Previous finding suggested that CS nanoparticles can potentially
provide protection to encapsulated plasmid DNA from nuclease attack. This was
established by evaluating degradation in the presence of DNase I. Further the incor-
poration of the plasmids with incubated nanoparticles was investigated by galacto-
sidase assay. Plasmid DNA based model present as combination of both supercoiled
and open circular forms. Utilization of si-RNA as a significant therapeutic agent for
the management of several diseases is inadequate due to its rapid degradation and
low intracellular organization in vitro and in vivo. Recent report suggested the role
of chitosan–polyguluronate NPs in delivering siRNA to HEK 293 FTand HeLa cells
[190]. To transport siRNA into cells, chitosan–polyguluronate NPs have a great
promise and exhibit low cytotoxicity cells [190].
5.4 Marine Polysaccharide-Based Nanomaterials and Its Biomedical… 213
5.4.1.4 Algal Polymers and Its Applications in Tissue Engineering
Algal polymers has their various applications in tissue engineering e.g. in the devel-
opment of bio-artificial implants and/or promote modification in tissues with the
objective of repairing, maintaining, replacing, or enhancing tissue or organ func-
tion. With the aid of bio-artificial constructs consisting living cells and biomaterials
tissue engineering offers various applications in science and technology. According
to report investigated by Noh et al. [191], cytocompatibility of etecrospinned chitin
nanofibers for tissue engineering applications was established by cell attachment
and spreading of normal human keratinocytes and fibroblasts. Similarly carboxy-
methyl chitin (CMC)/poly (vinyl alcohol) (PVA) blend was prepared by using elec-
trospinning technique [192]. During this study it was observed that CMC/PVA
scaffold supports cell adhesion/attachment and proliferation, and therefore, these
scaffolds are useful for tissue engineering applications. CS–gelatin/nanophase
hydroxyapatite composite scaffolds was developed by CS and gelatin with nano-
phasehydroxyapatite [193], exhibited well swelling characteristic, which could be
modified by altering the quantity of chitosan and gelatin. Nanocomposite scaffolds
showed superior response on MG-63 cells in terms og improved cell attachment,
higher proliferation, and spreading than CS–gelatin scaffold.
5.4.1.5 For Delivery of Anticancer Drugs
Cancer is a terrible human disease which when happens affects the immune sys-
tem of whole body. One of the significant properties of nanomaterials is that they
are highly preferable for parenteral injection of aqueous insoluble drugs. This
property can be utilized for drug targeting applications because their particle sizes
are less than 1000 nm. Potential anticancer drug like doxorubicin was incorpo-
rated in to nano-materials using methoxy poly (ethylene glycol)-grafted carboxy-
methyl chitosan nanoparticles to investigate antitumor activity. Possible
interaction between these two ingredients was due to the presence of positive
amine groups which lead to the formation of nanoparticles. These nanomaterials
were tested against DOX-resistant C-6 glioma. It has been observed that these
nanoparticles exhibited higher cytotoxicity to DOX alone [194]. In another find-
ing it was reported that chitosan nanoparticles were utilized as carrier for the
mitotic inhibitor paclitaxel. These nanoparticles were fabricated by a solvent
evaporation and emulsification cross-linking method. It was observed that pacli-
taxel-loaded CS nanoparticles had higher cell toxicity than individual paclitaxel.
Additionally confocal microscopy investigation confirmed strong cellular uptake
efficiency [195]. Potential chemotherapeutic agent, doxorubicin was incorporated
in to fucodain acetate to form nanoparticles. These nanoparticles were tested for
immunotherapy and chemotherapy in cancer treatment. According to observation
acetate nanoparticles showed important function in immunomodulation and drug
efflux pump inhibition [196].
5.4.1.6 Treatment of Infection and Wounds
According to current research antibacterial therapy-resistant pathogens is the most

critical setback that requires more development in antimicrobial therapeutic agents
in form of their formulation, delivery and physico-chemical properties. Advancement
in this field lead to the development of newly designed wound dressing which has
offered a main step forward for the treatment of infection and wounds. Current sci-
ence is focusing on various strategies to develop novel therapies antibacterial agents
to treat wounds infected with antibacterial treatment-resistant pathogens. Among
the metallic nanoparticles silver nanoparticles are now become more effective bac-
tericidal agents therefore exhibit various biomedical applications ranging from
silver-based dressing to silver-coated therapeutic devices [197]. Various investiga-
tions are available on the utilization of chitosan scaffolds and membranes to treat
patients with deep burns, wounds, etc. Electrospunned collagen-chitosan complex
nanofibers were prepared by Chen et al. [198], showed positive effect on wound
healing. Chitin scaffolds were utilized by Madhumathi et al. [21] for silver nanopar-
ticles preparation. These nanoparticles showed effective wound-healing applica-
tions by showing antibacterial activity against pathogenic bacteria, with good
blood-clotting ability. These outcomes proved that chitin/nanosilver composite
scaffolds could be useful for wound-healing applications.
5.4.2 Role of Marine Based Polysaccharides

for Biotechnological Applications
5.4.2.1 Biosensor Technology
Recent innovations in biosensor technology exploring its beneficial properties as

analytical tools such as low cost, simple, portable, and laboratory-based well estab-
lished method as well as allows miniaturization [199]. Several reports are available
on chitosan nanofibrous membrane and its recent application in enzyme immobili-
zation. Due to the favorable properties such as good biocompatibility, high surface,
and large porosity of chitosan nanofibrous membrane has recently explored as bet-
ter substrate for enzyme immobilization. The concentration of chitosan nanofibrous
membrane that was utilized to immobilize lipase was 63.6 mg/g. Further the reported
activity retention of the immobilized lipase was 49.8 % less than the optimum
condition.
Developed chitosan based system can be used for biosensors [200]. According to
previous investigation electrochemical tyrosinase biosensor showed good repeat-
ability and stability. This electrochemical tyrosinase biosensor was used for
determining phenolic compounds on the basic of the use of a glassy carbon elec-
trode modified with tyrosinase-Fe3O4 magnetic nanoparticles-chitosan nanobio-
composite film. Such chitosan based novel tyrosinase biosensor offers wonderful
applications for eco-friendly, fast and simple methods of phenolic contaminants in
5.5 Marine Polysaccharide-Based Nanomaterials and Its Patents 215
ecological samples [201]. Amperometric biosensor was developed by Chauhan

et al. [202] for the determination of glutathione by covalently immobilizing a gluta-
thione oxidase onto the surface of gold-coated magnetic nanoparticles-modified Pt
electrode. It was observed that glutathione oxidase/chitosan/gold-coated magnetic
nanoparticles were an outstanding candidate for the production of extremely respon-
sive glutathione biosensor.
5.4.2.2 Waste Water Management
Current innovations in polymeric sciences lead to its exploration in waste water

management. Owing to the presence of reactive amino groups chitosan is consid-
ered as potential candidate in waste water management. Chitosan and chitin both
have been widely investigated for the removal of toxic elements such as heavy
metal ions from waste water [203]. Chitosan bead-immobilized algae system with
the association of Scenedesmus sp. was investigated for removing phosphate and
nitrate from water and it was observed that this system was proved to be more effi-
cient conventional free cell system [204]. Since waste contains large amount patho-
genic bacteria, fungi, viruses, therefore efficient antimicrobial system is required to
reduce chances of infections or any other disease. For these purpose silver nanopar-
ticles using polysaccharide-based bioflocculant was developed by Manivasagan
et al. [32]. These nanoparticles were synthesized using polysaccharide-based bio-
flocculant by Streptomyces sp. MBRC-91. Fabricated silver nanoparticles showed
potential antibacterial activity in sewage water. Therefore these types of researches
can make a new opportunity in the waste water management.
5.5 Marine Polysaccharide-Based Nanomaterials

and Its Patents
There are almost fifty patents are existing on marine polysaccharides-based nano-
materials and their applications. Among these polysaccharides only few claimed
that nanocomposite materials based on metallic nanoparticles were stabilized with
branched polysaccharides. More specifically chitosan derivatives such as alditolic
or aldonic monosaccharide and oligosaccharide and their products was obtainable
with these polysaccharide sin the presence or absence of reducing agents claimed to
be stabilized metallic nanoparticles in their matrix. In these studies polysaccharides
applications were explored for antimicrobial activities and molecular biosensors by
exploring their features associated with the nanometric dimensions and the presence
of biological signals on polymeric chains [205]. Claimed protocol suggested that
these polysaccharides based nanocomposite materials are present in the form of
3-dimensional structure. This structure is formed by a polymeric matrix consisting
of a polysaccharidic composition of neutral or anionic polysaccharides and branched
cationic polysaccharides. It has been claimed that metallic nanoparticles are homo-
geneously dispersed and stabilized in this 3-D matrix [206].
References
1. Nitta SK, Numata K. Biopolymer-based nanoparticles for drug/gene delivery and tissue engi-
neering. Int J Mol Sci. 2013;14(1):1629–54.
2. Dutta J, Tripathi S, Dutta PK. Progress in antimicrobial activities of chitin, chitosan and its
oligosaccharides: a systematic study needs for food applications. Food Sci Technol Int.
2012;18(1):3–34.
3. Vu B, Chen M, Crawford RJ, Ivanova EP. Bacterial extracellular polysaccharides involved in
biofilm formation. Molecules. 2009;14:2535–54. doi:10.3390/molecules14072535.
4. Manivasagan P, Oh J. Marine polysaccharide-based nanomaterials as a novel source of nano-
biotechnological applications. Int J Biol Macromol. 2016;82:315–27. doi:10.1016/j.
ijbiomac.2015.10.081. Epub 2015 Oct 30.
5. Jayakumar R, Menon D, Manzoor K, Nair SV, Tamura H. Biomedical applications of chitin
and chitosan based nanomaterials-a short review. Carbohydr Polym. 2010;82(2):227–32.
6. Jesus Raposo MF, Morais AMB, Morais RMSC. Marine polysaccharides from algae with
potential biomedical applications. Mar Drugs. 2015;13:2967–3028. doi:10.3390/
md13052967.
7. Jayakumar R, Prabaharan M, Nair SV, Tamura H. Novel chitin and chitosan nanofibers in
biomedical applications. Biotechnol Adv. 2010;28(1):142–50.
8. Toida T, Amornrut C, Linhardt RJ. Structure and bioactivity of sulfated polysaccharides.
Trends Glycosci Glycotechnol. 2003;15:29–46.
9. Wu XZ. Effects of sulfated polysaccharides on tumor biology. West Indian Med
J. 2006;55(4):270–3.
10. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated
oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays
for angiogenesis and heparanase activity. Cancer Res. 1999;593:433–3441.
11. Costa L, Fidelis G, Cordeiro S, Oliveira R, Sabry D, Câmara R, Nobre L, Costa M, Almeida-
Lima J, Farias E. Biological activities of sulfated polysaccharides from tropical seaweeds.
Biomed Pharmacother. 2010;64:21–8.
12. Gustafson S. The influence of sulfated polysaccharides on the circulating levels of hyaluro-
nan. Glycobiology. 1997;7:1209–14.
13. Renn D. Biotechnology and the red seaweed polysaccharide industry: status, needs and pros-
pects. Trends Biotechnol. 1997;15:9–14.
14. Luscher-Mattli M. Polyanions-a lost chance in the fight against HIV and other virus diseases?
Antivir Chem Chemother. 2000;11:249–59.
15. Lahaye M, Robic A. Structure and functional properties of ulvan, a polysaccharide from
green seaweeds. Biomacromolecules. 2007;8:1765–74.
16. Pillai C, Paul W, Sharma CP. Chitin and chitosan polymers: chemistry, solubility and fiber
formation. Prog Polym Sci. 2009;34:641–78.
17. Ehrlich H, Steck E, Ilan M, Maldonado M, Muricy G, Bavestrello G, Kljajic Z, Carballo J,
Schiaparelli S, Ereskovsky A. Three-dimensional chitin-based scaffolds from Verongida
sponges (Demospongiae: Porifera). Part II: biomimetic potential and applications. Int J Biol
Macromol. 2010;47:141–5.
18. Xia W, Liu P, Zhang J, Chen J. Biological activities of chitosan and chitooligosaccharides.
Food Hydrocolloid. 2011;25:170–9.
19. Lin SB, Lin YC, Chen HH. Low molecular weight chitosan prepared with the aid of cellulase,
lysozyme and chitinase: characterisation and antibacterial activity. Food Chem.
2009;116:47–53.
20. Liao FH, Shieh MJ, Chang NC, Chien YW. Chitosan supplementation lowers serum lipids
and maintains normal calcium, magnesium, and iron status in hyperlipidemic patients. Nutr
Res. 2007;27:146–51.
21. Madhumathi K, Sudheesh Kumar PT, Abhilash S, Sreeja V, Tamura H, Manzoor K, Nair SV,
Jayakumar R. Development of novel chitin/nanosilver composite scaffolds for wound dress-
ing applications. J Mater Sci Mater Med. 2010;21(2):807–13.
References 217
22. Jayakumar R, Nwe N, Tokura S, Tamura H. Sulfated chitin and chitosan as novel biomateri-
als. Int J Biol Macromol. 2007;40:175–81.
23. Madhumathi K, Binulal N, Nagahama H, Tamura H, Shalumon K, Selvamurugan N, Nair S,
Jayakumar R. Preparation and characterization of novel beta-chitin-hydroxyapatite compos-
ite membranes for tissue engineering applications. Int J Biol Macromol. 2009;44:1–5.
24. Xia W. Physiological activities of chitosan and its application in functional foods. J Chin Inst
Food Sci Technol. 2003;3:77–81.
25. Zhao X, Xia W. Antimicrobial activities of chitosan and application in food preservation.
Chin Food Res Dev. 2006;27:157–60.
26. Sun C, Wang JW, Fang L, Gao XD, Tan RX. Free radical scavenging and antioxidant activi-
ties of EPS2, an exopolysaccharide produced by a marine filamentous fungus Keissleriella
sp. YS 4108. Life Sci. 2004;75:1063–73.
27. Manivasagan P, Kim SK. Extracellular polysaccharides produced by marine bacteria. Adv
Food Nutr Res. 2014;72:79–94.
28. Manivasagan P, Sivasankar P, Venkatesan J, Senthilkumar K, Sivakumar K, Kim SK. Marine
actinobacterial metabolites: current status and future perspectives. Int J Biol Macromol.
2013;59:29–38.
29. Chi Z, Su C, Lu W. A new exopolysaccharide produced by marine Cyanothece sp. Bioresour
Technol. 2007;98:1329–32.
30. Mishra A, Jha B. Isolation and characterization of extracellular polymeric substances from
micro-algae Dunaliellasalina under salt stress. Bioresour Technol. 2009;100:3382–6.
31. Zhang ML, Zhang PCK, Cheung VEC. Molecular weight and anti-tumor activity of the
water-soluble polysaccharides isolated by hot water and ultrasonic treatment from the sclero-
tia and mycelia of Pleurotus tuber-regium. Carbohydr Polym. 2004;56:123–8.
32. Manivasagan P, Kang KH, Kim DG, Kim SK. Production of polysaccharide-based biofloc-
culant for the synthesis of silver nanoparticles by Streptomyces sp. Int J Biol Macromol.
2015;77:159–67.
33. Lee JW, Park JH, Robinson JR. Bioadhesive-based dosage forms: the next generation.
J Pharm Sci. 2000;89:850–66.
34. Sinha V, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm.
2001;224:19–38.
35. Vandamme TF, Lenourry A, Charrueau C, Chaumeil J. The use of polysaccharides to target
drugs to the colon. Carbohydr Polym. 2002;48:219–31.
36. Lemarchand C, Gref R, Couvreur P. Polysaccharide-decorated nanoparticles. Eur J Pharm
Biopharm. 2004;58:327–41.
37. Berteau O, Mulloy B. Sulfated fucans, fresh perspectives: structures, functions, and biologi-
cal properties of sulfated fucans and an overview of enzymes active toward this class of
polysaccharide. Glycobiology. 2003;13:29–40.
38. Li B, Lu F, Wei X, Zhao R. Fucoidan: structure and bioactivity. Molecules.
2008;13:1671–95.
39. Leung TCY, Wong CK, Xie Y. Green synthesis of silver nanoparticles using biopolymers,
carboxymethylated-curdlan and fucoidan. Mater Chem Phys. 2010;121:402–5.
40. Lira MCB, Santos-Magalhães NS, Nicolas V, Marsaud V, Silva MPC, Ponchel G, Vauthier
C. Cytotoxicity and cellular uptake of newly synthesizedfucoidan-coated nanoparticles. Eur
J Pharm Biopharm. 2011;79(1):162–70.
41. Huang YC, Liu TJ. Mobilization of mesenchymal stem cells by stromal cell-derived factor-1
released from chitosan/tripolyphosphate/fucoidan nanoparticles. Acta Biomater.
2012;8(3):1048–56.
42. Shibata H, Nagaoka M, Takagi IK, Hashimoto S, Aiyama R, Yokokura T. Effect of oligofu-
cose derivatives on acetic acid-induced gastric ulcer in rats. Biomed Mater Eng.
2001;11(1):55–61.
43. Wang J, Liu L, Zhang Q, Zhang Z, Qi H, Li P. Synthesized oversulphated, acetylated and
benzoylated derivatives of fucoidan extracted from Laminaria japonica and their potential
antioxidant activity in vitro. Food Chem. 2009;114(4):1285–90.
44. Wang J, Zhang Q, Zhang Z, Zhang J, Li P. Synthesized phosphorylated and aminated deriva-
tives offucoidan and their potential antioxidant activity in vitro. Int J Biol Macromol.
2009;44(2):170–4.
45. Hou Y, Wang J, Jin W, Zhang H, Zhang Q. Degradation of Laminaria japonica fucoidan by
hydrogen peroxide and antioxidant activities of the degradation products of different molecu-
lar weights. Carbohydr Polym. 2012;87(1):153–9.
46. Hahn T, Lang S, Ulber R, Muffler K. Novel procedures for the extraction of fucoidan from
brown algae. Process Biochem. 2012;47(12):1691–8.
47. Hayashi K, Nakano T, Hashimoto M, Kanekiyo K, Hayashi T. Defensive effects of a fucoidan
from brown alga Undaria pinnatifida against herpes simplex virus infection. Int
Immunopharmacol. 2008;8:109–16.
48. Becker CF, Guimarães JA, Mourão PA, Verli H. Conformation of sulfated galactan and sul-
fated fucan in aqueous solutions. Implications to their anticoagulant activities. J Mol Graph
Model. 2007;26:391–9.
49. Cumashi A, et al. A comparative study of the anti-inflammatory, anticoagulant, antiangio-
genic, and antiadhesive activities of nine different fucoidans from brown seaweeds.
Glycobiology. 2007;175:41–552.
50. Wang J, Zhang Q, Zhang Z, Li Z. Antioxidant activity of sulfated polysaccharide fractions
extracted from Laminaria japonica. Int J Biol Macromol. 2008;42:127–32.
51. Lira M, Santos-Magalhães N, Nicolas V, Marsaud V, Silva M, Ponchel G, Vauthier
C. Cytotoxicity and cellular uptake of newly synthesized fucoidan-coated nanoparticles.
Biopharm Eur J Pharm. 2011;79:162–70.
52. Lirdprapamongkol K, Warisnoicharoen W, Soisuwan S, Svasti J. Eco-friendly synthesis of
fucoidan-stabilized gold nanoparticles. Am J Appl Sci. 2010;7:1038–42.
53. Kimura R, Rokkaku T, Takeda S, Senba M, Mori N. Cytotoxic effects of fucoidan nanopar-
ticles against osteosarcoma. Mar Drugs. 2013;11:4267–78.
54. Rajaonarivony M, Vauthier C, Couarraze G, Puisieux F, Couvreur P. Development of a new
drug carrier made from alginate. J Pharm Sci. 1993;82:912–7.
55. Sarmento B, Ribeiro A, Veiga F, Ferreira D, Neufeld R. Insulin-loaded nanoparticles are
prepared by alginate ionotropic pre-gelation followed by chitosan polyelectrolyte complex-
ation. J Nanosci Nanotechnol. 2007;7:2833–41.
56. Ahmad Z, Sharma S, Khuller GK. Chemotherapeutic evaluation of alginate nanoparticle-
encapsulated azole antifungal and antitubercular drugs against murine tuberculosisNanomed.
Nanotechnol. 2007;3:239–43.
57. Anh NT, Van Phu D, Duy NN, Du BD, Hien NQ. Synthesis of alginate stabilized gold
nanoparticles by γ-irradiation with controllable size using different Au3+ concentration and
seed particles enlargement. Radiat Phys Chem. 2010;79:405–8.
58. Yang J, Pan J. Hydrothermal synthesis of silver nanoparticles by sodium alginate and their
applications in surface-enhanced Raman scattering and catalysis. Acta Mater.
2012;60:4753–8.
59. Zhang C, et al. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for
liver tumor chemotherapy. Biomaterials. 2012;33:2187–96.
60. Guo H, Lai Q, Wang W, Wu Y, Zhang C, Liu Y, Yuan Z. Functional alginate nanoparticles for
efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
Int J Pharm. 2013;451:1–11.
61. Pandey R, Khuller G. Nanotechnology base drug delivery system(s) for the management of
tuberculosis. Indian J Exp Biol. 2006;44:357–66.
62. Ahmad Z, Pandey R, Sharma S, Khuller GK. Pharmacokinetic and pharmacodynamic behav-
iour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int
J Antimicrob Agents. 2006;27:409–16.
63. Das RK, Kasoju N, Bora U. Encapsulation of curcumin in alginate-chitosan-pluronic com-
posite nanoparticles for delivery to cancer cells. Nanomed Nanotechnol Biol Med.
2010;6(1):153–60.
References 219
64. Muñiz ME, Iglesias I, Teijón JM, Blanco MD. Enhanced preclinical efficacy of tamoxifen
developed as alginate–cysteine/disulfide bond reduced albumin nanoparticles. Int J Pharm.
2012;436(1–2):574–81.
65. Strasdat B, Bunjes H. Incorporation of lipid nanoparticles into calcium alginate beads and
characterization of the encapsulated particles by differential scanning calorimetry. Food
Hydrocolloids. 2013;30(2):567–75.
66. Li Z, Chen P, Xu X, Ye X, Wang J. Preparation of chitosan–sodium alginate icrocapsules
containing ZnS nanoparticles and its effect on the drug release. Mater Sci Eng C.
2009;29(7):2250–3.
67. Idrisa A, Ismaila NSM, Hassana N, Misrana E, Ngomsik AF. Synthesis of magnetic alginate
beads based on maghemite nanoparticles for Pb(II) removal in aqueous solution. J Ind Eng
Chem. 2012;18(5):1582–9.
68. Morales MA, Finotelli PV, Coaquira JAH, Rocha-Leão MHM, Diaz-Aguila C, Baggio-
Saitovitch EM, Rossi AM. In situ synthesis and magnetic studies of iron oxide nanoparticles
in calcium-alginate matrix for biomedical applications. Mater Sci Eng C.
2008;28(2):253–7.
69. Ma HL, Xu YF, Qi XR, Maitani Y, Nagai T. Superparamagnetic iron oxide nanoparticles
stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting
liver cancers. Int J Pharm. 2008;354(1–2):217–26.
70. Finotelli PV, Morales MA, Rocha-Leão MH, Baggio-Saitovitch EM, Rossi AM. Magnetic
studies of iron(III) nanoparticles in alginate polymer for drug delivery applications. Mate Sci
Eng C. 2004;24(5):625–9.
71. Zhou J, Romero G, Rojas E, Ma L, Moya S, Gao C. Layer by layer chitosan/alginate coatings
on poly(lactide-co-glycolide) nanoparticles for antifouling protection and Folic acid binding
to achieve selective cell targeting. J Colloid Interface Sci. 2010;345(2):241–7.
72. Zhang S, Niu H, Cai Y, Shi Y. Barium alginate caged Fe3O4@C18 magnetic nanoparticles
for the pre-concentration of polycyclic aromatic hydrocarbons and phthalate esters from
environmental water samples. Anal Chim Acta. 2010;665(2):167–75.
73. Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug
carriers against experimental tuberculosis. Int J Antimicrob Agents. 2005;26(4):298–303.
74. Niu H, Dizhang MZ, Cai Y. Fast defluorination and removal of norfloxacin by alginate/Fe@
Fe3O4 core/shell structured nanoparticles. J Hazard Mater. 2012;227–228:195–203.
75. Joshi A, Solanki S, Chaudhari R, Bahadur D, Aslam M, Srivastava R. Multifunctional algi-
nate microspheres for biosensing, drug delivery and magnetic resonance imaging. Acta
Biomater. 2011;7(11):3955–63.
76. Gazori T, Khoshayand RM, Azizi E, Yazdizade P, Nomani A, Haririan I. Evaluation of algi-
nate/chitosan nanoparticles as antisense delivery vector: formulation, optimization and
in vitro characterization. Carbohydr Polym. 2009;77(3):599–606.
77. Sarmento B, Ferreira D, Veiga F, Ribeiro A. Characterization of insulin-loaded alginate
nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr
Polym. 2006;66(1):1–7.
78. Gazori T, Haririan I, Fouladdel S, Namazi A, Nomani A, Azizi E. Inhibition of EGFR expres-
sion with chitosan/alginate nanoparticles encapsulating antisense oligonucleotides in T47D
cell line using RT-PCR and immunocytochemistry. Carbohydr Polym. 2010;80(4):1042–7.
79. Seo SY, Lee GH, Lee SG, Jung SY, Lim JO, Choi JH. Alginate-based composite sponge
containing silver nanoparticles synthesized in situ. Carbohydr Polym. 2012;90(1):109–15.
80. Silva MS, Cocenza DS, Grillo R, Silva NFM, Tonello PS, Oliveira LC, et al. Paraquat-loaded
alginate/chitosan nanoparticles: preparation, characterization and soil sorption studies.
J Hazard Mater. 2011;190(1–3):366–74.
81. Cafaggi S, Russo E, Stefani R, Leardi R, Caviglioli G, Parodi B, Bignardi G, Totero DD,
Aiello C, Viale M. Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl
chitosan and a cisplatin–alginate complex. J Control Release. 2007;121(1–2):110–23.
82. Ma H, Qi X, Maitani Y, Nagai T. Preparation and characterization of superparamagnetic iron
oxide nanoparticles stabilized by alginate. Int J Pharm. 2007;333(1–2):177–86.
83. Martínez A, Iglesias I, Lozano R, Teijón JM, Blanco MD. Synthesis and characterization of
thiolated alginate-albumin nanoparticles stabilized by disulfide bonds. Evaluation as drug
delivery systems. Carbohydr Polym. 2011;83(3):1311–21.
84. Boissière M, Allouche J, Chanéac C, Brayner R, Devoisselle JM, Livage J, Coradin
T. Potentialities of silica/alginate nanoparticles as Hybrid Magnetic Carriers. Int J Pharm.
2007;344(1–2):128–34.
85. Paul W, Sharma CP. Synthesis and characterization of alginate coated zinc calcium phosphate
nanoparticles for intestinal delivery of insulin. Process Biochem. 2012;47(5):882–6.
86. Kim HW, Kim BR, Rhee YH. Imparting durable antimicrobial properties to cotton fabrics
using alginate–quaternary ammonium complex nanoparticles. Carbohydr Polym.
2010;79(4):1057–62.
87. Xu XQ, Shen H, Xu JR, Xie MQ, Li XJ. The colloidal stability and core-shell structure of
magnetite nanoparticles coated with alginate. Appl Surf Sci. 2006;253(4):2158–64.
88. Yang JS, Xie YJ, He W. Research progress on chemical modification of alginate: a review.
89. Wingender J, Winkler UK. A novel biological function of alginate in Pseudomonas aerugi-
nosa and its mucoid mutants: stimulation of exolipase. FEMS Microbiol Lett.
1984;21(1):63–9.
90. Peng P, Xie H, Lu L. Surface modification of sphalerite with sodium alginate. Colloids Surf
A Physicochem Eng Asp. 2006;274(1–3):150–3.
91. Pawar SN, Edgar KJ. Alginate derivatization: a review of chemistry, properties and applica-
tions. Biomaterials. 2012;33(11):3279–305.
92. Cheng Y, Lu L, Zhang W, Shi J, Cao Y. Reinforced low density alginate-based aerogels:
preparation, hydrophobic modification and characterization. Carbohydr Polym.
2012;88(3):1093–9.
93. Wells LA, Sheardown H. Photosensitive controlled release with polyethylene glycol–anthra-
cene modified. Eur J Pharm Biopharm. 2011;79(2):304–13.
94. Bubenikova S, Stancu IC, Kalinovska L, Schacht E, Lippens E, Declercq H, Cornelissen M,
Santin M, Amblard M, Martinez J. Chemoselective cross-linking of alginate with thiol-terminated
peptides for tissue engineering applications. Carbohydr Polym. 2012;88(4):1239–50.
95. Fonseca KB, Bidarra SJ, Oliveira MJ, Granja PL, Barrias CC. Molecularly designed alginate
hydrogels susceptible to local proteolysis as three-dimensional cellular microenvironments.
Acta Biomater. 2011;7(4):1674–82.
96. Xu Y, Li L, Yu X, Gu Z, Zhang X. Feasibility study of a novel crosslinking reagent (alginate
dialdehyde) for biological tissue fixation. Carbohydr Polym. 2012;87(2):1589–95.
97. Tan R, She Z, Wang M, Fang Z, Liu Y, Feng Q. Thermo-sensitive alginate-based injectable
hydrogel for tissue engineering. Carbohydr Polym. 2012;87(2):1515–21.
98. Xu Y, Li L, Wang H, Yu X, Gu Z, Huang C, Peng H. In vitro cytocompatibility evaluation of
alginate dialdehyde for biological tissue fixation. Carbohydr Polym. 2012.
99. Yadav M, Mishra DK, Sand A, Behari K. Modification of alginate through the grafting of
2-acrylamidoglycolic acid and study of physicochemical properties in terms of swelling
capacity, metal ion sorption, flocculation and biodegradability. Carbohydr Polym.
2011;84(1):83–9.
100. Huq T, Khan A, Dussault D, Salmieri S, Khan RA, Lacroix M. Effect of gamma radiation on
the physico-chemical properties of alginate-based films and beads. Radiat Phys Chem.
2012;81(8):945–8.
101. Gomez CG, Chambat G, Heyraud A, Villar M, Auzély-Velty R. Synthesis and characteriza-
tion of a β-CD-alginate conjugate. Polymer. 2006;47(26):8509–16.
102. Yang JS, Jiang B, He W, Xia YM. Hydrophobically modified alginate for emulsion of oil in
water. Carbohydr Polym. 2012;87(2):1503–6.
103. Birdi G, Bridson RH, Smith AM, Bohari SPM, Grover LM. Modification of alginate degrada-
tion properties using orthosilicic acid. J Mech Behav Biomed Mater. 2012;6:181–7.
104. Oddo L, Masci G, Meo CD, Capitani D, Mannina L, Lamanna R, et al. Novel thermosensitive
calcium alginate microspheres: physico-chemical characterization and delivery properties.
Acta Biomater. 2010;6(9):3657–64.
References 221
105. Choudhary S, Bhatia SR. Rheology and nanostructure of hydrophobically modified alginate
(HMA) gels and solutions. Carbohydr Polym. 2012;87(1):524–30.
106. Kong HJ, Smith MK, Mooney DJ. Designing alginate hydrogels to maintain viability of
immobilized cells. Biomaterials. 2003;24(22):4023–9.
107. Zain NAM, Suhaimi MS, Idris A. Development and modification of PVA–alginate as a suit-
able immobilization matrix. Process Biochem. 2011;46(11):2122–9.
108. Bardajee GR, Hooshyar Z, Rostami I. Hydrophilic alginate based multidentate biopolymers
for surface modification of CdS quantum dots. Colloids Surf B Biointerfaces.
2011;88(1):202–7.
109. Tafaghodi M, Eskandari M, Khamesipour A, Jaafari MR. Exp Parasitol. Alginate micro-
spheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced par-
tial protection and enhanced immune response against murine model of leishmaniasis. Exp
Parasitol. 2011;129(2):107–14.
110. Haji E, Shariatifar N, Tafaghodi M, Ofogh-e-Danesh Salari Z. Evaluation of immune
response against cutaneous leishmaniasis induced by alginate microspheres encapsulated
with autoclaved Leishmania major (ALM), Quillaja saponin or CpG-ODN adjuvants.
Horizon Med Sci. 2008;13(4):44–50.
111. Shadab, Ahuja A, Khar RK, Baboota S, Chuttani K, Mishra AK, Ali J. Gastroretentive drug
delivery system of acyclovir-loaded alginate mucoadhesive microspheres: formulation and
evaluation. Drug Deliv. 2011;18(4):255–64.
112. Girish GK, Kansal S, Misra P, Dube A, Mishra PR. Uptake of biodegradable Gel-assisted
LBL Nanomatrix by Leishmania donovani-infected macrophages. AAPS PharmSciTech.
2009;10(4):1343–7.
113. Babu GD, Chandra SR, Devi AS, Reddy BVV. Formulation and evaluation of novel efferves-
cent metronidazole floating tablets. Int J Res Pharmaceut Biomed Sci. 2011; 2(4).
114. Coppi G, Sala N, Bondi M, Sergi S, Iannuccelli V. Ex-vivo evaluation of alginate micropar-
ticles for Polymyxin B oral administration. J Drug Target. 2006;14(9):599–606.
115. Coppi G, Iannuccelli V, Sala N, Bondi M. Alginate microparticles for Polymyxin B Peyer’s
patches uptake: microparticles for antibiotic oral administration. J Microencapsul.
2004;21(8):829–39.
116. Coppi G, Bondi M, Coppi A, Rossi T, Sergi S, Iannuccelli V. Toxicity and gut associated
lymphoid tissue translocation of polymyxin B orally administered by alginate/chitosan mic-
roparticles in rats. J Pharm Pharmacol. 2008;60(1):21–6.
117. Tafaghodi M, Abolghasem S, Tabasi S, Payan M. Alginate microsphere as a delivery system
and adjuvant for autoclaved Leishmania major and Quillaja Saponin: preparation and char-
acterization. Iranian J Pharm Sci. 2007;3(2):61–8.
118. Wang FQ, Li P, Zhang JP, Wang AQ, Wei Q. pH-sensitive magnetic alginate-chitosan beads
for albendazole delivery. Pharm Dev Technol. 2011;16(3):228–36.
119. Singodia D, Khare P, Dube A, Talegaonkar S, Khar RK, Mishra PR. Development and per-
formance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral
leishmaniasis. J Biomed Nanotechnol. 2011;7(1):123–4.
120. Mandal TK, Bostanian LA, Graves RA, Chapman SR, Idodo TU. Porous biodegradable mic-
roparticles for delivery of pentamidine. Eur J Pharm Biopharm. 2001;52(1):91–6.
121. Buranapanitkit B, Oungbho K, Ingviya N. The efficacy of hydroxyapatite composite impreg-
nated with amphotericin. Clin Orthop Relat Res. 2005;437:236–41.
122. Hori Y, Winans AM, Irvinea DJ. Modular injectable matrices based on alginate solution/
microsphere mixtures that Gel in situ and Co-deliver immunomodulatory factors. Acta
Biomater. 2009;5(4):969–82.
123. Patel RP, Dadhani B, Ladani R, Baria AH, Patel J. Formulation, evaluation and optimization
of stomach specific in situ gel of clarithromycin and metronidazole benzoate. Int J Drug
Deliv. 2010;2:141–53.
124. Gupta GK, Kansal S, Misra P, Dube A, Mishra PR. Uptake of biodegradable Gel-assisted
LBL nanomatrix by leishmania donovani-infected macrophages. AAPS PharmSciTech.
2009;10(4):1343–7.
125. Shchipunov YA. Sol-gel-derived biomaterials of silica and carrageenans. J Colloid Interface
Sci. 2003;268:68–76.
126. Luo Y, Wang Q. Recent development of chitosan-based polyelectrolyte complexes with natu-
ral polysaccharides for drug delivery. Int J Biol Macromol. 2014;64:353–67.
127. Daniel-da-Silva AL, Trindade T, Goodfellow BJ, Costa BF, Correia RN, Gil AM. In situ
synthesis of magnetite nanoparticles in carrageenan gels. Biomacromolecules.
2007;8:2350–7.
128. De Souza MCR, Marques CT, Dore CMG, da Silva FRF, Rocha HAO, Leite EL. Antioxidant
activities of sulfated polysaccharides from brown and red seaweeds. J Appl Phycol.
2007;19:153–60.
129. Stiles J, Guptill-Yoran L, Moore GE, Pogranichniy RM. Effects of lambda-carrageenan on
in vitro replication of feline herpesvirus and on experimentally induced herpetic conjunctivi-
tis in cats. Invest Ophthalmol Vis Sci. 2008;49:1496–501.
130. Grenha A, Gomes ME, Rodrigues M, Santo VE, Mano JF, Neves NM, Reis RL. Development
of new chitosan/carrageenan nanoparticles for drug delivery applications. J Biomed Mater
Res A. 2010;92:1265–72.
131. Rodrigues S, da Costa AMR, Grenha A. Chitosan/carrageenan nanoparticles: effect of cross-
linking with tripolyphosphate and charge ratios. Carbohydr Polym. 2012;89:282–9.
132. Hezaveh H, Muhamad II. The effect of nanoparticles on gastrointestinal release from modi-
fied k-carrageenan nanocomposite hydrogels. Carbohydr Polym. 2012;89:138–45.
133. Salgueiro AM, Daniel-da-Silva AL, Fateixa S, Trindade T. k-Carrageenan hydrogel nano-
composites with release behavior mediated by morphological distinct Au nanofillers.
134. Datta K, Srinivasan B, Balaram H, Eswaramoorthy M. Synthesis of agarose-metal/semicon-
ductor nanoparticles having superior bacteriocidal activity and their simple conversion to
metal-carbon composites. J Chem Sci. 2008;120:579–86.
135. Kattumuri V, Chandrasekhar M, Guha S, Raghuraman K, Katti KV, Ghosh K, Patel R,
Agarose-stabilized gold nanoparticles for surface enhanced Raman spectroscopic detection
of DNA nucleosides. Appl Phys Lett. 2006;88:153114–153114-3.
136. Sahoo D, Baweja P, Kushwah N. Developmental studies in Porphyra vietnamensis: a high-
temperature resistant species from the Indian coast. J Appl Phycol. 2006;18:279–86.
137. Bhatia S, et al. Novel algal polysaccharides from marine source: Porphyran. Pharmacogn
Rev. 2009;2(4):271–6.
138. Bhatia S, et al. Immuno-modulation effect of sulphated polysaccharide (porphyran) from
Porphyra vietnamensis. Int J Biol Macromol. 2013;57:50–6.
139. Bhatia S, et al. Significance of algal polymer in designing amphotericin B nanoparticles. Sci
World J. 2014, 564573. doi:10.1155/2014/564573
140. Bhatia S, et al. Investigation of the factors influencing the molecular weight of porphyran and
its associated antifungal activity. Bioact Carbohydr Dietary Fibre. 2015;5(2):153–68.
141. Bhatia S, et al. Structural characterization and pharmaceutical properties of Porphyran. Asian
J Pharm. 2015;9(2).
142. Bhatia S, et al. Factors affecting the gelling and emulsifying property of natural polymer. Syst
Rev Pharm. 2010;1(1):86.
143. Bhatia S, et al. Anti-oxidant potential of Indian porphyra. Pharmacol Online.
2011;1:248–57.
144. Kwon MJ, Nam TJ. Porphyran induces apoptosis related signal pathway in AGS gastric can-
cer cell lines. Life Sci. 2006;79:1956–62.
145. Venkatpurwar V, Shiras A, Pokharkar V. Porphyran capped gold nanoparticles as a novel car-
rier for delivery of anticancer drug: In vitro cytotoxicity study. Int J Pharm.
2011;409:314–20.
146. Venkatpurwar V, Mali V, Bodhankar S, Pokharkar V. In vitro cytotoxicity and in vivo sub-
acute oral toxicity assessment of porphyran reduced gold nanoparticles. Toxicol Environ
Chem. 2012;94:1357–67.
References 223
147. Toskas G, Hund RD, Laourine E, Cherif C, Smyrniotopoulos V, Roussis V. Anofibers based
on polysaccharides from the green seaweed Ulva rigida. Carbohydr Polym.
2011;84:1093–102.
148. Raveendran S, Poulose AC, Yoshida Y, Maekawa T, Kumar DS. Bacterial exopolysaccharide
based nanoparticles for sustained drug delivery, cancer chemotherapy and bioimaging.
149. Wibowo S, Velazquez G, Savant V, Torres JA. Surimi wash water treatment for protein recov-
ery: effect of chitosan–alginate complex concentration and treatment time on protein adsorp-
tion. Bioresour Technol. 2005;96:665–71.
150. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release.
2003;89:151–65.
151. Chang PR, Jian R, Yu J, Ma X. Starch-based composites reinforced with novel chitin nanopar-
ticles. Carbohydr Polym. 2010;80:420–5.
152. Song Y, Onishi H, Nagai T. Pharmacokinetic characteristics and antitumor activity of the
N-succinyl-chitosan-mitomycin C conjugate and the carboxymethyl-chitin-mitomycin C
conjugate. Biol Pharm Bull. 1993;16:48–54.
153. Dev A, Mohan JC, Sreeja V, Tamura H, Patzke G, Hussain F, Weyeneth S, Nair S, Jayakumar
R. Novel carboxymethyl chitin nanoparticles for cancer drug delivery applications. Carbohydr
Polym. 2010;79:1073–9.
154. Gnanadhas DP, Thomas MB, Elango M, Raichur AM, Chakravortty D. Chitosan-dextran sul-
phate nanocapsule drug delivery system as an effective therapeutic against intraphagosomal
pathogen Salmonella. J Antimicrob Chemother. 2013;68:2576–86.
155. Smitha K, Nisha N, Maya S, Biswas R, Jayakumar R. Delivery of rifampicin-chitin nanopar-
ticles into the intracellular compartment of polymorphonuclear leukocytes. Int J Biol
Macromol. 2015;74:36–43.
156. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv
Rev. 2010;62:3–11.
157. Rather MA, Sharma R, Gupta S, Ferosekhan S, Ramya V, Jadhao SB. Chitosan-
nanoconjugated hormone nanoparticles for sustained surge of gonadotropins and enhanced
reproductive output in female fish. Plosone. 2013;8:1–10.
158. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MAJ. Chitosan nanoparticles as
delivery systems for doxorubicin. J Control Release. 2001;73:255–67.
159. Mitra S, Gaur U, Ghosh P, Maitra A. Tumour targeted delivery of encapsulated dextran-
doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release.
2001;74:317–23.
160. Campos AMD, Sánchez AM, Alonso AJ. Chitosan nanoparticles: a new vehicle for the
improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int
J Pharm. 2001;224:159–68.
161. Banerjee T, Mitra S, Singh AK, Sharma RK, Maitra A. Preparation, characterization and
biodistribution of ultrafine chitosan nanoparticles. Int J Pharm. 2002;243:93–105.
162. Qi L, Xu Z, Jiang X, Hu C, Zou X. Preparation and antibacterial activity of chitosan nanopar-
ticles. Carbohydr Res. 2004;339:2693–700.
163. Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and
morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloid
Surf B. 2005;44:65–73.
164. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA
delivery. J Control Release. 2006;115:216–25.
165. Min KH, Park K, Kim YS, Bae SM, Lee S, Jo HG, Park RW, Kim IS, Jeong SY, Kim
K. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin
enhance the drug stability and tumor targeting in cancer therapy. J Control Release.
2008;127:208–18.
166. Ali SW, Rajendran S, Joshi M. Synthesis and characterization of chitosan and silver loaded
chitosan nanoparticles for bioactive polyester. Carbohydr Polym. 2011;83:438–46.
167. Lima JMD, Sarmento RR, Souza JRD, Brayner FA, Feitosa APS, Padilha R, Alves LC, Porto
IJ, Batista RFBD, Oliveira JED. Evaluation of hemagglutination activity of chitosan nanopar-
ticles using human erythrocytes Padlock. BioMed Res Int. 2015;1–6
168. Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug
delivery. Adv Drug Deliv Rev. 2010;62:83–99.
169. Luo Y, Wang TT, Teng Z, Chen P, Sun J, Wang Q. Encapsulation of indole-3-carbinol and 3,
3′-diindolylmethane in zein/carboxymethyl chitosan nanoparticles with controlled release
property and improved stability. Food Chem. 2013;139:224–30.
170. Thein-Han W, Saikhun J, Pholpramoo C, Misra R, Kitiyanant Y. Chitosan–gelatin scaffolds
for tissue engineering: physico-chemical properties and biological response of buffalo
embryonic stem cells and transfectant of GFP–buffalo embryonic stem cells. Acta Biomater.
2009;5:3453–66.
171. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based
micro- and nanoparticles in drug delivery. J Control Release. 2004;5–28.
172. Wei XH, Niu YP, Xu YY, Du YZ, Hu FQ, Yuan H. Salicylic acid-grafted chitosan oligosac-
charide nanoparticle for paclitaxel delivery. J Bioact Compat Polym. 2010;25:319–35.
173. López-Cruz A, Barrera C, Calero-DdelC VL, Rinaldi C. Water dispersible iron oxide
nanoparticles coated with covalently linked chitosan. J Mater Chem. 2009;19:6870–6.
174. Bae KH, Park M, Do MJ, Lee N, Ryu JH, Kim GW, Kim C, Park TG, Hyeon T. Chitosan
oligosaccharide-stabilized ferrimagnetic iron oxide nanocubes for magnetically modulated
cancer hyperthermia. ACS Nano. 2012;6:5266–73.
175. Liu X, Huang H, Liu G, Zhou W, Chen Y, Jin Q. Multidentate zwitterionic chitosan oligosac-
charide modified gold nanoparticles: stability, biocompatibility and cell interactions.
J Nanoscale. 2013;5:3982–91.
176. Lin YS, Wu MF, Takamori Y, Okamoto Y, Minami S. In vivomodulatory effects of chitooli-
gosaccharide nanoparticles on mouse serum cytokines and splenocytes. J Exp Nanosci.
2014;9:860–70.
177. Lu C, Park MK, Lu C, Lee YH, Chai KY. A mussel-inspired chitooligosaccharide based
multidentate ligand for highly stabilized nanoparticles. J Mater Chem B. 2015;3:3730–7.
178. Wang W, Wang SX, Guan HS. The antiviral activities and mechanisms of marine polysac-
charides: an overview. Mar Drugs. 2012;10:2795–816.
179. Mohanty S, Mishra S, Jena P, Jacob B, Sarkar B, Sonawane A. An investigation on the anti-
bacterial, cytotoxic, and antibiofilm efficacy of starch-stabilized silver nanoparticles.
Nanomed Nanotechnol. 2012;8:916–24.
180. Allaker R. The use of nanoparticles to control oral biofilm formation. J Dent Res.
2010;89:1175–86.
181. Kora AJ, Sashidhar R, Arunachalam J. Gum kondagogu (Cochlospermum Gossypium): a
template for the green synthesis and stabilization of silver nanoparticles with antibacterial
application. Carbohydr Polym. 2010;82:670–9.
182. Shukla MK, Singh RP, Reddy C, Jha B. Synthesis and characterization of agar-based silver
nanoparticles and nanocomposite film with antibacterial applications. Bioresour Technol.
2012;107:295–300.
183. Venkatpurwar V, Pokharkar V. Green synthesis of silver nanoparticles by Chrysanthemum
morifolium Ramat. extract and their application in clinical ultrasound gel. Mater Lett.
2011;65:999–1002.
184. Jong WHD, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int
J Nanomed. 2008;3:133–49.
185. Salamanca AED, Diebold Y, Calonge M, García-Vazquez C, Callejo S, Vila A, Alonso
MJ. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxic-
ity, uptake mechanism and In Vivo tolerance. Invest Ophthalmol Vis Sci. 2006;47:1416–25.
186. Fuente MDL, Raviña M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. Chitosan-based nano-
structures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev. 2010;62:100–17.
187. Wu SJ, Don TM, Lin CW, Mi FL. Delivery of berberine using chitosan/fucoidan-taurine
conjugate nanoparticles for treatment of defective intestinal epithelial tight junction barrier.
Mar Drugs. 2014;12:5677–97.
References 225
188. You JO, Liu YC, Peng CA. Efficient gene transfection using chitosan-alginate core-shell
nanoparticles. Int J Nanomed. 2006;1:173–80.
189. Bozkir A, Saka OM. Chitosan nanoparticles for plasmid DNA delivery: effect of chitosan
molecular structure on formulation and release characteristics. Drug Deliv. 2004;11:107–12.
190. Lee DW, Yun KS, Ban HS, Choe W, Lee SK, Lee KY. Preparation and characterization of
chitosan/polyguluronate nanoparticles for siRNA delivery. J Control Release.
2009;139:146–52.
191. Noh HK, Lee SW, Kim JM, Oh JE, Kim KH, Chung CP, Choi SC, Park WH, Min
BM. Electrospinning of chitin nanofibers: degradation behavior and cellular response to nor-
mal human keratinocytes and fibroblasts. Biomaterials. 2006;27:3934–44.
192. Shalumon K, Binulal N, Selvamurugan N, Nair S, Menon D, Furuike T, Tamura H, Jayakumar
R. Electrospinning of carboxymethyl chitin/poly (vinyl alcohol) nanofibrous scaffolds for
tissue engineering applications. Carbohydr Polym. 2009;77:863–9.
193. Peter M, Ganesh N, Selvamurugan N, Nair S, Furuike T, Tamura H, Jayakumar R. Preparation
and characterization of chitosan–gelatin/nanohydroxyapatite composite scaffolds for tissue
engineering applications. Carbohydr Polym. 2010;80:687–94.
194. Jeong YI, Jin SG, Kim IY, Pei J, Wen M, Jung TY, Moon KS, Jung S. Doxorubicin-
incorporated nanoparticles composed of poly(ethylene glycol)-grafted carboxymethyl chito-
san and antitumor activity against glioma cells in vitro. Colloid Surf B. 2010;79:149–55.
195. Li F, Li J, Wen X, Zhou S, Tong X, Su P, Li H, Shi D. Anti-tumor activity of paclitaxel-loaded
chitosan nanoparticles: An In Vitro study. Mater Sci Eng C. 2009;29:2392–7.
196. Lee KW, Jeong D, Na K. Doxorubicin loading fucoidan acetate nanoparticles for immune
and chemotherapy in cancer treatment. Carbohydr Polym. 2013;94:850–6.
197. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials.
Biotechnol Adv. 2009;27:76–83.
198. Chen Z, Mo X, He C, Wang H. Intermolecular interactions in electrospun collagen–chitosan
complex nanofibers. Carbohydr Polym. 2008;72:410–8.
199. Teles F, Fonseca L. Applications of polymers for biomolecule immobilization in electro-
chemical biosensors. Mater Sci Eng C. 2008;28:1530–43.
200. Huang XJ, Ge D, Xu ZK. Preparation and characterization of stable chitosan nanofibrous
membrane for lipase immobilization. Eur Polym J. 2007;43:3710–8.
201. Wang S, Tan Y, Zhao D, Liu G. Amperometric tyrosinase biosensor based on Fe3O4 nanopar-
ticles–chitosan nanocomposite. Bioelectron. 2008;23:1781–7.
202. Chauhan N, Narang J, Pundir C. An amperometric glutathione biosensor based on chitosan-
iron coated gold nanoparticles modified. Int J Biol Macromol. 2012;51:879–86.
203. Gandhi MR, Viswanathan N, Meenakshi S. Preparation and application of alumina/chitosan
biocomposite. Int J Biol Macromol. 2010;47:146–54.
204. Fierro S, Pilar Sanchez-Saavedra M, Copalcua C. Nitrate and phosphate removal by chitosan
immobilized. Bioresour Scenedesmus Technol. 2008;99:1274–9.
205. Donati I, Marsich E, Travan A, Paoletti S. Nanocomposite materials based on metallic
nanoparticles stabilized with branched polysaccharides. US 2011/0129536 A1. 2009.
206. Donati I, Marsich E, Travan A, Paoletti S. Three-dimensional nanocomposite materials con-
sisting of a polysaccharidic matrix and metallic nanoparticles, preparation and use thereof in.
US 2011/0123589 A1. 2009.

Natural Polymer Drug Delivery Systems

Uploaded by

Copyright:

Available Formats

Natural Polymer Drug Delivery Systems

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Natural Polymer Drug Delivery Systems

Uploaded by

Copyright:

Available Formats

What is the book about?

What is the book about?

What are some applications of nanotechnology discussed in the book?

What are some applications of nanotechnology discussed in the book?

Saurabh

Natural Polymer Drug

ISBN 978-3-319-41128-6 ISBN 978-3-319-41129-3 (eBook)

Library of Congress Control Number: 2016944154

© Springer International Publishing Switzerland 2016

Printed on acid-free paper

This Springer imprint is published by Springer Nature

Saurabh Bhatia, is currently working as an Assistant Professor at the School of

1 Nanotechnology and Its Drug Delivery Applications............................. 1

2.4 Preparation of Nanoparticles.............................................................. 44

4.6 Physical-Chemical Modification of Plant Based

Keywords Drug delivery • Cancer therapy • Nanoparticles • Toxicology •

Various researchers are currently working on nanotechnology especially in medi-

© Springer International Publishing Switzerland 2016 1

matrices. For nanoparticles the knowledge on particle toxicity as obtained in

1.2 Historical Prospects of Nanotechnology

1.3 Promising Role in Drug Delivery

Recent researches have evidenced extraordinary development of research and appli-

Table 1.1 List of historical events reported in nanotechnological science

Table 1.1 (continued)

Table 1.1 (continued)

Table 1.1 (continued)

1.3.1 Nanoparticles and Drug Delivery

Current nanomedicine science constitutes nanometer scale complex systems (10–

agglomeration. This can be achieved by and keeping the particles in colloidal

1.3.2 Use of NPs Formulation in Drug Delivery

Different physiological barriers, solubility of drug under in vivo conditions (dif-

Signiﬁcant features of liposomes(nanosized phospholipid “fatty” structures)

tration of cyanoacrylate and polystyrene nanoparticles [57]. He has also reported

1.3.3 Cellular and Intracellular Targets

1.3.4 The Brain—The Ultimate Target for Drug Delivery

1.4 Innovations in Nanotechnology

Revolution has started in 1989, when IBM researchers established a scientiﬁc

1.5 Nanotechnology Theory to Applications

Nanotechnology is serving to signiﬁcantly develop, even reform, many technol-

Table 1.2 Applications of nanotechnology in different domain

Table 1.2 (continued)

1.6.1 Nanomedicine and Drug Delivery

Emergence of nanotechnology in medicine led to the exploration of more speciﬁed

1.6.1.1 Advantages of Nanoparticles for Nanomedicine

• More improved understanding of the patho-physiological basis of disease is

1.6.2 Nanoengineering and Drug Delivery

Abraxane, Doxil, C-dots Commercially NANO Carbon nanowires

In vivo imaging Lab-on-a-chip

Fig. 1.1 Nano medicine and its applications

1.7 Types of Nanodelivery: Natural or Synthetic

1.7.1 Synthetic Polymers

1.7.2 Natural Polymers

Due to some unique and relatively safe features of biocompatibility, biodegradability,

Table 1.3 Advantages and disadvantages of natural and synthetic polymers

1.8 Natural and Synthetic Polymeric Nanoparticles

Collective term nanoparticle constitute nanospheres and nanocapsules which are

1. Santamaria A. Historical overview of nanotechnology and nanotoxicology. Methods Mol

Abstract The most emerging branch in pharmaceutical sciences known as

Keywords Nanotechnology • Nanoparticles • Types • Applications • Fabrication

© Springer International Publishing Switzerland 2016 33